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Abstract 
Duchenne muscular dystrophy (DMD) is caused by mutations at the DMD locus leading to a 
lack of the dystrophin protein in muscle cells. Dystrophin associates with a group of 
membrane-associated proteins called the dystrophin-associated protein complex (DAPC) 
via an interaction with the membrane spanning glycoprotein 13-dystroglycan. The exact 
functions of dystrophin and the DAPC have not been elucidated and little is known about 
the regulation of protein:protein interactions within this complex. However, the proteins 
are ideally placed to transduce signals from the extracellular matrix to the cytoskeleton 
and have been implicated in a wide variety of cell signalling events. The aim of this study 
was to identify novel phosphorylation events within the DAPC and determine their 
effects on the regulation of protein:protein interactions in the complex. 
Upon treatment of C2/C4 cells (a mouse muscle cell line) with peroxyvanadate, a potent 
tyrosine phosphatase inhibitor, 3-dystroglycan is tyrosine-phosphorylated. This 
phosphorylation event was initially detected by mobility shifts on SDS-polyacrylamide 
gels, and confirmed by immunoprecipitation and two-dimensional gel electrophoresis. The 
potential functional significance of this tyrosine phosphorylation was investigated using 
peptide 'SPOTs' assays. Phosphorylation of tyrosine in the 15 most C-terminal residues of 
-dystroglycan disrupts its interaction with dystrophin. The tyrosine residue in 13-
dystroglycan's WW domain-binding motif PPPY appears to be the most crucial in 
disrupting the interaction. Therefore the j3-dystroglycan/dystrophin interaction appears 
to be regulated by tyrosine phosphorylation. 
Various methods were used to investigate the protein:protein interactions of 0-
dystroglycan. In a yeast two-hybrid assay f3-dystroglycan was found to interact with actin. 
This novel interaction was further characterised by F-actin sedimentation assays and it 
was demonstrated f3-dystroglycan facilitated the sedimentation of F-actin during low 
speed centrifugation. Furthermore, electron microscopy studies revealed that 13-
dystroglycan bundles actin filaments. 
These studies highlight the importance of 13-dystroglycan, not only in the regulation of the 
interaction between dystrophin and the rest of the DAPC but also its possible role in the 
regulation of the actin cytoskeleton. Understanding more about functions of dystrophin and 
the DAPC allows a greater insight into the pathogenesis of Duchenne muscular dystrophy. 
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Introduction 
1.1. Duchenne muscular dystrophy 
Duchenne muscular dystrophy (DMD) is the most frequent lethal X-
linked recessive disease with an incidence of 1 in every 3500 live male 
births (Emery, 1993). It is characterised by progressive muscle fibre 
degeneration and is caused by mutations at the DMD locus leading to a 
lack of dystrophin protein in muscle cells (Hoffman et al., 1988). DMD 
patients are clinically normal at birth although the disease is characterised 
by elevated levels of the muscle isoform of creatine kinase (CK) in the 
serum. The first clinical sign of DMD is the delayed ability to walk and 
difficulty running due to the progressive weakening of the limb muscles. 
Wheelchair dependence is usually evident by the end of the first decade 
and the disease is fatal in the third decade resulting from the degeneration 
of diaphragm and cardiac muscles. 
Becker muscular dystrophy (BMD) is a less severe and more variable form 
of muscular dystrophy which occurs in 1 male per 18500 (Bushby et al., 
1991). BMD patients have an abnormal dystrophin protein and/or altered 
levels of dystrophin expression usually due to in-frame deletions of the 
DMD gene. 
Although the genetic defect underlying Duchenne and Becker muscular 
dystrophy has been known for some years (Hoffman et al., 1987), the 
function of dystrophin and the sequence of events leading to the observed 
pattern of muscle fibre necrosis is unknown. It is hypothesised that 
dystrophin deficiency initiates a complex pathophysiological response 
which determines the clinical phenotype which develops. Early in the 
disease process, the absence of dystrophin causes elevated CK levels, 
grouped myofibre necrosis, pseudohypertrophy of muscles (apparent 
increased muscle mass due to replacement of muscle fibres with fibrotic 
3 
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and adipose tissue) and muscle fibre size variability. The long-term effects 
of dystrophin deficiency include progressive fibrosis (excessive 
proliferation of connective tissue) and the failure of muscle regeneration 
due to inhibition by fibrotic proliferation or the exhaustion of the 
regenerative capacity of the cells. Both the fibrosis and lack of muscle 
regeneration lead to progressive fibre loss which causes gross muscle 
wasting and muscle weakness. 
Neuronal nitric oxide synthase (nNOS) is associated with the sarcolemma 
of fast-twitch fibres in skeletal muscle (Kobzik et al., 1994) as the result of 
its interaction with dystrophin (Brenman et al., 1995). nNOS regulates and 
synthesises nitric oxide (NO) a major endogenous mediator involved in 
diverse developmental and physiological processes (Bredt & Snyder, 
1992). nNOS has been found to be absent from the sarcolemma in patients 
with Duchenne muscular dystrophy and it is hypothesised that the 
disturbed regulation of NO contributes to the preferential necrosis of fast-
twitch fibres in DMD. 
One longstanding hypothesis is that the membrane defect in DMD leads 
to 	an abnormal influx of Ca 2,  (Emery, 1993). Dystrophic muscle 
membranes undergo more frequent nonlethal tears (microdisruptions) 
than normal cell membranes, especially during exercise. Calcium entry 
through these micro disruptions leads to elevated calcium levels which 
alter the activity of the calcium leak channels. This is thought to 
contribute to the eventual necrosis of muscle cells in DMD due to 
increased calcium-dependent proteolysis (McCarter & Steinhardt, 2000) 
Expression profiling using microarray technology has recently been used 
in an effort to to define biochemical cascades underlying the progressive 
pathophysiology of muscular dystrophies (Chen et al., 2000). This work 
has provided insights into the disease processes involved and proteins 
Ll 
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which may be involved in early stages of muscle fibre necrosis and 
inflammatory responses. There appears to be a persistant expression of 
developmentally regulated genes, suggesting that DMD muscle may 
assume a chronically dedifferentiated state. Many calcium-regulated 
signaling molecules are downregulated, which is thought to be a 
consequence of a negative-feedback loop caused by the chronic calcium 
influx through muscle membrane micro disruptions. More research using 
this method of expression profiling will no doubt lead to more 
understanding of the disease mechanisms of DMD and other muscular 
dystrophies. 
1.1.1. Animal models of DMD 
The mdx mouse is a naturally occurring animal model for DMD caused by 
a premature stop codon leading the generation of a dystrophin transcript 
only 27% of its full length. Overall, the mdx mouse has a milder 
pathology than humans. There is an assumption that the sarcolemmal 
membrane of mouse skeletal muscle endures less mechanical stress per 
unit area than in humans due the smaller size of the organism and the 
individual muscle fibres (Petrof et al., 1993; Grady et al., 1997b). This 
would account for the mild phenotype of the mdx mouse compared to the 
severity of DMD in humans. 
There are many murine models for congenital muscular dystrophy 
(CMD) which is caused by a deficiency in the laminin a2 chain (Hillaire et 
al., 1994). The absence of laminin a2 chain presumably leads to a 
disruption of the linkage between the sarcolemmal membrane and the 
extracellular matrix (Campbell, 1995). This dystrophic dy/dy mouse has a 
dysmyelination of the peripheral nervous system in addition to muscle 
degeneration (reviewed in Allamand & Campbell, 2000). 
5 
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Mice with null mutations for utrophin (the ubiquitous homologue of 
dystrophin) also have a mild phenotype with no outward signs of 
muscular dystrophy (Deconinck et al., 1997; Grady et al., 1997a), suggesting 
that dystrophin and utrophin functionally compensate for one another. 
This potential compensation is demonstrated by mice deficient in both 
dystrophin and utrophin which have a severe phenotype comparable to 
DMD, including widespread loss of myocytes, myofibrosis and premature 
death. It has been suggested that this double knockout model is a more 
valid disease model for DMD due to its severity (Allamand & Campbell, 
2000), but this is questionable. A disease model with utrophin present 
equates more accurately to the pathology of DMD patients. 
The dystrophic golden retriever dog (GRMD) is perhaps a more attractive 
model for DMD because of its larger size (Cooper et al., 1988) but there is 
phenotypic variability between litters, more ethical considerations than 
with mice, and their maintenance is more problematic and costly. 
Inherited muscular dystrophy was first observed in the chicken in 1956, 
and when chicken dystrophin cDNA was sequenced, it was found to have 
a striking conservation of its C-terminal coding region with human 
dystrophin (Lemaire et al., 1988). There has been very little research on 
the dystrophic chicken since the 1980s when it was used extensively in 
drug trials (Pisenti et ai.,1999). 
no 
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1.2. Dystrophin 
The gene responsible for the Duchenne muscular dystrophy phenotype 
was identified by positional cloning (Koenig et al., 1987) and its protein 
product dystrophin subsequently characterised (Koenig et al, 1988; 
Hoffman et al., 1987). The DMD locus is located on the X chromosome at 
Xp21.1 and is the largest known gene covering 2.7 megabases and 
containing at least 79 exons. 
The dystrophin protein is 427kDa in size, consists of at least eight 
identified protein domains (figure 1.1), and is expressed predominantly in 
skeletal, smooth and cardiac muscle and to a lesser extent in the brain 
(Chamberlain et al., 1988). 
In muscle cells dystrophin is localised to the cytoplasmic face of the 
sarcolemma via interactions at its C-terminus with a complex of 
membrane-spanning proteins termed the dystrophin-associated protein 
complex (DAPC) (section 1.3). DAPC proteins which dystrophin directly 
interacts with include dystrobrevin, syntrophin and f3-dystroglycan. a-
dystroglycan interacts with f3-dystroglycan and extracellular matrix 
proteins, thus linking dystrophin to the extracellular matrix (ECM). At its 
N-terminus dystrophin interacts with the actin cytoskeleton. 
Consequently, dystrophin forms a link between the actin cytoskeleton and 
the extracellular matrix. The loss of dystrophin destroys this essential link 
and as a result leads to muscle degeneration. 
The exact function of dystrophin is unknown, but it is proposed to 
stabilise myofibres during muscle contraction and relaxation (Petrof et al., 
1993). On the basis of dystrophin's homology to a-actinin and spectrin 
(Koenig et al.,1988), the assumption was that dystrophin forms dimers. It 
has been suggested that dystrophin homodimers interact, forming an 
hexagonal array which confers flexibility to the membrane cytoskeleton 
7 
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Domain structure of dystrophin 
Representation of dystrophin domain structure indicating the principle domains.Numbers refer to amino-acid residues delimiting the 
domains or regions. Actin-binding sites ABS 1-3 represent the major actin-binding regions. The central triple helical coiled-coil region 
comprises over 70% of the protein and consists of 24 coiled-coil repeats separated by five proline-rich hinge regions. This region also 
contains ABS 4 (repeats 11-17) and ABS 5 (repeat 18).The WW domain (WW), EF hand region (EF) and ZZ domain (ZZ) are involved in 
binding 3-dystroglycan The C-terminal coiled-coil region comprises two a-helices (Hi & 1-12). 
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during muscle contraction and relaxation (Koenig & Kunkel, 1990). 
However, more recent evidence, including biochemical and electron 
microscopy studies, indicate that whole dystrophin does not form dimers 
in solution (reviewed in Winder, 1997). 
In addition to its structural properties, dystrophin itself is phosphorylated 
and has links to signalling molecules via the DAPC (section 1.9) and has 
therefore been implicated in cell signalling events. However, it is not 
clear what the functional consequences of these events are. 
1.2.1. Dystrophin isoforms and related proteins. 
Dystrophin is now one member of a growing family of related proteins 
(see figure 1.2). These include products of the same gene by the use of 
alternative promoters, and related proteins encoded by different genes. At 
least three promoters give rise to full length dystrophin (Dp427) found in 
muscle and brain tissue. Further promoters near the C-terminus of the 
DMD gene drive the expression of lower molecular weight isoforms 
known as Dp260, Dp140, Dp116, Dp71 and Dp45 (according to their 
molecular weights) which have a wider tissue distribution (reviewed in 
Sadoulet-Puccio & Kunkel, 1996). The promoters are cell-type specific, and 
the isoforms all have the same C-terminal domains as dystrophin thus 
facilitating interactions with components of the DAPC, suggesting 
multiple roles for this complex. For example, Dp116 is expressed in 
Schwann cells of the peripheral nervous system (PNS) and co-localises 
with the dystroglycans, syntrophin and members of the sarcoglycan 
complex indicating that a complex similar to the skeletal muscle DAPC is 
formed in the PNS (Matsumura et al., 1993). 
Dystrophin also has alternatively spliced variants, the roles of which are 
unclear (reviewed in Amalfitano et al., 1997). Dystrophin-related proteins 
include utrophin (the chromosome-6 encoded dystrophin related protein 
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Figure 1.2 
Dystrophin isoforms and related proteins 
figure adapted from Winder, 1997) 
A Dystrophin Isoforms 
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Dystrophin structure and isoforms: 
Translated products of the dystrophin gene. 
Dp = dystrophin protein with number which denotes kDa. 
Different shaped regions depict different domains. ABS= actin binding sites, WA! = WA! 
domain, EF= EF hands, ZZ= ZZ zinc finger domain, DCC = predicted coiled-coil domain. 
Utrophin and isoforms: Utrophin is shorter than dystrophin by 2 triple helical coiled 
coil repeats. 
DRP2: dystrophin related protein 2. 
Dystrobrevin (87kDa acetylcholine receptor associated protein) 
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(DRP) (Love et al., 1989)), dystrobrevin (Blake et al., 1996) and DRP2 
(Roberts et al., 1996). 
Both utrophin and dystrophin share considerable sequence, domain and 
functional homology with the cytoskeletal proteins spectrin and cc-actinin, 
and together they form a broad family (Koenig et al., 1988). All members 
of this family share an actin-binding domain, triple-helical coiled-coil 
repeat units and regulatory/ membrane binding region. The homology 
between dystrophin and utrophin extends over their entire length, 
although utrophin is shorter by two triple helical coiled-coil repeats 
(Tinsley et al., 1992). In non-muscle cells and at the neuromuscular 
junction (NMJ) of muscle cells, utrophin associates with a complex 
similar to the DAPC which has been termed the utrophin-associated 
protein complex (UAPC) (James et al., 1996). 
Whereas full length dystrophin isoforms (Dp427) are expressed 
predominantly in muscle, utrophin has a ubiquitous expression pattern 
(Tinsley et al., 1992). During fetal muscle development, utrophin is 
expressed before dystrophin. It is localised to the sarcolemma and 
neuromuscular junctions (NMJ) until dystrophin is expressed and 
replaces utrophin at the sarcolemma, thus leaving utrophin localisation 
only at the NMJ (Clerk et al., 1993). NMJ5 are highly developed structures 
which ensure communication between the central nervous system and 
contracting muscle fibres. Both dystrophin and utrophin are concentrated 
at the NMJ, dystrophin in the depths (crypts) and utrophin in the crests 
and upper parts of the postsynaptic folds of the muscle fibre membrane. 
Knockout mice studies have shown that utrophin is essential for the 
development of fully functional NMJs (Deconinck et al., 1997; Grady et al., 
1997a), whereas neuromuscular transmission is normal in dystrophin-
minus muscle and morphological alterations in the NMJ are slight 
(reviewed in Sealock & Froehner, 1997). 
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In DMD affected muscle, utrophin is overexpressed and appears to 
colonise the dystrophin-free space in mdx mice (Pons et al., 1994) 
suggesting that utrophin could be upregulated in dystrophic tissue as a 
possible therapy for DMD/BMD sufferers (Tinsley & Davies, 1993). 
Utrophin has been found to functionally replace dystrophin in the mdx 
mouse (Bulfield et al., 1984; Tinsley et al., 1998) and alleviates the problem 
of the immune response elicited by dystrophin. For this reason, studies of 
utrophin as well as dystrophin have been in the forefront of research into 
understanding and generating cures for DMD. Additionally, utrophin's 
ubiquitous expression makes it more accessible to biochemical analysis 
than dystrophin, particularly because dystrophin has such a low 
abundance (Hoffman et al., 1987) 
1.2.2. Dystrophin -primary structure. 
Dystrophin has several predicted functional domains in its protein 
structure (figure 1.1). There is an N-terminal actin binding domain 
(reviewed in (Winder et al., 1997)) and a large spectrin-like triple-helical 
coiled-coil domain which comprises over 70%  of the protein (Koenig et 
al., 1988). Towards the C-terminal end of the protein, there is a cysteine-
rich region which contains a WW domain (Bork & Sudol, 1994; Andre & 
Springael, 1994), a pair of EF-hands (Tufty & Kretsinger, 1975), and ZZ zinc 
finger domain (Ponting et al., 1996). At the most C-terminal domain there 
are two a helices which are predicted to form dimeric coiled-coils (Blake et 
al., 1995). 
1.2.3. Actin-binding properties of dystrophin 
The amino-terminal 246 amino-acids of dystrophin have strong sequence 
similarity with the actin-binding domains of several well characterised F-
actin cross-linking proteins (Koenig et al., 1988) and dystrophin has been 
shown to bind F-actin in a large number of studies (reviewed in Winder 
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et al., 1997) 
Dystrophin and utrophin are grouped into the calponin homology (CH) 
domain family (reviewed in Stradal et al., 1998). This nomenclature is 
based on a 100 amino-acid sequence motif originally identified in a 
muscle regulatory protein, calponin (Castresana & Saraste, 1995). 
Dystrophin and utrophin have two pairs of CH domains, each pair 
comprising a CHI domain and a CH2 domain in tandem. CHI domains 
have an intrinsic ability to bind actin and the CH2 domain contributes to 
the overall stability of the interaction. Additionally, dystrophin and 
utrophin have three actin-binding sites at their N-termini (ABS-1, ABS-2, 
ABS-3) (Winder et al., 1995). Experiments involving NMR, biochemical 
techniques using mutated residues/ regions of dystrophin/utrophin, and 
proteolytic cleavage experiments have shown that the highly conserved 
ABS-1 and ABS-2 are contained within a CHI domain and ABS-3 in a 
CH2 domain. 
Interestingly, it has been shown that ABS1-3 bind non-muscle actin 
(platelet 13-cytoplasmic actin) with an approximately four fold higher 
affinity than they bind muscle actin (skeletal muscle (x-actin) (Winder et 
al., 1995). This suggests that dystrophin is primarily associated with the 
cortical network of cytoplasmic f3-actin rather than the contractile 
apparatus of muscle a-actin. Biochemical analysis of dystrophin actin-
binding sites has revealed that they act as an intracellular anchor, playing 
no role in regulating actin re-organisation in the cell, just binding the F-
actin cytoskeleton (Winder et al., 1997). 
1.2.4. The central rod domain of dystrophin 
The central coiled-coil region of dystrophin comprises approximately 
300kDa of the protein. This region is made up of 24 triple-helical coiled-
coil repeats. The number of repeats varies between the members of the 
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dystrophin/spectrin family. In dystrophin, five regions in the central 
helical domain have been defined as "hinges" separating the coiled-coil 
repeats, and it has been suggested that they confer flexibility to the 
molecule (Koenig & Kunkel, 1990). 
Another function of the rod domain may involve its actin-binding 
properties. Native dystrophin binds F-actin with a higher affinity than the 
isolated N-terminal actin binding domain. This supports the idea of rod 
domain involvement in actin-binding (Rybakova et al., 1996). It has been 
shown that the DAPC can bind actin with a stoichiometry of 1 dystrophin: 
24 actin monomers. If these 24 actin monomers were arranged in a single 
strand of a filament, dystrophin could be binding actin along more than 
half its length. Furthermore, another ABS has been found within repeats 
12-16 of the central coiled-coil domain (ABS4) (Rybakova et al., 1996) and 
yet another within repeat 18 (ABS5) (Winder, 1997). The ABS4/actin 
association is facilitated by electrostatic interactions between a cluster of 
basic repeats in ABS4 (whose delineation has been expanded to repeats 11-
17) and the acidic actin filament (Amann et al., 1998). Therefore, the 
dystrophin-actin interaction appears to be complex and multifaceted. 
The importance of the N-terminus and rod domain of dystrophin is 
demonstrated by the failure of the dystrophin isoform Dp71 (figure 1.2) to 
correct the dystrophic phenotype. Dp71 comprises only the cysteine-rich 
and C-terminal domains of dystrophin and can restore the localisation of 
dystrophin-associated proteins to the cell membrane (Cox et al., 1994; 
Greenberg et al., 1994), but this is not sufficient to restore complete 
function. This strongly suggests that the N-terminus and rod domain are 
required for normal dystrophin function in skeletal muscle. 
However, a transgenic mdx mouse expressing a dystrophin construct 
lacking amino-acids 45-273 had a benign phenotype (Corrado et al., 1996). 
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Most mutations in the N-terminus of dystrophin lead to a severe BMD 
phenotype rather than a DMD phenotype. It is not clear whether the DMD 
patients which do have N-terminal defects or deletions have severe 
phenotypes because there is an important functional domain missing, or 
merely because an unstable truncated dystrophin protein is expressed. 
Nevertheless, these seemingly conflicting results can be rationalised if the 
dystrophin:actin interaction occurs over a number of low affinity sites 
dispersed over the length of dystrophin's N-terminal domains and the 
rod domain. This redundancy illustrates why the N-terminus and rod 
domain are required, but no individual sequences in these regions appear 
to be essential for normal dystrophin function. It also explains why the 
whole dystrophin molecule binds actin at a higher affinity than 
individual ABS domains (Way et al., 1992). 
1.2.5. C-terminal domains of dystrophin 
From a functional perspective, the carboxy-terminal domains of 
dystrophin are clearly the most important. Mutations in these domains 
have been found to cause the severest symptoms of muscular dystrophy 
(for review see (Amalfitano et al., 1997). The importance of the carboxy-
terminal regions is primarily because they associate with a group of 
membrane-associated proteins and glycoproteins called the dystrophin-
associated protein complex (DAPC). 
The domains in the C-terminal region of dystrophin include the WW, EF 
hand and ZZ domains which are involved in dystrophin's interaction 13-
dystroglycan, a transmembrane protein of the DAPC (discussed more fully 
in section 1.6.1). WW domains are protein:protein interaction domains 
which interact with proline-rich motifs in their ligands (see section 1.6.2). 
EF hand domains typically bind calcium (Tufty & Kretsinger, 1975) but it is 
a contentious issue whether dystrophin's two EF hand domains bind 
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calcium or not (Ervasti & Campbell, 1993; Koenig et al., 1988; Milner et al., 
1992). However, it appears unlikely due to the lack of several crucial 
liganding residues. Nevertheless, it is still not possible to predict whether 
the EF hands in dystrophin play a structural or regulatory role (reviewed 
in Winder et al., 1997). 
The ZZ domain consists of two pairs of conserved cysteine residues which 
are predicted to form a zinc finger involved in protein:protein 
interactions (Ponting et al., 1996). The ZZ domain has been shown to 
improve the dystrophin-3-dystroglycan interaction and mediates 
dystrophin binding to calmodulin (Anderson et al., 1996; Vignano et al., 
2000). Calmodulin is the major regulator of calcium-dependent kinases 
(see section 1.9.3.2). The functional relevance of the dystrophin-
calmodulin interaction is not established, but it appears that the binding 
of calmodulin and 3-dystroglycan to dystrophin are mutally exclusive 
(Vignano et al., 2000). 
The final structures at the carboxyl terminal end of dystrophin are a pair 
of highly conserved helices, predicted to form parallel dimers (Blake et al., 
1995). Syntrophin, an intracellular protein of the DAPC binds to 
dystrophin near the N-terminal end of helix 1 (Suzuki et al., 1994), and 
dystrophin interacts with dystrobrevin via coiled-coil interactions 
(Sadoulet-Puccio et al., 1997). 
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1.3. The dystrophin-associated protein complex 
The DAPC includes a- and f3-dystroglycan, a-, f3-, y-, and 6- sarcoglycans, a 
syntrophin triplet, dystrobrevin and sarcospan (figure 1.3). Proteins of the 
DAPC are greatly reduced in dystrophic tissue presumably because they 
are no longer stabilised by dystrophin (Ervasti et al., 1990). The tight 
association of the proteins of the DAPC has been demonstrated by co-
purification from rabbit muscle membranes, co-sedimentation in sucrose 
density centrifugation, immunoprecipitation, co-localisation to the 
sarcolemma and protein crosslinking experiments (Ervasti et al., 1990; 
Campbell & Kahl, 1989; Yoshida & Ozawa, 1990; reviewed in Campbell, 
1995). 
Dystrophin associates with the DAPC via its C-terminal interaction with 
the transmembrane glycoprotein 13-dystroglycan (Suzuki et al., 1992). a-
dystroglycan is an extracellular glycoprotein which binds to merosin, the 
muscle isoform of laminin, thus linking dystrophin to the ECM 
(Ibraghimov-Beskrovnaya et al., 1992). 
The functions and the interactions of the dystrophin and DAPC proteins 
are not clearly defined. They are however, crucial in maintaining muscle 
cell integrity, as demonstrated by the severe defects when they are 
disrupted (Ervasti et al., 1990). The C-terminal portion of dystrophin and 
therefore its interactions with other components of the DAPC, are 
particularly important for its function. This is demonstrated by deletions 
in this region give which rise to a severe dystrophic phenotype in which 
the DAPC fails to form (Koenig et al., 1989), (Roberts et al., 1992). 
However, not only mutations in the DMD locus cause muscular 
dystrophy - mutations in the sarcoglycans also cause distinct diseases 
called limb girdle muscular dystrophies (LGMD) (reviewed in Bushby, 
1999). 
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Figure 1.3 
The dystrophin-associated protein complex (DAPC) 
The DAPC includes a- and 3-dystroglycan (100-200kDa, 43kDa), a-, 3-, y-, and - 
sarcoglycans (50, 43, 35, 35kDa), a syntrophin triplet (59kDa), dystrobrevin (87kDa) (N- and 
C-termini marked) and sarcospan (25kDa). Dystrophin (grey) (N- and C-termini marked) 
associates with the DAPC via its C-terminal interaction with the transmembrane glycoprotein 
3-dystroglycan (red). a-dystroglycan (red) is an extracellular glycoprotein which binds to 
merosin (not shown), the muscle isoform of laminin, thus linking dystrophin to the ECM. 
Dystrophin interacts with the actin cytoskeleton (yellow) via actin binding domains in its N-
terminus and rod domain. Dystrobrevin and the c-terminus of dystrophin interact via their 
coiled-coil domains. Both proteins have a syntrophin-binding domain (syntrophin is shown in 
magenta) upstream from their first coiled-coil. The sarcoglycans are transmembrane proteins 
(green) which form a tight complex which also includes sarcospan (grey) which has multiple 
membrane spanning domains. Dystrobrevin is thought to associate with the sarcoglycan-
sarcospan complex at its N-terminus, and there is evidence to suggest that o-sarcoglycan lies 
in close proximity to the dystroglycan complex. Additional protein:protein interactions 
between DAPC proteins and proteins outside of the DAPC are not shown i.e. dystrobrevin 
and syntrophins associate with nNOS, a-dystroglycan interacts with the extracellular proteins 
laminin, perlecan and agrin. -dystroglycan interacts with Grb2, rapsyn and caveolin-3. 
Animal models have been useful in attempts to dissect the functions of 
the individual DAPC components. Mice null for each of the DAPC 
proteins have been generated over the last few years (reviewed in 
Allamand & Campbell, 2000) and will be discussed in the context of the 
individual DAPC proteins below. 
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1.4. The Dystroglycans 
The dystroglycan gene encodes both u.-dystroglycan and 13-dystroglycan as a 
single transcript which is post translationally cleaved into the two 
individual proteins (Ibraghimov-Beskrovnaya et al., 1992), see figure 1.4. 
Both the proteins are heavily glycosylated and widely expressed (reviewed 
in Durbeej et al., 1998). 
The importance of the dystroglycans is demonstrated by the gene 
knockout in mice which leads to embryonic lethality at day 6.5 due to 
structural and functional perturbations of the Reichert's membrane 
(Williamson et al., 1997). The Reichert's membrane is one of the earliest 
basement membranes to form in the rodent embryo. Embryonic stem cells 
deficient for dystroglycans also have a defect in early basement membrane 
synthesis due to the lack of laminin recruitment to basal sites which leads 
to a disruption in collagen V and perlecan organisation in the basement 
membrane (Henry & Campbell, 1998). It is not clear whether the role of 
dystroglycan in the formation of basement membranes is primarily 
structural or it is also involved in mediating signalling events. 
Antibody perturbation experiments have also suggested that dystroglycan 
might be involved in kidney epithelial morphogenesis and salivary gland 
morphogenesis (reviewed in (Durbeej et al., 1998)). The use of inhibitory 
antibodies to block the dystroglycan/laminin interaction in primary 
muscle cell cultures leads to myotubes of reduced size which lack 
spontaneous contractile activity, and myofibril disorganisation. These 
findings implicate the dystroglycans in a signalling pathway important for 
skeletal muscle maturation and maintenance, possibly involving laminin 
(Brown et al., 1999). 
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Figure 1.4 	- 
Processing of the dystroglycan propeptide 
(lbraghimov-Beskrovnaya et al. 1992) 
cx/3-dystrogIycan propeptide 
















100-200 kDa 	 TIC 
mature 3-dystroglycan 
43 kDa 
The dystroglycan gene encodes both a- and 3-dystroglycan as a single 895 amino-acid 
polypeptide which is post-translationally cleaved and glycosylated. This propeptide has a 
signal sequence (SS), mucin-like region (ML) and transmembrane domain (TM) and is 
cleaved by an unknown protease at residue 653 (F) to yield a- and -dystroglycan. The 
mature dystroglycans are glycosylated (over 50% of their mass comprises carbohydrate 
moieties). a-dystroglycan is a dumbbell shape as predicted by electron microscopy, - 
dystroglycan is shown inserted into the lipid bilayer. 
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In order to elucidate more about the role of dystroglycans in muscle, 
chimeric mice were generated with skeletal muscle essentially devoid of 
dystroglycan (Cote et al., 1999). Interestingly, in muscle cells of these mice, 
the composition and structure of their basement membrane appeared 
normal, suggesting that dystroglycan is not required for the development 
of the basement membrane in skeletal muscle. The chimeric mice lacking 
dystroglycan developed muscular dystrophy and infact, resemble the 
severely affected dystrophin/utrophin double knockout mouse (Grady et 
al., 1997b), although dystroglycan deficient muscle has more severely 
disrupted neuromuscular synapses. Presumably there is a residual 
amount of dystroglycan in the dystrophin/utrophin double knockout 
which facilitates the partial function of the NMJs. The study by Cote et cii. 
(1999) also showed that the dystroglycan complex is necessary for 
localisation of dystrophin and the sarcoglycan complex at the sarcolemma. 
Therefore, it can be concluded from this research that the dystroglycan 
complex is essential for the maintenance of the integrity of the 
sarcolemma and the development and/or stability of NMJs, and its 
absence leads to muscular dystrophy. 
No clinical effects of dystroglycan mutations have been identified, 
presumably because the consequences are too profound for survival. 
However, a deficiency of 3-dystroglycan has been noted in one patient 
(Salih et al., 1996). The normal expression of a-dystroglycan suggests there 
was either a mutation in the 13-dystroglycan coding region or a primary 
mutation in another protein which affects the stability of 3-dystroglycan. 
In addition, the correct localisation of all the DAPC components apart 
from 3-dystroglycan in this case, suggests that dystrophin has another 
anchoring site, possibly in the sarcoglycan complex. 
The dystrophin-dystroglycan and utrophin-dystroglycan complexes can be 
thought of cell adhesion structures, linking the ECM to the actin 
cytoskeleton, and anchoring cells to the ECM. Dystroglycan has been 
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shown to serve as a cell adhesion receptor in primary endothelial cell 
cultures (Shimizu et al., 1999). The phenotype of the dystroglycan-null 
mouse definitively demonstrates that dystroglycan is essential for the 
formation of the Reichert's basement membrane (Williamson et al., 1997). 
It is also well established that dystroglycan is required for the clustering of 
agrin, laminin and perlecan on the surface of skeletal muscle cells 
(reviewed in Henry & Campbell, 1999). The 13-dystroglycan-dystrophin 
interaction is well characterised, but it is becoming clear that 13-
dystroglycan has other roles because it has been shown to interact with 
other proteins, such as Grb2, caveolin-3 and rapsyn (section 1.6.4), 
although the exact function of these interactions has yet to be established. 
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1.5. c-dystrog1ycan 
a-dystroglycan is a 100-200kDa widely expressed peripheral membrane 
protein which links to the ECM via several ligands. Therefore, it 
comprises the extracellular component of the DAPC and provides the 
main linkage of the DAPC to the basement membrane. It binds the ECM 
proteins laminin, perlecan and agrin which interact with carbohydrate 
groups on a-dystroglycan. In muscle, o-dystroglycan interacts with the 
laminin-2 (merosin) which is a muscle specific isoform of laminin. 
Defects in laminin-2 expression cause congenital muscular dystrophy 
(CMD) (Hillaire et al., 1994) and there is a reduction in laminin-2 
expression in a number of other muscular dystrophies (Hayashi et al., 
1993). 
Dystrophin and utrophin are concentrated at the NMJ and it has been 
demonstrated that o-dystroglycan binds the NMJ protein agrin. Agrin is a 
basement membrane-associated proteoglycan which induces the 
formation of postsynaptic specialisations at the NMJ. One of the earliest 
events of postsynaptic differentiation involves agrin-induced clustering 
of acetylcholine receptors (AChRs) at nerve-muscle contacts (Nitkin et al., 
1987). When it was identified that agrin bound a-dystroglycan, it was 
thought that a-dystroglycan was the signal-transducing agrin receptor, 
thus facilitating synapse formation (Gee et al., 1994). However, further 
investigation suggests that a-dystroglycan does not fulfil the criteria for an 
agrin-signalling receptor (Ruegg & Bixby, 1998). Firstly, a-dystroglycan 
binds to inactive muscle isoforms and active neuronal isoforms of agrin 
with a similar affinity (Sugiyama et al., 1994) whereas a receptor for agrin 
would be expected to bind the nerve isoform (which induces postsynaptic 
specialisations) exclusively or with a much higher affinity than any other 
isoform. Additionally, two research groups have demonstrated that the 
blocking of agrin-dystroglycan binding in vitro has no affect on agrin-
induced acetylcholine receptor clustering (Sugiyama et al., 1994; 
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Campanelli et al., 1994). The physiological role of a-dystroglycan in 
synapse formation is now unclear but it may function more as a 
structural, rather than signalling component of postsynaptic apparatus 
assembly (reviewed in (Ruegg & Bixby, 1998)), as shown by the disruption 
of NMJs in chimeric mice with muscles devoid of dystroglycan (Cote et 
al., 1999). 
Additionally, perlecan is implicated in acetyicholinesterase (AChE) 
clustering at the NMJ (Peng et al., 1999). Like agrin, perlecan is a heparan 
sulphate proteoglycan which resides on the surface of muscle cells and 
therefore is a likely candidate to localise AChE to the cell surface. The 
dystroglycan complex which mediates a transmembrane linkage between 
the ECM and the cytoskeleton could easily be part of the machinery for the 
sequestration and clustering of AChE and other ECM components in 
skeletal muscle during synaptogenesis. Perlecan and the laminins have 
an overlapping binding site on c-dystroglycan which raises the possibility 
of competitive interactions, but the biological significance of this is 
unclear. It is possible that different glycosylation patterns of (X-dystroglycan 
could specify different ligand affinities (reviewed in Henry & Campbell, 
1999). 
oc-dystroglycan has also recently been identified as a receptor for human 
pathogens including Mycobacterium leprae and several types of 
arenaviruses (Rambukkana et al., 1998; Cao et al., 1998). oc-dystroglycan is 
therefore an important mediator of microbial pathogenesis and could be a 
useful target for therapeutic intervention. 
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1.6. 3-dystrog1ycan 
3-dystroglycan is a 43kDa glycoprotein with a N-terminal transmembrane 
domain and an unstructured C-terminal cytoplasmic tail. 3-dystroglycan is 
considered to form the essential link between dystrophin and the rest of 
the DAPC. 3-dystroglycan also binds other members of the dystrophin 
family, namely utrophin, Dp71 and Dp260 (Jung et al., 1995). 
1.6.1. The f3-dystroglycan -dystrophin interaction 
It has been shown previously that the complete cysteine-rich region of 
dystrophin (later shown to contain the WW, EF hand and ZZ domains) is 
required for the binding of 3-dystroglycan and this binding affinity is 
strengthened by the C-terminal domain (Suzuki et al., 1994). The proline-
rich cytoplasmic tail of 3-dystroglycan contains two potential W W 
domain-interacting motifs, namely PPEY (commencing at residue 828) 
and PPPY (commencing at residue 889). The dystrophin binding site was 
subsequently localised to a 15-20 amino-acid proline-rich region at the 
extreme C-terminus of 3-dystroglycan (amino-acids 876/881-895) by 
peptide-binding studies and fusion protein puildown assays (Jung et al., 
1995; Rosa et al., 1996). This region is necessary and sufficient for binding 
to dystrophin and the PPPY motif is now well characterised as a W W 
domain binding motif (see figure 1.5). 
Rentschler et cii. (1999) have now shown that this WW-domain mediated 
interaction, is necessary, but not sufficient for binding of dystrophin to 3-
dystroglycan. The interaction also requires the adjacent EF-hand regions 
(Rentschler et al., 1999). This requirement is explained by the crystal 
structure of the dystrophin WW domain/EF-hand region complexed to a 
f3-dystroglycan peptide, which shows that the two EF-hand regions form a 
composite surface which is required for dystrophin to bind to the PPxY 
motif in f3-dystroglycan (Huang et al., 2000). 
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Figure 1.5 
The dystrophin--dystrogIycan interaction 
3-dystrogIycan 
In muscle cells, the C-terminus of dystrophin interacts with the cytoplasmic domain of - 
dystroglycan via its WW, EF-hand and ZZ domains. The WW domain of dystrophin binds to a 
PPxY motif in the proline rich region of 3-dystroglycan. The WW domain is necessary but not 
sufficient for the binding of dystrophin to 3-dystroglycan. The interaction also requires the 
adjacent EF-hand region. In addition, the ZZ domain appears to stabilize the interaction. 
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The EF hand region stabilises the fold of the WW domain and provides 
additional specificity for the recognition of 13-dystroglycan. Therefore, both 
WW and the EF hands are rquired to stabilise and orientate the 
unstructured C-terminus of 3-dystroglycan. This characteristic of the 
dystrophin WW domain, i.e. necessary but not sufficient for the 
interaction with its ligand, is unique amongst WW-domain mediated 
interactions 
It is unclear whether the ZZ domains are essential for the dystrophin-13- 
dystroglycan interaction or not. Phage display analysis suggest that the 
UAPC cannot be formed if the ZZ domain is deleted from the c-terminus 
of utrophin (Vignano et al., 2000). However, peptide assays suggest that 
the ZZ domain is not essential, but appears to significantly stabilise the 
dystrophin-3-dystroglycan interaction (Rentschler et al., 1999). 
1.6.2. WW domains 
WW domains and their interaction with 13-dystroglycan are the best 
characterised of dystrophin's C-terminal domains. WW domains are the 
smallest of all domains, comprising only 38-40 amino-acids and are 
involved in protein:protein interactions, mediated by proline-rich 
sequences in their ligands. They occur in single or multiple copies and are 
distributed in all species from yeasts and plants to mammals. W W 
domains were originally identified as highly conserved regions during 
sequence searches, independently by Bork and Sudol (1994) and Andre 
and Springael (1994). They derived their name WW due to two highly 
conserved tryptophan residues (single letter code W) spaced 20-22 amino-
acids apart in the semi-conserved region of the 38-40 amino-acid domain 
(Bork & Sudol, 1994; Andre & Springael, 1994). Further studies have 
revealed that these conserved tryptophans are essential for the structure 
and function of the domain (reviewed in Sudol & Hunter, 2000). 
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Other features of WW domains are the presence of aromatic amino-acids 
between the two tryptophans, and the presence of a proline at position +2 
in relation to the second tryptophan. 
Similarly to other domains such as SH2, SH3 and PH domains, the W W 
domain is present in many different organisms and in a diverse range of 
proteins with seemingly unrelated functions, now reaching a total of 200. 
In addition to utrophin and dystrophin, these include the adapter protein 
Yes-associated protein (YAP), nuclear proteins such as the formin binding 
proteins (FBPs) and ubiquitin ligases such as Nedd4. Despite this diversity 
of proteins, a large proportion have a shared involvement in regulatory 
or signalling processes. Proteins which contain WW domains have been 
found to participate in cellular processes such as ubiquitin-mediated 
protein degradation, viral budding, RNA splicing, transcriptional 
activation and mitotic regulation (Bedford et al., 2000). In addition to 
Duchenne muscular dystrophy, proteins involved in diseases such as 
Altzheimer's disease, Huntington's disease (Huntingtin interacting 
proteins) and Liddle's syndrome (amiloride-sensitive epithelial Na+ 
channel subunits) also contain WW domains (Kay et al., 2000). 
1.6.3. WW domain ligands and regulation 
WW domains are often compared to 5H3 domains due to their shared 
affinity for proline-rich ligands. Although the two domains resemble each 
other functionally, their structures are quite distinct. The different 3-
dimensional structure of their ligand binding surfaces rules out direct 
competition. All WW domains so far characterised bind to a variety of 
short proline-containing motifs (summarised in table 1.1). 
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Table 1.1. 
Classification of WW domains based on optimal ligand 
specificity 
Class Motif WW domains Reference 
I PPXY Dystrophin Rentschler et al. 
Nedd4 WW-3 (99) 
YAP65 Chen&Sudol (95) 
II PPLP FBP11 Bedford et al.(97) 
FE65 Ermevoka et 
al.(97) 
ifi PPR FBP30 
FBP21 Bedford et cil.(OO) 
FE65 
IV (pS/pI) P Pini Lu et al. (99) 
Nedd4 WW-2  
The first WW domain-binding motif identified was named PY due to 
conserved prolines and a tyrosine in its sequence. This was originally 
characterised by Chen and Sudol (1995) who carried out a functional 
screen of a cDNA expression library and identified two ligands of the WW 
domain of Yes associated protein YAP65 (Chen & Sudol, 1995). They 
discovered a PPPPY motif in both ligands (WBP-1 and WBP-2) which the 
WW domain bound to. Site-directed mutagenesis showed that the second 
and third proline plus the tyrosine residue are essential for these ligands 
to bind YAP65 (PPPPY). Therefore the core consensus for WW ligands was 
denoted as PPXY, and termed PY. The WW domains in dystrophin and 
ubiquitin ligase Nedd4 also recognise the PPXY binding motif in their 
ligands. 
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On discovering that the WW binding motif contained a tyrosine residue, 
it was hypothesised that the WW/PY interaction could be regulated by 
tyrosine phosphorylation (Pirozzi et al., 1997) in a manner analagous to 
the regulation of SH3 domain interactions when the ligand contains a 
tyrosine within the PxxP SH3-binding motif. Subsequently it has been 
shown biochemically that phosphorylation of the tyrosine residue in the 
PY motif disrupts its interaction with WW domains in its binding 
partner. These interactions include YAP65 and its ligand (Chen et al., 
1997), and utrophin with 13-dystroglycan (James et al., 2000). 
As more WW-binding proteins were found, variations in the PY motif 
were revealed. In fact, four distinct binding motifs are now defined as 
WW domain-binding (table 1.1). The PPLP motif was found during a 
screen for binding partners of the WW domain in FBP11 (Bedford et al., 
1997), and subsequently the neural adapter protein FE65 was also found to 
bind a PPLP motif in its ligands (Ermekova et al., 1997). Another formin 
binding protein FBP21 (a spliceosome-associated protein) was originally 
thought to bind a proline, glycine and methionine-rich motif (Bedford et 
al., 1998). This PGM motif was defined as another specific class of proline-
rich WW domain ligands. However, further analysis of binding 
experiments revealed a PPR or RPP motif in all the fusion peptides 
examined, and FBP21 was re-designated into class III of WW domain-
containing proteins. (Bedford et al., 2000). Drawing on further studies, 
Bedford's group also place FE65 into class III of WW-containing proteins 
stating that FE65 binds the Pro-Arg motif more strongly than PPLP 
(Bedford et al., 2000). FE65 does bind PPLP but a substitution of Arg or Lys 
for the Leu increases the affinity (Ermekova et al., 1997) which may 
suggest a dual specificity interaction. 
The mitotic prolyl isomerase Pini and WW domain 2 of ubiquitin ligase 
Nedd4 in the fourth class of WW domains interact with their target 
proteins in a phosphorylation-dependent manner (Lu et al., 1999; 
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Ranganathan et al., 1997). These proteins only recognise their ligands 
when a serine or threonine in the binding motif is phosphorylated. 
The binding of classes I and IV WW domains to their ligands has been 
definitively shown to be regulated by phosphorylation within the binding 
motif. However, there is also evidence of regulation by phosphorylation 
of serines and threonines flanking the PPxY motif (Kay et al., 2000), 
although this hypothesis has not been tested on the other classes of 
motifs. 
1.6.4. Interactions of 3-dystrog1ycan with other proteins 
13-dystroglycan has an unstructured cytoplasmic tail which has multiple 
binding sites for interactions with other proteins. More specifically, 3-
dystroglycan has two potential WW domain-binding motifs and several 
potential SH3 domain-binding motifs, providing a high possibility that 13-
dystroglycan interacts with signalling molecules. 
1.6.4.1.Grb2 
3-dystroglycan has been shown to interact with growth factor receptor 
hinding protein 2 (Grb2) via its SH3 domain binding site (Yang et al., 
1995). Grb2 functions as an adaptor protein through its SH2 and SH3 
domains and is involved in signal transduction pathways and cytoskeletal 
organisation ((Lowenstein et al., 1992), reviewed in (Chardin et al., 1995)). 
Grb2 links receptor tyrosine kinases to GTP-binding protein signalling. 
Ras, Rac and Rho are small GTP-binding proteins which are involved in 
cytoskeletal organisation such as stress fibre formation at focal adhesions 
and ruffle induction. The dystroglycan complex may regulate cellular 
functions through Grb2, where signal transduction could be triggered by 
the extracellular matrix. 
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The Grb2/ 13-dystroglycan interaction is mediated through f3-dystroglycan 
proline-rich domains and Grb2 SH3 domains (Yang et al., 1995). The 
interaction may be important for linking 13-dystroglycan and the DAPC 
into signalling pathways, for example, the transduction of signals between 
the extracellular matrix and the cytoskeleton leading to cytoskeletal re-
organisation. There are few clues as to what these signalling pathways 
may be because binding partners for the 3-dystroglycan/Grb2 complex 
have remained elusive. However, in a recent study, a complex containing 
Grb2, focal adhesion kinase (FAK) and dystroglycan was isolated from 
bovine brain synaptosomes by laminin chromatography (Cavaldesi et al., 
1999). It is not clear whether FAK and dystroglycan are connected through 
Grb2 (possibly through SH2- and SH3-mediated interactions) but this 
finding does implicate 13-dystroglycan in focal adhesion signalling 
pathways. 
1.6.4.2. Caveolin-3 
Caveolins are integral membrane proteins which comprise the principle 
protein component of caveolae, which are vesicular invaginations of the 
plasma membrane. The caveolin family consists of caveolins 1, 2 and 3. 13-
dystroglycan has been recently shown to interact with the muscle-specific 
form, caveolin-3 (Sotgia et al., 2000). Caveolins are scaffolding proteins 
which are thought to be structurally involved in the formation of the 
caveolae membranes by facilitating the assembly of signalling complexes 
(Okamoto et al., 1998). Caveolins have been shown to interact with 
signalling proteins such as heterotrimeric C-proteins, Ha-Ras, Src family 
tyrosine kinases and endothelial nitric oxide synthase (eNOS) and have 
been termed as "molecular velcro" holding these proteins in complexes 
(reviewed in Okamoto et al., 1998). 
Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle 
dystrophy (Minetti et al., 1998), but paradoxically, an upregulation of 
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caveolin-3 protein expression leads to a Duchenne muscular dystrophy 
phenotype (Galbiati et al., 2000). In DMD-affected muscle, the caveolae 
increase in size and there is a significant structural change which may be 
indicative of muscle regeneration. This increase in density of the caveolae 
is matched by an upregulation of caveolin-3 expression both in DMD 
patients and the mdx mouse (Vaghy et al., 1998; Repetto et al., 1999). 
Along with this upregulation of caveolin-3 in transgenic mice, a 
downregulation of dystrophin and 13-dystroglycan is observed (Galbiati et 
al., 2000). The 13-dystroglycan-caveolin-3 interaction is mediated by a WW-
like domain. Caveolin-3 and dystrophin share exactly the same binding 
motif in 13-dystroglycan. Infact, caveolin-3 has been shown to compete 
with dystrophin so that it can no longer bind 13-dystroglycan (Sotgia et al., 
2000). Therefore, if caveolin-3 is upregulated in DMD, the dystrophin/0-
dystroglycan interaction may be compromised, thus contributing to the 
degradation of the DAPC. Interestingly, caveolin-3 interacts directly with 
nNOS (Venema et al., 1997). The correct localisation of nNOS to the 
membrane is lost in DMD muscle which may be due to the changes in 
expression levels of caveolin-3. 
Caveolin-3 was thought to be the 25kDa unidentified dystrophin-
associated protein until sarcospan was identified. However, it is possible 
that both sarcospan and caveolin-3 are part of the DAPC and their 
visualisation as part of the complex depends on the extraction conditions 
used. Whether caveolin-3 is part of the DAPC or just transiently 
associated with it, its ability to recruit signalling proteins is an exciting 
prospect for signal transduction in the DAPC. 
1.6.4.3. Rapsyn 
Dystroglycans have been shown to co-localise with rapsyn and AChRs in a 
heterologous system (Apel et al., 1995) and in situ (Cartaud et al., 1998). 
Further investigation has identified a rapsyn binding site corresponding 
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to amino-acids 787-819 of the cytoplasmic domain of 3-dystrog1ycan 
(Cartaud et at., 1998). 
Rapsyn is a NMJ protein which has a central role in clustering of 
acetylcholine receptors (AChR) at the postsynaptic membrane and 
organising many other protein components of the post-synaptic 
apparatus. It is thought to faciliate the association between AChRs and 
utrophin and 3-dystroglycan (Fuhrer et at., 1999). This is demonstrated in 
a rapsyn -/- knockout cell line whereby AChRs no longer associate with 
the UAPC. It is not clear what role the 3-dystroglycan/rapsyn/AChRs 
association has, but because -dystroglycan is also bound to utrophin at 
the NMJ, the utrophin-cytoskeleton link may be the main structural 
framework for anchoring AChR macroclusters at the developing NMJ. 
These multiple links between AChRs and the UAPC would allow their 
maximum stabilisation. 
cx-dystroglycan has also been linked with AChRs i.e. it has been shown to 
interact with agrin and laminin which are both involved in AChR 
clustering (section 1.5). Agrin induces tyrosine phosphorylation of the 
AChR 13-subunit and it is thought that rapsyn is downstream of agrin 
because in rapsyn -I- knockout cells AChRs are not efficiently 
phosphorylated (Fuhrer et al., 1999). a-dystroglycan may have a direct role 




1.7. Other DAPC proteins 
1.7.1. Syntrophins 
Syntrophins are 58-6OkDa intracellular dystrophin-associated proteins 
which were originally identified as proteins enriched at the postsynaptic 
apparatus of the Torpedo electric organ (Cartaud et al., 1993; Froehner et 
al., 1987). Syntrophins are a family of multi-domain proteins which are 
likely to function as modular adapter proteins involved in recruiting 
signalling proteins to the DAPC. The domain structure of syntrophins 
includes two pleckstrin homology (PH) domains, a PDZ domain and a 
syntrophin-unique (SU) domain (Adams et al., 1995). To date, neuronal 
nitric oxide synthase (nNOS), voltage gated sodium channels (VGSCs), 
stress-activated protein kinase-3 (SAPK3) (-a member of the MAPK 
family) and microtubule-associated serine/threonine kinase have been 
identified as interactors of the syntrophin PDZ domain (Brenman et al., 
1996; Gee et al., 1998; Lumeng et al. 1999; Schultz et al., 1998; Hasegawa et 
al., 1999). 
Dystrophin has a syntrophin binding site near the N-terminal end of a-
helix 1 (amino-acids 3447-3481) (Jung et al., 1995). Dystrophin and 
dystrobrevin associate via coiled-coil interactions in their C-terminal 
domains and between them recruit two syntrophin molecules via their 
SU domains (Ahn et al., 1996; Sadoulet-Puccio et al., 1997). However 
recent evidence suggests that there are 2 syntrophin binding sites on each 
of dystrobrevin and dystrophin which could potentially facilitate the 
recruitment of four syntrophin molecules per DAPC (Newey et al., 2000). 
There are three syntrophin isoforms ((A, 131 and 132) which are encoded by 
separate genes but have the same domain structure (Ahn et al., 1996). al-
syntrophin is predominantly expressed in skeletal and cardiac muscle 
whereas 131- and 02-syntrophin are more widely expressed. In muscle, 
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there is a distribution of al- and 131-syntrophin at the sarcolemma and 
NMJ5 although 31-syntrophin is confined to fast twitch fibres. 132-
syntrophin is restricted to the NMJ. (Peters et al., 1997). In DMD, 
localisation of cd- and 131-syntrophin at the sarcolemma is lost but 132-
syntrophin remains present at the NMJ. 
Disruption of the al-syntrophin gene does not cause a myopathy despite 
reduced levels of a-dystrobrevin-2 (Adams et al., 2000). This suggests that 
syntrophin is not a major player in causing muscular dystrophies, or 
alternatively, that other syntrophin isoforms compensate for the lack of 
al-syntrophin. However, it is evident that al-syntrophin plays an 
important role in synapse formation. The neuromuscular junctions of 
the al-syntrophin null mice are disorganised with undetectable levels of 
utrophin and reduced levels of acetylcholine receptors and 
acetyicholinesterase (Adams et al., 2000). 
1.7.2. Dystrobrevin 
Dystrobrevin is a dystrophin-related protein (figure 1.2) and a dystrophin-
associated protein i.e. it is homologous to, and interacts with, the C-
terminus of dystrophin. It was originally identified as a 87kDa 
postsynaptic membrane protein associating with syntrophin in the 
Torpedo electric organ, and is a substrate for tyrosine kinases (Wagner et 
al., 1993). 
Dystrobrevin and dystrophin interact via their two C-terminal coiled-coil 
domains (Sadoulet-Puccio et al., 1997). Both proteins have a syntrophin-
binding domain upstream from their first coiled-coil domain. 
There are two dystrobrevin genes which encode a- and 13-dystrobrevin. 
Only a-dystrobrevin is expressed in muscle and it is alternatively spliced. 
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al—dystrobrevin and u.2—dystrobrevin have a widespread expression 
pattern. In muscle they are localised primarily at the NMJ and 
sarcolemma, respectively. 0—dystrobrevin lacks domains which interact 
with syntrophin and dystrobrevin and its expression is restricted to 
muscle (Nawrotski et al., 1998). 
In recent studies, transgenic mice were generated expressing dystrophins 
with C-terminal deletions. It was found that if the dystrobrevin and 
syntrophin binding sites are removed from dystrophin, the DAPC is still 
correctly formed (Crawford et al., 2000). This suggests that dystrobrevin 
and/or syntrophin have additional binding sites to the DAPC and there is 
now biochemical evidence to show that the N-terminal half of 
dystrobrevin associates with the sarcoglycan-sarcospan complex (Yoshida 
et al., 2000). 
Mice deficient in x-dystrobrevin have no defects in sarcolemmal structure 
or depletion of other DAPC components, but still have a muscular 
dystrophy phenotype, with defects in NO-mediated signalling, thus 
implicating cL-dystrobrevin in the signalling functions of the DAPC (Grady 
et al., 1999). The fact that nNOS is missing from the sarcolemma despite 
the presence of syntrophins, suggests that syntrophin is not sufficient to 
localise nNOS to the sarcolemma. It is becoming clear that both 
dystrobrevin and syntrophin are involved in nNOS localisation (Grady et 
al., 1999). 
1.7.3. Sarcoglycans 
and '-sarcoglycans are transmembrane proteins of the DAPC and 
are restricted to muscle except 13-sarcoglycan which is expressed at low 
levels in other tissues. Together the sarcoglycans form an independent 
subcomplex within the DAPC and a mutation in one sarcoglycan gene 
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destabilises the whole sarcoglycan complex (Yoshida et al., 1994). 
Little is known about the functional or structural role of sarcoglycans but 
their importance is demonstrated by mutations in their genes which give 
rise to limb-girdle muscular dystrophies (Mizuno et al., 1994). This 
suggests that, like dystroglycan, they are involved in membrane-matrix 
interactions. Evidence to support this theory is growing. For example, the 
merosin composition of muscle fibre basal lamina is altered in patients 
lacking a-sarcoglycan (Higuchi et al., 1994; Yamada et al., 1995). Yoshida et 
al. (1998) reported that the treatment of cultured muscle cells with 
antisense oligonucleo tides to a-sarcoglycan inhibits their adhesion to 
substrata (Yoshida et al., 1996) and went on to demonstrate that 
bidirectional signalling between sarcoglycans and the integrin adhesion 
system occurs in cultured myocytes (Yoshida et al., 1998). From these 
findings, one hypothesis is that the sarcoglycans and dystroglycans 
mediate interactions of muscle cells with the basal lamina, which is 
crucial for membrane integrity (Ettinger et al., 1997). 
It has been suggested that the sarcoglycan complex stabilises dystroglycan 
interactions and thus strengthens the membrane-protecting system. This 
is demonstrated by the destabilisation of dystroglycan interactions in the 
skeletal muscle of sarcoglycan-deficient animal models, leading to 
impaired localisation of a-dystroglycan to the sarcolemma (Roberds et al., 
1993; Holt et al., 1998) and an unstable DAPC in 13-sarcoglycan deficient 
mice (Araishi et al., 1999). How the sarcoglycans might stabilise 
dystroglycan binding interactions is not known but there is evidence to 
suggest that -sarcoglycan lies in close proximity with the dystroglycan 
complex (Chan et al., 1998). 
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1.7.4. Sarcospan 
The 25kDa protein sarcospan co-localises and co-purifies with the DAPC 
therefore demonstrating that it is an integral member of the DAPC. 
Additionally, it has dramatically reduced expression in muscle from 
patients with DMD suggesting that the localisation of sarcospan to the 
membrane is dependent on proper dystrophin expression. Sarcospan has 
been shown to interact tightly with the sarcoglycans, thus forming the 
sarcoglycan-sarcospan complex (Crosbie et al., 1999). Consequently, 
sarcospan is also depleted in LGMD where the sarcoglycan complex is 
lacking. 
Sarcospan has multiple sarcolemmal spanning domains and is a member 
of the tetraspanin superfamily (Crosbie et al., 1997). Each member 
possesses four transmembrane domains and a large extracellular loop, 
and they are thought to play important roles in mediating 
transmembrane protein interactions (Maecker et al., 1997). In addition, 
these transmembrane domains hold sarcospan firmly within the lipid 
bilayer and thus could provide a solid anchorage for the DAPC as a whole. 
However, sarcospan-deficient mice have no muscle abnormalities 
histologically which suggests that sarcospan is not required for normal 
functioning of the DAPC or is compensated for by another protein 
(Lebakken et al., 2000). 
Members of the tetraspanin family are known to interact with integrins 
(Hemler et al., 1996). Sarcospan has not been shown to interact with 
integrins as yet but it is an exciting prospect which could link the DAPC to 
focal adhesions and possibly shed more light on the signalling between 
integrins and sarcoglycans. 
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1.8. Redundancy within the DAPC 
The redundancy of the DAPC is highlighted by the different isoforms of 
proteins which are available to make up the DAPC. Not only can 13-
dystroglycan associate with dystrophin, utrophin, but also the 
alternatively spliced transcripts of dystrophin. 
s-sarcoglycan has a high homology to a-sarcoglycan (44% amino-acid 
identity) but is more widely expressed (McNally et al., 1998; Ettinger et al., 
1997) and can take the place of a-sarcoglycan in the sarcoglycan complex. 
A second syntrophin-binding site has recently been identified in both 
dystrophin and dystrobrevin, upstream from the first, in a region which 
can be alternatively spliced (Newey et al., 2000). Therefore, it appears that 
there is a mechanism to confer flexibility to the DAPC by altering the 
number of syntrophin binding sites. This increases the potential for 
specialised signalling complexes in different locations and stages of 
development. 
Syntrophin isoforms share only 50% identity which suggests that each 
isoform could recruit different signalling proteins to the DAPC (Peters et 
al., 1997). Moreover, two further brain specific isoforms of syntrophins 
have been found which increases the number of differential associations 
in the DAPC even further (Piluso et al., 2000). Differential association of 
dystrophin with certain syntrophin isoforms may play a role in tailoring 
the DAPC for a particular membrane specialisation in different tissues. 
This redundancy of the DAPC components provides a variety of ways that 
the complex could be assembled and regulated pairings with different 
signalling capabilities could be produced in different tissue types. 
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1.9. Regulation of the DAPC by phosphorylation 
The spatial organisation of dystrophin and the DAPC suggests that their 
role is mainly concerned with stabilisation of the sarcolemma of muscle 
fibres. However, there is evidence which also implicates the complex in 
the transduction of extracellular signals which may be involved in the 
modulation of protein:protein interactions and regulation of cytoskeletal 
organisation. 
Dystrophin and the DAPC have 	been 	implicated in 	transducing 
intracellular signals for the following reasons: they colocalise 	at the 
membrane and could easily transduce signals from the ECM to the 
cytoskeleton, they have been linked to various signalling molecules, and 
there is evidence of direct phosphorylation of dystrophin and the DAPC 
components. 
1.9.1. Evidence of phosphorylation of dystrophin 
Inspection of the amino-acid sequence of the dystrophin molecule 
indicates that it contains a number of consensus sites for phosphorylation 
by different protein kinases. These include cAMP/cGMP-dependent 
kinases, protein kinase C (PKC), casein kinase II, p34 2 kinase and MAP 
Kinase (Luise et al., 1993; Milner et al., 1993; Shemanko et al., 1995). This 
suggests that dystrophin may be a target for multi-site phosphorylation. 
Dystrophin has been shown to be phosphorylated in vitro and in vivo by 
several types of protein kinases (table 1.2). Experiments have been carried 
out in vivo on cultured skeletal muscle cells (Milner et al., 1993), isolated 
sarcolemmal vesicles (Luise et al., 1993; Milner et al., 1993; Madhavan & 
Jarrett, 1994; Shemanko et al., 1995; Walsh et al., 1995), the isolated DAPC 
(Madhavan and Jarrett, 1994) and muscle cell extract (Shemanko et al., 
1995). 
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Table 1.2. 
Summary of studies demonstrating phosphorylation of 
dystrophin and the DAPC. 
Phosphoprotein Residues Enzymes implicated Reference 
(amino-acid region) phosphory lated 
Dystrophin serine, threonine endogenous Luise et al. (1993) 
cAMP/cGMP-dep in 	vitro 
kinases 
CaM kinase II 
Casein kinase II 
Protein kinase C 
Dystrophin serine, threonine p34 2  Milner et al. (1993) 
(3485-3685) in vitro 
Dystrophin serine "DAPC protein Madhavan & Jarrett 
(2618-3074) kinase" (1994) 
175kDa CaM kinase II 
59kDa 
5OkDa 
Dystrophin serine, threonine PKA, PKC, CK-II Senter et al. (1995) 
Dystrophin threonine MAP kinase p42/p44 Shernanko et al. 
(3485-3685) (1995) 
Dystrophin serine, threonine CK II Walsh et al. (1995) 
(3485-3685) (dephosphorylated 
by calcineurin) 
Dystrophin serine, tyrosine endogenous kinases Wagner et al. (1993) 
Dystrobrevin Wagner & Huganir 
syntrophin (1994) 
a-sarcoglycan tyrosine Src-family? Yoshida et al. (1998) 
y-sarcoglycan 
3-dystroglycan tyrosine ? James et al. (2000) 
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The DAPC has "endogenous protein kinase activity" i.e. when purified 
DAPC preparations are made from skeletal muscle, there is co-purifying 
protein kinase activity (Luise et al., 1993; Madhavan & Jarrett, 1994). Since 
the purification of the DAPC involves isolation of a sarcolemma-enriched 
microsome fraction, solubilising in detergent, affinity chromatography on 
a lectin agarose and finally ion-exchange chromatography, it seems 
unlikely that a protein kinase would co-purify with the DAPC unless it 
had some specific association with one or more constituents of the DAPC 
(Madhavan & Jarrett, 1994). A high affinity of the kinase for its substrates 
could explain the co-isolation. 
1.9.2. Evidence of phosphorylation of DAPC proteins 
Whilst incubating purified DAPC preparation with Mg2+ and [y-32p]  ATP, 
Madhavan and Jarrett (1994) found that not only was dystrophin 
phosphorylated but also proteins of 175 kDa, 59kDa and 50kDa which they 
tentatively identified as an unknown DAPC-associated protein, 
syntrophin and a-sarcoglycan respectively. However, they were cautious 
because CaM kinase II subunits are also 59kDa and 50kDa (Madhavan & 
Jarrett, 1994). 
In another in vitro study using the DAPC and its co-purifying protein 
kinase activity only, in addition to dystrophin, there were phosphorylated 
proteins in the 40-60 kDa range which were immunoprecipitated with the 
dystrophin antibody. These were thought to be components of the DAPC 
(13-dystroglycan, sarcoglycans and syntrophins all fall into this molecular 
weight range) or more conservatively, proteolytic products of dystrophin 
(Senter et al., 1995). 
Two-dimensional gel electrophoresis of the DAPC indicated that the 
syntrophins, a-sarcoglycan and 13-dystroglycan could be phosphorylated 
(Yamamoto et al., 1993). Silver staining of the 2D gels revealed many 
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more spots than were expected from the results of one-dimensional SDS-
PAGE, some of which disappeared after alkaline phosphatase treatment. 
It has been demonstrated that x— and y-sarcoglycans are tyrosine 
phosphoryated in response to cell adhesion (Yoshida et al., 1998) and 
dystrobrevin was initially identified as a tyrosine phosphorylated protein 
associated with dystrophin and syntrophin in the Torpedo electric organ 
(Wagner et al., 1993). To date, the kinases responsible for these tyrosine 
phosphorylation events have not been identified. 
1.9.3. Links to signalling molecules 
The DAPC has been linked to many signalling proteins, such as Grb2 
(section 1.6.4.1), calmodulin and nitric oxide (NO). In addition, the 
syntrophins recruit a wide variety of signalling molecules via their PDZ 
domains (section 1.7.1). 
1.9.3.1. Nitric oxide 
NO is major endothelial-derived relaxing factor in the body. It is a short-
lived free radical, therefore the regulation of signalling occurs largely at 
the level of NO biosynthesis i.e. via NO synthase (NOS). NO may 
function as a vasodilator in muscle, thus controlling blood flow so that 
the muscle gets more oxygen whilst it is contracting. nNOS is absent from 
the sarcolemma in DMD (Brenman et al., 1995) and it is suggested that the 
membrane localisation of nNOS is necessary to regulate blood flow to the 
muscle during exercise and DMD pathogenesis is exacerbated if blood flow 
is not high enough (Sander et al., 2000). 
nNOS is tethered to the sarcolemma (in healthy muscle) via its PDZ 
domain interacting with the PDZ domain in al-syntrophin, but its 
localisation also appears to depend on a-dystrobrevin (Grady et al., 1999) 
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and may involve its association with caveolin-3 (Venema et al., 1997). It 
has been demonstrated by the dystrobrevin null mouse and the al-
syntrophin-null mouse that reduced association of nNOS with the DAPC 
does not itself contribute significantly to the dystrophic process. Both null 
mice lack nNOS localisation to the sarcolemma but only the dystrobrevin 
null mouse has a dystrophic phenotype (Grady et al., 1999; Kameya et al., 
1999). 
Activation of nNOS is poorly understood but requires 
calcium/ calmodulin (section 1.9.4.2) and nNOS homodimerisation (Klatt 
et al., 1994). In the model proposed by Peters et cii. (1997), the close pairing 
of syntrophin to dystrophin and dystrobrevin could facilitate activation of 
nNOS by localising it to the sarcolemma and spatially assisting 
dimerisation (Peters et al., 1997). 
1.9.3.2. Calmodulin 
Dystrophin and the DAPC have also been associated with calmodulin, a 
ubiquitous intracellular Ca 2' receptor. Calmodulin mediates many Ca2 -
dependent processes, for example, the regulation of calcium-dependent 
kinases which phosphorylate serine and threonine residues in target 
proteins. A high affinity calmodulin binding site has been described in 
dystrophin (between residues 3293 and 3349) and it has been demonstrated 
that the ZZ domain in both dystrophin and utrophin mediates binding to 
calmodulin (Anderson et al., 1996; Vignano et al., 2000). In addition, there 
are two low affinity calmodulin-binding sites in the N-terminus of 
dystrophin and utrophin (Jarrett & Foster, 1995); Campanelli et al., 1994; 
Winder & Kendrick-Jones, 1995). Syntrophin also has calmodulin binding 
sites, one in the PH domain and the other in the PDZ domain. Therefore, 
it is possible that calmodulin modulates the binding of syntrophins to 
signalling modules e.g. nNOS, which bind to the PDZ domain 
(Madhavan et al., 1992; Iwata et al., 1998). 
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The precise function of calmodulin in the DAPC is unknown but the 
interaction of calmodulin with the ZZ domain of dystrophin inhibits the 
dystrophin-13-dystroglycan interaction (Vignano et al., 2000) and Ca2 -
calmodulin antagonises syntrophin binding to dystrophin in vitro 
(Newbell et al., 1997). Conflictingly, calmodulin has been shown to inhibit 
the actin-dystrophin interaction in some assays (Jarrett & Foster, 1995; 
Campanelli et al., 1994), but not in others (Bonet-Kerrache et al., 1994; 
Winder & Kendrick-Jones, 1995). 
1.9.4. Does the disruption of a-dystrobrevin cause signalling 
defects? 
Further evidence to support the role of the DAPC in signal transduction 
was brought about by disrupting the a-dystrobrevin gene in mice (Grady et 
al., 1999). The pathology of the a-dystrobrevin knockout mouse resembles 
that of the mdx mouse with a dystrophic phenotype developing within 
one month of age. Interestingly, the mice have very few structurally 
damaged muscle fibres and the structural components of the DAPC and 
the integrity of the sarcolemma is intact. This lack of structural 
abnormalities suggests that it is a disruption of signalling events which 
causes the phenotype. nNOS is absent from the sarcolemma in these 
mice. This signalling molecule is known to associate with dystrobrevin, 
but there are possibly more. 
1.9.5. Functional consequences of phosphorylation of the DAPC 
The DAPC clearly has associated kinase activity and there is evidence of 
the phosphorylation of dystrophin and a- and y-sarcoglycans, and 
potentially, 13-dystroglycan and syntrophin are phosphorylated. The 
association of DAPC proteins with signalling molecules such as nNOS, 
calmodulin and Grb2 also implicate the DAPC in the functioning of 
signalling pathways. Despite these extensive studies gathering evidence 
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for the phosphorylation of dystrophin and the DAPC, and attempts to 
identify the kinases involved, we are are still no further forward in 
elucidating the functional consequences of these phosphorylation events. 
It is possible that phosphorylation events could purely modulate 
protein:protein interactions within the DAPC, controlling the assembly, 
disassembly and general maintenance of the DAPC. 
In addition, phosphorylation events could modulate interactions between 
the DAPC and proteins which associate with it. For example, 
phosphorylation of dystrophin could modulate its interaction with actin. 
Senter et cii. (1995) demonstrated that the phosphorylation of the rod 
region and residues near to dystrophin's ABS 1-3 had affects on 
dystrophin binding to actin. In addition, phosphorylation of dystrophin by 
PKA caused a 3-fold increase in actin binding, and phosphorylation by 
CKII and PKC inhibited actin binding (Senter et al., 1995). 
There is also the possibility that the DAPC is involved in the 
transduction of signals from the ECM to the cytoskeleton. This idea is 
reinforced by the findings that various signalling molecules associate with 
the DAPC (section 1.9.4). One putative role of dystrophin and the DAPC in 
transducing signals maybe the control of cytoskeletal organisation via 
links with the Ras/Rac/Rho signalling pathways. Evidence for this 
includes 13-dystroglycan associating with Grb2 (Yang et al., 1995), and with 
activated MAPK in non-muscle cells (M. James & S.J. Winder, 
unpublished results). In the study by Yoshida et cii. (1998), a- and y-
sarcoglycans were tyrosine-phosphorylated in response to cell adhesion to 
the ECM (via integrins). The DAPC was also shown to have a role in 
recruitment of proteins to focal adhesions (Yoshida et al., 1998) which 
strengthens the idea that phosphorylation events in the DAPC could be 
involved in cell adhesion by way of the assembly and disassembly of focal 
contacts. 
47 
Interactions in the DAPC regulated by phosphorylation 
1.10. Aims and objectives 
Dystrophin and the DAPC play a critical role in protecting muscle cells 
from damage, as shown by the devastating consequences when one or 
more of the component proteins are absent. Despite extensive research, 
the functions and the interactions of the dystrophin and DAPC proteins 
are still not clearly defined. However, it is becoming increasingly evident 
that the DAPC does not simply play a structural role, but is a dynamic 
complex involved in signalling pathways. 
The organisation of the DAPC is becoming clearer but still little is known 
about the regulation of the interactions within the DAPC. It is known that 
13-dystroglycan directly associates with dystrophin, as does syntrophin and 
dystrobrevin. It has recently come to light that dystrobrevin associates 
with the sarcoglycan-sarcospan complex and it is suggested that the 
sarcoglycan-sarcospan complex also stabilises dystroglycan localisation and 
dystroglycan interactions. But if components of the DAPC are involved in 
phosphorylation events, how does this phosphorylation affect the 
protein:protein interactions within the complex? To date, this question 
has not been adequately addressed. 
The initial aims of this study were to identify and characterise 
phosphorylation events in the DAPC with the aim of elucidating their 
effect on the interactions within the DAPC, the prospect being that this 
information would broaden the wealth of knowledge about the 
organisation of the DAPC. In principle, this information could help to 
identify the likely functions of the DAPC and their role in muscular 
dystrophy pathogenesis. 
During the course of this study, a phosphorylation event was identified 
namely, the tyrosine phosphorylation of 13-dystroglycan (chapter 5). The 
exact role of 13-dystroglycan is ill-defined but is thought to be crucial in 
10. 
Chapter 1 Introduction 
linking dystrophin to the membrane-spanning components of the DAPC. 
The phosphorylation of 13-dystroglycan was found to disrupt its 
interaction with dystrophin, thus demonstrating that at least one of the 
interactions within the DAPC is regulated by phosphorylation. 
In order to shed light upon the functions of f3-dystroglycan and its role in 
signal transduction, extensive studies were carried out to identify novel 
binding partners of 13-dystroglycan. Both protein biochemistry techniques 
(chapter 3) and yeast two-hybrid assays (chapter 4) were used. It was 
discovered that 3-dystroglycan binds to F-actin, and unlike dystrophin, has 
F-actin-bundling activity. This raises exciting possibilities for the role of 13-
dystroglycan and the DAPC in regulation of the cytoskeleton. 
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Materials and Methods 
2.1. Bacterial methods. 
2.1.1. Bacterial strains and media 
Table 2.1 
Escherichia coli strains 
Strain Genotype Reference/ 
source 
JM109 e14 (McrA) recAl endAl gyrA96 tin-I Stratagene 
/isdrl 7(rK-mK-) supE44 relA I z2(lac-proA B) 
[F'traD36 proAB lacI1ZL.M151  
BL2I(DE3) B F- dcrn ompT hsdS(rB-mB-) gal(DE3) Stratagene 
MC1066 (lac1 POZYA) 74 galU galK strAt P. Legrain, 
leuB6trpC9830 pyrF74::Tn5(Knr)  hsdR Institut Pasteur 
JM1O9 cells cells were used for cloning, propagation of plasmid DNA and protein expression. 
BL21 (DE3) cells were used for protein expression. MCi 066 cells were used for the rescue 
of prey plasmids from yeast cells in two-hybrid screens (section 2.5.7.1). 
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LB 1% (w/v) Bacto-tryptone 
0.5% (w/v) Bacto-yeast extract 
0.5% (w/v) NaCl 
pH adjusted to 7.2 with 5 M NaOH 
2xTY 16gTryptone 
(pH 7.4) 10 g  Yeast extract 
5 g NaCl 
1 1 Distilled water 
M9 -L 0.1% (w/v) —L dropout powder 
10% (v/v) IN M9 salts 
0.2% (w/v) Glucose 
2 mM MgSO4 
0.2 mM CaC12 
pH adjusted to 6.5 with SM NaOH 
SOB 2% (w/v) Bacto-tryptone 
0.5% (w/v) Bacto-yeast extract 
10 mM NaCl 
lOniMMgSO4 
2.5 mM KC1 
10 mM M902 
SOC SOB medium 
20 mlvi Glucose 
* for solid media, 2% ((w/v)) agar was added prior to autoclaving. 
added after autoclaving. 
2.1.2. Growth of Bacteria 
E. coli strains were routinely grown at 37°C in LB medium or 2x TY (table 
2.2) for protein expression. To maintain selection for plasmid DNA, 
transformed bacteria were grown in medium containing ampicillin 
(100tg/m1). 
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2.1.3. Transformation of E. coli 
2.1.3.1. Preparation of Electro-competent Cells 
E. coil cells were taken from a frozen glycerol stock and grown overnight 
at 37°C on solid 2x TY medium (table 2.2). A single colony from this plate 
was used to inoculate lOml of 2x TY liquid medium and left to grow at 
37°C overnight. This culture was used to inoculate 500 ml of LB liquid 
medium to an QD600 of 0.1. The culture was incubated at 37°C until the 
0D600 was 0.5-0.7. At this time, the cells were placed on ice for 15 minutes. 
From this point, the cells were always kept on ice and all solutions and 
containers used were pre-chilled. The cells were subjected to 
centrifugation for 10 minutes at 5000 	The cells were gently 
resuspended in lOOmi sterile 10% (v/v) glycerol and centrifuged for 20 
minutes at 5000 xga ,. The cells were resuspended in 5m1 of 10% (v/v) 
glycerol and aliquoted into Eppendorf tubes on ice (lOOpi aliquots). Cells 
were then snap frozen on dry ice and stored at -70°C. 
2.1.3.2. Transformation of Electro-competent E. coli Cells 
50tl electro-competent cells (section 2.1.3.1) were thawed on ice, and 
mixed with the DNA to be transformed. Cells were then transferred to a 
pre-chilled electroporation cuvette (0.2cm electrode gap) on ice. 
Electroporation was performed using a Biorad Gene Pulser II set at 200 
ohms resistance, 25tF capacity and 2.5kV voltage. Immediately upon 
electroporation, lml of SOB medium (table 2.2) was added and the cells 
transferred to an Eppendorf tube. Cells were allowed to recover for 60 
minutes at 37°C in a shaking incubator. The cells were then spread onto 
solid medium (table 2.2) supplemented with ampicillin and incubated at 
37°C overnight. 
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2.2. Nucleic Acid Methods 
2.2.1. Plasmids and clones used in this work 
Table 2.3. 
Plasmids 
Plasmid Features Reference! Source 
pUC18 General cloning vector: LacZ' gene, LacI PharmaciaBiotech 
gene, multiple cloning site, pBR322 on, 
Amp' 
pcDNAII T7 promoter, Sp6 promoter, multiple Invitrogen 
cloning site, AmpR,F1  origin, LacZ gene 
pCEP4F Mammalian expression vector with EBNA Invitrogen 
(-EBNA) sequence removed. Multiple cloning site, modified by B. 
CMV and SV40 promoters, OriP, AmpR,  Christy 
Co1E1, TKpA. 
pCMV5 Mammalian expression vector: CMV Invitrogen 
promoter, multiple cloning site, SV40 on, 
fl ori, hGH, Amp',  
pSJW pBR322 with T7 insert, multiple cloning Winder et al. (1995) 
site, Amp' 
PinpointX-3a For expression of biotin tagged fusion Promega 
proteins: In vivo biotinylation tag, tac 
promoter, T7 promoter, multiple cloning 
site, Factor Xa protease recognition site, 
AmpR 
pGEX-5X-3 GST gene fusion vector: GST gene, tac PharmaciaBiotech 
promoter, Lac Iq  gene, Factor Xa protease 
recognition site, multiple cloning site, 
pBR322 on, AmpR 
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Plasmid Features Reference 
/source 
pAS2AA Ga14 DNA binding domain fusion shuttle Fromont-Racine et al., 
and expression vector: Multiple cloning (1997) 
site, Amp', colEl ori., PADHI,  Ga14 DNA 
binding domain sequence, ADHI 
transcriptional terminator, 211,  TRPI. 
Deletion of CYH2 by EcoRV partial digest 
and HA by EcoRI-NdeI digest. 
pACTII [stop] Ga14 activation domain fusion shuttle and Fromont-Racine et al., 
expression vector: Multiple cloning site, (1997) 
Amp', colEl on., PADHI,  Ga14 activation 
domain sequence, HA-epitope sequence, 
ADHI transcriptional terminator, 211, 
LEU2. 
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Table 2.4. 
Clones used in this work 
Clones Features Source/ Reference 
pAS2A-13-DG 3-dystroglycan cytoplasmic This work 
domain (a-a 781-895) cloned 
into NdeI/SalI sites of 
pAS2AA  
pcDNAII- mDG.clone2 part of the transmembrane D. Blake 
region of 3-dystroglycan and Dept. of Human 
entire cytoplasmic domain Anatomy amd 
including 3' untranslated Genetics, University of 
region (a-a 757-895) cloned Oxford. 
into EcoRI/BstXI sites of 
pcDNAII 
Pinpoint- 3-DG 13-dystroglycan cytoplasmic This work 
domain (a-a 775-895) cloned 
into HindIII/NotI sites of 
PinpointXa-3 vector 
pSJW-3-DG 3-dystroglycan cytoplasmic Ann Nuttall 
domain (a-a 781-895) cloned University of 
into NdeI/SalI sites of pSJW Edinburgh 
pSJW--3-DG 3-dystroglycan cytoplasmic Ann Nuttall 
domain (a-a 781-880) cloned University of 
into NdeI/SalI sites of pSJW Edinburgh 
Dystrophin mini-gene 6.4kb fragment of dystrophin J. Tinsley, MRC 
(bp 112-2200 & bp 7307- Harwell. 
12101) cloned into the SallI England et al. (1990) 
site of pUC18 
pCEP4F(-EBNA)-DYS Dystrophin WW-EF-ZZ This work 
domains (a-a 3055-3354) 
cloned into HindIII/NotI 
sites of pCEP4F(-EBNA) 
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Clones Features Source! Reference 
pCMV5-HA-DYS Dystrophin WW-EF-ZZ This work 
domains (a-a 3055-3354) 
cloned into KpnI/SrnaI sites 
of pCMV5-HA 
Pinpoint-DYS Dystrophin WW, EF and ZZ This work 
domains (a-a 3055-3354) 
cloned into HindIII/NotI 
sites of PinpointXa-3 vector 
pCMV5-HA-FHOS HA tag and the entire FHOS J. Westendorf. 
coding region cloned into Vanderbilt 
EcoRI/BarnHI sites of University, 
pCMV5 Nashville, USA. 
(Westendorf et al. 
(1999)) 
pCEP4F(-EBNA)-mJAB1 Coding region of full length B. Christy, University 
JAB1 cloned into of Texas Health 
Hindlil site of pCEP4F Science Center, San 
(-EBNA) Antonio, USA. 
pGEX5X-3-JAB1 Full length JAB1 cDNA E. Bianchi, Scientific 
cloned into EcoRI/Sinal sites Institute, San 
of pGEX5X-3 Raffaele-DIBIT, 
Milan, Italy. 
2.2.2. Preparation of Plasmid DNA 
2.2.2.1. Small Scale Preparation of Plasmid DNA by Spin Column 
Plasmid DNA was prepared using the QlAprep spin miniprep kit 
(Qiagen), following the manufacturers' guidelines. DNA was extracted 
from 3m1 of E. coil culture, resuspended in 50tl of distilled water and 
stored at -20°C. 
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2.2.2.2. Large Scale Preparation of Plasmid DNA from cDNA 
library amplification 
Library clones were scraped off LB-amp agar plates into LB-amp media 
(table 2.2). The resultant 600m1 of media was centrifuged at 4°C for 30mm 
at 5,000 xg to harvest the cells. The cell pellet was resuspended in 60m1 of 
GTE (50mM glucose, 25mM Iris pH8, 10mM EDTA pH8) plus RNase 
(10mg/mi). 120m1 of solution 11(0.2 M NaOH, 1% (w/v) SDS) was added 
and mixed gently. 200m1 of solution III (3M KOAc/2M glacial acetic acid) 
was added next. Cell debris and chromosomal DNA were peileted by 
centrifugation at 2,000 xg, for 10 minutes at 4°C. The supernatant was 
decanted to a fresh tube and incubated at 37°C for 30 min to allow RNase 
activity. An equal volume of phenol: chloroform: isoamyl alcohol (24:24:1) 
was added to the supernatant, mixed, and centrifuged at 2000 xg, for 10 
minutes. The aqueous layer was carefully removed and an equal volume 
isopropanol added to precipitate the plasmid DNA. The DNA was 
pelleted by centrifugation at 12,000 xg for 10 minutes at 4°C and the pellet 
was washed with 70% (v/v) ethanol and allowed to air dry. The dried 
pellet was fully resuspended in 5m1 of lx TE, pH8 (10mM Tris-HC1, pH 7.5, 
1mM EDTA) and stored at -20°C. 
2.2.3. Spectrophotometric Quantification of Nucleic Acids. 
The concentration of DNA or RNA was determined by measuring the 
absorption of diluted solutions at 260nm using a Cecil CE 2040 
spectrophotometer, and a quartz cuvette. For double-stranded DNA, an 
0D260 value of 1.0 represents a DNA concentration of approximately 
50mg/mi. 
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2.2.4. Restriction Digestion of DNA 
Restriction enzymes were purchased from Boehringer Mannheim or 
New England BioLabs. DNA was digested in volumes of 20-100jil. These 
contained the requisite quantity of DNA and the appropriate buffer (as 
supplied by the manufacturer) at lx concentration. Between one and five 
units of restriction enzyme per tg of DNA were added, with the 
restriction enzyme volume kept below lO%  of the total reaction volume. 
The digest was incubated at the recommended temperature, typically for a 
period of 2 hours. 
2.2.5. Amplification of DNA using the Polymerase Chain Reaction 
Specific regions of DNA were amplified using the polymerase chain 
reaction (PCR). A PCR reaction mix was set-up in an 0.5m1 Eppendorf tube 
as follows: 
Template DNA 
Oligonucleotide primer 1 
Oligonucleotide primer 2 
dNTPs (dATP, dCTP, dGTP, dTTP) 
MgC12 
lOx Polymerase buffer 
Taq polymerase 
Distilled water 






5 units per 100tl 
to 1OOt1 
All PCRs were carried out in a Biometra 13 thermocycler programmed 
according to the annealing temperature of the oligonucleotide primers 
used. A typical cycling program is shown below: 
25 cycles of: 
	
94°C for 30 seconds 
Td0C#  for 30 seconds. 
72°C for 1 minute. 
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#, Td°C is the temperature at which 50% of the primers are annealed to 
target sequence. It can be calculated by the equation: 4(G+C) + 2(A+T), for 
oligonucleotides below 20bp in length. The Td°C of the oligonucleotide 
with the lowest value is used as the annealing temperature in the 
thermal cycling. It is often necessary to use an annealing temperature a 
few degrees lower than the Td°C. 
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2.2.6. Oligonucleotides used in this work. 
Table 2.5 
Oligo. Function Sequence (5'-3') 
5' DYS/ Dystrophin ATAAAGCTTACGTCTGTCCAGGGTC 
BamH I WWEFZZ primer CGTGGGAG 
with HindIII site  
5' DYS/ Dystrophin ATAGGTACCACGTCTGTCCAGGGTC 
KpnI WWEFZZ primer CCTGGGAG 
with KpnI site  
3' DYS/ Dystrophin CCGCGGCCGCUAATAGTGCA1TFT 
NotI WWEFZZ primer ATGGCCTTT 
with NotI site  
3' DYS/ Dystrophin CCGCCCGCGTTAATAGTGCAIITIA 
SmaI WWEFZZ primer TGGCC1TF 
with Smal site  
5'P-DG 13-dystroglycan CGCAAGCTTTATCGCAAGAAGCGT 
/BamHI cytoplasmic domain AAGGGCAAG 
primer with 
HindlIT site  
3'P-DG/ 13-dystroglycan TAAGCGGCCGCTTAAGGTGGAACA 
NotI cytoplasmic domain TACGGAGGTGG 
primer with NotI 
site  
J0E17 pAS2A A AAGAAGCTTTCTAGAATGAAGCTA 
sequencing primer CTGTC1ITCT 
PinPoint PinPointXa-3 GCGGTCAGGGTCTCATCAAG 
Xa-3 seq sequencing primer 
Seq F pACTII forward GGCflACCCATACGATGTTC 
sequencing primer 
Seq R pACTII reverse TGAGATGGTGCACGATGC 
sequencing primer 
All oligonucleotides were purchased from Genosys Biotechnologies Ltd. (Cambridge). 
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2.2.7. Purification of PCR Products 
DNA fragments generated by PCR (section 2.2.5) were purified from 
oligonucleotide primers, unincorporated nucleotides, polymerases and 
salts using the QlAquick PCR purification kit (Qiagen), following the 
manufacturer's guidelines. Purified DNA was typically eluted in 30il of 
sterile, distilled water and stored at -20°C. 
2.2.8. Agarose gel electrophoresis 
Agarose gel electrophoresis of DNA fragments was typically performed 
with 1.5% (w/v) agarose gels. Gels were prepared by melting the 
appropriate amount of agarose in 0.5 x TBE buffer (0.045M Tris-borate, 
0.001M EDTA pH8) and adding ethidium bromide to a final concentration 
of 0.5jg/ml. Samples to be analysed were loaded directly using agarose gel 
loading buffer (0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol 
FF, 30% (w/v) glycerol) . The gel was placed in 0.5x TBE and typically run 
at bOy for 30 minutes. 1kb DNA ladder and lOObp DNA ladder (New 
England BioLabs) were used as size markers. 
2.2.9. Isolation of DNA from Agarose Gel Slices 
2.2.9.1. Isolation of DNA from Agarose Gel Slices by Spin 
Column 
DNA fragments were separated by agarose gel electrophoresis (section 
2.2.8) and the bands visualised on an UV transifluminator. The band to be 
purified was excised with a clean razor blade. DNA was isolated from 
agarose gel slices using the QlAquick gel extraction kit (Qiagen), following 
the manufacturer's guidelines. DNA was typically eluted in 30p1 of sterile, 
distilled water and stored at -20°C. 
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2.2.9.2. Isolation of DNA from Agarose Gel Slices by GeneClean 
kit 
DNA fragments were excised from agarose gels as above (section 2.2.9.1). 
The Geneclean III kit (BlO 101) was used to extract the DNA, following the 
manufacturers' protocol. The DNA was typically eluted in 20d of Elution 
solution (RNase/DNase/Pyrogen free water) and stored at -20°C. 
2.2.10. Ligation of DNA Molecules 
Ligation reactions were typically performed in a final volume of 10tl. The 
vector and insert were gel purified (section 2.2.9) and their concentration 
measured by their 0D260 (section 2.2.3). The amount of vector and insert to 
add to the ligation reaction was calculated using the following equations: 
pg insert 	=180 x 33.33 x iO x kb 
tg insert =60 x 33.33 x 10 x kb 
The reactions usually contained contained approximately bOng of vector 
DNA, the amount of insert DNA as calculated, lx T4 ligase buffer and 5 
units of T4 DNA ligase (Boehringer Mannheim). Reactions were 
incubated at 16°C for 16 hours and stopped by 15 minutes incubation at 
65°C. Control ligations were set up as above but without insert DNA. 
65 
Interactions in the DAPC regulated by phosphorylation 
2.2.11. DNA Sequencing by PCR-mediated Cycle Sequencing 
Plasmid DNA to be sequenced was prepared using the QlAprep spin 
columns (Section 2.2.7). 	Reactions 	were performed 	with the 
dRhodamine terminator cycle sequencing kit (Perkin Elmer) in a PTC-100 
Hot Lid reactor (MJ Research). A reaction mix was set-up as follows: 
0.5 jig of double-stranded DNA or 
180ng of PCR product 
3.2pmol 
8ji1 
make-up volume to 20jil 
Template DNA 
Primer 
Terminator reaction mix 
Distilled water 
Twenty-five cycles as described below were performed: 
Step 1: 
	
96°C for 30 seconds 
Step 2: 50°C for 15 seconds 
Step 3: 
	
60°C for 4 minutes 
DNA was precipitated from the reaction mix by adding 50jil of ethanol 
and 2ji1 of 3 M NaOAc, pH 5.2, incubating on ice for 10 minutes followed 
by centrifugation at 18,000 xg(fl, for 30 minutes. The pellet was washed with 
250jil of 70% (v/v) ethanol and dried under vacuum. Samples were run 
by Nicola Preston (University of Edinburgh) on an ABI PRISM 377 DNA 
sequencer and the sequence analysed using the Gene Jockey II program. 
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2.3. Cell culture 
2.3.1. Growth of cell lines 
C2/C4 (Yoshida et al., 1996) (a generous gift from Dr. Simon Hughes, 
King's College, London), C2/C12 (Yaffe & Saxel, 1977) (European 
Collection of Cell Cultures), and C2/C7 (a re-cloned C2/C12 cell line 
generously donated by Dr. M. Buckingham, Institute Pasteur, Paris, 
France) myoblasts were maintained in DMEM media (Gibco BRL) 
supplemented with 20% (v/v) foetal calf serum (Gibco BRL) in 5% CO2 
atmosphere at 37°C. Confluent cells were passaged using 1% (v/v) trypsin 
in 1mM EDTA/PBS and seeded at dilutions 1:4 -1:10. In order to induce 
differentiation, the amount of foetal calf serum in the growth media of 
confluent or semi-confluent myoblasts was reduced to 2% for up to 9 days. 
Myoblasts fused to form myotubes from day 4. 
2.3.2. Harvesting of cells in RIPA buffer 
Cells were washed once in cold phosphate buffered saline (50mM sodium 
phosphate pH 7.2, 150mM NaCl) before being harvested in ice cold radio-
immunoprecipitation assay (RIPA) buffer (50mM Tris-HC1, pH 7.5, 
150mM NaCl, 1mM ethylene glycol-bis-(13-aminoethyl ether) N,N,N',N'-
tetraacetic acid (EGTA), 1mM ethylenediaminetetra acetic acid (EDTA), 1% 
(v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 
1mM sodium orthovanadate, 100.xM leupeptin, 1mM 
phenylmethylsuiphonyl fluoride (PMSF), 100M N-tosyl-L-
phenylalanine chloromethyl ketone (TPCK). After harvesting, cells were 
briefly sonicated to shear the DNA, centrifuged (18,000 	20 mm) and 
stored at -20°C until required. 
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2.3.3. Alternative extraction conditions 
Alternative extraction buffers were tried to improve extraction of the 
DAPC, namely: 1% (w/v) Brij 98 (20 Oleyl ether), 1% (w/v) CHAPS, 1% 
(w/v) digitonin, 1% (v/v) Triton X-100, 1% (v/v) Triton X-100/ 0.1% 
(w/v) SDS, or 1% (v/v) Tween-20 in PBS pH 7.2, 2mM MgC12 plus 
protease inhibitors. When using these extraction buffers, the cells were 
incubated at 4°C for 1 hour in the buffers prior to harvesting. To make I% 
(w/v) digitonin, 10% (w/v) stock of digitonin was prepared, and 
solubilised by heating to 98°C for 15 minutes followed by incubation on ice 
for 2 hours. The solution was centrifuged to remove any unsolubilised 
solid, and the supernatant was used. 
2.3.4. Differentiation Timecourse 
Approximately 1 x106 cells per 20cm2 dish were seeded in DMEM media 
supplemented with 20% (v/v) foetal calf serum. After the cells reached 
50% confluency, the growth media was replaced with DMEM media 
supplemented with 2% (v/v) foetal calf serum. Dishes of cells were lysed 
in RIPA buffer at 24 hour intervals over the course of 9 days. Protein 
concentrations of the samples were measured using the BCA kit (section 
2.3.9). Equal amounts of protein were separated by SDS-PAGE, western 
blotted with dystrophin, utrophin and 13-dystroglycan antibodies (table 
2.6). 
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2.3.5. Peroxyvanadate treatment 
C2/C4 myotubes were treated with peroxyvanadate in order to inhibit the 
activity of tyrosine phosphatases (Volberg et al., 1992). The cells were 
washed with serum-free DMEM and then incubated at 37'C in 
peroxyvanadate (2mM H202, 1mM sodium orthovanadate in serum-free 
DMEM media). Initially, a timecourse of peroxyvanadate treatment was 
carried out, and then treatment for 45 minutes was carried out in all 
subsequent experiments. Control cells which were not treated with 
peroxyvanadate were incubated for an equivalent time in serum-free 
media. After treatment, the cells were harvested in RIPA buffer (section 
2.3.2). 
2.3.6. Calyculin A treatment 
C2/C4 myotubes were treated with 100mM calyculin A (Calbiochem) in 
order to inhibit the activity of type 1 and 2A serine/threonine 
phosphatases (Ishihara et al., 1989). The treatment was carried out in the 
same manner as peroxyvanadate treatment (section 2.3.5) but for 5 
minutes at room temperature. 
2.3.7. Replating of myoblasts onto ECM components. 
ECM components used were gelatin, laminin, and fibronectin (all 21g/ml 
solutions). The solutions were pipetted onto tissue culture dishes and 
incubated overnight at 4°C. The next day, the excess liquid was pipetted off 
before using the dishes. Cells were trypsinised, resuspended in DMEM 
supplemented with 20% (v/v) FCS and seeded onto ECM components or 
tissue culture plastic as a control, for 1, 2 or 4 hours at 37°C and 
subsequently lysed in RIPA buffer. 
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2.3.8.Transfection of C2/C4 myoblasts 
C2/C4 cells were grown to 70% confluency in 6-well tissue culture dishes 
for transfection experiments. DNA used included pCMV-HA and pCEP4-F 
vectors with FHOS, JAB1 or dystrophin WW-EF-ZZ domains as inserts 
(Table 2.5). 1-2g of DNA was added to lOOjil DMEM (solution A). 2-15d 
Lipofectamine reagent (GIBCO BRL) was added to lOOjil DMEM (solution 
B). Solutions A and B were gently mixed in a sterile Eppendorf tube and 
incubated at room temperature for 40 minutes. The C2/C4 cells were 
washed with serum-free DMEM. 0.8ml of DMEM was added to the 
DNA/Lipofectamine, and this mixture was gently pipetted into each well 
of washed C2/C4 cells. The transfection was allowed to take place over 6 
hours at 37°C in 5% CO2 atmosphere. Subsequently, 3m1 DMEM 
supplemented with 20% (v/v) FCS was added to each well of cells and 
they were placed at 37°C overnight. Cells were lysed in RIPA buffer 
(section 2.3.2) or other extraction buffers (section 2.3.3) 24 or 48 hours after 
the start of the transfection, and analysed by SDS-PAGE and western 
blotting (sections 2.4.4 & 2.4.6). 
2.3.9. Quantification of protein concentration 
The protein concentration in cell extracts was quantified using the BCA 
protein assay (Pierce) following the manufacturers' instructions. A series 
of bovine serum albumin (BSA) standards were prepared by diluting 
2mg/ml BSA in water to give a dilution series ranging from 20-2000pg/ml 
BSA. 2ml of BCA working reagent (WR) was added to each standard 
solution and incubated at 37°C for 30 minutes. The 0D562 of each sample 
was measured and the values used to plot a graph of BSA concentration 
versus 0D562. Protein samples of unknown concentration was treated in 
the same manner and the concentration was extrapolated from the 
standard plot. 
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Antibody - 	Directed against Dilutions Source/ 




MANDAG2* 13-dystroglycan (a-a 881- 1:500 G.E. Morris (NE Wales 
895) [1:10] Institute, Wrexham) 
(Helliwell et al. 1994) 
NCL-b-DG 3-dystrog1ycan 1:50 Dr. L.V.B Anderson 
15 a-a peptide of [1:5-1:10] (University of 
clone extreme C-terminus (a-a Newcastle) 
43DAG/8D5* 881-895) 
Poly 13-DG 3-dystrog1ycan 15 a-a - S.Winder (University of 
17100 peptide of extreme C- [1:10] Glasgow) 
terminus (a-a 881-895) 
NCLDYS1* Dystrophin mid rod 1:100 L. Anderson (University 
domain (a-a 1181-1388). [1:10] of Newcastle) 
Clone Dy4/6D3 
NCLDYS2* Dystrophin C-terminal 1:10 L. Anderson (University 
17 a-a (3669-3685). [1:10] of Newcast1e) 
Clone Dy8/6C5 
VIA4-2A3 Dystrophin C-terminus - Upstate Biotechnology 
& part of rod domain [1:25] 
XIXC2-D1 1 Dystrophin a-a 1415- - Upstate Biotechnology 
1494 (rod domain) [1:25] 
D. Blake (Dept. of 
a-dystrobrevin-1 1:1000 Human Anatomy amd 
Dystrobrevin C-terminus Genetics, University of 
Oxford). Blake et al. 
(1998) 
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Antibody Directed against Dilutions Source/ 
name for Reference 
western 
blotting 
and [IP]  
IVD3-1 a-sarcoglycan - Upstate Biotechnology 
[1:25] 
NCL-6-SC -sarcog1ycan clone 	- 1:500 Dr. L.V.B Anderson 
Sarc3/12C1 (University of 
Newcast1e) 
RAB5 Utrophin C-terminal 1:10000 S. Winder (Winder & 
coiled-coil domain Kendrick-Jones 1995) 
GRB2* Rat growth factor 1:5000 Transduction 
receptor 2 (C-terminus) Laboratories 
FAK* chicken focal adhesion 1:1000 Transduction 
kinase Laboratories 
MAPK Non phosphorylated 1:1000 New England BioLabs 
NEB91020 p42 and p44 MAP kinase 
Pa xillin* chick paxillin 1:10,000 Transduction 
Laboratories 
PY20* Anti-phosphotyrosine 1:1000 Transduction 
Laboratories 
RC20W Anti-phosphotyrosine 1:500 Transduction 
coupled to biotin Laboratories 
SHC 3 human SHC isoforms 1:1000 Transduction 
Laboratories 
v-Src (Ab1)*  5H3 domain of pp60 1:40 Oncogene Research 
Products 
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Antibody Directed against Dilutions Source/ 




Ta lin* chicken talin, clone 8d4 1:100 Sigma Aldrich 
Vinculin Human Vinculin 1:1000 Sigma Aldrich 
hVIN-1 clone 
HA HA tag 1:1000 Roche 
clone 3F10 [1:100]  
JAB1* Bacterially expressed 1:2000 E. Bianchi (Scientific 
full length JAB1. [1:100] Institute San Raffaele - 
Clone SP682 (subclone DIBIT, Milano, Italy) 
F3) (Bianchi et al, 2000) 
M2 Flag Tag 1:100 Sigma Aldrich 
[1:10]  
*mouse  monoclonal 
q rabbit polyclonal 
W recombinant 
§ antibodies commercially available from Novacastra Laboratories Ltd. 
P = immunoprecipitation 
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Extravidin Binds biotin HRP - 1:1000 
Anti-mouse IgG whole molecule HRP goat 1:1000 
Anti-rabbit IgG whole molecule HRP goat 1:1000 
Anti-mouse 1gM si-chain specific AP goat 1:10000 
Anti-rabbit IgG y-chain specific AP mouse 1:10000 
Anti-mouse IgG whole molecule AP goat 1:30000 
Anti-rat IgG whole molecule biotin sheep 1:333* 
all purchased from Sigma Aldrich except * (Vector Laboratories) 
HRP = horseradish peroxidase 
AP = alkaline phosphatase 
2.4.2. Immunoprecipitation assays. 
Cell extracts in RIPA (section 2.3.2) were initially cleared by incubation 
with protein A-Sepharose (Pharmacia) or protein G-Sepharose (Sigma 
Aldrich) for 1-2 hours at 4°C. The required amount of antibody (table 2.6) 
was added to the cleared extract and the cells were incubated overnight at 
4°C. In order to precipitate the antibody-protein complex, 50t1 of a 50% 
(v/v) slurry of protein A- or G- Sepharose was added per sample, and 
incubated for a further 1-2 hours at 4°C. The samples were centrifuged 
briefly to pellet the Sepharose beads, and the beads were washed 4 times 
with cold RIPA buffer followed by a wash in cold 0.6M LiC1. The final 
pellet was re-suspended in SDS-PAGE loading buffer. 
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2.4.3. Lambda phosphatase treatment 
Lambda phosphatase (Xppase) (New England BioLabs) was used to treat 
immunoprecipitates of 3-dystroglycan. A cocktail of 200 units Xppase, 1X 
Xppase buffer, 2mM MnC12  and H20 to 10tl was added directly to the 
washed protein A Sepharose beads. The 13-dystroglycan 
immunoprecipitates were treated at 30°C for 40 minutes. The reaction 
was stopped by boiling in SDS-PAGE loading buffer for 2 minutes. 
2.4.4. SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Large SDS-polyacrylamide gels (16cm x 20cm x 1mm) were run using the 
BlO-RAD Protean II vertical electrophoresis cell and mini-gels (10cm x 
10cm x 0.75/1mm) were run using Cambridge Electrophoresis mini-gel 
cells. The separating gels were 3%-15% or 7.5%-20% gradient gels with 3% 
or 5% stacking gels, respectively. The gels were made individually, or 10 at 
a time in a gel casting chamber. The separating gel solutions were 
prepared (see table 2.8), poured between two sealed plates using a gradient 
mixer and overlaid with water-saturated butanol. The gels were allowed 
to set at room temperature, the butanol was washed off with sterile, 
distilled water and the stacking gel was poured and comb put in place. 
After polymerisation was complete, the seal was removed from the plates, 
the comb was gently taken out and the wells were washed with distilled 
water. The gels were assembled in the appropriate electrophoresis 
apparatus and the chambers filled with lx SDS-PAGE running buffer 
(table 2.9). Protein samples were mixed with an equal volume of 2x SDS 
loading buffer (table 2.9), boiled for 2 minutes and loaded onto the gels. 
Pre-stained markers (size range 26.5-180 kDa) (Sigma-Aldrich) were loaded 
onto gels. Broad range molecular weight protein markers (size range 6.5-
175 kDa) (BlO-RAD) were additionally loaded on to gels to be stained. 
Mini-gels were typically run for 35-45 minutes at 400V and large gels for 
127.5mA/hours per gel. 
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Table 2.8 
Quantities of gel mixes for SDS-PAGE 
(a sinale 16cm x 20cm x 1 m aefl 











1.5m1 3.75m1 7.5ml lOmi imi 1.66m1 
Separating/ 
stacking 3.75m1 
gel buffer  
3.75m1 3.75m1 3.75m1 2.5m1 2.5m1 
50% (v/v) glycerol 0.84m1 0.84m1 1.68m1 1.68m1 - - 
Water 8.84m1 6.60m1 2.02m1 - 6.42ml 5.76m1 
TEMED 7.5jiJ 7.5p1 7.5jil 7.5jt1 20i1 20i1 
10% (w/v) APSW 60tl 60l 45p1 45tl 60tl 60fl 
Bromophenol blue 
+ + + + 
*30% (w/v) acrylamide/0.8% (w/v) bisacrylamide (Severn Biotech Ltd.) 
N,N,N,N'-tetramethylethyenediamine 
i ammonium persuiphate 
Proteins separated by SDS-PAGE were either stained with Coomassie blue 
stain for 15-30 minutes (and the gels subsquently destained with destain 
(table 2.9)), silver stained (section 2.4.5) or the proteins subjected to 
western blotting followed by antibody binding and detection (sections 
2.4.6 & 2.4.7). Western blotting conditions and antibody concentrations 
were fully optimised for the DAPC and other relevant proteins. 
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2.4.5. Silver staining 
(Adapted from (Morrissey, 1981)) 
SDS-PAGE gels were soaked in 50% methanol/10% acetic acid (v/v) for 30 
minutes and subsequently washed in water (3 x 20 minute washes). Gels 
were soaked in DTT (0.5mg/10rnT) in water for 30 minutes, and then 
0.1% (w/v) silver nitrate for 30 minutes. The silver nitrate was briefly 
rinsed off in water and gels rinsed twice with developer (3% (w/v) 
sodium carbonate, 0.05% (v/v) formaldehyde) and the silver stain was 
developed for 10-30 minutes. The colour development was stopped by 
0.115M citric acid solution and the gels washed in water. 
2.4.6. Western blotting 
Proteins were transferred electrophoretically from the SDS-
polyacrylarnide gel to polyvinylidene difluoride (PVDF) membrane 
(Biotrace) using the BlO-RAD Trans-Blot cell transfer system. All transfers 
were performed in CAPS/methanol transfer buffer (table 2.9). Large gels 
were blotted for 1500mA.hours or 3000mA.hours to transfer large proteins 
such as utrophin and dystrophin. Mini-gels were blotted for 400-
800mA.hours. The transfers were performed either in the 4°C controlled 
temperature room or at room temperature using a super cooling coil 
(BlO-RAD). 
77 
Interactions in the DAPC regulated by phosphorylation 
2.4.7. Antibody binding and detection 
After protein transfer was complete, PVDF membranes were blocked in 
5% (w/v) skimmed milk powder in Tris-buffered saline (TBS; 50 mM 
Tris-HCl, pH 7.5,150mM NaCl) with 0.5% (v/v) Tween-20 (TBST) for 30 
minutes and incubated overnight at 4°C in appropriately diluted primary 
antibody (table 2.6) in TBST on a roller. The membranes were 
subsequently washed 3 times in TBST before addition of the appropriate 
secondary antibody (table 2.7) diluted in TBST. Membranes were 
incubated for 2 hours in secondary antibody at room temperature. After 
washing in TBST, blots incubated with alkaline phosphatase-conjugated 
secondary antibodies were developed using 0.4 mM nitro blue 
tetrazolium and 0.4 mM 5-bromo-4-chloro-3-indolyl phosphate in AP 
buffer (100mM NaCl, 5mM MgC12, 100mM Tris-HCl, pH 9.5). 
Alternatively, for blots incubated with peroxidase-conjugated secondary 
antibodies, detection was carried out using Amersham ECL kit 
(AmershamPharmaciaBiotech), according to manufacturers' instructions. 
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Table 2.9 
Solutions for SDS-PAGE and western blotting 
Separating gel buffer 1.5 M Tris-HC1, pH 8.8 
4% (w/v) SIDS 
Stacking gel buffer 0.5M Tris-HC1 pH 6.8 
0.4% (w/v) SIDS 
2x SIDS loading buffer 100 mM Tris-HC1, pH 6.8 
0.85M 3-mercaptoethanoI 
4% (w/v) SIDS 
0.2% (w/v) Bromophenol blue 
20% (v/v) Glycerol 
IN SIDS-PAGE running 2.5mM Tris 
buffer 1.9 M Glycine 
1% (w/v) SIDS 
Coomassie Blue stain 0.1% (w/v) Coomassie blue R250 
10% (v/v) acetic acid 
50% (v/v) ethanol 
10% (v/v) methanol 
Destain 10% (v/v) acetic acid 
5% (v/v) methanol 
Western blotting transfer 10mM CAPS pHil 
buffer 20% (v/v) methanol 
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2.4.8. Two-dimensional gel electrophoresis. 
All 2-D gel electrophoresis equipment was purchased from 
AmershamPharmaciaBiotech. 3-dystroglycan was immunoprecipitated 
from equal amounts of protein from peroxyvanadate treated or untreated 
C2/C4 cell extracts, prepared in RIPA buffer (section 2.3.2). The Sepharose 
beads were re-suspended in rehydration buffer (8M urea, 2% (w/v) 
CHAPS, 2% (v/v) ampholine, 20mM DTT) and incubated for 1 hour at 
room temperature on a rolling incubator. After centrifugation, the 
supernatant (400d per strip) was used to rehydrate 180mm pH3-10 
Immobiline Drystrips in an Immobiline DryStrip Reswelling tray, 
overnight at room temperature. Strips were then subjected to isoelectric 
focusing on an Amersham PharmaciaBiotech Multiphor System in 
gradient mode (lmA, 5 Watts and 300V for 0.01 hour, 300V for 3 hours, 
3500V for 5 hours, 3500V for 12.5 hours). Strips were stored at -80°C prior 
to SDS-PAGE. Strips equilibrated in equilibration buffer (50mM Tris-HCL 
(pH 8.8), 6M urea, 30% (v/v) glycerol, 2% (w/v) SIDS, 1% (w/v) DTT) for 30 
minutes were separated in the second dimension on reducing 3-15% SDS-
polyacrylamide gels (with no stacking gel) for 150 mA/hours per gel and 
western blotted (section 2.4.6). 
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2.4.9. Production of recombinant proteins 
Unless stated otherwise, recombinant proteins were produced as follows: 
Proteins were expressed by growing transformed E.coli BL21(DE3) or 
JM109 (table 2.1) at 37°C in 2x TY media (table 2.2) until the 0D60, reached 
0.6, then inducing protein production for 2 hours with 0.5mM isopropyl-
!3-D-thiogalactopyranoside. Following harvesting by centrifugation (5000 
xg,1,, 10 minutes), the cell pellet was stored at -70°C overnight. After 
thawing, the pellet was re-suspended in SET buffer (25% w/v sucrose, 
50mM Tris-HC1, pH 8, 1mM EDTA, 100M leupeptin, 1mM PMSF, 100jtM 
TPCK, 10mg/mi STI) and the cell suspension treated with iysozyme 
(0.5mg/mi) for 10 minutes at room temperature, followed by DNasel 
(1ig/mi) (with 10mM MgC12 and 1mM MnC12) for 10 minutes. The lysed 
cells were then sonicated and centrifuged (24,000 xg, 20 mm) to remove 
cell debris. The resultant supernatant was clarified by ultracentrifugation 
(95,000 	1 hr). Samples were taken throughout the expression process 
(pre-induction, post-induction, post-iysis, soluble fraction, insoluble 
fraction) and analysed by SDS-PAGE to monitor the expression of the 
fusion protein. 
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2.4.10. Generation of Pinpoint fusion-proteins for pulldowns and 
'SPOTs' assays 
2.4.10.1. Expression of Pinpoint fusion proteins 
The limits of the dystrophin cysteine rich domains WW, EF and ZZ were 
identified by sequence alignment and secondary structure prediction 
(James et al., 2000). cDNAs encoding residues 3055-3354 of human 
dystrophin (encompassing the WW, EF and ZZ domains, see figure 1.1) 
and residues 775-895 of 13-dystroglycan cytoplasmic domain (see figure 1.4 
& appendix) were amplified by polymerase chain reaction (PCR) (section 
2.2.5) from the dystrophin mini-gene (cloned in pUC18) and mDG.clone2 
respectively (table 2.4). The 5' primers contained a Hindill restriction site 
and the 3' primers contained a stop codon and Noti restriction site (table 
2.5) which facilitated the cloning of the PCR products into the unique 
Hindlil and Noti restriction enzyme sites of the PinPoint Xa-3 vector 
(Promega) to produce the PinPoint-DYS and PinPoint-13-DG constructs. 
The inserts were checked for mismatches by sequencing with the Pinpoint 
sequencing primer (table 2.5, section 2.2.11). E. coli JM109 (as suggested by 
the manufacturer) was transformed with PinPoint Xa-3, PinPoint-DYS or 
PinPoint-13-DG to express PIN (biotin tag alone, as a control) and the 
fusion proteins DYS-PIN and 13-DG-PIN respectively (section 2.4.10.1). All 
the aforementioned fusion proteins were localised in the soluble fraction 
post cell lysis. Clarified supernatants were used directly in pulidown 
experiments (section 2.4.13.3). PIN and DYS-PIN were also purified for use 
in 'SPOTs' assays (section 2.4.10.2). 
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2.4.10.2. Purification of expressed Pinpoint fusion proteins. 
PIN and DYS-PIN were purified by incubation of the crude cell 
supernatant with Softlink soft release Avidin resin (Promega: lml resin 
per 2 litre culture) overnight, at 4°C. The resin was subsequently washed 
four times with lysis buffer (50mM Tris-HCL, pH 7.5, 50mM NaCl, 5% 
(v/v) glycerol) and protein eluted with 5mM free biotin in lysis buffer, 
overnight, at 4°C). The free biotin was subsequently removed by dialysis 
in lysis buffer. The purification was monitored by SDS-PAGE and western 
blotting using ExtraAvidin-HRP (SigmaAldrich) followed by detection 
with ECL. 
2.4.10.3. Hybridisation of 'SPOTs' membranes with DYS-PIN 
fusion protein. 
The 'SPOTs' membranes were a generous gift from Dr. Marius Sudol, 
Mount Sinai School of Medicine, New York). The 'SPOTs' technique of 
peptide synthesis on derivatised cellulose membrane was performed as 
previously described (Blankenmeyer-Menge et al., 1990; Frank & Doring, 
1988; Kramer et al., 1993). All reagents and equipment, including amino 
acids, derivatised membranes, incubation trays and software ('SPOTs', 
release 1.0), were purchased from Cambridge research Biochemicals and 
Genosys Bio technologies, Inc. 'SPOTs' membranes were moistened with 
ethanol and blocked overnight in 10% (w/v) skimmed milk powder in 
TBST, at 4°C. The membranes were washed with TBST and probed 
overnight with DYS-PIN protein or PIN alone (10g/ml). The membrane 
was washed four times with TBST and incubated with Extravidin-HRP 
diluted 1:1000 in TBST for 2 hours. After four washes with TBST, the blot 
was developed using ECL. 
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2.4.10.4. Regeneration of SPOTs' membranes 
The 'SPOTs' membranes may be stripped and reused. The membranes 
were washed three times for 10 minutes with each of the following: 
distilled water, stripping buffer A (8M Urea, 1% (w/v) SIDS, 0.5% (v/v) - 
mercaptoethanol), stripping buffer B (10% (v/v) acetic acid, 50% v/v) 
ethanol), and finally, ethanol. The membranes were stored at -20°C in a 
Zipock bag until next needed. 
2.4.11. Expression of 0-dystroglycan cytoplasmic domain 
(Method developed and carried out by Ann Nuttall & S. J. Winder, 
University of Edinburgh). 
A construct of 13-dystroglycan cytoplasmic domain (amino-acids 781-895) 
was cloned into pSJW (tables 2.3 & 2.4). pSJW-f3-DG was transformed into 
E.coli BL21(DE3) and expressed as previously described (section 2.4.9). - 
dystroglycan was successfully expressed and subsequently purified by 
anionic exchange chromatography using DEAE Sepharose, followed 
purification through a hydroxyapatite column. 13-dystroglycan was eluted 
from the DEAE Sepharose column using a NaCl concentration of 200-
300mM and was collected from the flowthrough of the hydroxyapatite 
column. A construct of 13-dystroglycan cytoplasmic domain less the last 15 
amino-acids (amino-acids 781-880) was also made, and the protein 
expressed and purified using the same method as for the full length 
cytoplasmic domain. 
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2.4.12. Expression of GST-JAB1 fusion protein 
A construct of full length Jun activation-domain binding protein (JAB1) 
cloned into pGEX-5X-3 was used (tables 2.3 & 2.4). The construct was 
transformed into E.coli BL21(DE3) cells and expressed as in section 2.4.9. 
The fusion protein generated was largely present in the insoluble fraction 
of the lysed cells and the expression conditions were modified to produce 
a more soluble fusion protein. The temperature of expression was 
lowered to 20°C and expression time lengthened to 5 hours. 
The GST-JAB1 fusion protein was purified using glutathione Sepharose 
4B resin (AmershamPharmaciaBiotech) and following the manufacturers' 
instructions for batch purification. Clarified bacterial supernatant 
containing the GST-JAB1 fusion protein was added to a 75% (v/v) slurry 
of glutathione Sepharose 4B resin (prewashed three times with ice-cold 
PBS) and incubated on a roller for 1 hour at 4°C. The resin was 
sedimented by centrifugation at 5000 xg(1%, for 5 minutes and the 
supernatant discarded. The resin was washed five times with PBS. The 
GST fusion protein was eluted with glutathione elution buffer (0.3% 
(w/v) reduced glutathione dissolved in 50mM Tris-HC1 (pH 8.0)). The 
elution buffer was added and left to incubate for 10 minutes at 4°C before 
centrifugation to sediment the resin and removal of supernatant 
containing GST-JAB1 fusion protein. This step was repeated three times 
to ensure a high yield of GST-JAB1. 
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2.4.13. Pulldowns 
2.4.13.1 Coupling of f3-dystroglycan cytoplasmic domain to 
CNBr-activated Sepharose 4B 
The coupling method to couple 13-dystroglycan cytoplasmic domain to 
CNBr-activated Sepharose 4B (AmershamPharmaciaBiotech) was carried 
out using the manufacturers' instructions. ig of CNBr-activated 
Sepharose 4B was swelled with 1mM HO and washed with 1mM HO to 
remove additives. 4.5mg of purified 13-dystroglycan cytoplasmic domain 
(section 2.4.11) was dialysed into coupling buffer (0.1M NaHCO3 pH 8.3, 
0.5M NaCl) overnight at 4°C. The protein solution was made up to 5m1 
using coupling buffer, added to the HO-washed CNBr-activated 
Sepharose 4B and rotated end-over-end at 4°C overnight. Any excess 
ligand was washed away with 5 gel volumes of coupling buffer. Any 
remaining active groups on the Sepharose were blocked by an overnight 
incubation with 0.1M Tris-HC1 buffer, pH8 or 1M ethanolamine, pH8. The 
Sepharose was subsequently washed with 3 cycles of alternating pH, each 
cycle consisted of a wash with 0.1M sodium acetate, pH 4, 0.5M NaCl 
followed by O.1M Tris-HO, pH 8, 0.5M NaCl. The resulting CNBr-
activated Sepharose coupled to the 13-dystroglycan cytoplasmic domain 
was stored in O.1M Tris, pH8 plus 1mM Azide as a 50% (v/v) slurry. The 
coupling efficiency was calculated using the concentration of the excess 
ligand and varied from 80-90% in the various couplings carried out. 
2.4.13.2 Pulldowns using f3-dystroglycan cytoplasmic domain 
coupled to CNBr-activated Sepharose 4B 
As a control, and for pre-clearing cell extracts, the coupling process 
(section 2.4.13.1) was carried out without any protein added to the CNBr-
activated Sepharose 4B. 
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Approximately 15j.ig of 13-dystroglycan (coupled to Sepharose beads) was 
added to every 350tg of protein (quantified from cell extracts (section 
2.3.9). Myoblast or myotube extracts were pre-cleared for 1 hour with 
CNBr-activated Sepharose with no ligand coupled to it. Extracts were 
subsequently incubated for 4 hours or overnight at 4°C with CNBr-
activated Sepharose coupled to the 13-dystroglycan cytoplasmic domain. 
The beads were washed 4 times with RIPA buffer followed by a wash with 
0.6M LiC1. SDS-PAGE sample buffer was added to the washed beads and 
boiled for 2 minutes. The supernatant was analysed by SDS-PAGE and 
western blotting (sections 2.4.4 & 2.4.6). 
In further controls, the CNBr-Sepharose beads were blocked with 
skimmed milk powder (5% w/v) or BSA (5% w/v) for one hour prior to 
the pulldown assay. Other controls included washing the beads in high 
salt (the salt concentration of RIPA buffer was raised from 150mM to 
300mM) or increasing the number of washes from 4 to 10. In some 
instances, the C2/C4 cell extracts were pre-cleared for 1 hour with control 
or 13-dystroglycan-coupled CNBr-Sepharose beads. 
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2.4.13.3. Pulldowns using DYS-PIN and f3-DG-PIN fusion 
proteins 
Clarified E.coli supernatants containing DYS-PIN or 3-DG-PIN fusion 
proteins (section 2.4.10.1.) were incubated with ImmunoPure immobilised 
Streptavidin (Pierce) for 2 hours at 4°C to capture the fusion proteins onto 
the Streptavidin beads. The beads were collected by centrifugation and 
washed 4 times in RIPA buffer and added to C2/C4 myoblast or myotube 
cell extracts (pre-cleared with the streptavidin beads) and incubated 
overnight at 4°C. The beads were collected by centrifugation and washed 4 
times with cold RIPA buffer followed by a wash in cold 0.6M LiC1 and 
SDS-PAGE sample buffer was added to the beads. After 2 minutes boiling, 
the supernatant was run on SDS-PAGE gels and western blotted (sections 
2.4.4 & 2.4.6). 
2.4.13.4. Pulldowns using GST-JAB1 fusion protein 
Approximately lig of purified GST-JAB1 fusion protein was added to 
350iig of C2/C4 cell extract (pre-cleared for one hour with glutathione 
Sepharose) and incubated overnight at 4°C. 501a1 of a 50% (v/v) slurry of 
glutathione Sepharose was subsequently added per sample and the tubes 
incubated for a further 2 hours at 4°C. The samples were centrifuged 
briefly to pellet the Sepharose beads, and the beads were washed 4 times 
with cold RIPA buffer followed by a wash in cold 0.6M LiCJ. The final 
pellet was re-suspended in SDS-PAGE loading buffer, boiled for 2 minutes 
and analysed by SDS-PAGE and Western blotting (2.4.4 & 2.4.6). 
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2.5. Yeast two-hybrid assay 
2.5.1. Yeast strains and media 
Strains were routinely grown at 30°C on YPDA medium (Table 2.11). To 
maintain selection for plasmid DNA, and/or for auxotrophic markers 
inserted on the genome, cells were grown in the appropriate drop-out 
medium (table 2.11). 
Table 2.10 
Saccharomyces cerevisiae strains used in this work 
Strain Genotype Reference! Source 
MATa ura3-52 his3-200 ade2-101 lys2-801 trpl-901 CLONTECH 
CG1945 leu2-3,1 12 LYS2::GAL1 UAS-GAL1TATA-HIS3 gal4- 
542 ga180-538 cyh2 URA3::GAL4i7mers  (0) 
CYC1 TATA  -lacZ Feilotter et al. (1994)* 
MATa trpl-901, leu2-3, 112, ura3-52 his3-200 P. James et al. (1996) 
PJ6894A gal4A ga180A LYS2: :GAL1-HIS3 GAL2-ADE2 
met2::GAL7-lacZ 
MATa ura3-52 his3-200 ade2-101 lys2-801 trpl-901 Flick & Johnson (1990) 
Y190 leu2-3, 112, gal4A ga180A, cyhr2,  LYS2::GAL1UAS - 
HIS3TATA-HIS3, URA3 : :GAL1UAS-GAL 1TATA-lacZ 
*CG 1945 is a derivative of HF7c (Feilotter etal. 1994) 




1% (w/v) Bacto-yeast extract 
YPDA 2% (w/v) Bacto-peptone 
2% (w/v) Glucose 
0.004% (w/v) Adenine sulphate 
-W/-LWH dropout 2% Yeast nitrogen base w/o amino acids 
media 2% (w/v) Glucose 
2x CSM W*/CSM LWH* 
lx adenine 
-LW dropout media 2% Yeast nitrogen base w/o amino acids 
2% (w/v) Glucose 
2x CSM LWH* 
Ix Adenine 
Ix Histidine 
-LWA dropout media 2% Yeast nitrogen base w/o amino acids 
2% (w/v) Glucose 




for solid media, 2% (w/v) agar was added prior to autoclaving. 
*Complete  supplement mixture (CSM) minus specific amino-acids (BlO 101,Inc). Prepared to 
manufacturers' instructions and adjusted to pH 7.5 with NaOH. 
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Table 2.12 
Nutrients and Supplements 









U ra cii* 
3 
* stored at room temperature. 
Stock solutions of the growth supplements were filter sterilised, stored at 4°C and added to 
media after autoclaving. 
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2.5.2. Transformation of Yeast 
Yeast cells were transformed using the method of Gietz et al. (1993). 
A single colony of the yeast strain to be transformed was inoculated into 
10m1 of liquid medium (table 2.11) and grown overnight at 30°C. The 
following day, the cells were diluted into 50ml of fresh medium to an 
0D600 of 0.1 and incubated at 30°C. Upon reaching an 0D600 -0.5, the cells 
were harvested by centrifugation at 3,500 	for three minutes. Cells were 
transferred to an Eppendorf tube washed twice with lml of LiOAc mix 
(100mM LiOAc, 10mM Tris (pH7.4), 1mM EDTA). The pelleted cells 
(pelleted by centrifugation at 3,000 xg0 , for 1 minute) were finally 
resuspended in 0.5ml of LiOAc mix and were ready for transformation. 
1-5tg DNA to be transformed was mixed with 0-200tg of single stranded 
salmon sperm carrier DNA (incubated at 90°C for 10 minutes prior to 
use). 100t1 of yeast cells in LiOAc mix were added to the DNA followed by 
700 p1 of PEG mix (40% (v/v) PEG2000 in LiOAc mix). The mixture was 
pipetted up and down with a P1000 Pipetteman to mix and incubated at 
30°C for 30 minutes on a rotating wheel. Cells were heat-shocked at 42°C 
for 15 minutes, then sedimented by centrifugation at 3,000 	for 30 
seconds. The pelleted cells were resuspended in 200p1 of water and plated 
onto the appropriate solid medium (Table 2.11) to maintain selection for 
the transforming DNA. Plates were incubated at 30°C for 2-3 days. 
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2.5.3. The yeast two-hybrid library 
The yeast two-hybrid library used was a MATCHMAKER human skeletal 
muscle cDNA library (CLONTECH). The library cDNA is XhoI-(dT)15  
primed and cloned into the XhoI/EcoRI restriction sites of the pACT2 
vector (table 2.3) which contains a LELJ2 selection marker. The library is 
purchased already transformed into E.coli BNN132 as a frozen glycerol 
stock. The library has 3.5x106 independent clones and the cDNA clones 
range from 0.4-4kb with an average size of 2kb. 
2.5.3.1. Library titering protocol 
The library titre was calculated so that the amount of library stock 
amplified represents 2-3 times the number of independent clones in the 
library. 
1tl of frozen glycerol stock culture of library was added to lml of LB broth 
(dilution A (1:10). 1il of dilution A was removed and added to lml of LB 
broth (dilution B (1:106).  
1i1 of dilution A was added to 50jt1 of LB broth and plated into an LB agar 
plate. 100t1 and 500d aliquots of dilution B were also plated onto LB agar 
plates and incubated overnight at 37°C. 
The next day, the number of colonies were counted in order to determine 
the titer of the library (colony forming units (cfu)/ml) using the following 
formulae: 
Number of colonies from dilution A x 103 X103=   cfu/ml 
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Number of colonies from dilution B/plating volume x 103  x 103x iO = 
cfu/ml. 
Number of colonies 
	
Library titer (cfu/ml) 




4.6 x 10 
100 tl dilution B 4 4 x iO 




4.6 x 107 
Therefore, the library titer is 4.6 x 107  cfu/ml. 
The library has 3.5 x 106  independent clones and to get a representative 
amplification of the library, 2-3 times this needs to be plated. Plating 2x the 
library would give 7 x 106  colonies. 
ml of library to plate 	= 	number of colonies required 
cfu/ml 
= 	7x106 	= 0.152m1 
4.6 x 107 
2.5.3.2. Amplification of the skeletal muscle cDNA library 
0.152m1 of cDNA library was diluted in LB and was plated onto fifty nine 
25cm2 LB agar plates supplemented with ampicillin (Table 2.2). The plates 
were incubated at 30°C for 48 hours. The colonies were subsequently 
scrapped off in 5m1 LB-Amp and the plates rinsed with a further 5ml LB-
Amp, and the colonies in LB-Amp incubated for 2 hours at 30°C in a 
shaking incubator. 5m1 of the culture was taken to make glycerol stocks of 
the library (25% (v/v) glycerol was added to the culture and imi aliquots 
were frozen at -70°C). 
From the remainder of the culture, plasmid DNA was extracted from the 
cells using the large scale preparation of plasmid DNA protocol (section 
2.2.2.2). 
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2.5.4. The bait plasmid. 
3-dystroglycan cytoplasmic domain (amino-acids 781-895) (see appendix) 
was cloned into the shuttle vector pAS2AA (Table 2.3) using restriction 
sites NdeI and Sail. The cloning was checked by automated sequencing of 
the plasmid (section 2.2.11) using sequencing primer J0E17 (table 2.5) 
which binds to the GAL4 DNA-binding domain. Subsequently, this bait 
plasmid was transformed into the appropriate yeast strain (table 2.10) and 
propagated on -w drop-out medium (table 2.11). 
The yeast cells carrying the bait plasmid were tested for expression of 3-
dystroglycan cytoplasmic domain by carrying out a crude extract of the 
total cellular protein of the cells (section 2.5.5). 10d of this extract was run 
on SDS-PAGE gels and western blotted with MANDAG2 anti-13-
dystroglycan antibody (table 2.6) to check for 3-dystroglycan expression. 
2.5.5. Crude Extraction of Total Cellular Protein from Yeast 
lOmi of the -w dropout media (table 2.11) was inoculated with a single 
colony of bait cells (3-DG/pAS2M in a host strain) and incubated at 30°C 
overnight. 50m1 of fresh medium was inoculated with the pre-culture to 
an 0D600 of 0.1 and incubated again at 30°C. Upon reaching an 0D600 of 
—0.5, the cells were harvested by centrifugation at 3,500 xg, for 5 minutes. 
The pelleted cells were resuspended in 150d 2x SDS-sample buffer (table 
2.9) with 1mM phenylmethylsulphonyl fluoride (PMSF) added 
immediately before use. The cell suspension was transferred to a fresh 
Eppendorf tube containing 80jil of glass beads (425-600jim) and 
homogenised for 1 minute at high speed in a Mini BeadBeater (BIOSPEC 
Products). Centrifugation (13,000 xg, for 10 minutes) was subsequently 
carried out at 4°C. The supernatant was removed to a fresh tube and used 
for analysis by SDS-PAGE and western blotting with f3-dystroglycan 
antibodies. 
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2.5.6. Screening for yeast two-hybrid interactors 
2.5.6.1 Titration of 3-aminotriazole. 
In order to eliminate false positives in the yeast two-hybrid screen, 
titration of 3-aminotriazole (3-AT) was carried out by plating 
transformants on -LWH media containing different 3-AT concentrations 
ranging from 0 to 40mM. The transformants were allowed to grow for up 
to 5 days and their growth carefully monitored over this time to see what 
concentration of 3-AT inhibited growth. 
2.5.6.2. Calculation of Transformation Efficiency and number of 
transformants screened 
Cells growing on —LW media represent diploid cells containing both bait 
and prey (library) plasmid DNA. Bait cells were grown in —W drop-out 
liquid medium to an 0D600 of approximately 0.5, and 0.5-1.5ig skeletal 
muscle library was transformed in using the standard transformation 
method (section 2.5.2). 1/20th of each transformation was plated onto -LW 
media. The number of colonies growing after two days on these plates 
were counted. 
To calculate the transformation efficiency: 
Transformation Efficiency (%) 
= Number of colonies on —LW plate x dilution factor (20) x 100 
To calculate the amount of transformants screened: 
Amount of transformants screened 
= colonies on —LW x dilution factor (20) x number of tranformations. 
Different amounts of carrier DNA were used in the transformations to 
elucidate the amount gave the highest transformation efficiency. The 
different strains (table 2.10) were also compared for transformation 
efficiency. 
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2.5.6.3 The yeast two-hybrid screen 
Transformants containing both the bait plasmid and library plasmids 
were selected for on -LW media. In order to find interactors of 1-
dystroglycan, transformants were plated onto -LWH or -LWA media to 
select for colonies where the HIS or ADE reporter gene was activated. To 
double-check the result, colonies from -LWH plates were re-streaked onto 
-LWA dropout media to check for growth. Colonies from -LWA plates 
were re-streaked onto -LWH dropout media. Activation of the LacZ 
reporter gene was also checked by X-Gal filter lift assays. 
2.5.6.4 X-Gal Filterlift Assay 
Filterlift assay solution (0.27% (v/v) 13-mercaptoethanol, 0.04% (w/v) X-
Gal (in dimethyl formamide)) was prepared in Z-buffer (60 mM Na2HPO4 
(71-120), 40mM NaH2PO4 (H20), 10mM KC1, 1mM MgSO4 (71-120)) fresh 
from stock solutions immediately prior to use. Cells were transferred to 
Hybond-C extra filters (Amersham), and the filters immersed in liquid 
nitrogen for five seconds. Filters were placed (cell side-up) onto Whatman 
3MM paper soaked in filterlift assay solution, incubated at 30°C and 
examined at regular intervals. The reaction was stopped by transferring 
the filter to Whatman 3MM paper soaked in 1M Na2CO3 for 1 minute, 
and then to Whatman 3MM paper soaked in distilled water for 1 minute. 
2.5.7. Analysis of Positive Clones from Two-hybrid Screens 
The His/Ade+/LacZ+ colonies isolated by the yeast two-hybrid assay 
were analysed to identify the library plasmid responsible for the two-
hybrid interaction. To achieve this the library plasmids were rescued from 
the yeast cells and sequenced. 
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2.5.7.1 Plasmid rescue from yeast cells 
This method of analysis is dependent upon isolating the prey plasmid 
DNA. Yeast cells carrying a library plasmid were collected with a toothpick 
and added to 200t1 of lysis buffer (2% (v/v) Triton X-1001% (w/v) SDS, 
100mM NaCl, 10mM Tris-HC1 pH 8.0, 1mM EDTA), 200t1 of glass beads 
(150-212 m) and 200tl of phenol: chloroform: isoamyl alcohol (25:24:1). 
This was mixture was vortexed for 5 minutes and subjected to 
centrifugation at 18,000 xg for 5 minutes. 160d of the supernatant was 
removed and added to 500 jtl of ethanol and 80i1 of 7.5 M NH40Ac, placed 
on dry-ice for 10 minutes and subjected to centrifugation at 18,000 xg for 
10 minutes at 4°C. The DNA pellet was washed with 70% (v/v) ethanol, 
dried under vacuum and resuspended in 10t1 of distilled water. 1-2il of 
the rescued plasmid DNA was transformed (section 2.1.3.2) into electro-
competent MC1066 cells (table 2.1). The transformants were plated onto 
M9 —L medium (table 2.2) which allows growth of only those E. coli cells 
carrying a plasmid with the LEU2 gene (i.e. library plasmid). Mini-prep. 
DNA was prepared (section 2.2.2.1) from single colonies of the 
transformants. The size of the genomic DNA inserts in these plasmids 
was determined by restriction digestion (section 2.2.4) with BglII (which 
cuts in the library adaptor sequence at both ends of the insert) and agarose 
gel electrophoresis (section 2.2.8). The identity of the insert was 
determined by DNA sequencing (section 2.2.11) with primers Seq F and 
Seq R (table 2.5) and subsequent analysis using the BLAST program 
(section 2.5.7.2). 
2.5.7.2 Computer Analyses: BLAST 
Protein database searches were performed on the NCBI server 
(http://www.ncbi.nlm.nih.gov/BLAST) using the BLAST program. DNA 
were sequences analaysed using Sequencher and full length sequences 
were acquired from the Genbank database. 
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2.5.7.3 Controls 
Library plasmids which elicited an interaction with the bait plasmid were 
plasmid rescued (section 2.5.7.1) and transformed back into yeast cells 
(section 2.5.2) containing the bait plasmid and selected for on -LWH and 
-LWA dropout media to check that the reporter genes were still activated. 
The library plasmids were also transformed into yeast carrying no bait 
plasmid and the transformed cells plated into -LA and -LH dropout media 
to verify that the reporter genes were only activated in the presence of the 
bait plasmid. 
Interactions in the DAPC regulated by phosphorylation 
2.6. F-Actin binding experiments 
Actin experiments to verify the actin/13-dystroglycan interaction brought 
to light in the yeast two-hybrid screen were carried out using monomeric 
actin purified from acetone powder by Tommy Jess (Winder Lab, 
University of Glasgow). f3-dystroglycan cytoplasmic domain was expressed 
and purified as in section 2.4.11. The molar concentration of the proteins 
was determined by measuring their absorbance at 280nm and calculating 
their concentration from this using their extinction coefficients. 
2.6.1. Sedimentation Assays 
50 or lOOpi of reaction mixes of concentrated G-actin was mixed at the 
desired molar ratio (final actin concentration 51tM) with a dilution series 
of 13-dystroglycan cytoplasmic domain (concentrations of 10, 20, 40, 60, 80 
and lOOjtm) and initiation mix (1mM EGTA, 2mM MgC12, 0.5mM ATP) 
were allowed to polymerise (overnight at 4°C or for 4 hours at room 
temperature) and subsequently subjected to high and low speed 
sedimentation assays. Controls included actin alone (i.e. 5JM actin, no 1-
dystroglycan) and the highest concentration of f3-dystroglycan (100mM) 
alone (no actin). The centrifugation step were carried out in a TA-100.2 
Ultracentrifuge rotor (Beckman) at 100,000 xg or 20,000 xg for 15 
minutes at 4°C. 
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Following the centrifugation, the supernatant was carefully removed and 
added to an equal volume of 2x SDS-PAGE sample buffer (Table 2.9). 50jil 
or 100il (whatever the assay volume used) of 2x SDS-PAGE sample buffer 
was then added to the F-Actin pellet fraction. This was incubated at room 
temperature for 10 minutes, to allow the pellet to completely dissolve. 
The pellet fraction was then transferred to a fresh tube and the original 
washed with an further 50d or 100il of 2x SDS-PAGE sample buffer. This 
was then added to the pellet fraction. Equal volumes of the supernatant 
and pellet fractions were then subjected to SDS-PAGE analysis. 15% (w/v) 
polyacrylamide gels were used and run as described (section 2.4.4). The 
gels were stained with Coomassie blue protein stain to visualise the 
proteins. 
2.6.2. Falling Ball Assay 
Viscosity measurements of F-actin with or without 13-dystroglycan were 
carried out using microcapillary falling ball viscometry (MacLean-Fletcher 
& Pollard, 1980). Reaction mixes of actin and 13-dystroglycan identical to 
those used in the co-sedimentation assays (section 2.6.1) were set up. 
The samples were drawn up into 100tl capillary tubes. The capillary tubes 
were plugged at one end with plasticine and held vertically. The actin was 
left to polymerise, either overnight at 4°C or for 4 hours at room 
temperature. The velocity of a 0.64mm diameter stainless steel ball was 
measured by recording the time it took to travel 10cm down the capillary 
tube. 
In some cases the falling ball and sedimentation assays were also carried 
out using KME buffer (100mM KC1, 2mM MgC12, 1mM EGTA, 0.5mM 
ATP) instead of initiation mix, as a polymerisation agent. 
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2.6.3. Electron microscopy of actin filaments. 
Reaction mixes of 5iM actin and 60tM 13-dystroglycan, identical to those 
used in the co-sedimentation assays (section 2.7.1), were allowed to 
polymerise (overnight at 4°C or for 4 hours at room temperature) and 
electron microscopy was carried out by Tommy Jess (Winder lab, 
University of Glasgow). In brief, the sample was pipetted onto a charged 
carbon coated disc and negatively stained with Nanovan stain before 
viewing under the electron microscope. 
2.6.4. Computer Analyses: MPsearch 
The 13-dystroglycan cytoplasmic domain amino-acid sequence was divided 
up into 20 amino-acid peptides, each overlapping by 10 amino-acids: 
Peptide 1. RKKRKGKLTLEDQATFIKKG 
Peptide 2. EDQATFIKKGVPIIFADELD 
Peptide 3. VPIIFADELDDSKPPPSSSM 
Peptide 4. DSKPPPSSSMPLILQEEKAP 
Peptide 5. PLILQEEKAPLPPPEYPNQS 
Peptide 6. LPPPEYPNQSVPETTPLNQD 
Peptide 7. VPETTPLNQDTMGEYTPLRD 
Peptide 8. TMGEYTPLRDEDPNAPPYQP 
Peptide 9. EDPNAPPYQPPPPFTVPMEG 
Peptide 10. PPPFTVPMEGKGSRPKNMTP 
Peptide 11. KGSRPKNMTPYRSPPPYVPP 
A protein-protein database search was carried out, using MP search 
(Edinburgh Biocomputing Systems Ltd ) based on the Smith-Waterman 
algorithm. Available at http://ambler.icmb.ed.ac.uk. Any actin-binding 
proteins homologous to regions of 13-dystroglycan were noted. 
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Proteins associating with 3-dystroglycan 
3.1. Introduction 
The transmembrane glycoprotein 13-dystroglycan is an essential 
component of the DAPC because it forms a link between dystrophin and 
extracellular matrix. However, evidence suggests the role of 13-
dystroglycan stretches far beyond this function, since in addition to 
dystrophin, f3-dystroglycan interacts with proteins such as Grb2, caveolin-3 
and rapsyn (section 1.6.4). Despite these findings, it is still not clear what 
the exact functions of 3-dystroglycan are and more research is required. 
The objective of this study was to investigate interactions of 13-
dystroglycan with proteins outside of the DAPC, in addition to studying 
protein:protein interactions within the DAPC. The aim was to gain a 
greater understanding of the function of 13-dystroglycan by identifying 
novel interacting proteins, and also to investigate whether the 
phosphorylation of 13-dystroglycan regulates any of these interactions. 
In the first instance methods were developed in order to carry out 
experiments investigating interactors of 13-dystroglycan. This included 
characterisation of mouse muscle cell lines which were the model system 
of choice, and optimisation of techniques used to extract proteins from 
the cells. 
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3.2. Characterisation of C2 mouse muscle cell lines 
Mouse skeletal muscle cell lines have been widely used as a model for 
studying myogenesis. Initially, the majority of studies carried out to gain 
more information about dystrophin involved the extraction of 
dystrophin and DAPC proteins from skeletal muscle. This method yields 
adequate amounts of the desired proteins but is lengthy and time 
consuming. Due to its naturally low abundance, bacterial expression and 
purification of dystrophin constructs has proved useful to produce high 
quantities of the protein for biochemical assays and structural studies. 
However, using a muscle cell line provides a more in vivo approach 
compared to the aforementioned methods. Growing cultured cells allows 
the treatment of endogeneous proteins with chemical reagents such as 
phosphatase inhibitors while the cells are still viable, and easier protein 
extraction conditions compared to those from whole muscles. 
Three mouse skeletal muscle cell lines were assessed for their use in this 
study, namely C2/C12, C2/C7 and C2/C4 (section 2.3.1). On reaching 
confluency and/or reduction in serum levels, myoblasts spontaneously 
fuse to form multinucleated myotubes (figure 3.1A) and express proteins 
required specifically for differentiated muscle cells e.g. creatine kinase 
(Yaffe & Saxel, 1977). The cell lines were tested for their ability to fuse (this 
property is lost if cell lines are not maintained properly at low 
confluence), and for their expression patterns of dystrophin, 3-
dystroglycan and utrophin. 
Whilst testing the cells for their expression of dystrophin, it was found in 
all three cell lines that dystrophin protein was not expressed in myoblasts 
but only in differentiated myotubes (figure 3.113). 
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Figure 3.1 
Dystrophin is expressed only in myotubes 
A 	Myoblasts (day 1) Myotubes (day 9) 
B Day  Day  
E ft--~ IB: Dystrophin 
C2/C4 myoblasts on day 1 (left) compared to multinuclear myotubes after 9 days (right) in 
low serum differentiation medium. Scale bar = 50tm. 
Western blot of myoblast extracts (day 1) and myotube extracts (day 9) blotted (IB) with 
DYS 1 and DYS 2 monclonal antibodies (table 2.6). Dystrophin was only detected in 
differentiated myotubes, and not in myoblasts. 
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To determine more accurately when the expression of dystrophin 
commences, a timecourse of differentiation was carried out (section 2.3.4). 
The serum level in the growth media of the myoblasts was reduced from 
20% (v/v) to 2% (v/v) to induce differentiation. Cell extracts were taken 
at daily intervals and western blotted for DAPC proteins. 
During the differentiation timecourse of the C2/C4 cell line, it was found 
that 13-dystroglycan and utrophin were expressed equally in myoblasts and 
myotubes, whereas dystrophin was only expressed in fairly advanced 
stages of differentiation (day 5) when myotubes are fully formed (figure 
3.2). The predicted expression pattern of utrophin was that it is 
maintained at a steady level or decreases throughout differentiation as 
dystrophin takes over utrophin's localisation at the sarcolemma (Clerk et 
al., 1993; Rigoletto et al., 1995). It was found that in the C2/C4 cells, the 
overall expression levels of utrophin remained constant throughout 
differentiation. 
The C2/C4 cell line demonstrated the predicted expression patterns of 
dystrophin, 13-dystroglycan and utrophin (figure 3.2), and in addition, had 
higher expression levels of dystrophin compared to the other cell lines. 
Dystrophin has a very low abundance in any case (Hoffman et al., 1987), 
and this higher expression of dystrophin in the C2/C4 cell line was 
considered an advantage for experiments involving the DAPC proteins, 
and it was the cell line of choice in subsequent experiments. 
W. 
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Figure 3.2 




The serum content in the growth media was reduced from 20% (v/v) to 2% (v/v) on day 1 
when the myoblasts were approximately 50% confluent. Myoblast fusion first started to occur 
at days 3/4. Myotubes appeared fully formed by day 5. Cell extracts taken at daily intervals 
and equal amounts of protein loaded onto SDS-PAGE gels, and western blotted with 
antibodies DYS 1 and DYS 2 (dystrophin), NCL-43DAG/8D5 (f3-dystroglycan) and RAB5 
(utrophin) (see table 2.6). 
Dystrophin is only expressed in fully fused myoblasts (day 5 onwards) whereas the 
ubiquitous utrophin and 3-dystroglycan are expressed equally in myoblasts and 
myotubes.The C2/C4 cell line was considered to represent accurately the in vivo expression 
pattern of DAPC proteins. 
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3.3. Extraction conditions 
The optimisation of protein extraction conditions of myoblasts and 
myotubes was required to carry out analysis of interactions within the 
DAPC and investigate their regulation by phosphorylation. The aim was 
to isolate a high concentration of dystrophin and DAPC proteins for use 
in immunoprecipitation and western blotting experiments. In addition, 
the objective was to isolate the DAPC and any associated proteins in an 
intact state so that protein:protein interactions could be investigated. 
Dystrophin is a notoriously difficult protein to extract from muscle cells. 
This is because it is of very low abundance (0.002% of total skeletal muscle 
protein (Hoffman et al., 1987)). For this study, it was necessary to extract 
sufficient amounts of dystrophin for visualisation by western blotting. 
Another complication is that certain members of DAPC are membrane 
proteins (13-dystroglycan and sarcoglycans) and others are cytoplasmic 
proteins (dystrophin, syntrophins). Therefore it is essential that 
conditions are optimised to accommodate both these characteristics. 
A further requirement of methods used here was that they could facilitate 
a high throughput of small tissue culture samples (ranging from 200p1 to 
lml). If expensive pharmacological reagents were to be used to dissect 
signalling pathways, large scale preparations would not be economically 
feasible. In addition, specialised tissue culture equipment is required for 
large scale growth of adherent cell cultures. 
Several different extraction conditions were used in order to accomplish 
these aims. Little is known about the exact process by which each 
detergent works, therefore the detergent best used in a particular system is 
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usually worked out by trial and error and by surveying literature to gauge 
what has been successful previously. RIPA buffer has been used 
successfully to isolate DAPC proteins from rat L6 myotubes (Yoshida et al., 
1998) and was used in this study to lyse C2/C4 myoblasts and myotubes 
(section 2.3.2). RIPA buffer contains three detergents, namely 1% (v/v) 
Triton X-100, 0.5% (w/v) sodium deoxycholate and 0.1% (w/v) SIDS. SDS-
PAGE electrophoresis of protein extracts, followed by western blotting 
with dystrophin antibodies demonstrated that RIPA buffer was far 
superior in extracting dystrophin than other buffers tested (data not 
shown). Further western blotting of DAPC proteins and utrophin showed 
that RIPA buffer adequately extracted all the proteins required. In 
addition, RIPA buffer delivered reproducible results and was easy to use. 
Therefore, RIPA buffer was considered as the best option and was used for 
the majority of extractions in this study. 
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3.4. Co-immunoprecipitation experiments 
Using RIPA extraction buffer, co-immunoprecipitation experiments 
(section 2.4.2) were subsequently carried out to verify whether the DAPC 
was extracted as a whole entity. DYS 1 + DYS 2 monoclonal antibodies 
(table 2.6) were successful in immunoprecipitating dystrophin itself from 
RIPA extracts (figure 3.3A). Antibodies against representatives of the 
dystroglycan and sarcoglycan complexes (3-dystrog1ycan and -sarcoglycan) 
were also used to western blot dystrophin immunoprecipitates. In 
addition to DYS 1 & DYS 2, the evaluation of dystrophin antibodies VIA4-
2A3 and XIXC2-D11 (table 2.6) was carried out. a-sarcoglycan antibody 
IVD3-1 was also analysed to clarify whether it has the ability to co-
immunoprecipitate the whole DAPC. In the past, a-sarcoglycan antibodies 
have been shown to co-immunoprecipitate not only members of the 
sarcoglycan complex but other DAPC proteins too. For example, an a-
sarcoglycan antibody was coupled to beads and incubated with partially 
purified DAPC complex and the immunoaffinity beads selectively 
absorbed dystrophin, sarcoglycans, and syntrophins (Ervasti et al., 1990). 
Using DYS1 + DYS2 antibodies, neither 13-dystroglycan or 5-sarcoglycan 
were co-immunoprecipitated with dystrophin (data not shown), 
suggesting the DAPC was not remaining intact during extraction with 
RIPA buffer. However, VIA4-2A3 and XIXC2-D11 co-immunoprecipitated 
6-sarcoglycan (figure 3.313) but not 13-dystroglycan. a-sarcoglycan antibody 
IVD3-1 also appeared to immunoprecipitate the whole DAPC because 6-
sarcoglycan and dystrophin were co-immunoprecipitated with it, but 
again not 13-dystroglycan. 
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Figure 3.3 
Co-immunoprecipitation experiments 
A 	Sup DYS IP extract 
IB: DYS 
B' 1 2 3456 
-4 	-- 




Immunoprecipitation of dystrophin 
Dystrophin was immunoprecipitated (IP) from RIPA extracted myotubes using DYS1 and 
DYS2 monoclonal antibodies (table 2.6). A sample of the immunoprecipitate (DYS IF), the 
supernatant from the immunoprecipitation (SUP) and untreated extract (extract) was 
analysed by SDS-PAGE and western blotted (IB) with DYS1 and DYS2. A small amount of 
dystrophin was immunoprecipitated and the supernatant contained the residual dystrophin. 
Co-immunoprecipitation of dystrophin and ö-sarcoglycan 
The same myotubes extracts were used to immunoprecipitate (IP) dystrophin with antibodies 
VIA4-2A3 and XIXC2-D1 1, and cx-sarcoglycan with antibody IVD3-1. The immunoprecipitates 
were loaded in the even numbered lanes and the supernatants of the immunoprecipitates 
were loaded in the odd numbered lanes. All three immunoprecipitates were western blotted 
(IB) with dystrophin antibodies (DYS1 & DYS2) and —sarcoglycan antibody (NCL--SC). 
Lanes 1 and 2 show a-sarcoglycan IF, Lanes 3 and 4 show dystrophin IF (VIA4-2 A3). Lanes 
5 and 6 show dystrophin IF (XIXC2-D1 1). All three antibodies immunoprecipitated dystrophin 
and &sarcoglycan i.e. VIA4-2A3 and XIXC2-D11 co-immunoprecipitated -sarcoglycan and 
NCL-&-SC co-immunoprecipitated dystrophin and -sarcoglycan. 
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3-dystrog1ycan antibodies (table 2.6) were also used in an attempt to co-
immunoprecipitate dystrophin and Grb2, both of which have been shown 
previously to interact with 13-dystroglycan (Jung et al., 1995; Yang et al., 
1995). However, despite the use of several different 3-dystroglycan 
antibodies, these interactions could not be demonstrated by co-
immunoprecipitation. 
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3.5. 3-dystroglycan interacts with at least three 
phosphoproteins 
One of the initial aims of this study was to identify phosphorylation 
events within the DAPC. In order to do this, cell extracts were treated 
with peroxyvanadate in order to inhibit the activity of tyrosine 
phosphatases (Volberg et al., 1992, section 2.3.5). Tyrosine phosphatase 
inhibitors preserve any transient phosphorylation events and this 
facilitates their visualisation by western blotting with anti-phospho 
tyrosine antibodies. 
The first technique used to identify proteins associating with 3-
dystroglycan was co-immunoprecipitation experiments using 3-
dystroglycan antibodies (section 2.4.2). To elucidate whether 1-
dystroglycan is tyrosine phosphorylated and whether it associates with 
other 	proteins 	under 	these 	conditions, 	3-dystroglycan 
immunoprecipitates from peroxyvanadate treated myoblast/myotube 
extracts were western blotted with anti-phospho tyrosine antibodies. It 
was discovered that at least three proteins, recognised by the phospho-
tyrosine antibodies, co-immunoprecipitated with f3-dystroglycan in 
peroxyvanadate treated cells (figure 3.4A). These phosphoproteins were in 
the approximate molecular weight ranges of 55kDa, 80-90kDa and 116-
130kDa. This phenomenon was seen in both myoblast and myotube 
extracts and was highly reproducible. The phosphoproteins were not 
detected by anti-phospho tyrosine antibodies in untreated extracts or in 
the controls. The control immunoprecipitations contained no 3-
dystroglycan antibody and were used to detect any proteins non-
specifically pulled down by the Sepharose beads. 
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Figure 3.4 
Phosphoproteins co-immunoprecipitate with 3-dystroglycan in 
peroxyvanadate treated myoblasts and myotubes. 
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Western blot of 3-dystroglycan immunoprecipitates (3-DG IF) (immunoprecipitated using 
poly 1710 antibody) blotted (IB) with phosphotyrosine antibody FY20 (P-Tyr). The control 
(con) contained no 1710, therefore represents any non-specific pulldown by the protein A 
Sepharose, of which there was none. In peroxyvanadate-treated extracts (+PV), 
phosphoproteins of approximate molecular weights of 55kDa, 80-90kDa and 116-1 30kDa 
were co-immunoprecipitated with 3-dystroglycan (shown by filled arrows). This was observed 
in myoblast extracts (blasts) as well as myotube extracts (tubes). The unfilled arrow points to 
3-dystroglycan (J3-DG) which is detected by FY20 in peroxyvanadate treated extracts only. 
Western blot of 3-dystroglycan immunoprecipitates (3-DG IF) from myotube extracts, 
treated with peroxyvanadate, and treated (+Xppase) or untreated (-?ppase) with X 
phosphatase, and blotted with phosphotyrosine antibody RC20 (P-Tyr). The three groups of 
phosphoproteins (fainter in this experiment) in -Xppase immunoprecipitates are no longer 
detected by RC20 after Xppase treatment. A residual amount of 3-dystroglycan still remains 
phosphorylated in the Xppase treated immunoprecipitate. 
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In addition, 13-dystroglycan itself was also detected by phospho-tyrosine 
antibodies in extracts treated with peroxyvanadate. The tyrosine 
phosphorylation of 13-dystroglycan is discussed more fully in chapter 5. 
When 13-dystroglycan immunoprecipitates are treated with lambda 
phosphatase (Xppase) (section 2.4.3), a serine, threonine and tyrosine 
phosphatase, the three phosphoproteins were no longer detected by 
phospho-tyrosine antibodies (figure 3.413). This confirmed that they were 
in fact phosphorylated proteins. 
In an attempt to identify these phosphoproteins, the use of mass 
spectrometry or protein sequencing was considered. However, it can be 
observed on a silver stained gel (section 2.4.5) of the immunoprecipitates 
that there is a large number of proteins co-immunoprecipitating either 
non-specifically (in controls) or specifically with 3-dystroglycan, and it is 
likely that more than three phosphoproteins are associating with 3-
dystroglycan (figure 3.5). Some of the proteins which are specifically 
immunoprecipitated by 3-dystroglycan antibodies do so in both 
peroxyvanadate treated and untreated extracts. This suggests that the 
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Figure 3.5 
Silver staining of 3-dystroglycan immunoprecipitates. 
123456 
3-dystroglycan was imm unoprecipitated 
(13-DG IP) from peroxyvanadate treated 
(+PV) and untreated (-PV) myotube 
extracts using polyclonal antibody 1710. 
The controls contained (con) no 1710 in 
order to detect any non-specific pulldown 
of proteins by the protein A Sepharose 
beads. 
A. The immunoprecipitates were run on 
SIDS-PAGE gels and silver stained. In 
the first lane is pre-stained molecular 
weight markers (SIGMA-Aldrich). No 
protein was loaded in the second lane. 
The controls were loaded into the third 
and fourth lanes, and 3-dystroglycan 
immunoprecipitates in the fifth and sixth 
lanes. 
3-dystroglycan was not clearly visible on 
the gel because it is obscured by the lgG 
heavy chain (unfilled arrow points to the 
location of 3-dystroglycan, confirmed by 
western blotting with MANDAG2 -see B). 
The filled arrows denote the approximate 
location of phosphoproteins as seen on 
western blots (see figure 3.4). In the 3-
dystroglycan immunoprecipitates there 
are no proteins present in the 116-
1 4OKDa range, non-specific bands in the 
80-90kDa range (i.e. also present in the 
controls) and a protein clearly 
associating with 3-dystroglycan in the 
55kDa range. 
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There appeared to be no proteins visible on the silver stained gel 
associating with 13-dystroglycan in the 116-130 kDa range. This might be 
because they are present in very small amounts and the silver staining is 
not sensitive enough to detect them, but anti-phospho tyrosine antibodies 
are. 
In the 80-90kDa range, many proteins appeared to be associated with 13-
dystroglycan, however, some of these proteins were also present in the 
controls, suggesting non-specific puildown of proteins. In this range, 
there were small amounts of many proteins, therefore, it is difficult to 
gauge which proteins are specifically associating with 13-dystroglycan. 
In the 55kDa range, there is a protein specifically associating with 3-
dystroglycan, present in both peroxyvanadate treated and untreated 
extracts. Interestingly, there appears to be more of the protein in untreated 
extracts compared to treated. 
13-dystroglycan itself is not clearly visible in the immunoprecipitates, this 
is because it is obscured by the large IgG Heavy chain band which is just 
above 13-dystroglycan. 
Due to the complex mixture of proteins seen in the silver stained 
immunoprecipitates, it was decided that mass spectrometry and protein 
sequencing were not viable options for identifying the phosphoproteins. 
There were many proteins visible on the silver stained gel but even so, 
these might not be the phosphoproteins, due to the difference in 
sensitivity of silver staining compared to immunoblotting. 
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Using the approximate molecular weights of the three main 
phosphoproteins detected on western blots (figure 3.4), putative 
interactors of f3-dystroglycan were tested by western blotting 13-dystroglycan 
immunoprecipitates with antibodies directed against candidate proteins. 
The two groups of proteins investigated were signalling proteins and 
focal adhesion proteins. Many of these proteins are tyrosine 
phosphorylated, therefore, they were considered prime candidates for 
phosphoproteins associating with 13-dystroglycan. In addition, proteins 
such as FAK (125kDa), vinculin (116kDa) and Src (60kDa) are in the 
molecular weight range of the phosphoproteins identified here. 
Other focal adhesion/ signalling proteins were also tested for association 
with 13-dystroglycan, even if they were not in the molecular weight ranges 
of the phosphoproteins e.g. talin. The reason for this was that, if 13-
dystroglycan was associating with one member of the focal adhesion 
complex, many components of the complex may be pulled down in an 
immunoprecipitation experiment (Yoshida et al., 1998). Additionally, 
some proteins migrate higher or lower then their molecular weight on 
SDS-PAGE gels, e.g. paxillin was considered as a viable candidate, it is 
68kDa but runs at very diverse molecular weights on SDS-PAGE gels due 
to its different hyper-phosphorylated states. 
Co-immunoprecipitation experiments proved unsuccessful and the focal 
adhesion proteins FAK, vinculin, paxillin and talin did not appear to co- 
immunoprecipitate 	with 	13-dystroglycan 	(a 	13-dystroglycan 
immunoprecipitate blotted with FAK antibody is shown in figure 3.6A). 
In western blots of 13—dystroglycan immunoprecipitate blotted with an 
antibody against the signalling protein MAPK, it was unclear whether the 
two proteins were associated due to background on the blot (figure 3.613). 
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Figure 3.6 
Western blots of -dystrogIycan immunoprecipitates blotted with 
antibodies to focal adhesion and signalling proteins. 
3-DG 
kDa IP Extract 
125 




-dystroglycan immunoprecipitate (13-DG  IP) (using 81D5 monoclonal antibody) blotted (lB) 
with focal adhesion kinase (FAK) antibody. Extract alone was loaded onto the righthand lane. 
FAK (125kDa) was not co-immunoprecipitated with 3-dystroglycan. 
3-dystroglycan immunoprecipitate (using MANDAG2 monoclonal antibody) blotted (IB) 
with a MAPK kinase antibody which detects both the p42 and p44 isoforms of MAPK. The 
blot had some background and it is difficult to interpret if a small amount of MAPK is co-
immunoprecipitated with 3-dystroglycan. 
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3.6. Pulldowns using 3-dystroglycan coupled to CNBr-
Sepharose 
The rationale was to couple purified 13-dystroglycan cytoplasmic domain 
(section 2.4.11) to CNBr-Sepharose and use this to "pulidown" any 
proteins associating with I3-dystroglycan from cell extracts (section 
2.4.13.2). A truncated construct of the cytoplasmic domain (-3-
dystroglycan) with the last 15 amino-acids missing was also coupled to 
CNBr-Sepharose. Using this, the interaction site of any association could 
be narrowed down. It was hoped that this method would generate less 
non-specific bands than the co-immunoprecipitation experiments used 
previously, and additionally overcome the potential problem of the 3-
dystroglycan antibodies having the same epitope as the one confirmed 
protein: protein interaction site of 3-dystroglycan. In this procedure, 3-
dystroglycan would be anchored by the N-terminal end of its cytoplasmic 
domain, thus leaving the rest of the domain free for interactions. 
Initially, many proteins appeared to be pulled down with the 13-
dystroglycan cytoplasmic domain coupled to CNBr-Sepharose. Not only 
known interactors such as dystrophin, utrophin, Grb2, but also many of 
the candidate interactors of 13-dystroglycan, such as focal adhesion proteins 
(vinculin, FAK, V-Src, paxillin), the DAPC protein dystrobrevin and 
signalling proteins SHC (SH2-Containing sequence) and MAPK. The large 
number of proteins associating with 13-dystroglycan was deemed plausible: 
the DAPC has been shown to associate with focal adhesion complexes, 
and dystrophin co-immunoprecipitates with all the member proteins 
tested (Yoshida et al., 1998), dystrobrevin is part of the DAPC (it interacts 
with the C-terminus of dystrophin (Sadoulet-Puccio et al., 1997)) and 13-
dystroglycan has been shown to associate with MAPK in non-muscle cells 
(M. James & S. J. Winder, unpublished observation). However, a 
phospho-tyrosine western blot of the f3-dystroglycan-CNBr-Sepharose 
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pulidown showed a tremendous number of proteins being pulled down 
(figure 3.7). It is unlikely that all these proteins are interacting with 13-
dystroglycan specifically, therefore this indicated that many proteins were 
non-specifically sticking to the Sepharose beads. 
Figure 3.7 
Western blot of pulldowns using 13-dystroglycan cytoplasmic 









Proteins associating with 3-dystrogIycan were pulled down from peroxyvanadate treated 
(+PV) or untreated (-PV) myoblasts using the f3-dystroglycan construct coupled to 
Sepharose beads. These pulldowns were western blotted (IB) with the phospho-tyrosine 
antibody RC20 (P-Tyr). The antibody detected proteins (phosphorylated on tyrosine 
residues) which were pulled down in the peroxyvanadate treated extracts. It is unlikely that - 
dystroglycan interacts with so many proteins, therefore it was concluded that they were non-
specific interactions. 
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On further inspection, many of these proteins pulled down by 13-
dystroglycan coupled to CNBr-Sepharose were being pulled down in the 
controls as well. This phenomenon can be observed in figure 3.8 where 
the control beads (CNBr-Sepharose beads subjected to the entire coupling 
process, but with no protein added) and 13-dystroglycan-coupled CNBr-
Sepharose beads pulled down comparative amounts of vinculin and 
paxillin. Similar results were noted for other proteins tested, such as 
dystrobrevin, SHC, MAP kinase and Grb2. 
Figure 3.8 
Western blot of pulldowns from myoblast extracts using 13-
dystroglycan coupled to CNBr Sepharose. 
CNBr -DG 
Control CNBr Extract 
IB: Vinculin 
IB: Paxillin 
Myoblast extracts were incubated overnight with 3-dystroglycan coupled to CNBr Sepharose 
(f3-DG CNBr) or CNBr Sepharose with no protein coupled to it (CNBr control). The beads 
were washed thoroughly and loaded onto SIDS-PAGE gels and western blotted (IB) with 
paxillin and vinculin monoclonal antibodies. Extract alone was loaded into the right hand lane. 
Comparable amounts of protein were pulled down by the 3-dystroglycan coupled beads and 
the control beads. 
Representative of at least 5 similar experiments. 
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In order to evaluate whether any of the interactions shown by the 
pulldowns were real, more stringent controls were carried out. The 
rationale was that if the amount of proteins pulled down non-specifically 
was reduced (background), then any specific interactions could be 
visualised more easily. A panel of control beads were used. This panel 
included batches of beads which were blocked with skimmed milk 
powder or BSA (5% (w/v)) before addition to the cell extracts. It was 
expected that if proteins were non-specifically sticking into the pores of 
the Sepharose, this could be prevented by the treatment with BSA or 
skimmed milk powder. To minimise non-specific ionic interactions, 
another control involved increasing the salt concentration in the RIPA 
buffer used in the post-pulldown washes from 150mM to 300mM. In the 
final control, the beads were washed 10 times with RIPA buffer instead of 
the usual 4 times. 
The non-specific interactions were not affected by any of these conditions 
except the blocking with skimmed milk powder which reduced the 
binding of paxillin significantly and the binding of Grb2 to a small extent. 
However, blocking with skimmed milk powder was not considered a 
viable option to reduce non-specific binding generally, because it did not 
affect all interactions equally. 
In a final attempt to identify interactors with 3-dystroglycan by this 
method, the extracts were precleared with blank beads prior to the 
experiment. The theory was that pre-clearing could remove any proteins 
that non-specifically bind the CNBr-Sepharose so that any further 
interactions with 3-dystroglycan-coupled CNBr-Sepharose could be 
considered as genuine interactions. However the pre-clearing could also 
have a detrimental affect on the assay, i.e. by removing all the proteins 
that do in fact interact with 3-dystroglycan. Figure 3.9 shows that there 
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were equal amounts of vinculin in the pre-cleared and non pre-cleared 
pulldowns. Blank beads were used for the clearing and the subsequent 
pulidown was carried out using blank beads (control) or 13-dystroglycan-
coupled beads. These results suggest that pre-clearing has no effect on the 
non-specific interactions, or if it does then there is still sufficient protein 
remaining to non-specifically bind the Sepharose in the pulidown step. 
Perhaps the short pre-clearing step (1 hour) does not allow non-specific 
binding to the same extent as the overnight pulidown step. 
Figure 3.9 
Pre-clearing extracts with blank CNBr Sephorose does not 
reduce non-specific binding. 
IB: VIN 
Western blot of pulldowns from myoblast extracts. 
Myoblast extracts 1 and 3 were pre-cleared with blank beads prior to the experiment. 
Samples 1 and 2 were incubated with blank CNBr Sepharose, 3 and 4 with 3-dystroglycan 
cytoplasmic domain coupled to CNBr Sepharose. Any proteins pulled down with the beads 
were run on SDS-PAGE gels and western blotted (IS) with vinculin monoclonal antibody 
(VIN). Extract alone was loaded in Lane 5. 
There is vinculin in the pre-cleared and non pre-cleared pulldowns suggesting that if pre-
clearing does remove some of the protein, there is still sufficient remaining to non-specifically 
bind to the Sepharose. For example, in lane 2, the extract is pre-cleared with blank beads 
and subsequently incubated with blank beads and vinculin is still pulled down. 
After detailed and thorough testing of this method, it was decided that it 
was not a reliable or successful procedure for analysing protein:protein 
interactions with 3-dystroglycan. This was due to the high number of 
non-specific interactions caused by the CNBr-Sepharose. 
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3.7. Pulldowns using biotin tag -fusion proteins and 
Streptavidin beads 
Experiments using 13-dystroglycan cytoplasmic domain coupled to CNBr-
activated Sepharose had proved to be unreliable due to non-specific 
binding of proteins to the Sepharose. In this assay, the aim was to pull out 
any proteins associating with 3-dystroglycan using a biotin tag (section 
2.1.13.3). This method was chosen because it avoided the complications 
that the coupling procedure had potentially caused, and it was anticipated 
that using a tag to pull down interacting proteins would give a cleaner 
results than co-immunoprecipitation assays used previously. A fusion 
protein of 3-dystroglycan with a biotin tag was made, added to cell extracts 
and pulled down (with any associating proteins) by Streptavidin 
immobilised onto Sepharose beads. 
In this strategy, the Streptavidin beads were first checked for non-specific 
binding of proteins (figure 3.10). Only a very minimal amount of non-
specific binding occurred in the case of vinculin and paxillin, but this was 
considered to be a low background, and not considerable enough to 
obscure the identification of any real interaction. Other proteins such as 
Grb2 and MAPK showed no non-specific interaction with the avidin 
beads, therefore the experiment was embarked upon. 
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Figure 3.10 
Western blots of control pulldowns using Streptavidin-
Sepharose beads. 
Control 






Before commencing experiments using Streptavidin immobilised on to Sepharose beads, 
the beads were incubated with myoblast extracts to check for non-specific protein 
interactions. The resultant pulldowns were run on SDS-PAGE gels (lefthand lane) with 
myoblast extract (righthand lane) and western blotted (lB) with FAK, vinculin, paxillin, 3-
dystroglycan (MANDAG2) or Grb2 antibodies (Table 2.6). A small amount of vinculin and 
paxillin was non-specifically pulled down with the beads but not a large enough quantity to 
disrupt the experiments. FAK, -dystroglycan and Grb2 appeared not to non-specifically 
interact with the Sepharose beads. 
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A f3-dystroglycan cytoplasmic domain construct (table 2.4) was cloned into 
the Pinpoint Xa-3 vector which facilitates the expression of biotin-tagged 
fusion proteins (table 2.3 & section 2.4.10.1). The fusion protein was 
successfully expressed in E.coli. (JM109 strain, table 2.1) and affinity 
purified from bacterial supernatants using Streptavidin beads (figure 
3.11). The beads were thoroughly washed and subsequently added to 
myoblast or myotube extracts. It was predicted that any proteins 
interacting with 13-dystroglycan would be pulled down with the fusion 
protein bound to the Streptavidin beads. However, none of the proteins 
tested were shown to interact with 3-dystroglycan by this method (figure 
3.12A). This still held true when the amount of fusion protein used was 
raised as high as lOj.tg per assay. 
Figure 3.11 
Western blot of biotin tag (PIN) and biotin tag-dystrophin/ - 
dystroglycan fusion proteins 
The fusion proteins were affinity purified from bacterial supernatants using streptavidin 
beads. The resultant proteins were run on SIDS-PAGE gels, and detected with Extravidin-
HRP. The lefthand panel shows the 13kDa biotin tag (PIN) and its breakdown products. The 
biotin tag alone can also be seen in the other two panels where the tag has separated from 
the fusion protein. The middle panel shows the 26kDa 3-dystroglycan-PIN fusion protein. 
The righthand panel shows the 47kDa dystrophin-PIN fusion protein and its degradation 
products. 
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Figure 3.12 
Western blots of pulldowns using biotin tagged 3-dystroglycan/ 
dystrophin fusion proteins 
3-DG-PIN 








3-DG-PIN was added to myoblast or myotube extracts to pulldown proteins interacting 
with dystrophin. Any interacting proteins were run on SDS-PAGE gels (Iefthand lane) next to 
myoblast or myotube extract (righthand lane) and western blotted with antibodies against 
dystrophin (DYS1 & DYS2), utrophin (UTR) (RAB5), paxillin, MAP kinase (NEB9102), or Grb2 
(Table 2.6). None of the interactions investigated were identified. 
In an attempt to verify the dystrophin-f3-dystroglycan interaction, DYS-PIN bound to 
streptavidin beads was added to myoblast or myotube extracts. The beads were 
subsequently washed and run on SDS-PAGE gels and blotted with a 3-DG antibody 
(MANDAG2). The dystrophin-3-dystrogIycan interaction could not be demonstrated by this 
method. 
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3.8. 3-dystroglycan interaction with dystrophin 
The f3-dystroglycan/dystrophin interaction was thoroughly investigated 
in this study. It is the best characterised of interactions within the DAPC 
and in order to elucidate whether the the interaction is regulated by 
phosphorylation, it was essential to have a biochemical method showing 
the association of these two proteins, so that any changes in that 
association can be monitored during phosphorylation events. 
An assay to show that phosphorylation of f3-dystroglycan or dystrophin 
disrupts its interaction with dystrophin would involve demonstrating 
that the two proteins can no longer co-immunoprecipitate in 
peroxyvanadate treated extracts. However, no antibody has been found 
which co-immunoprecipitates these two proteins per Se. Attempts with 
both anti-dystrophin antibodies and anti-13-dystroglycan antibodies were 
unsuccessful (section 3.4). Therefore, a construct of the WW, EF hands 
and ZZ domains of dystrophin (table 2.4) was made and cloned into the 
Pinpoint Xa-3 vector in the attempt to pull out 13-dystroglycan from cell 
extracts using a biotin-tagged dystrophin fusion protein and Streptavidin 
beads (as above). 3-dystroglycan showed no non-specific interaction with 
the Streptavidin beads, but neither was the dystrophin fusion protein able 
to pull out li-dystroglycan from the cell extracts (figure 3.12B). 
The subsequent approach to show an association between dystrophin and 
13-dystroglycan involved expressing a tagged dystrophin protein in C2/ C4 
cells. This would enable the immunoprecipitation of the tagged protein 
using an antibody directed against the tag, and hopefully, the co-
immunoprecipitation of 13-dystroglycan. Once dystrophin and - 
dystroglycan were successfully co-immunoprecipitated from cell extracts 
then this interaction could be investigated in peroxyvanadate treated cell 
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extracts. Myoblasts rather than myotubes were transfected because the 
static nature of myotubes may have deleteriously affected the transfection 
process. Additionally, there is no native dystrophin expressed in 
myoblasts, so any dystrophin expressed in the cell would be purely the 
tagged form. Initially a construct encompassing the WW, EF hands and 
ZZ domains of dystrophin was cloned into the pCEP4F vector which has 
CMV and SV40 promoters which express a FLAG tag fused to the cloned 
protein. pCEP4F-DYS was transfected into myoblasts using Lipofectamine 
reagent (section 2.3.8). As discussed further in section 4.4.5, the anti-FLAG 
antibody available (M2) was not reliable. The western blot of 
untransfected myoblast extracts and pCEP4-DYS transfected myoblast 
extracts showed exactly the same banding pattern. The anti-FLAG 
antibody did not appear to adequately immunoprecipitate FLAG-tagged 
proteins either, which prevented successful co-immunoprecipitation 
experiments using the FLAG tag. 
As an alternative, the dystrophin construct was cloned into a pCMV-HA 
vector and transfected into myoblasts. HA-tagged dystrophin protein was 
successfully expressed, and the anti-HA antibody successfully 
immunoprecipitated the HA-tagged dystrophin protein (figure 3.13A). 
This immunoprecipitate was western blotted with a 3-dystroglycan 
antibody, but f3-dystroglycan did not co-immunoprecipitate with the HA-
tagged dystrophin protein (figure 3.13B). Purified 13-dystroglycan 
cytoplasmic domain was also added to the immunoprecipitation 
experiments to see if it associated with HA-tagged dystrophin. It did 
appear to do so, however, it was concluded that the purified 3-
dystroglycan was interacting non-specifically with the protein G 
Sepharose because it was also in the control immunoprecipitation (figure 
3.13B). 
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Figure 3.13 
HA-tagged dystrophin and 3-dystroglycan do not co-
immunoprecipitate 
HA HA 




IB: HA IB: -DG 
+ 
Western blot of HA-DYS immunoprecipitated by anti-HA antibody. 
pCMV-HA-DYS transfected myoblast extracts were immunoprecipitated with anti-HA 
antibody (HA IP) and western blotted (IB) with anti-HA antibody. The 34kDa HA-DYS protein 
was successfully immunoprecipitated from the transfected extracts (denoted by filled arrow). 
3-dystroglycan does not co-immunoprecipitate with HA-DYS 
HA-DYS was immunoprecipitated (IP) from pCMV-HA-DYS transfected myoblasts with anti-
HA antibody, and western blotted with -dystroglycan monoclonal antibody MAN DAG2 
(Table 2.6). Purified -dystroglycan cytoplasmic domain was added (+) or omitted (-) from the 
immunoprecipitation experiment. In the control (Con), untransfected myoblasts were used. 
Native 3-dystroglycan (molecular weight denoted by unfilled arrow) was not co-
immunoprecipitated with HA-DYS. Purified 3-dystroglycan (denoted by shaded arrow) 
appeared to immunoprecipitate with HA-DYS but was also immunoprecipitated in the control 
which suggests that it interacts non-specifically with the protein G Sepharose. 
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3.9. Discussion 
The aim of the studies documented in this chapter was to identify 
proteins which interact with 13-dystroglycan using protein biochemistry 
techniques. Several methods were thoroughly tested for their use in 
identifying proteins associating with 13-dystroglycan, including co-
immunoprecipitation, and different methods of "pulldowns" using I-
dystroglycan cytoplasmic domain coupled to CNBr-Sepharose, and f3-
dystroglycan cytoplasmic domain fused to a biotin tag. Transfection 
experiments were also undertaken, in order to demonstrate the 
interaction between 13-dystroglycan and dystrophin. 
3.9.1. Characterisation of C2 cell lines 
Following the thorough testing of three mouse muscle cell lines, the 
C2/C4 cell line was considered to be the most suitable for use in this 
study. C2/C4 has efficient and consistent myoblast fusion, a higher 
expression of dystrophin protein than the other cell lines and displays the 
predicted expression pattern of DAPC proteins as in vivo (figure 3.2). 
The predicted expression pattern of the ubiquitous proteins utrophin and 
13-dystroglycan is that they are expressed equally throughout all stages of 
differentiation. In vivo, it has been shown that dystrophin protein in 
foetal muscle samples (at 9 weeks of gestation), is barely detectable with 
antibodies on western blots and only distinct populations of larger 
myotubes are recognised by dystrophin immunostaining. However, this 
staining pattern increases and becomes more uniform with age and 
reaches the adult pattern of expression at 26 weeks of gestation (Clerk et 
al., 1992). In cultured cells it has been previously shown that dystrophin 
mRNA is expressed only in fused myotubes and not myoblasts (Oronzi- 
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Scott et al., 1988). In this study, it was found that dystrophin protein was 
not expressed in myoblasts but only in advanced stages of differentiation, 
which is in agreement with the described expression of dystrophin 
mRNA. 
In addition to having high levels of myoblast fusion and the anticipated 
expression patterns of DAPC proteins, the C2/C4 cell line had consistent 
properties from batch to batch. For these reasons, it was the cell line of 
choice for use in this study. 
3.9.2. Co-immunoprecipitation experiments 
Co-immunoprecipitation is a well established method for testing 
protein:protein interactions. In this study co-immunoprecipitation 
experiments were used to elucidate whether RIPA buffer permitted the 
extraction of the DAPC as a whole entity, and to gain understanding of 
protein:protein interactions within the DAPC, and attempt to identify 
proteins associating with 13-dystroglycan outwith of the DAPC. 
The co-immunoprecipitation of dystrophin and 6-sarcoglycan, but not f3-
dystroglycan, using dystrophin antibodies (VIA4-2A3 and XIXC2-D11) and 
the cc-sarcoglycan antibody IVD3-1 (figure 3.3) suggests that dystrophin 
and the sarcoglycan complex are more tightly linked than 13-dystroglycan 
with dystrophin or 13-dystroglycan with the sarcoglycan complex. This is 
unexpected because 3-dystroglycan and dystrophin are directly linked 
(Jung et al., 1995), and it has been demonstrated that they have a tight 
association (Finn & Ohlendieck, 1997). Moreover, the sarcoglycan 
complex has not, to date, been shown to be directly linked to dystrophin. 
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It has been demonstrated that 6-sarcoglycan can be chemically crosslinked 
to the dystroglycan complex suggesting that they lie in close proximity 
(Chan et al., 1998). In addition, studies on the 3-sarcoglycan deficient mice 
have led to the hypothesis that the sarcoglycan complex stabilises the link 
between dystrophin and the dystroglycan complex (Araishi et al., 1999). 
From these findings one would expect that there is a higher likelihood of 
the sarcoglycan complex co-immunoprecipitating with 13-dystroglycan 
than dystrophin. However, although 8-sarcoglycan can be crosslinked to 
the dystroglycan complex, it has been demonstrated that cc-sarcoglycan is 
less tightly associated with the rest of the sarcoglycan complex (Chan et al., 
1998). This may explain why the a-sarcoglycan antibody cannot co-
immunoprecipitate 13-dystroglycan but it does not explain why 5-
sarcoglycan can be co-immunoprecipitated with dystrophin but f3-
dystroglycan cannot. The association between o-sarcoglycan and the 
dystroglycan complex may be weak and the o-sarcoglycan antibody 
possibly co-immunoprecipitates with dystrophin via dystrobrevin. 
Dystrobrevin has recently been shown to interact directly with the 
sarcoglycan-sarcospan complex (Yoshida et al., 2000), and interacts with 
dystrophin, as demonstrated by co-immunoprecipitation data (Sadoulet-
Puccio et al., 1997). Therefore, dystrobrevin could act as a link between the 
sarcoglycans and dystrophin. 
The co- immunoprecipitation assays were not effective in demonstrating 
other known protein:protein interactions with 13-dystroglycan (i.e. 13-
dystroglycan with dystrophin and Grb2). One reason for this may be 
because that the best 13-dystroglycan antibodies available are directed 
against the most C-terminal 15 amino-acids of 13-dystroglycan cytoplasmic 
domain. This region contains the dystrophin / 13-dystroglycan, Grb2/ 13-
dystroglycan and caveolin-3 / 13-dystroglycan interaction sites and is 
possibly where other proteins associate with 13-dystroglycan as well. This 
means that the antibody may be competing off proteins which interact 
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with 13-dystroglycan in vivo, or vice versa i.e. the 13-dystroglycan:protein 
interaction is so strong that the antibody can not access the epitope. 
In addition, the Grb2 binding site on f3-dystroglycan overlaps with the 
dystrophin/13-dystroglycan binding site. The two proteins have been 
shown to be in direct competition with one another in vitro for 13-
dystroglycan binding (Russo et al., 2000). In addition, dystrophin competes 
with caveolin-3 for the WW-domain binding motif (PPxY) in 0-
dystroglycan (Sotgia et al., 2000). The competitiveness of these interactions 
may explain why they could not be demonstrated by co-
immunoprecipitation experiments. The dynamic nature of the 
interactions in the complex may make them difficult to capture by the co-
immunoprecipitation process. 
It was also unexpected that the dystrophin/13-dystroglycan interaction 
could not be detected in C2/C4 cells transfected with a HA-tagged 
dystrophin construct (HA-DYS) (figure 3.13B). It is unlikely that the HA 
tag obscured any binding sites of the fusion protein because it is designed 
to be as small as possible to avoid any obstructions or interference with 
protein folding. The most probable reason for HA-DYS not associating 
with 13-dystroglycan is that the HA-DYS protein was not folded properly in 
the cell. Like any protein:protein interaction, the dystrophin/13-
dystroglycan interaction is highly dependent on the structure of 
dystrophin because the interaction requires stabilisation by the 
orientation of EF hand regions as well as the WW domain-mediated 
interaction (Huang et al., 2000). The HA-DYS fusion protein could also 
have been mis-localised so that was not in the correct compartment of the 
cell in order to interact with li-dystroglycan. 
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3.9.3. 13-dystroglycan interacts with three phosphoproteins 
However, during co-immunoprecipitation assays using 13-dystroglycan 
antibodies, three phosphoproteins associating with 3-dystroglycan were 
identified (figure 3.4). This suggests that if these proteins are directly 
interacting with 13-dystroglycan, they are doing so at regions other than 
the C-terminal 15 amino-acids of 3-dystroglycan (see above). 
When the f3-dystroglycan immunoprecipitates were analysed by silver 
staining, a complex mixture of proteins were observed (figure 3.5). Many 
of these proteins were thought to be contaminants from the anti-sera and 
proteins non-specifically interacting with the Sepharose. But it was also 
clear that more than just three proteins were specifically associated with 
3-dystroglycan. In addition, in the 116-130kDa range on the silver stained 
gel, no proteins appeared to associate with 3-dystroglycan, contrary to the 
results 	obtained 	whilst 	western 	blotting 	3-dystroglycan 
immunoprecipitates with anti-phosphotyro sine antibodies. This 
highlights the sensitivity of the anti-phosphotyrosine antibodies 
compared to silver staining. The complex mixture of proteins viewed in 
the silver stained gels ruled out the prospect of using mass spectrometry 
or protein sequencing to identify the phosphoproteins associating with 3-
dystroglycan. 
Focal adhesion complexes are specialised sites of cell adhesion which 
occur in many cell types in culture. ECM-integrin interactions occur at 
various cell-substrate linkages, for example, at neuromuscular junctions 
(NMJ), costameres and focal adhesion sites. Integrins are a large family of 
heterodimeric transmembrane proteins which, among other functions, 
mediate attachment to the ECM and are therefore involved in the 
regulation of many cellular functions. Ligand occupancy and clustering of 
integrins leads to the recruitment of signalling and actin-binding proteins 
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at focal adhesion sites, which in turn activate a variety of intracellular 
signalling events. Focal adhesions provide a model for studying the 
structural links and signalling between the ECM and the cytoskeleton, 
and the modulation of cell adhesion. 
It was hypothesised that the three phosphoproteins found associating 
with 13-dystroglycan were signalling or focal adhesion proteins. The DAPC 
has been shown previously to have links to focal adhesion proteins. 
Immunofluoresence studies have shown that dystrophin and utrophin 
co-localise with focal adhesion structures in tissue culture cells (James et 
al., 1996; Belkin & Burridge, 1995; Belkin & Smallheiser, 1996). Yoshida et 
cii. (1998) demonstrated that a dystrophin antibody co-
immunoprecipitated focal adhesion proteins (FAK, vinculin, and talin) 
and integrin subunits, and an a-sarcoglycan antibody co-
immunoprecipitated FAK (Yoshida et al., 1998). 13-dystroglycan itself has 
been associated with focal adhesions via the Grb2: FAK interaction in 
brain synaptosomes (Cavaldesi et al., 1999), but a direct interaction has not 
been shown. Due to these previous studies, focal adhesion proteins were 
thought to be strong candidates for proteins which interact with f3-
dystroglycan. 
MAP kinase was another candidate protein for interacting with 0-
dystroglycan in this study. There is evidence for MAP kinase (ERK) 
involvement in adhesion-mediated signalling and it has been 
demonstrated that active MAP kinase is targeted to newly forming focal 
adhesion complexes (Fincham et al., 2000). In addition, Grb2 (which 
associates with 13-dystroglycan) is involved in the Ras signalling pathway 
which leads to MAP kinase activation. 13-dystroglycan has also been 
observed associating with MAP kinase in non-muscle cells (M. James & S. 
J. Winder, unpublished observation). 
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In order to identify whether focal adhesion and signalling proteins were 
in fact associating with 13-dystroglycan, a range of antibodies directed 
against candidate proteins (table 2.6) were used to probe f3-dystroglycan 
immunoprecipitates (figure 3.6). However, the findings proved 
inconclusive. The results often were difficult to analyse due to 
background. Therefore "pulldown" experiments were attempted. 
3.9.4. Puildown experiments 
The puildown experiments devised for this study using 3-dystrog1ycan 
coupled to CNBr-Sepharose were not useful in identifying any proteins 
associating with 3-dystroglycan. The Sepharose proved to be very "sticky" 
i.e. many proteins non-specifically and preferentially associated with the 
Sepharose rather than to 3-dystroglycan. There appeared to be an equal 
amount of paxillin and MAPK pulled down in the controls compared to 
the 13-dystroglycan-CNBr Sepharose pulldowns (figure 3.8). In the case of 
some proteins, there appeared to be even more protein in the control 
than in the experiment e.g. dystrobrevin, SHC. Overall, vinculin and SHC 
proved to be the "stickiest" of all the proteins analysed during the course 
of this study i.e. were pulled down in the largest quantities by the 
Sepharose beads. 
Extensive attempts to minimise the non-specific binding to the CNBr-
Sepharose were carried out. The use of ethanolamine rather than a Tris 
buffer to deactivate any remaining active groups after the coupling 
procedure did reduce the level of non-specific binding to some extent, but 
still the quantities were equal to the amount of protein pulled down by 
the CNBr-Sepharose coupled to 13-dystroglycan. Other attempts to reduce 
non-specific binding included blocking the Sepharose beads with 
skimmed milk powder or BSA, pre-clearing the extracts before use, 
reducing the time that the extracts were incubated with CNBr-Sepharose 
140 
Chapter 3 Proteins associating with fi-dystroglycan 
from overnight to 4 hours, or using more stringent washing conditions 
on the beads before analysis by SDS-PAGE and western blotting. However, 
no procedure succeeded in reducing non-specific binding to a level which 
made the assay workable. Whilst the controls were pulling down the 
same quantity of protein as the experiment, there was no way of detecting 
any real interactions by this method. 
Interestingly, the Streptavidin-Sepharose used in puildown experiments 
did not non-specifically interact with any proteins tested (figure 3.10). This 
suggests that the non-specific binding to the CNBr-Sepharose was due to 
its active groups, rather than the Sepharose itself -perhaps they were not 
fully deactivated despite the deactivation steps used in the protocol. It is 
also plausible that the purified f3-dystroglycan cytoplasmic domain (which 
was coupled to the CNBr-Sepharose) interacts non-specifically with the 
Sepharose, but the tagged fusion protein (PIN-0-DG) does not. - 
dystroglycan cytoplasmic domain has been observed in Sepharose-only 
controls, interacting non-specifically with protein A/C Sepharose (figures 
3.1313 & 4.5). 
The assay using Streptavidin-Sepharose provided the desired lack of 
background, but still, protein interactions with 13-dystroglycan were not 
observed, possibly because the conditions were not ideal and as the in 
vivo situation. Despite careful optimisation of extraction conditions of 
myoblasts and myotubes, the extraction conditions may not have been 
optimal to maintain protein:protein interactions. 13-dystroglycan is a 
transmembrane protein, therefore, very gentle conditions will not 
solubilise it, but very stringent conditions will potentially disrupt 
protein:protein interactions. Therefore, a fine balance is required to 
maintain the in vivo situation as much as is attainable. In addition, some 
interactions are transient, or competitive e.g. Crb2 and dystrophin 
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competing for association with 13-dystroglycan. This phenomenon 
demonstrates the dynamic nature of the DAPC and therefore its fragility 
when it comes to analysing the interactions biochemically. 
13-dystroglycan associates with dystrophin in DAPC, but there is also 
evidence to suggest that there is another pool of 13-dystroglycan which is 
not associated with the DAPC (Finn & Ohiendieck, 1998). During the 
extraction of proteins from myoblasts/myotubes using RIPA buffer, it 
appears that after sonication and centrifugation of the extracts, there are 
equal amounts of 13-dystroglycan in the supernatant and the pellet (data 
not shown). It is possible that the 13-dystroglycan in the soluble fraction is 
mainly 13-dystroglycan which is not part of the DAPC. If this is the case, it 
is not surprising that 3-dystroglycan antibodies can immunoprecipitate 1-
dystroglycan but do not co-immunoprecipitate any known associating 
proteins. This could also explain why the pulldowns show no proteins 
associating with 3-dystrog1ycan because it would mean that the 13-
dystroglycan added to the extracts (in the form of the purified 13-
dystroglycan or fusion protein) is not competing with the 3-dystroglycan 
pool which is part of the DAPC or other complexes. 
Despite the limited success of the methods used, it has still been 
demonstrated here that 13-dystroglycan associates with a number of 
phosphoproteins. It is possible that the phosphoproteins indirectly 
associate with 13-dystroglycan via other interactors of li-dystroglycan. For 
example, the phosphoproteins observed may be focal adhesion proteins 
indirectly associating with 13-dystroglycan. In this case, the "linker" 
protein connecting 13-dystroglycan to the focal adhesions so far remains 
elusive. Subsequently, f3-dystroglycan was used as bait in yeast two-hybrid 
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A yeast two-hybrid screen using - 
dystroglycan cytoplasmic domain as a bait to 
screen a skeletal muscle cDNA library. 
4. 1. Introduction 
The yeast two-hybrid assay is a highly sensitive technique that can be used 
to identify protein:protein interactions which are sometimes not revealed 
by other less sensitive methods (for reviews see Fritz & Green, 1992; Fields 
& Sternglanz, 1994; Brent & Finley, 1997). Additionally, because the assay 
is in vivo, proteins are present in the natural environment of the cell 
nucleus and not subjected to harsh chemical conditions. The aim of this 
screen was to identify interactors of 0-dystroglycan which had so far 
proved difficult by biochemical methods, in particular unidentified 
phosphoproteins which had been shown to associate with f3-dystroglycan 
in co-immunoprecipitation experiments (figure 3.4). These proteins also 
appear to associate with 13-dystroglycan in pharmacologically untreated 
cells (see silver staining, figure 3.5) suggesting that the interactions are not 
necessarily phosphorylation-dependent, and therefore the yeast two-
hybrid assay was considered to be a suitable method to potentially identify 
them. 
The yeast two-hybrid assay was originally based on the observation that 
many eukaryotic transcriptional activators are composed of two distinct 
domains (DNA binding domain and transcriptional activating domain) 
which can be physically separated and can only function as an activator 
when brought together (Fields & Song, 1989; Chien et al., 1991). 
The yeast two-hybrid system utilises two plasmid-borne gene fusions that 
are co-transformed into a host yeast strain containing inducible reporter 
genes. The protein of interest (or "bait") is encoded as a gene fusion to 
DNA binding domain from either the GAL4 or LEXA protein. A second 
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protein, or library of proteins, is encoded as a gene fusion to a 
transcription activation domain. The interaction between the bait protein 
and a library protein results in the localisation of the transcription 
activation domain to the DNA of the host strain, activating transcription 
of the reporter genes and generating a phenotypic signal. 
Uses of the yeast two-hybrid assay include identifying factors which 
interact with a protein of interest by screening a pool of clones (method 
used in this study), providing molecular evidence for a suspected 
interaction, and defining domains or individual amino-acids which are 
critical for a particular interaction. 
The expectation was, that using the yeast two-hybrid assay in this study 
would substantiate known interactions with f3-dystroglycan and 
additionally, identify new interacting proteins. 
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4.2. Setting up the yeast two-hybrid screen 
4.2.1. The bait and the cDNA library. 
13-dystroglycan cytoplasmic domain (amino-acids 781-895) was cloned 5' of 
the GAL4 DNA binding domain in the yeast two-hybrid bait vector pAS2 
(section 2.5.4). The 5' vector-insert junction of f3-DG/pAS2 was verified by 
DNA sequencing, confirming that 3-dystroglycan was in frame. The 3-
dystroglycan monoclonal antibody MANDAG2 (table 2.6) was used to 
verify the expression of the GAL4-0-dystroglycan fusion protein by 
western blotting of proteins isolated from the host yeast strains 
transformed with 13-DG/pAS2. 
One factor which is critical for the success of a yeast two-hybrid screen is 
the quality of the library used. The MATCHMAKER human skeletal 
muscle cDNA library (section 2.5.3) was used for this yeast two-hybrid 
screen. This library has 3.5 x 106  independent clones, cloned into the 
pACT2 vector. 90% of these clones have an insert and the average insert 
size is 2kb. The titre of the library was calculated and the library re-
amplified accordingly for this screen. 
4.2.2. The Saccharomyces cerevisiae host strains 
A good two-hybrid host strain should be extremely sensitive to small 
changes in reporter activity, therefore allowing detection of weak or 
transient interactions, but also providing a very low incidence of false 
positives. For this screen, 13-DG/pAS2 was transformed into three host 
strains namely CG-1945, PJ49-6A, and Y190 (table 2.10) to compare their 
transformation efficiencies, and the relative sensitivities of their HIS3 
reporters during expression of the GAL4-3-dystroglycan fusion protein. 
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Some polypeptides are capable of activating the transcription of reporter 
genes when fused to a DNA-binding domain, even in the absence of an 
activation domain. The sensitivity (or "leakiness") of the HIS3 reporter 
can be adjusted by adding a competitive inhibitor of the HIS3 gene 
product, namely 3-aminotriazole (3-AT). For baits that activate HIS3, 3-AT 
is added at a level which makes the strain auxotrophic for histidine so 
that the library can be screened to detect interacting proteins that result in 
further activation of HIS3. However, if high concentrations of 3-AT are 
required, then the sensitivity of the system can be compromised. 
The 13-DG/pAS2 bait vector was transformed into the three yeast host 
strains to compare their suitability for this screen. Transformants were 
isolated using the tryptophan marker on pAS2 and grown up in media 
devoid of tryptophan (-W) ready for transformation with the skeletal 
muscle cDNA library. The leucine marker on the pACT2 plasmids allows 
the selection of library plasmids. The strains containing both bait and 
library plasmids were isolated on media lacking tryptophan and leucine 
(-LW) and the transformation efficiencies of the three strains were 
compared. The amount of salmon sperm DNA used as a carrier in the 
transformation was also varied because this can have an effect on the 
transformation efficiency. When the -dystroglycan containing strains 
were transformed with 0.6tg library DNA, the 13-DG/PJ69-4A strain clearly 
yielded the highest transformation efficiency (figure 4.1). -DG/Y190 
transformed reasonably well, but the transformation efficiency of 3-
DG/CG-1945 was very low indeed. In both PJ694A and Y190 it can be seen 
that using lOoiig salmon sperm DNA as a carrier gave the optimum 
transformation efficiency. 
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Figure 4.1. 
Comparison of three yeast two-hybrid host strains: 
















Salmon sperm DNA (jig) 
The three Saccharomyces cerevisiae host strains CG1945, PJ69-4A and Y190 were 
transformed with J3-DG/pAS2 followed by 0.6ig of skeletal muscle cDNA library, using 0, 50, 
100 or 1 50ig salmon sperm DNA as a carrier.The transformants were selected by plating 
onto -LW dropout media. The transformation efficiencies are shown as number of colonies 
per transformation (y-axis) against amount of carrier DNA used (x-axis). CG1 945 had the 
poorest transformation efficiency, which was not affected by altering the amount of carrier 
DNA. PJ69-4A had by far the highest transformation efficiency. 1 00tg of salmon sperm DNA 
gave the optimum transformation efficiency in both PJ69-4A and Yl 90 strains. 
After transforming the library into the three strains, the amount of 3-AT 
required to increase the stringency of the HIS3 reporter was titrated 
(section 2.5.6.1). This was carried out by transforming library DNA into 
the f3-dystroglycan containing strains and plating the transformants onto 
media containing different mM concentrations of 3-AT, but lacking 
tryptophan, leucine and histidine (-LWH). Figure 4.2 shows that 3-
DG/Y190 required an exceptionally high concentration of 3-AT (more 
than 40mM) to eliminate false positives. For 13-DG/CG-1945, the growth of 
His colonies were significantly reduced by 3-AT concentrations over 
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10mM. f3-DG/PJ69-4A required less than 1mM 3-AT to eliminate the 
growth of His colonies. 
Figure 4.2 
Titration of 3-AT concentration to maintain sensitivity of the 











3-AT concentration (mM) 
1.5g library DNA was transformed into CG1945, PJ69-4A and Y190 strains containing 13-
DG/pAS2 and the transformants plated onto tryptophan, leucine and histidine dropout 
plates (-LWH) containing different mM concentrations of 3-AT. mM concentrations of 3-AT 
are shown on the X-axis and number of colonies per transformation on the y-axis. The titration 
of 3-AT was carried out to test whether 3-DG/pAS2 activates the HIS3 reporter gene without 
the presence of an activation domain, and what concentration of 3-AT is required to inhibit 
this so that the strain remains auxotrophic for histidine. 
The growth of His+ 13-DGIY190 colonies was very high and over 40mM 3-AT would be 
required to reduce this background. Growth of His+ 13-DG/CG1945 colonies was reduced at 
3-AT concentrations over 10mM. Growth of His+ 13-DG/PJ69-4A colonies was totally 
abolished by less than 1 m 3-AT. 
After the comparison of the three yeast strains, PJ694A was chosen for 
use in this yeast two-hybrid screen. This was because it facilitated the 
highest transformation efficiency when transforming library DNA into 
the strain containing 13-DG/pAS2, and required the least amount of 3-AT 
to counteract leakiness of the HIS reporter gene. In fact, such a small 
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amount of 3-AT was required that it was excluded from the screen 
entirely. 
4.3. Results of the yeast two-hybrid screen using PJ694A 
The screen was carried out in three stages, each stage consisted of 20 
individual transformations. A schematic of the screen is shown in figure 
4.3. In total, approximately 900,000 transformants were screened (the 
transformation efficiency was calculated as in section 2.5.6.2). In stage 1, 
the transformations were plated onto -LWH dropout media and any His 
colonies were re-streaked onto -LWA dropout media. In stages 2 and 3, 
the transformations were plated onto -LWA dropout media and any Ade 
colonies were re-streaked onto -LWH dropout media. Any His, Ade 
candidates were considered to represent real two-hybrid interactions. The 
prey plasmids responsible for the observed two-hybrid interactions were 
plasmid-rescued from these cells (section 2.5.7.1). 
4.3.1. Clones isolated from the yeast two hybrid screen 
Out of the approximately 900,000 transformants screened by the yeast two-
hybrid assay, 150 His or Ade colonies were picked and restreaked onto 
media lacking Adenine or Histidine respectively. 78 of these colonies 
were His and Ade and the plasmids from these colonies were rescued 
and BglII digested. Out of these, 95% contained inserts. These 74 plasmids 
were subsequently sequenced and the sequences compared to sequence 
databases using BLAST (section 2.5.7.2). A summary of the sequencing 
results is shown in table 4.1. 
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Figure 4.3 
Yeast two-hybrid scheme 
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Table 4.1 





Nedd4-like uhiquitin-protein ligase (WWP1) 16 
RAD6, huBC9,UBE21, E21 (ubiquitin-conjugating enzymes) 10 
Rev7p/ MAD2-like 2/ MAD2B 7 
Novel centrosomal protein RanBPM 6 
Yes-associated protein 65kDa (YAP65) 4 
Jun activation domain binding protein (JAB1) 3 
Cytochrome C oxidase subunit II (mitochondrial) 3 
Actin cd 2 
Collagen type VI, 0 (COL6A3) 2 
FH1/FH2 domain containing protein (FHOS) 2 
p51 delta / p53 homology 2 
Acetyl-coezyme A acetyltransferease 1 1 
Adaptor-related protein complex mul subunit (CLAPM1)/ 
clathrin assembly protein 50 (AP50)  
1 
ATPase (Ca" transporting) 1 
BCL-2-associated athanogene 3 (BAG3)/ BAG family 
chaperone regulator 3 / BCL-2 binding protein  
1 
Chromosome 4 clone C0483123 1 
Chromosome 16 BAC clone CIT987SK-A-962B4 1 
Creatine kinase 1 
DKFZp586K1922 1 
Enoyl coenzyme A hydratase (mitochondrial) 1 
Eukaryotic translation initiation factor 3, subunit 6/ subunit 
p48 (Int-6)  
1 
HIV type 1 enhancer binding protein 2 (HIVEP2) 1 
HSPC147/ pt-wd mRNA for WD-40 repeat protein/ unr- 
interacting protein (UNRIP)/ Mus musculus serine- 
threonine kinase receptor-associated protein  
I 
Kaliman syndrome 1 (KAL1) /ADMLX=putative adhesion 
molecule 
1 
Mitogen-activated protein kinase 7 (MAPK7) 1 
Myoglobin 1 
Skeletal muscle troponin T 1 
Sterol regulatory binding transcription factor 1 (SREBF1) 1 
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As controls, the rescued library plasmids were transformed back into the 
13-DG/PJ69-4A strain to check whether the reporter genes were still 
activated by an interaction between the two plasmids (section 2.5.7.3). The 
library plasmids were also transformed into PJ694A with no 13-DG/pAS2 
present to confirm that the library plasmid alone did not activate the 
reporter genes. 
4.3.2. Selection of interactors of 0-dystroglycan to study in more 
depth 
Sequencing of the 74 plasmids isolated from the yeast two-hybrid screen 
produced intriguing findings (table 4.1). Interestingly, the results did not 
include any known or previously described putative interactors of 3-
dystroglycan (sections 1.6.1, 1.6.4). 
Despite the highly significant frequency of isolation, the top five proteins 
with the highest number of "hits" in the two-hybrid screen were 
disregarded for further analysis: 
Nedd4-like ubiquitin-ligase WWP1 was pulled out of the skeletal muscle 
library 16 times with the f3-dystroglycan bait. This is a highly significant 
result (22% of all clones sequenced) but was considered as a non-specific 
interaction and consequently discounted. WWP1 contains a type I W W 
motif which recognises a PPxY motif in its ligands, which is the same as 
the WW-binding motif in f3-dystroglycan's cytoplasmic domain, used in 
this screen. In biochemical peptide ligand assays, it has been shown that 1-
dystroglycan interacts with other WW domains apart from the one in 
dystrophin, including those from Nedd-4-like proteins (Pirozzi et al., 
1997). These may be non-specific interactions or perhaps WW-interacting 
proteins are regulated by the ubiquitin-mediated degradation pathway (see 
discussion, section 4.7.6). However, apart from involvement in the 
ubiquitin-mediated degradation pathway, the relevance of the 3- 
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dystroglycan-WWP1 interaction is tenous. The interaction of f3-
dystroglycan with YAP65 was also regarded as a non-specific WW-domain 
mediated interaction because like WWP1, YAP65 also interacts with the 
PPxY motif in its ligands. 
Several different ubiquitin-conjugating enzymes were identified as 
interactors of 13-dystroglycan in the yeast two-hybrid screen. One of these, 
RAD6, was found to self-activate in the controls i.e. the RAD6 clone 
activated the HIS3 reporter gene without the presence of pAS2-13-
dystroglycan. huBC9, UBE21 and E21 are highly homologous to RAD6, so 
presumably were self-activating HIS3 as well. Therefore, these ubiquitin-
conjugating enzymes were not considered as candidates for real 
interactors of 13-dystroglycan. 
Rev7p/MAD2-like protein was pulled out by 3-dystroglycan cytoplasmic 
domain 7 times in the yeast two-hybrid screen. MAD2 (mitosis arrest-
deficient-2) is a cell cycle mitotic spindle assembly checkpoint protein. 
This interaction was disregarded because MAD2 and MAD2-like proteins 
are frequently found as unlikely interactors in yeast two-hybrid screens. 
For example, recently it has been demonstrated that MAD2 interacts with 
tumour necrosis factor alpha convertase (TACE), a MHC- (major 
histocompatibility complex) encoded ubiquitin-like protein FAT10, the 
insulin receptor and oestrogen receptor-3 (Nelson et al., 1999; Liu et al., 
1999; O'Neill et al., 1997; Poelzl et al., 2000). These protein:protein 
interactions were all identified in yeast two-hybrid screens and the 
biological relevance is difficult to substantiate (Kevin Hardwick, personal 
communication). 
Ran binding protein (RanBPM) is a novel centrosomal protein. It binds to 
Ran, a GTPase which has many roles in the cell. Ran has been implicated 
in nuclear transport, cell cycle control, and spindle assembly (reviewed in 
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Dasso, 2001) but it appears that RanBPM is involved in microtubule 
nucleation (Nakamura et al., 1998). No obvious roles for RanBPM 
interacting with 13-dystroglycan were deduced, therefore more biologically 
relevant interactions were tackled with the highest priority. 
Out of the 74 plasmids sequenced, three proteins were chosen to study 
more fully, namely JAB1, FHOS and actin al. These proteins were chosen 
as potential genuine interactors of 13-dystroglycan because some degree of 
biological relevance was ascertained. JAB1 is implicated in integrin-
mediated signalling, as is the DAPC (Bianchi et al., 2000, Yoshida et al., 
1998). FHOS is potentially involved in actin cytoskeleton reorganisation 
(Westendorf et al., 1999; Tanaka, 2000). The actin cytoskeleton is linked to 
the DAPC via dystrophin and it would be a very important outcome if f3-
dystroglycan was also found to have a direct link to actin. 
In the screen, the library plasmids encoding JA131, FHOS and actin al 
were all selected as positive clones (Ade, His) more than once (3x, 2x and 
2x respectively). In addition, these plasmids did not activate the reporter 
genes alone, but activated the GAL2-ADE and GALl-HIS reporter genes in 
conjunction with f3-DG/pAS2. Furthermore, when checked by a 0-
galactosidase filter assay, the GAL7-LacZ reporter gene was also activated 
by pACT2-JAB1, pACT2-FHOS or pACT2-actin al in association with 13-
DG/pAS2 (data not shown). 
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4.4. Characterisation of the JAB1-13-dystroglycan 
interaction 
4.4.1. Jun activation-domain binding protein (JAB1). 
JAB1 was isolated as an interactor of 13-dystroglycan three times in the 
yeast two-hybrid screen. The three clones isolated all contained the entire 
1.5kb coding sequence of the JAB1 gene. Human JAB1 was first described 
as a co-activator of the c-Jun and Jun D transcription factors (Claret et al., 
1996). JAB1 is also a component of the constitutive photomorphogenesis 9 
(COP9) signalosome which is thought to be involved in modulating 
multiple signalling pathways in plants. 
JAB1 was considered as a potential in vivo interactor of 13-dystroglycan 
because it has recently been implicated in integrin-mediated signalling 
(Bianchi et al., 2000) and is part of complex (COP9) involved in regulation 
of signalling pathways. 
The DAPC also has links to integrin-mediated signalling: a- and y- 
sarcoglycans are phosphorylated on tyrosine residues in response to 
integrin-dependent cell adhesion (Yoshida et al., 1998); sarcospan is in the 
tetraspanin family and tetraspanins are known to associate with integrins 
(Hemler et al., 1996); and 3-dystroglycan has recently been shown to 
interact with 34 integrin (Bittner et al., 2001). 
It was thought that a protein which is involved in integrin-mediated 
signalling, such as JAB1, could potentially associate with a member of the 
DAPC, a complex which is involved in cell adhesion. Therefore, a variety 
of experiments were carried out in order to elucidate whether the JAB1 / 13-
dystroglycan interaction occurs in C2/C4 myoblasts. 
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4.4.2. Co-immunoprecipitation experiments 
Firstly, a JAB1 monoclonal antibody (table 2.6) was used to confirm that 
JAB1 protein is expressed in C2/C4 myoblasts and myotubes. A clear 
37kDa band of JAB1 protein was detected when C2/C4 extracts were 
separated on SDS-PAGE gels and western blotted with JAB1 antibody 
(figures 4.4A & 4.4C, extract lanes). The JAB1 antibody also successfully 
immunoprecipitated JAB1 (figure 4.4A). The ability of 13-dystroglycan 
antibody 1710 to immunoprecipitate 13-dystroglycan is well characterised 
(chapter 5, (lisley et al., 2001a)). Reciprocal immunoprecipitations (section 
2.4.2) with JAB1 and 3-dystroglycan antibodies, followed by western 
blotting showed no association between the two proteins (figures 4.413 & 
4.4C). 
It is possible that the two proteins were not co-immunoprecipitating 
because they are compartmentalised in different parts of the cell. 
Therefore purified 3-dystroglycan cytoplasmic domain was added to the 
JAB1 immunoprecipitation experiments to elucidate whether this "free" 
t3-dystroglycan could associate with JAB1. These JAB1 immunoprecipitates 
were subsequently western blotted with 13-dystroglycan antibodies (figure 
4.5). The purified 13-dystroglycan protein appeared to co-
immunoprecipitate with JAB1, but on further inspection, it was also 
present in the control immunoprecipitate (to which no JAB1 antibody 
was added). It is feasible that the purified 13-dystroglycan protein was non-
specifically interacting with the protein A Sepharose beads, possibly due to 
its high concentration in the mixture. Due to this occurrence, it was not 
possible to substantiate a real interaction between JAB1 and the purified f3-
dystroglycan protein by co-immunoprecipitation techniques. Therefore, 
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Figure 4.4. 
3-dystrogIycan and JAB1 do not co-immunoprecipitate. 
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IB: JAB1 
JAB1 is immunoprecipitated by the JAB1 antibody. 
JAB1 was immunoprecipitated (IP) from myoblast extracts, loaded onto an SDS-PAGE gel 
and western blotted (IB) with JAB1 monclonal antibody. Extract (Ex) was also run on the gel. 
JAB1 (37kDa) was clearly seen in the immunoprecipitate and the extract (shown by unfilled 
arrow). 
JAB1 was immunoprecipitated (IP) from myoblast extracts, loaded onto an SDS-PAGE gel 
and western blotted (IB) with -dystroglycan monoclonal antibody MANDAG2. 3-dystroglycan 
(43kDa) (shown by an filled arrow in myoblast extract (Ex) was clearly not present in the JAB1 
immunoprecipitate. 
3-dystroglycan was immunoprecipitated from myoblast extracts using 1710 polyclonal 
antibody, loaded onto an SDS-PAGE gel and western blotted with JAB1 monclonal antibody. 
The control (Con) was an immunoprecipitate prepared using 1710 pre-immune sera. JAB1 
(37kDa) shown by an unfilled arrow in myoblast extract (Ex) was clearly not present in the l-
dystroglycan immunoprecipitate or control. 
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Figure 4.5 
Purified 3-dystroglycan protein does not co-immunoprecipitate 
with JAB1. 
JAB1 








JAB1 was immunoprecipitated from myoblast extracts and purified 3-dystroglycan 
cytoplasmic domain was added to (+) or omitted (-) from the experiment. The 
immunoprecipitates were western blotted with 3-dystroglycan monclonal antibody 
MANDAG2. No native 3-dystroglycan (43kDa) was co-immunoprecipitated (unfilled arrow) but 
the purified 3-dystroglycan appeared to be co-immunoprecipitated (filled arrow). However 
purified 3-dystroglycan was also pulled down in the control (no antibody) IF (Con) suggesting 
that it was non-specifically interacting with the protein A Sepharose. 
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4.4.3. "Pull-downs" using bacterially expressed GST-JAB1 fusion 
protein 
GST-JAB1 fusion protein was expressed in E.coli cells transformed with 
pGEX5X-2-JAB1 (section 2.4.12). The protocol included an induction step 
of 2 hours at 37°C. However, this produced largely insoluble fusion 
protein which was present in the pellet of the bacterial cell extracts. 
Insolubility is a widely documented problem for a variety of proteins 
expressed in E.coli. many of which are only recoverable from insoluble 
inclusion bodies (Marston, 1986; Wilkinson & Harrison, 1991). In an 
endeavour to increase the solubility of the protein, induction was carried 
out at lower temperatures (30°C, 25°C and 200C). Despite these reductions 
in temperature, the GST-JAB1 fusion protein remained largely insoluble. 
However, induction for 5 hours at 20°C produced enough soluble GST-
JAB1 to carry out "pull-down" experiments. The GST-JAB1 fusion was 
purified using glutathione-Sepharose beads (see figure 4.6) and added to 
purified 3-dystroglycan cytoplasmic domain protein (section 2.4.13.4). The 
rationale was that if JAB1 was associating with f3-dystroglycan then f3-
dystroglycan would be pulled out with GST-JAB1 by glutathione-
Sepharose beads. The pulldowns were western blotted with a 
dystroglycan antibody. Although purified 13-dystroglycan was pulled down 
with JAB1-GST and the Sepharose beads, this phenomenon also occurred 
in a control pulldown using GST alone instead of GST-JAB1 (figure 4.7). 
Therefore, the pulling down of 13-dystroglycan was not specific to an 
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Figure 4.6 
Coomassie staining of purified GST-JAB1. 
GST-JAB1 
GST-JAB1 was purified from bacterial 
extracts using glutathione-Sepharose 
413. The SDS-PAGE gel stained with 
Coomassie blue shows GST (26kDa) GST  (unfilled arrow) and GST-JAB1 (63 
kDa) (filled arrow) and its degradation 
products. 
In vitro pulldowns using GST-JAB1 and purified 3-dystroglycan 
cytoplasmic domain. 
Purified 3-dystroglycan cytoplasmic domain was incubated with GST (lanes 1 & 2) or GST-
JA131 (lanes 3 & 4) overnight. The GST or GST-JAB1 was subsequently pulled down using 
gluthathione-Sepharose beads. The proteins associating with the beads (B) and the 
supernatants (S) were run on SDS-PAGE gels and western blotted with 3-dystroglycan 
monoclonal antibody MAN DAG2. The 1 3kDa 3-dystroglycan protein appeared in the beads, 
pulled down with GST-JAB1 (shown by arrow) but it was also pulled down in the control (GST 
alone). This suggested that JA131 was not specifically interacting with 3-dystroglycan 
cytoplasmic domain. Excess 3-dystroglycan was also present in the supernatants (S) 
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4.4.5. Transfection of JAB1 into myoblasts 
In a subsequent experiment to demonstrate an interaction between JAB1 
and 13-dystroglycan, pCEP4F-JAB1 DNA was transfected into myoblasts to 
express a FLAG-tagged JAB1 protein (section 2.3.8). A range of conditions 
were tested to optimise the transfection procedure, e.g. varying the 
quantities of Lipofectamine and DNA, and the time of exposure to the 
reagents. Despite this, it was not clear whether the FLAG-tagged JAB1 
protein was being expressed. The M2 monoclonal antibody directed 
against the FLAG tag (table 2.6) recognised approximately the same 
banding pattern of proteins in transfected and untransfected cells (figure 
4.8A -compare control to other lanes) and none of these bands appeared to 
be same size as JAB1. This peculiarity of the M2 antibody was not 
restricted to this pCEP4F-JAB1 transfection. The M2 antibody was found to 
give exactly the same banding pattern on western blots of myoblasts 
transfected with pCEP4F-DYS (a dystrophin construct) as the western blots 
of pCEP4F-JAB1 transfected cell extracts in figure 4.8A (see section 3.8). 
However, on further inspection the myoblasts transfected with 10t1 
Lipofectamine and pCEP4F-JAB1, and western blotted with M2, an 
additional band around the molecular weight of a FLAG-tagged JAB1 was 
observed. Transfected extracts separated by SDS-PAGE and western blotted 
with JAB1 antibody showed the presence of JAB1 protein in all 
transfections (see figure 4.813) but this was interpreted to be native JAB1 
exclusively. Yet the myoblasts transfected with 10t1 Lipofectamine had 
another slightly higher molecular weight protein which was detected by 
the JAB1 antibody which was potentially FLAG-tagged JAB1. Therefore, it 
was deduced that only the transfection using 10p1 Lipofectamine and 
pCEP4F-JAB1 facilitated the expression of FLAG-tagged JAB1. But the co-
immunoprecipitation of FLAG-tagged JAB1 and f3-dystroglycan could not 
be tested fully because the M2 antibody did not immunoprecipitate FLAG-
tagged proteins adequately. 
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Figure 4.8. 
Western blots of myoblasts transfected with pCEP4F-JAB1. 
A 	 B 
111 Lipofectamine 	111 Lipofectamine 









IB: Flag IB: JAB1 
Myoblasts transfected with 2tg pCEP4F-JAB1 DNA and 2, 5, 10 or 15pi Lipofectamine. 
Extracts from the cells were run on SDS-PAGE gels and western blotted (IB) with monoclonal 
antibodies M2 (anti-FLAG) or anti-JAB1 to detect the expression of FLAG-tagged JAB1. 
The same pattern of expression was seen in the non-transfected control (Con) and the 
transfected cells, when blotted with M2. The M2 antibody only detected a protein of 37kDa 
(FLAG-tagged JA131) in the 10tl Lipofectamine lane (denoted by unfilled arrow) which ran 
below the non-specific bands. 
The JAB1 antibody did detect 37kDa JAB1 protein (shown by filled arrow) but this was 
interpreted as native JAB1. In the 1 Opi Lipofectamine lane only, a band running above native 
JAB1 (denoted by unfilled arrow) but still detected by the JAB1 antibody was observed. This 
band was running at the same molecular weight as the extra band detected by M2 in the 1 Opi 
Lipofectamine lane in 4.8A. Therefore this was presumed to be FLAG-tagged JAB1. 
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4.5. Characterisation of the FHOS- 0-dystroglycan 
interaction 
4.5.1. Formin Homology Overexpressed in Spleen (FHOS). 
The C-terminal region of FHOS (amino-acids 943-1165) was identified 
twice as an interactor of -dystroglycan in the yeast two-hybrid screen. 
FHOS was originally identified during a yeast two-hybrid screen of a B cell 
cDNA library, using AML-1B transcription factor as bait (Westendorf et 
al., 1999). FHOS is a member of the formin family of proteins. Formin 
family members contain the Formin Homology domains FH1 and FH2 
and are found in a diverse range of organisms. Proteins in the formin 
family include the gene products of mDia in mouse, diaphanous and 
cappuccino in Drosophila, bnil in Saccharomyces cerevisiae and fusl and 
cdc12 in Schizosaccharomyces porn be. The founder members of this 
family, formin, were originally identified as transcripts of the limb 
deformity gene required for the proper formation of the two 
morphogenetic centres in mouse limb bud development (Woychik et al., 
1990). At least four major isoforms of formin are expressed during mouse 
embryogenesis and they are phosphoproteins localised largely in the 
nucleus. 
The FH domains were first identified as regions of sequence homology in 
diaphanous, bnil and vertebrate formin (Castrillon & Wasserman, 1994). 
Many of the proteins with FH domains are involved in actin-dependent 
processes e.g. diaphanous, cappuccino and bnil mutations result in defects 
in cytokinesis, and the overexpression of truncated inDia causes abnormal 
organisation of the actin cytoskeleton. In fact, many of the proteins were 
identified genetically in the first instance via their defects in actin-
mediated processes. Although FHOS was identified only recently and its 
function is unknown, it was a plausible candidate as an interactor of 13-
dystroglycan because other proteins in the formin family are involved in 
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reorganisation of the actin cytoskeleton. A potential function of 3-
dystroglycan and the DAPC is regulation of the cytoskeleton via signal 
transduction, therefore the FHOS/ f3—dystroglycan interaction was 
considered to be relevant in vivo. 
4.5.2. Transfection of FHOS into myoblasts 
To confirm the FHOS/13-dystroglycan yeast two-hybrid interaction, pCMV-
HA-FHOS DNA was transfected into C2/C4 myoblasts to express HA-
tagged FHOS protein in vivo. The transfection was successful and the 
expression of the 128kDa HA-tagged FHOS was confirmed by western 
blotting and immunoprecipitation experiments using a monoclonal HA 
antibody (table 2.6) (figures 4.9 & 4.10). Subsequently, the HA 
immunoprecipitate containing HA-tagged FHOS was western blotted with 
a 13-dystroglycan antibody to determine whether 13-dystroglycan and FHOS 
were interacting. Purified 3-dystroglycan cytoplasmic domain was also 
added to the immunoprecipitation experiment to ascertain whether 
FHOS interacted with this in addition to, or instead of, native 13-
dystroglycan. Figure 4.11 shows that native 13-dystroglycan was not present 
in the HA immunoprecipitate with HA-FHOS. The purified 13-
dystroglycan protein was in the immunoprecipitate, but controls revealed 
that the purified protein associating non-specifically with the protein G 
Sepharose beads, as seen previously (figures 3.13B & 4.5). 
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Figure 4.9 
Expression of HA-tagged FHOS in C2/C4 myoblasts. 
Con 24hr 48hr 









02/04 myoblasts were transfected with either 1ig or 2g pCMV-HA FHOS DNA and 
Lipofectamine and analysed after 24 hours or 48 hours transfection. Proteins were extracted 
from the cells using RIPA buffer. The extracts were loaded onto SDS-PAGE gels and 
western blotted (IB) with anti-HA monoclonal antibody. 
The controls (Con) were untransfected myoblasts. 
HA-FHOS is 128kDa and can be seen in all the transfection experiments (shown by arrow), 
therefore 1 ig of DNA and a 24 hour transfection time was considered to be sufficient for 
expression of HA-FHOS. There was no HA-FHOS expressed in the controls. 
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Figure 4.10 
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,ji -  ij 	 antibody and western blotted with anti-HA 
antibody. The 128kDa HA-FHOS protein 
was clearly immunoprecipitated from the 





3-dystroglycan does not co-immunoprecipitate with HA-FHOS 
HA 
kDa IP Ex 
36.5 
26. 
Western blot of HA-FHOS immunoprecipitated 
(IF) with anti-HA antibody from pCMV-HA-
FHOS transfected myoblasts, and western 
blotted with 3-dystroglycan monoclonal antibody 
MANDAG2. 3-dystroglycan (43kDa) is present 
in the extract (Ex) (shown by filled arrow) but 
not in the immunoprecipitate with FHOS. 
Purified protein of 3-dystroglycan cytoplasmic 
domain (13kDa) was also added during the 
immunoprecipitation experiment. This appears 
in the IF (unfilled arrow) but was later found to 
be non-specifically interacting with the protein G 
Sepharose rather than HA-FHOS. 
IB: 3-DG 
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It was speculated that the FHOS/-dystroglycan interaction was not 
observed in the transfected myoblast extracts due to the extraction 
conditions used. Therefore, to discount this possibility, pCMV-HA-FHOS 
transfected myoblasts were extracted with a panel of extraction buffers 
which included detergents from each of the three classifications of 
detergents, namely SDS and sodium deoxycholate (ionic), Brij 98, 
Digitonin, TritonX-100 and Tween-20 (non-ionic) and CHAPS 
(zwitterionic) (section 2.3.3). All the detergents adequately extracted HA-
tagged FHOS (as shown by western blotting of the extracts with anti-HA 
antibody, figure 4.12A). Immunoprecipitations using anti-HA antibody 
were carried out using the different extracts, and western blotted with a 
dystroglycan antibody (figure 4.12B). Regardless of the different extraction 
conditions tested, 13-dystroglycan did not appear to co-immunoprecipitate 
with HA-FHOS. 
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Figure 4.12 
3-dystroglycan is not co-immunoprecipitated with HA-tagged 







Western blot of pCMV-HA-FHOS transfected myoblasts extracted under 
different conditions. 
Myoblasts were transfected with pCMV-HA-FHOS and lysed 24 hours later with 1% (w/v) Brij 
98 (lane 1), 1% (w/v) CHAPS (lane 2), RIPA buffer (lane 3), 1% (v/v) TritonX-1 00 (lane 4), 1 % 
(v/v) TritonX-1 00/ 0. 1 % (w/v) SIDS (lane 5) or 1% (v/v) Tween-20 (lane 6). The extracts were 
run on SDS-PAGE gels and western blotted with anti-HA antibody. The expressed HA-
tagged FHOS protein was successfully extracted by all the detergents tested. 
Co-immunoprecipitations 
Myoblasts were transfected with pCMV-HA-FHOS and lysed 24 hours later with 1% (w/v) Brij 
98 (lane 1), 1% (w/v) CHAPS (lane 2), RIPA buffer (lane 3), 1% (v/v) TritonX-100 (lane 4), 1% 
(v/v) TritonX-100/ 0.1% (w/v) SDS (lane 5) or 1% (v/v) Tween-20 (lane 6). The extracts were 
immunoprecitated with anti-HA antibody, run on SDS-PAGE gels and western blotted with 1 -
dystroglycan monoclonal antibody. Lane 7 is anti-HA immunoprecipitate from untransfected 
(control) myoblasts. The arrow points to 3-dystroglycan in the myoblast extract loaded in lane 
8. 
No 3-dystroglycan co-immunoprecipitated with HA-FHOS from the transfected myoblasts. 
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4.6. Characterisation of the actin (A--dystrog1ycan 
interaction 
4.6.1. Actin o1 
Skeletal muscle actin x1 was identified twice in the yeast two-hybrid 
screen as a possible interactor of 3-dystroglycan cytoplasmic domain. The 
actin clones isolated from the skeletal muscle cDNA library were 
approximately 1.4kb in length and contained the full length coding 
sequence of the ACTA1 gene (1374bp). 
Actin al is one of six closely related actin isoforms. Actins are highly 
conserved proteins which are involved in cell motility and cell structure. 
The 42kDa actin monomer (G-actin) self-assembles to form long helical 
filaments (F-actin) both in vivo and in vitro. Alpha actins are a major 
constituent of the contractile apparatus and al actin expression is 
restricted to skeletal muscle. 
The interaction of 3-dystroglycan with actin has not been tested 
previously, although dystrophin's actin-binding properties have been 
well documented (section 1.2.3). 3-dystroglycan is part of a complex which 
interacts with actin (via dystrophin), therefore, it is plausible that 3-
dystroglycan could also interact with actin. Consequently, further 
experiments were carried out to substantiate this yeast two-hybrid result. 
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4.6.2. Controls to verify the actin x1-3-dystrog1ycan interaction 
The yeast two hybrid interaction of 3-dystroglycan cytoplasmic domain 
and actin al was verified by transforming pACT2-actin cd back into the - 
DG/PJ694-A yeast strain to check that the activation of the reporter genes 
(ADE and HIS) could be reproduced (section 2.5.7.3). Evidence for the 
activation of the H153 gene is demonstrated in figure 4.13, 2nd panel 
down. The lower two panels demonstrate that pACT2-actin al alone 
(without pAS2-13-DG) cannot activate the HIS or ADE reporter genes. 
Figure 4.13 
Yeast two-hybrid controls: Growth of PJ69-4A Saccharomyces 







*pJ694A transformed with pACT2/actin cd and pAS2AA/3-DG grows on -LW media, 
showing that both plasmids are present (pACT2 has a LEU marker gene and pAS2AA has a 
TRP marker gene) , and on -LWH media showing that the HIS reporter gene is activated due 
the the yeast two-hybrid interaction between actin a! and -dystrogIycan cytoplasmic 
domain. 
When PJ69-4A is transformed with pACT2/actin a! only, the yeast grows on -L media but not 
on -LH or -LA media because neither the HIS or ADE reporter genes are activated. This 
shows that pACT2/actin al does not self-activate. 
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4.6.3. Co-sedimentation assays 
Sedimentation assays were carried out to determine whether 13-
dystroglycan was having an effect on the supermolecular structure of 
actin (section 2.6.1). In a high speed sedimentation assay (centrifugation 
over 20,000 xg %.) F-actin sediments. Any 13-dystroglycan interacting with 
actin would be observed in the pellet with F-actin rather than in the 
soluble phase. In contrast, F-actin does not sediment under low speed 
sedimentation (less than 20,000 xg) unless complexed into 
supermolecular aggregates by a cross-linking protein (Meyer & Aebi, 1990). 
G-actin was polymerised to F-actin in the presence of increasing 
concentrations of purified f3-dystroglycan cytoplasmic domain (section 
2.4.11) and centrifuged at 100,000 xg for 15 minutes. Subsequently, equal 
volumes of the supernatant and pellet were analysed by SDS-PAGE. 
Figure 4.14B shows that F-actin sediments during high speed 
centrifugation in the actin-only control and 13-dystroglycan remains in the 
soluble phase in the 13-dystroglycan-alone control. However, when actin is 
polymerised in the presence of 100iM 13-dystroglycan, some 13-dystroglycan 
is found in the pellet with actin. This suggests that 13-dystroglycan and F-
actin are interacting in some way. 
In the low speed co-sedimentation assay, F-actin and 13-dystroglycan were 
centrifuged at 20,000 xg and equal volumes of the supernatant and pellet 
analysed by SDS-PAGE. The gels were studied for increasing amounts of 
actin in the pellet with increasing 3-dystroglycan concentration. This 
would show that 13-dystroglycan was bundling or crosslinking actin. 
Figure 4.14A shows that in the actin-alone control, F-actin did not 
sediment during low speed centrifugation as expected. The majority of 13-
dystroglycan was also in the supernatant in the 13-dystroglycan-alone 
control. However, when F-actin and 100iM 13-dystroglycan were 
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centrifuged together, a proportion of both proteins are found in the pellet. 
This suggests that f3-dystroglycan causes F-actin to form supermolecular 
aggregrates which can be pelleted by low speed centrifugation. 
4.6.4. Microcapillary falling ball viscometry 
Some proteins which bind to F-actin increase the viscosity of an F-actin 
solution in vitro (Ayscough, 1998). This increase in viscosity is caused by 
the crosslinking or bundling of actin filaments. If an actin-binding protein 
has two actin-binding sites (e.g. fimbrin) bundling of actin filaments can 
occur. If a protein binds actin at an exposed site on the filament and has 
the ability to self-associate (e.g. a-actinin) it should be capable of bundling 
or crosslinking actin filaments. The affects of actin-binding proteins on 
the viscosity of F-actin can be measured using microcapillary falling ball 
viscometry (section 2.6.2). 
The effect of f3-dystroglycan on the gelation of actin-filament solutions 
was examined by falling-ball viscometry. The speed of the steel ball was 
measured over a 10cm length of polymerised actin. 13-dystroglycan 
increased the viscosity of F-actin 4 fold when present at a 2.5 :1 molar ratio 
with actin (figure 4.15). It was verified that the high concentration of 13-
dystroglycan itself was not causing the raise in viscosity by testing the 
viscosity of 100tM 13-dystroglycan without F-actin. Therefore, the falling 
ball assay revealed that 13-dystroglycan was potentially crosslinking or 
bundling F-actin. 
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F-Actin co-sedimentation assays 
A 	Low speed B High speed 
1 	2 	3 	4 	5 	6 
Actin 3-DG Actin Actin 13-DG Actin 
-DG 	 -DG 
5tM G-actin was polymerised to F-actin in the presence of 100iM l3-dystroglycan cytoplasmic 
domain and centrifuged at 20,000 xg (low speed) or 100,000 xg (high speed) for 15 
minutes. Equal volumes of the supernatant (S) and pellet (P) were loaded onto15% SDS-
PAGE gels with pre-stained broad range marker (NEB) and subjected to electrophoresis, 
followed by Coomassie staining of the gel. The filled arrow denotes actin (42kDa), the unfilled 
arrow denotes 3-dystroglycan cytoplasmic domain (1 3kDa) 
Low speed centrifugation 
F-actin does not sediment under low speed centrifugation and is present in the supernatant 
(actin alone control-1), as is 3-dystroglycan (f3-dystroglycan alone control-2). When actin and 
3-dystroglycan are centrifuged together, the majority of the actin moves to the pellet (3) and 
some 3-dystroglycan also moves into pellet (highlighted by red boxes). This suggests that 3-
dystroglycan is causing actin to complex into supermolecular aggregates. 
High speed centrifugation 
F-actin sediments during high speed centrifugation (over 20,000 xg) -therefore actin is 
found in the pellet (actin alone control-4). The majority of 3-dystroglycan is in the supernatant 
(3-dystroglycan alone control-5). However, when actin and l3-dystroglycan are centrifuged 
together (6), there is more 3-dystroglycan in the pellet with actin, compared to the 3-
dystroglycan alone control (highlighted by red boxes). This suggests that 3-dystroglycan is 
interacting with F-actin. 
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Figure 4.15 





Viscosity measurements of F-actin polymerised in the presence of 3-dystroglycan were 
carried out using microcapillary falling ball viscometry. G-actin (concentration 5iM) was mixed 
with 3-dystroglycan cytoplasmic domain (concentrations 10, 20, 40, 60, 80, 100iM) and 
transferred to 1 00p capillary tubes. The velocity of a 0.64mm diameter stainless steel ball was 
measured by recording the time (in seconds) it took to travel 10cm down the capillary tube 
(relative velocity). With increasing concentration, 3-dystroglycan increased the viscosity of F-
actin. The viscosity of F-actin increased 4 fold when present at a 1:2.5 molar ratio with 3-
dystroglycan. 
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4.6.5. Electron microscopy studies 
Electron microscopy studies revealed that 13-dystroglycan was in fact 
bundling actin fibres, thus consolidating evidence from the co-
sedimentation and falling ball assays that 13-dystroglycan and F-actin 
interact in some fashion. Actin bundles are parallel arrays of closely 
packed actin filaments. Figure 4.16. clearly shows single actin filaments in 
the 5jtM F-actin alone experiment (upper lefthand panel) and when 5M 
F-actin is polymerised in the presence of 60tM 0-dystroglycan, bundles of 
actin filaments are formed (upper righthand and lower panel). 
4.6.5. Protein database searches to find homologous regions in 13-
dystroglycan cytoplasmic domain 
All actin-crosslinking proteins must have at least two actin-binding sites 
or form a dimer, where each site binds a separate actin filament. Since it 
was demonstrated that 3-dystroglycan bundles F-actin, sequence 
homology searches were carried out to identify potential actin-binding 
sites in the protein sequence of 13-dystroglycan. No significant matches 
were found in the database when the full length sequence of 3-
dystroglycan's cytoplasmic domain was used to search for homologous 
regions. Therefore, 13-dystroglycan's cytoplasmic domain was broken down 
into smaller regions to search the database. The amino-acid sequence was 
divided up into 20 amino-acid sections, each overlapping by 10 amino-
acids, and used in a protein:protein database search (MPsearch) (section 
2.6.4). Many proline-rich proteins were identified due to the stretches of 
proline residues in 13-dystroglycan e.g. VASP, WASP, proteins of the 
formin family (e.g. Formin, mDia, Cappuccino). Interestingly, peptide 1 
(amino-acids 776-795) of 13-dystroglycan had homologies to part of actin-
binding site 2 (ABS2) in the N-terminal domains of utrophin and 
dystrophin (figure 4.17A). These shared identical amino-acids include the 
recognised actin-binding motif KLTL. Peptide 2 (amino-acids 786-805) also 
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had homology to amino-acids in dystrophin's central rod domain (amino-
acids 1383-1402, coiled-coil number 10) (figure 4.17C). No actin-binding 
sites have been identified in this region of dystrophin although the rod 
domain does contain ABS4 and ABS5 (figure 1.1). 
Peptide 1 of 13-dystroglycan was also homologous to the actin-binding 
protein elongation factor 1 -alpha (EF-la) (figure 4.17B). EF-Rx is a member 
of a highly conserved family of proteins that catalyses the GTP-binding of 
aminoacyl-tRNA to ribosomes, thereby regulating the fidelity and rate of 
polypeptide elongation (reviewed in Condeelis, 1995). Numerous studies 
have demonstrated that EF-la binds and bundles actin filaments both in 
vitro and in vivo, and the bundling activity is potentially regulated by 
Ca"-Calmodulin (Kurasawa et al., 1996). The actin-binding sites of EF-la 
have not been defined, although the sites suggested are not in this region 
homologous to 13-dystroglycan (amino-acids 263-282) (Liu et al., 1996). 
However, this region is on the surface of the EF-la molecule and 
therefore it is possible that it is involved in actin-binding. In brief, at least 
three potential actin-binding regions were identified in the amino-acid 
sequence of 13-dystroglycan's cytoplasmic domain. More biochemical and 
structural studies are required to delineate exactly where and how 13-
dystroglycan binds actin. 
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Figure 4.16. 
3-dystroglycan bundles F-actin. 
-, 
. A 16" 1, 
Electron microscopy of 5tM actin alone (upper panel) shows individual actin filaments (and a 
few in pairs). Electron microscopy of 5jiM actin with 60tM 3-dystroglycan (J3-DG) (lower 
panels) shows bundles of actin filaments (indicated by arrows). 
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Figure 417 
Homologies between J-dystroglycan and actin-binding proteins 
LAI 
116 IVDGNHKLTL 	GLLWSIILHW 	134 Utrophin 
99 IVDGNHKLTL GLIWNIILHW 118 Dystrophin 
776 RKKRKGKLTL 	EDQATFIKKG 	795 3-dystrog1ycan 
(peptide 1) 
25% match 
263 RLDRRSGKAL EDDPKFIKTG 282 EF-1-alpha 




1383 QESLTFIDKQ 	LAAYIADKVD 	1402 Dystrophin 
786 EDQATFIKKG VPIIFADELD 805 3-dystrog1ycan 
(peptide 2) 
35% match 
Sequence homology searches were carried out to identify potential actin-binding sites in the 
protein sequence of 3-dystroglycan.The cytoplasmic domain of -dystroglycan was divided 
into 20 amino-acid sections, overlapping by 10 amino-acids (section 2.64) and used in a 
protein:protein database search. 
Peptide 1 has amino-acids matches to dystrophin ABS2 and utrophin ABS2. This region 
also contains the motif KLTL which is recognised as a n actin-binding motif. 
Peptide 1 also has amino-acids matches to the actin-binding protein EF-1 -alpha, although 
this region of EF-1 -alpha is not recognised as an actin-binding region. 
Peptide 2 contains further amino-acids matches with dystrophin, in coiled-coil number 10 
No actin-binding sites have been identified in this region of dystrophin. 
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4.7. Discussion 
4.7.1. Selection of the appropriate yeast strain for the yeast two-
hybrid screen 
The expression of every bait protein elicits a different responses in yeast 
host strains. Therefore, three strains of Saccharornyces cerevisiae were 
characterised for their suitability in this screen. 
The CG-1945 strain contains two reporter genes, LacZ and HIS3 which are 
under the transcriptional regulation of the GAL4 and GAD promoters 
respectively. This provides a dual level of selection for interactions. 
Unfortunately, CG-1945 cells display bait-specific toxicity in some cases 
(usually characterised by the cells flocculating in liquid culture), which 
can be so severe that CG-1945 cannot be used for that particular bait. 
The Y190 strain has LacZ and HIS3 reporter genes which are both 
controlled by a GALl promoter. The HIS3 reporter is sensitive but very 
leaky. This sometimes necessitates the use of high concentrations of 3-AT 
to counteract this "leakiness" and this may compromise the sensitivity of 
a screen. 
PJ694A is a host yeast strain which was constructed in order to provide an 
extremely sensitive yeast two-hybrid assay with the elimination of false 
positives. Many of the host strains used in screens have a single promoter 
element to drive each reporter gene (e.g. Y190), whereas PJ69-4A has been 
constructed so that it contains three reporter genes (HIS3, ADE2, LacZ) 
each driven by a different reporter (GALl, GAL2, GAL7). This reduces the 
incidence of promoter-specific false positives. In PJ69-4A, the GAL1-HIS3 
reporter construct used has a very stringent regulation compared to other 
constructs. In general, it only requires 0-2mM 3-AT in order to eliminate 
growth due to leakiness of the reporter. However, this GAL1-HIS3 
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reporter still produces a background of false positives but this is overcome 
by the GAL2-ADE2 reporter used in conjunction with it, which is very 
stringent but remains very sensitive to weak interactions. 
During the comparison of the three yeast host strains, it was concluded 
that PJ69-4A/3-DG was the most appropriate for the screening of the 
skeletal muscle cDNA library. As for the other strains, Y190/13-DG had a 
reasonable transformation efficiency but required very high amount of 3-
AT, which creates the risk of lowering the overall sensitivity of the 
screen. CG-1945/13-DG did not require a high concentration of 3-AT but the 
transformation efficiency was very low (perhaps due to bait toxicity, 
although no flocculation was observed in liquid cultures). 
Transformations with PJ69-4A/13-DG  yielded high transformation 
efficiencies and required less than 1mM 3-AT. A high transformation 
efficiency is preferred because it facilitates the screening of more 
transformants at a time. The requirement for so little 3-AT made its use 
redundant in the screen, and therefore no sensitivity was compromised. 
Additionally, the use of 3-AT increases the time required for growth 
selection of positive clones from 2 days to 5 days, therefore, withdrawing 
its use shortened the timescale of the screen. 
4.7.2. Putative interactors of 13-dystroglycan identified in the 
yeast two-hybrid screen 
From the results of the yeast two-hybrid screen using 13-dystroglycan as a 
bait in a human skeletal muscle cDNA library, many proteins were 
identified as potential interactors of 13-dystroglycan (table 4.1). The top five 
interactors were discounted because it was postulated that they were 
pulled out of the cDNA library due to non-specific WW domain-
mediated interactions (WWP1, YAP65); or the library plasmids self-
activated the reporter genes (ubiquitin-conjugating enzymes); or the 
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protein is a common yeast two-hybrid interactor (MAD213); or no obvious 
biological relevance for the interaction could be predicted (RanBPM). 
It was decided that three of the 74 sequenced interactors would be pursued 
further, namely JAB1, FHOS and actin all. These three proteins were 
thought to be sensible candidates as interacting partners of f3-dystroglycan 
because they are potentially involved in cell adhesion via associations 
with integrin signalling (JA131), or actin cytoskeleton reorganisation 
(FHOS) or part of the actin cytoskeleton itself (actin al). 
4.7.3. Candidate interactor of f3-dystroglycan : JAB1 
4.7.3.1. The COP9 signalosome 
Human JAB1 was first identified as a co-activator of the c-Jun and Jun D 
transcription factors (Claret et al., 1996), but it is also a subunit (S5) of the 
CON signalosome (also termed the CON complex or JA131-containing 
signalosome). The CON signalosome is a protein complex comprising 8 
subunits which are highly conserved between plants and mammals (Wei 
et al., 1998; reviewed in Wei & Deng, 1999). 
The CON signalosome was originally isolated as a repressor of 
photomorphogenesis (light-activated development) in Arcibidopsis 
(Chamovitz et al., 1996). It is ubiquitous, but enriched in the nucleus. The 
function of the CON signalosome in mammalian cells is not clearly 
defined but the subunits are involved in diverse signalling events such as 
regulation of thestress-activated protein kinase/c-Jlun N-terminal kinase 
(SAPK/JNK)-mediated MAP kinase pathway (subunits Si and S5), nuclear 
hormone receptor-mediated functions (S2) and cell cycle regulation (S6). 
The CON signalosome also has associated kinase activity which 
phosphorylates regulators of transcription (Seeger et al., 1998). A kinase 
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must associate with the complex because none of the subunits have 
recognisable kinase domains. Consequently, the COP9 signalosome is 
thought to be an important cellular regulator involved in modulating 
multiple signalling pathways. 
4.7.3.2. PCl/MPN domains 
The subunits of the CON signalosome are closely related to subunits of 
the lid of the 19S regulatory particle of the 26S proteasome (which 
degrades ubiquitinated proteins) and the translation initiation complex 3 
(eIF-3) (Glickman et al., 1998). These three large multicomplexes all share 
PCI (Proteasome, COP9, Initiation factor 3) and MPN (Mprlp  and iad1p 
N-terminal) domains (Hofmann & Bucher, 1998). Either a PCI or MPN 
domain is present in all 8 subunits of the CON signalosome, 7 of the 8 
subunits of the proteasome lid and 5 of the 10 eIF2 subunits. The 
structural and functional roles of these domains are unknown. Although 
these complexes share similarities in their subunits, they are very distinct 
structural and functional entities. The presence of PCI and MPN domains 
in all these complexes suggests that they may have a role in 
macromolecular assembly e.g. they could homodimerise or 
heterodimerise to form a structural scaffold. Or perhaps they are docking 
sites for complexes to interact with common targets, such as ubiquitin, 26S 
base units (which link the lid of the 26S proteasome to the core) or other 
substrates. It is possible that all these complexes interact with the 26S 
proteasome through their MPN/PCI domains and fulfil their functions 
via protein degradation. 
JAB1 has an N-terminal MPN domain and is closely related to p40 in the 
eIF3 complex and the POH (human homolog of Sacchciromyces cerevisiae 
Pad-1) subunit of the 26S proteasome. Other motifs in the protein include 
five potential casein kinase II phosphorylation sites, two protein kinase C 
phosphorylation sites, four N-myristoylation sites and a 
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glycosaminoglycan attachment site (detected by PROSITE). JAB1 can be 
found in the nucleus as part of the COP9 signalosome or in a free 
monomeric form which is mostly cytosolic. Equilibrium between the two 
forms might be physiologically relevant and subject to regulation (Kwok 
et al., 1998). The fact that JAB1 can be found in a free form in the 
cytoplasm, and not just part of the nuclear COP9-signalosome, creates the 
possibility that it is available to interact with 13-dystroglycan in muscle 
cells. 
4.7.3.3. JAB1 interacts with LFA-1 (cxL//32) integrin 
JAB1 was recently found to interact with LFA-1 ((xL/132) integrin in a yeast 
two-hybrid screen (Bianchi et al., 2000). The researchers wanted to identify 
molecules directly involved in transducing adhesion-mediated signals, 
and used the intracellular domain of LFA-1 32 integrin as bait in a 
lymphocyte DNA library. A fraction of JAB1 was also found to co-localise 
with LFA-1 at the membrane of COS7 cells by immunofluorescence. LFA-
1 is thought to regulate JAB1 localisation because the engagement of LFA-
1 caused an increase in the nuclear pool of JAB1, thus allowing enhanced 
binding of JAB1 to c-Jun. 
In this study, JAB1 was considered as a relevant find in the yeast two-
hybrid assay. It is involved in the regulation of signalling pathways 
(SAPK/JNK-mediated MAPK pathway) and is a component of a large 
signalling complex (COP9). Since little is known about the signalling role 
of the DAPC, it was considered that a JAB1/3-dystroglycan interaction may 
shed light on the signalling pathways that the DAPC is potentially 
involved in. In addition, the JAB1/LFA-1 32 integrin interaction 
implicates JAB1 in the regulation of integrin-mediated adhesion. 
Considering that the DAPC acts as a cell adhesion structure, the possibility 
of a true JAB1/ 13-dystroglycan interaction was regarded as an intriguing 
prospect. 
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Interestingly, in the yeast two-hybrid screen, a member of the eIF3 
complex was also pulled out as a potential interactor of 13-dystroglycan. 
This was subunit p48/mammary-tumour-associated protein INT-6 which 
has a C-terminal PCI domain, and is similar to the S2 subunit of the COP9 
signalosome and subunit 9 of the 26S proteasome. This could be just a 
coincidence that another protein related to JAB1 was identified in the 
screen or it could strengthen a hypothesis of 13-dystroglycan having links 
to the PCl/MPN domain-containing complexes. 
4.7.4. Candidate interactor of 13-dystroglycan: FHOS 
4.7.4.1. FHOS 
FHOS contains a FH1 domain and a FH2 domain and is consequently 
classed as a member of the formin family.The FHOS open reading frame 
encodes 1165 amino-acids, and therefore a protein of approximately 
128kDa (figure 4.18). The C-terminus of FHOS (amino-acids 716-1070) has 
significant homology to human diaphanous 1 and 2, murine p140mDia 
and formin, and Drosphilci Diaphanous and Cappuccino proteins. The 
most conserved regions of FHOS with other FH proteins are in the FH1 
and FH2 domains. In FHOS, the FH1 domain is small with only three 
poly-proline stretches. In addition, FHOS contains a predicted coiled-coil 
motif, a glycine and proline-rich segment homologous to regions in 
collagen proteins, a bipartite nuclear localisation signal (NLS) , a basic 
NLS and a stretch of glutamines encoded by a CAG nucleotide repeat. 
FHOS mRNA is expressed in every tissue tested to date, but most 
abundantly in spleen (Westendorf et al., 1999). The cellular localisation of 
FHOS is predominantly in the cytoplasm. Unlike the formin, which are 
mainly localised in the nucleus, only a small amount of FHOS was 
observed in the nucleus by immunofluorescence studies (Westendorf et 
al., 1999). 
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Figure 4.18 
Open reading frame of FHOS showing domains and 3-




1 	 1165 
3-dystroglycan 
i nteractor 943 1165 
Homologous  
region 	 716 	1070 
Key 
aa 568 -611: FH1 domain (with 3 polyproline stretches) 
aa 801-863: FH2 domain 
aa 350-366: potential bipartite Nuclear Localisation Signal 
aa 621-629: potential basic Nuclear Localisation Signal 
aa 356-397: glycine and proline rich region (homologous to regions in 
collagen proteins) 
aa 891-918: predicted coiled-coil region 
aa 996-1001: stretch of glutamines (CAG repeat) 
The open reading frame of FHOS encodes 1 165 amino-acids (numbers on figure refer to 
amino-acid number). The key shows the various domains marked. The C-terminal end of 
FHOS (amino-acids 943-1165) labelled "3-dystroglycan interactor" interacted with - 
dystroglycan in the yeast two-hybrid screen. Amino-acids 716-1070 labelled "homologous 
region" represent the region highly homologous to Drosophila Diaphanous and Cappuccino, 
human Diaphanous 1 and 2, murine p140mdia and Formin proteins. 
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4.7.4.2. FH1 domains 
FH1 domains are 100 amino-acids long and characterised by a multiple 
repeats of 5-12 consecutive prolines. They are involved in protein:protein 
interactions due to their proline-rich regions which can bind to 
cytoskeletal and signalling proteins via SH3 and WW domain-mediated 
interactions (Ren et al., 1993; Chan et al., 1996). FH1 domains have been 
shown to interact with; profilin an actin-binding protein, involved in 
actin polymerisation and known to bind proline-rich sequences 
(Evangelista et al., 1997; Chang et al., 1997); cortactin, another actin-
binding protein which appears to be a substrate for Src phosphorylation 
(Chan et al., 1996; Wu et al., 1991); and Rho family small C-proteins which 
are involved in reorganisation of the actin cytoskeleton (Kohno et al., 
1996). It is hypothesised that some of the FH proteins are involved in 
modification of the actin cytoskeleton by bringing profilin and other 
cytoskeletal proteins together at specific locations in the cell cortex, i.e. 
they may function as a scaffolding protein for cytoskeletal and signalling 
components (Frazier & Field, 1997; Tanaka, 2000). 
4.7.4.3. FH2 domains 
FH2 domains are 130 amino-acids long and their function is unknown. 
However, they have conserved residues and conserved spacing and it is 
speculated that they are involved in protein:protein interactions. The 200 
amino-acid long intervening sequence between FM and FH2 is also 
conserved and it has been suggested that FH2 domain should be extended 
to include the sequences between the two domains (Frazier & Field, 1997). 
There are also stretches of sequence predicted to fold into coiled-coils 
which flank the FH region. 
Interestingly, the FHOS clones (amino-acids 943-1165) which were 
identified as interactors of 3-dystroglycan in the yeast two-hybrid screen 
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did not contain either of the FH domains or the coiled-coil region. The 
only motifs in this C-terminal end of FHOS are many phosphorylation 
sites (for Protein Kinase C and Casein kinase II, cAMP- and cGMP-
dependent kinases), and two N-myristoylation sites (detected by 
PROSITE). However, the fact that proteins in the formin family have 
roles in organisation of the actin cytoskeleton prompted interest in the 
FHOS/ 13-dystroglycan interaction and it was decided to investigate it 
further. 
4.7.5. JAB1 and FHOS: results of characterising their interactions 
with 13-dystroglycan 
Unfortunately, neither the interaction of 3-dystroglycan with JAB1 or 
FHOS could be substantiated in vivo by co-immunoprecipitation 
experiments of 3-dystroglycan and endogenous JAB1 or 3-dystroglycan 
and overexpressed HA-tagged FHOS from C2/C4 cell extracts. This could 
be due to problems with the immunoprecipitation experiments which 
have not proved entirely successful for identifying interactors of 13-
dystroglycan (see chapter 3). Or it is possible that an in vivo transcription-
based assay such as the yeast two-hybrid assay is a highly sensitive 
technique and can detect weak interactions which other assays such as co-
immunoprecipitation can not. 
On the other hand, these two proteins selected may have been false 
positives in the yeast two-hybrid screen. Although the technique is 
continually evolving to reduce the amount of false positives, and the 
PJ694A strain used was constructed in a manner to minimise them, false 
positives still frequently occur. False positives are caused by plasmids 
which activate reporter gene expression but do not encode a protein 
which binds the target protein (the bait). This phenomenon often occurs if 
the library plasmid encodes a protein involved in transcription e.g. Sterol 
regulatory binding transcription factor 1 (SREBF1) and HIV type 1 
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enhancer binding protein 2 (HIVEP2) picked up in this yeast two-hybrid 
screen (table 4.1). Transcription can also be activated by a cDNA whose 
product can bind to the minimal GAL4 DNA-binding domain or 
sequences upstream of the reporter gene or just by non-specific binding to 
the DNA. But often, there is no explanation for the occurrence of a false 
positive. 
One of the ''contraindications" of embarking on a yeast two-hybrid screen 
is that although two proteins may interact in this assay, they may never 
actually encounter each other during normal conditions. This may be 
because the two proteins are not present in the same cellular 
compartment or during the same stage of the cell cycle or perhaps the 
domain or domains involved in the interaction are not exposed or 
accessible in the native protein. 
Therefore, despite a putative biological relevance for the JAB1/13-
dystroglycan and FHOS/13-dystroglycan interactions, the existence of these 
interactions could not be unequivocally proved in C2/C4 myoblasts. This 
may be due to the restrictions of the assays used or that the interactions do 
not exist in vivo. 
4.7.6. 13-dystroglycan: links to the ubiquitin-mediated degradation 
pathway? 
During the course of the yeast two-hybrid screen, many proteins involved 
in the ubiquitin-mediated degradation pathway were identified as 
potential interactors of 13-dystroglycan. For example, Nedd4-like protein 
ligase (WWP1) (an E3 protein) and ubiquitin-conjugating enzymes (E2) 
RAD6, E21, UBB21 and hUBC9. The frequency of these proteins in the 
screen was 36%. 
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4.7.6.1. The ubiquitin-mediated degradation pathway 
Degradation of a protein by the ubiquitin-mediated degradation pathway 
involves three steps, namely the identification of the protein to be 
degraded, the marking of that protein by attachment of ubiquitin, and 
degradation of the tagged protein by the 26S proteasome. Ubiquitin or 
ubiquitin-like proteins are involved in a variety of fundamental cellular 
processes, some of which are non-proteolytic such as protein sorting, 
DNA repair, cell division, differentiation and development (reviewed in 
Ciechanover et al., 2000; Wilkinson, 2000). 
Ubiquitin is a highly conserved 76-residue protein which only exists in 
eukaryotic cells. It is activated by a ubiquitin-activating enzyme (El). A 
ubiquitin-conjugating enzyme (E2) transfers the activated ubiquitin to its 
substrate, which is specifically bound to a member of the ubiquitin protein 
ligase family (E3). The modified protein is subsequently targeted to the 
proteasome for degradation. 
The regulation protein ubiquitination is predicted to be controlled at the 
level of the E2 and E3 proteins. E3 ligase binds the substrate protein and 
E2, and serves as a scaffold protein. In most cases, an E3 recognises a subset 
of proteins that contain similar structural motifs and can be divided up 
into subtypes depending on what class of signals they recognise. HECT-
domain proteins (homologous  to E6-AP carboxyl terminus) comprise one 
of these subsets. The HECT domain has a conserved cysteine residue to 
which the activated ubiquitin protein is transferred to from E2. Nedd4-
like protein ligase (WWP1) is a member of this subset and has a HECT 
domain in addition to its four WW domains. The PPxY motif of 1-
dystroglycan has been shown previously to interact with WW domains 
other than dystrophin's in vitro (Pirozzi et al., 1997). Interestingly, these 
other WW domains were from proteins in the Nedd4-like family. 
However, these were purely biochemical assays and to date, no in vivo 
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evidence for these interactions has been demonstrated. Therefore it is 
assumed here that both the biochemical assays and the yeast two-hybrid 
screen gave rise to non-specific WW domain-mediated interactions, 
perhaps due to the high sensitivity of the assays. Nevertheless, the 
possible association of 3-dystroglycan with the ubiquitin-mediated 
degradation machinery is discussed below. 
4.7.6.2. Nedd4- a ubiquitin protein ligase 
Nedd4 has 4 WW domains and a HECT domain which targets the kidney 
epithelial Na channel. Liddle's syndrome, which manifests itself as a 
renal hypertension, is caused by an increased activity of the Na channels 
because they are not targeted to the proteasome properly by Nedd4. This is 
because the WW domains of Nedd4 can no longer bind the 13  subunit of 
the Na channels due to proline or tyrosine point mutations in their PPxY 
motifs, or deletions encompassing the PPxY motif (reviewed in Kay et al., 
2000). It is conceivable that other PPxY motifs are used as recognition sites 
of E3 ubiquitin ligases, such as 13-dystroglycan recognition by Nedd4-like 
protein ligase (WWP1). This suggests that proteins which interact with 
WW domains may be regulated by ubiquitin-mediated degradation. 
Ubiquitin signals on target proteins can be genetically programmed, 
acquired by phosphorylation or by binding to an adapter protein. Proteins 
which are damaged by oxidation or mutation or are misfolded or 
mislocalised are also substrates of the ubiquitin-mediated degradation 
pathway (reviewed in Laney & Hochstrasser, 1999). In the case of 13-
dystroglycan, it is possible that due to its overexpression in the yeast two-
hybrid screen, or the potential instability of the protein, that it was 
targeted by proteins of the degradation pathway, or that 13-dystroglycan is 
usually regulated by the ubiquitin-mediated degradation pathway, 
mediated by WW domain interactions between 13-dystroglycan and the 
ubiquitin ligase WWP1. Another possibility is that a non-specific W W 
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domain-mediated interaction manifested itself in the yeast two-hybrid 
assay due to the sensitivity of the procedure. 
4.7.7. Known interactors of 3-dystrog1ycan were not identified in 
the screen 
Disappointingly, previously characterised interactors of 13-dystroglycan, 
dystrophin, Grb2, caveolin-3 and rapsyn (section 1.6.4) were not identified 
in this yeast two-hybrid screen. 
These particular interactors may not have been revealed by this screen 
because only approximately 52% of the skeletal muscle cDNA library was 
screened. The reasons for this were time-constraints, and abundant results 
requiring further investigation which were generated from screening this 
percentage of the library. 
However, it is not surprising that rapsyn was not identified as an 
interactor of 13-dystroglycan - rapsyn is notoriously difficult to work with, 
and all the biochemical procedures tried, as well as yeast two-hybrid 
screens, have failed to identify its binding partners (reviewed in Colledge 
& Froehner, 1998). 
There are several possible reasons why the dystrophin/ 13-dystroglycan 
interaction was not identified in the yeast two-hybrid screen. Previously, 
dystrophin has proved problematic as a bait in yeast two-hybrid screens 
(M. James & S. J. Winder, personal communication). If cDNA boundaries 
used in constructs are not optimal, the cDNAs may be non-functional 
and/or lead to the expression of unstable or misfolded proteins. This may 
explain why overexpressed dystrophin WW, EF hands and WW domains 
in C2/C4 myoblasts did not appear to interact with native 13-dystroglycan 
(section 3.8). In addition, a large protein such as dystrophin is unlikely to 
be included in one library clone, and this is likely to affect its interactions 
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and folding. Furthermore, the very low abundance of dystrophin in 
skeletal muscle raises the possibility that the protein was under-
represented in the skeletal muscle cDNA library. 
Unfortunately, the yeast two-hybrid screen shed no more light on 13-
dystroglycan's interactions with signalling and focal adhesion proteins. 
The dynamic nature of these interactions (e.g. Grb2 competes with 
dystrophin to interact with 3-dystroglycan) potentially make them 
difficult to Strap' by this method. Many fusions in cDNA libraries are non-
functional due to low stability and incomplete or incorrect folding, but it 
is unlikely that all the interactors of 13-dystroglycan were non-functional. 
It is more feasible that insufficient colonies were screened. Moreover, 
interactions mediated by phosphorylation can not be detected by the yeast 
two-hybrid assay unless the relevant tyrosine kinase is present in the yeast 
strain or is co-expressed. Therefore SH2-mediated interactions which 
require phosphorylated tyrosines in the ligand cannot be investigated. 
Involvement of 13-dystroglycan itself in SH2-mediated interactions has not 
been demonstrated, but it may be indirectly involved due to SH2-
mediated interactions in focal adhesion assembly/ disassembly and other 
cell-adhesion induced signalling pathways. Alternatively, 13-dystroglycan 
could be involved in other interactions (possibly WW-mediated), 
positively regulated by phosphorylation. 
4.7.8. Candidate interactor of 13-dystroglycan : Actin 
Actin al was identified in the yeast two-hybrid assay as a potential 
interactor of 13-dystroglycan. In further biochemical assays, it was found 
that 13-dystroglycan bound F-actin and increased its viscosity, thus 
substantiating the idea that 13-dystroglycan interacts with actin. 
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If 13-dystroglycan was bundling or crosslinking F-actin, one would expect it 
to cause F-actin to form supermolecular aggregates which sediment in 
low speed centrifugation, which is what was observed (figure 4.14A). In 
addition, 13-dystroglycan significantly co-sedimented with F-actin during 
the high speed co-sedimentation assay. F-actin was pelleted as expected, 
and 13-dystroglycan moved from the supernatant to the pellet, indicating 
that it interacts with F-actin (figure 4.14B). Subsequently, actin bundles 
were observed by electron microscopy of 13-dystroglycan and F-actin (figure 
4.16). This finding corroborates the results of the biochemical co-
sedimentation assays and the falling ball assay, and provides direct 
evidence that 13-dystroglycan bundles actin. 
Bundles and meshworks of actin filaments form structures which act as a 
scaffold in cells. These scaffolds are involved in anchoring organelles and 
protein synthesis machinery in the cell, or supporting the plasma 
membrane or attaching cells to the ECM or to other cells. Large and small 
crosslinking proteins are thought to share similar actin-binding motifs 
despite causing actin to form different types of structures (reviewed in 
Matsudaira, 1991). Generally speaking, large flexible proteins crosslink 
actin filaments into networks or gels e.g. filamin (forms dimer of 240kDa) 
or spectrin (froms a tetramer of 920kDa) and small crosslinking proteins 
are more likely to pack actin filaments tightly into bundles e.g. EF-la 
(30kDa), fimbrin (68kDa) and possibly f3-dystroglycan cytoplasmic domain 
(l3kDa). 
Actin-crosslinking proteins must have at least two actin-binding sites, or a 
single actin-binding site and act as a dimer. At this stage it is not clear 
where 13-dystroglycan's actin-binding motif(s) are, although it does contain 
the actin-binding motif KLTL in the N-terminal region of the cytoplasmic 
domain, which it shares with ABS2 in dystrophin and utrophin. NMR 
studies predict that 13-dystroglycan does not form dimers (J. Bramham & S. 
J. Winder, personal communication) which makes it unlikely that I- 
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dystroglycan only has one actin-binding domain and acts as a dimer to 
bundle actin. 
There are two types of actin bundles. The first supports the finger-like 
shape of membrane projections such as microvilli, stereocilia and 
filopodia and sheet-like membrane extensions such as lameflipodia e.g. 
crosslinking by fimbrin, EF-la, villin. The second type of actin-bundle is 
characterised by its muscle sarcomere-like organisation and composition. 
Filaments in these bundles are crosslinked by proteins such as a-actinin 
and form stress fibres, the contractile belt and contractile ring. The 
bundles are anchored to specialised adhesion sites of the plasma cell 
membrane, for example, focal adhesion sites or immediate junctions. It is 
not apparent what type of actin bundles 3-dystroglycan induces actin to 
form but the transfection of full length GFP-tagged dystroglycan into 
REF52 fibroblast cells causes the cells to produce prominent actin-rich 
extensions known as filopodia (Yun-Ju Chen & S. J. Winder, personal 
communication). The ability of 13-dystroglycan to stimulate the production 
of filopodia is abolished if the intracellular domain of 13-dystroglycan is 
removed from the GFP-construct. This indicates that 13-dystroglycan 
causes actin to form the first type of bundles. However, 13-dystroglycan's 
role as a cell adhesion molecule implies that it may be involved in focal 
adhesion assembly/ disassembly. Therefore, one might expect 13-
dystroglycan to crosslink actin into the second type of bundles. Whatever 
the exact function, 13-dystroglycan's association with actin implicate it as 
an important mediator in the control of the cytoskeleton. 
In contrast to 13-dystroglycan, dystrophin does not display actin filament 
bundling or crosslinking properties. In dystrophin/F-actin co-
sedimentation assays, the DAPC was unable to effect the low speed 
sedimentation of F-actin, demonstrating that F-actin was not aggregated 
into supermolecular aggregates (Rybakova et al., 1996). In addition, 
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electron microscopy studies of F-actin and the purified DAPC exhibited no 
bundling of F-actin. However, the significant amount of the DAPC in the 
pellet with actin after high speed centrifugation confirms that dystrophin 
does bind F-actin (Rybakova et al., 1996). Dystrophin's inability to bind C-
actin suggests that dystrophin is not involved in actin polymerisation 
kinetics, and does not appear to crosslink or bundle F-actin either. 
Therefore it is conceivable that it has a purely structural role (Winder et 
al., 1995). However, it appears that dystrophin slows down the 
depolymerisation of actin filaments (Rybakova et al., 1996). One 
hypothesis is that dystrophin binds along actin filaments, interacting with 
multiple actin monomers in a manner similar to other actin side-binding 
proteins (e.g tropomyosin). Therefore, dystrophin could prevent or retard 
the dissociation of actin monomers from the ends of the filaments to 
which it is bound, thereby stabilising the actin filaments (Rybakova & 
Ervasti, 1997). Further experiments are needed to find out what effect 3-
dystroglycan has on actin polymerisation kinetics, and it would be 
interesting to find out what the relationship is between dystrophin, 3-
dystroglycan and actin, i.e. do dystrophin and 13-dystroglycan bind 
competitively or synergistically with actin? 
Identifying actin as a potential interactor of 3-dystroglycan in this two-
hybrid assay, has significant implications for our understanding of the 
roles of the DAPC. It will be interesting to see what effect dystroglycan has 
on the actin dynamics in muscle cells, and whether it is the f3-dystroglycan 
which is a member of the DAPC which crosslinks F-actin. 3-dystrog1ycan 
could be interacting with actin in two ways, either as part of a multifaceted 
DAPC-actin interaction, or it could be a separate pool of 3-dystroglycan 
interacting with actin, which is not part of the DAPC. The concept of 13-
dystroglycan interacting with actin has not been previously considered 
and is raises exciting possibilities for the role of 13-dystroglycan as a cell 
adhesion molecule. 
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Chapter 5 Phosphorylation of 13-dystroglycan 
Investigating the phosphorylation of f3-
dystroglycan and its effect on the 13- 
dystroglycan-dystrophin interaction 
5.1. Introduction 
More and more evidence is emerging which demonstrates that the DAPC 
is a dynamic complex, interacting with signalling proteins (section 1.9.4) 
and potentially mediating signals between the outside and inside of cells. 
Therefore, the concept of the DAPC as a purely static structural support in 
muscle cells is gradually being challenged. 
Dystrophin, dystrobrevin, a- and y-sarcoglycans have already been 
identified as phosphoproteins. It is possible that more DAPC proteins are 
phosphorylated and one of the aims of this project was to identify novel 
phosphorylation events and elucidate the role of these phosphorylation 
events in the regulation of interactions within the DAPC. 
It became clear during J3-dystroglycan immunoprecipitation assays that it 
is possible to maintain the otherwise transient phosphorylation of 13-
dystroglycan using the phosphatase inhibitor peroxyvanadate (section 3.5, 
James et al., 2000). Considering that f3-dystroglycan forms a link between 
dystrophin and the ECM, it was of great interest to identify whether its 
phosphorylation had any effect on protein:protein interactions within the 
DAPC, and in particular, the dystrophin-13-dystroglycan interaction. 
This chapter incorporates investigations into the tyrosine 
phosphorylation of 13-dystroglycan in muscle cells. In addition, a 
functional relevance to this phosphorylation was identified: experiments 
showing that phosphorylation of 13-dystroglycan is important in the 
regulation of the dystrophin-13-dystroglycan interaction are also described 
in this chapter. 
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5.2. Treatment of C2/C4 cells with peroxyvanadate 
Peroxyvanadate is a potent tyrosine phosphatase inhibitor which was 
used to capture phosphorylation events in C2/C4 cells. This enables the 
visualisation of phosphorylated DAPC proteins by western blotting with 
antibodies directed against phosphorylated residues. In a timecourse of 
exposure of myotubes to peroxyvanadate, myotubes were treated with 
peroxyvanadate and lysed at intervals (section 2.3.5). The resultant extracts 
were western blotted with the phospho-tyrosine antibody FY20 (figure 
5.1). No proteins were recognised by PY20 in the untreated extracts but 
many proteins were phosphorylated during the first 10 minutes of 
peroxyvanadate treatment. A protein running at approximately the same 
electrophorectic mobility as 13-dystroglycan was phosphorylated after 
approximately 40 minutes of exposure to peroxyvanadate. The 
phosphorylation of some proteins decreases after 40 minutes and after an 
exposure of 1 hour, cells round up and detach from the tissue culture 
flask, presumably due to the loss of cellular adhesion. Taking all this into 
consideration, in the proceeding experiments, cells were routinely treated 
for 45 minutes with peroxyvanadate in order to analyse phosphorylation 
events. 
During immunoprecipitation experiments, it was noticed that anti-
phosphotyrosine antibodies detected a protein running at the same 
electrophoretic mobility as 3—dystroglycan in 13—dystroglycan 
immunoprecipitates (section 3.5). 
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Figure 5.1 
Timecourse of exposure of C2/C4 myotubes to peroxyvanadate. 
Exposure to 
peroxyvanadate (minutes) 













Myotubes were exposed to peroxyvanadate and lysed at intervals. The resultant extracts 
were western blotted (lB) with the phospho-tyrosine antibody FY20. No proteins were 
recognised by FY20 in the untreated extracts (0 minutes) but most proteins were 
phosphorylated by 10 minutes of peroxyvanadate treatment. However a protein running at 
approximately the same electrophorectic mobility as 3-dystroglycan (shown by arrow) was not 
phosphorylated until 40 minutes of exposure to peroxyvanadate. The phosphorylation of 
some proteins deceased after 40 minutes (see 60 minutes lane). 
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It has been previously found that peroxyvanadate treatment of HeLa cells 
causes a retardation in electrophorectic mobility of 13—dystroglycan when it 
is visualised by western blotting of SDS-PAGE gels (James et al., 2000). In 
this study, when extracts of peroxyvanadate treated C2/C4 myotubes were 
run on SDS-PAGE and western blotted with f3—dystroglycan antisera, a 
significant upward shift of —dystroglycan was observed in the treated 
cells due to a retardation in electrophorectic mobility compared to 13—
dystroglycan in non-treated cells (Figure 5.2). 
Figure 5.2 





Peroxyvanadate treated (+PV) and untreated (-PV) myotube extracts western blotted (IB) 
with MANDAG2 (13-dystroglycan monoclonal antibody).An upward mobility shift of 3-
dystroglycan was observed in peroxyvanadate treated myotube extracts compared to 3-
dystroglycan from untreated extracts. This is indicative of a phosphorylation event. 
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5.3. Tyrosine phosphorylation 3—dystroglycan 
Mobility shifts are often indicative of a post-translational modification of 
a protein, such as a phosphorylation event. Treatment of the myotubes 
with calyculin A (section 2.3.6) (an inhibitor of type 1 and 2A 
serine/threonine phosphatases (Ishihara et al., 1989)) did not cause any 
retardation in electrophoretic mobility of 3—dystroglycan (figure 5.3). This 
suggests that if the modification is due to a phosphorylation event, it is 
caused by the phosphorylation of tyrosine residues rather than serine or 
threonine residues. 
Figure 5.3 




Calyculin A treated (+CA) and untreated (-CA) myotube extracts western blotted (IB) with 
MANDAG2 (-dystroglycan monoclonal antibody). 
Treatment of myotubes with Calyculin A did not cause any retardation in electrophorectic 
mobility. i.e 3-dystrogIycan from untreated extracts looked identical to 3-dystroglycan from 
treated extracts. This suggests that the mobility shift of p-dystroglycan caused by treatment 
with peroxyvanadate is not due to a serine or threonine phosphorylation event. 
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To confirm further that the electrophoretic mobility shift was due to 
phosphorylation of f3-dystroglycan, lambda phosphatase (Xppase), a serine, 
threonine and tyrosine phosphatase, was used (section 2.4.3). When the 
3—dystrog1ycan immunoprecipitates from peroxyvanadate-treated cell 
extracts were treated with Xppase, the electrophorectic mobility of f3— 
dystroglycan was reduced to its previous levels i.e. equivalent to 13—
dystroglycan from untreated cells (figure 5.4). This strongly suggests that 
the mobility shift of 13—dystroglycan in peroxyvanadate treated myotubes is 
due to a phosphorylation event. Peroxyvanadate has previously been 
shown to directly modify thiol groups in proteins (Mikalsen & Kaalhus, 
1998). The reversal of the mobility shift of 13—dystroglycan by Xppase 
indicates that the modification of 13—dystroglycan during peroxyvanadate 
treatment is caused by phosphorylation events rather than by 
modification of thiol groups. Furthermore, it has been previously shown 
that direct treatment of purified 13—dystroglycan with oxidising agents does 
not result in mobility shifts on SDS-PAGE (James et al., 2000). 
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Figure 5.4. 






frdystroglycan immunoprecipitates from peroxyvanadate treated (+PV) or untreated (-PV) 
myotube extracts were treated with Xppase, and blotted (IB) with 3-dystroglycan monoclonal 
antibody MANDAG2. 
In peroxyvanadate untreated extracts, Xppase has no affect on the electrophorectic mobility 
of 3-dystroglycan, whereas in peroxyvanadate treated extracts, the mobility shift of i-
dystroglycan is abolished by Xppase, suggesting that it is caused by phosphorylation of 3-
dystroglycan. 
To establish that this phosphorylation event was in fact tyrosine 
phosphorylation of 3-dystroglycan, 3-dystroglycan immunoprecipitates 
were western blotted with anti -phospho tyro sine antisera (figure 5.5). 3-
dystroglycan was detected by anti-phosphotyrosine antisera but only in 
extracts from peroxyvanadate treated myotubes. Therefore, it can be 
concluded from this that 3-dystroglycan is tyrosine phosphorylated in 
peroxyvanadate treated myoblasts and myotubes. 
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Figure 5.5 
3-dystroglycan is recognised by anti-phosphotyrosine 




J3-dystroglycan immunoprecipitates (IF) blotted (IB) with anti-phosphotyrosine antibody 
FY20. PY20 recognises a band migrating at the same molecular weight as f3-dystroglycan 
only in peroxyvanadate treated cell extracts (+FV), suggesting that 3-dystroglycan is tyrosine 
phosphorylated under these conditions. 
This was further confirmed by western blotting Xppase-treated - 
dystroglycan immunoprecipitates with anti- phosphotyrosine antisera. 
After 2ppase treatment, 3-dystroglycan immunoprecipitated from 
peroxyvanadate treated cell extracts is no longer detected by anti-
phosphotyrosine antibodies (figure 5.6). Therefore, when the mobility 
shift of 3-dystroglycan is abolished by A.ppase treatment, 3-dystroglycan is 
no longer tyrosine phosphorylated and is undetectable by anti-
phosphotyrosine antibodies. 
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Figure 5.6. 
Detection of 3-dystroglycan by anti-phosphotyrosine antibodies 






3-dystroglycan immunoprecipitates (IF) from peroxyvanadate treated (+PV) or untreated (
PV) myotube extracts were treated with Xppase and blotted (lB) with anti-phosphotyrosine 
antibody FY20. 
3-dystroglycan is not detected in peroxyvanadate untreated extracts. 3-dystroglycan is only 
detected by FY20 in peroxyvanadate treated extracts but this detection is abolished by 
2.ppase treatment, presumably as 3-dystroglycan is no longer tyrosine phosphorylated. 
In order to examine the tyrosine phosphorylation of f3-dystroglycan in 
more detail, two-dimensional gel electrophoresis was carried out on 
immunoprecipitates of 3—dystroglycan from peroxyvanadate treated and 
untreated myoblast and myotube extracts (section 2.4.8). The 
immunoprecipitates were separated by isoelectric focusing, followed by 
SDS-PAGE, and western blotted with f3—dystroglycan antibodies. In 
myotube extracts from untreated cells, 3—dystroglycan appears as a single 
spot, whereas in peroxyvanadate treated cells, 3—dystroglycan appears as 
two or possibly three spots, indicative of additional charged species, likely 
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Figure 5.7 
Two-dimensional gel electrophoresis of 3-dystroglycan from 
peroxyvanadate treated myotubes. 
IEF 	IEF + 
-PV 	+Pv 
3—dystroglycan from untreated (-PV) or peroxyvanadate treated (+PV) myotube extracts was 
immunoprecipitated using 1710 polyclonal antibody, separated by isoelectric focusing (IEF) 
followed by SDS-PAGE and blotted (lB) with either 3—dystroglycan monoclonal antibody 
MANDAG2 or phospho-tyrosine antibodies (P-Tyr). 
MANDAG2 recognises two or possibly three spots of 3—dystroglycan as an ellipse in 
peroxyvanadate treated extracts (upper right panel) compared to one clear spot in untreated 
extracts (upper left panel). The phospho-tyrosine antisera detects two poorly defined spots 
migrating with the same mobility as the two most negatively charged 3—dystroglycan species, 
but only in peroxyvanadate treated myotube extracts (lower right panel). No species are 
detected by the phospho-tyrosine antisera at this electrophorectic mobility in untreated 
extracts (lower left panel). 
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When 3—dystroglycan immunoprecipitates separated by two-dimensional 
electrophoresis were blotted with anti-phosphotyrosine antibodies, two 
spots migrating in the same position as j3—dystroglycan were detected, but 
only in peroxyvanadate treated cells (figure 5.7, lower panels). These two 
spots recognised by anti -phospho tyro sine antibodies were migrating in 
the same location as the most negatively charged 3—dystroglycan species. 
This is consistent the idea that 13—dystroglycan is phosphorylated on 
tyrosines: i.e. it is recognised by anti- phosphotyrosine antibodies, and 
migrates nearer to the cathode due to the addition of negatively charged 
phosphate groups. 
Two-dimensional gel electrophoresis of peroxyvanadate treated and 
untreated myoblast extracts produced a slightly different spot pattern 
compared to the myotube extracts, although approximately the same 
phenomena were observed (figure 5.8). In untreated myoblast extracts, the 
3—dystroglycan antibody detected one or possibly two spots as an ellipse, 
compared to one clear spot in myotube extracts. In addition, in 
peroxyvanadate treated myoblast extracts, three distinct spots are detected 
by the 3—dystroglycan antibody and the anti-phosphotyrosine antibody 
(compared to two or possibly three spots in myotube extracts). Therefore, 
as in the myotube extracts, there were more 3—dystroglycan species in 
peroxyvanadate treated myoblast extracts compared to the untreated, 
presumably due to phosphorylation events. However, there is possibly 
one extra phosphorylated species in myoblast extracts compared to 
myotube extracts. 
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Figure 5.8 
Two-dimensional gel electrophoresis of 3-dystroglycan from 
peroxyvanadate treated myoblasts 
- 	IEF 	-i-- 	IEF 	+ 
DH3 	DH10DH3 	DH10 








3—dystroglycan from untreated (-PV) or peroxyvanadate treated (+PV) myoblast extracts was 
immunoprecipitated using 1710 polyclonal antibody, separated by isoelectric focusing (IEF) 
followed by SDS-PAGE and blotted (lB) with either 3—dystroglycan monoclonal antibody 
MANDAG2 or phospho-tyrosine antibody PY20 (P-Tyr). MANDAG2 recognises three spots 
of 3—dystroglycan in peroxyvanadate treated extracts (upper right panel) compared to one or 
possibly two spots (as an ellipse) in untreated extracts (upper left panel). The phospho-
tyrosine antisera also detects three spots migrating with the same mobility as 3—dystroglycan 
in peroxyvanadate treated myoblast extracts (lower right panel), but detects no - 
dystroglycan in the untreated extracts (lower left panel). 
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5.4. Does the phosphorylation of f3-dystroglycan affect 
its interaction with dystrophin? 
The identification of the phosphorylation of f3-dystroglycan on tyrosine 
residues raised the question of whether this phosphorylation is involved 
in the regulation of 13-dystroglycan's protein:protein interactions. 1-
dystroglycan has been shown to interact with dystrophin, Grb2, rapsyn, 
caveolin-3 (sections 1.6.1. & 1.6.4) and three unidentified phosphoproteins 
(section 3.5). The dystrophin-13-dystroglycan interaction is the best 
characterised of these interactions, and is important for the stability of the 
DAPC (Rafael et al., 1996) and was therefore studied further. 
The dystrophin- 13-dystroglycan interaction is mediated by dystrophin's 
WW domain and a proline-rich motif (PPxY) in the cytoplasmic domain 
of 13-dystroglycan (section 1.6.1). Type 1 and Type IV WW domains have 
been shown to be regulated by phosphorylation events (table 1.1). Type IV 
WW domains are positively regulated by phosphorylation of serine and 
threonine residues in their ligands (Lu et al., 1999; Ranganathan et al., 
1997) and type I WW domains are negatively regulated by 
phosphorylation of tyrosine in the PPxY motif of their ligands (Chen et 
al., 1997; James et al., 2000). In the work of James et cii. (2000), it was 
demonstrated that the interaction between 3-dystroglycan and utrophin is 
regulated by phosphorylation. Consequently, it was highly plausible that 
the interaction between 13-dystroglycan and dystrophin is also regulated by 
phosphorylation. This could be highly significant for understanding more 
about the general functions of, and the regulation of interactions within, 
the DAPC. 
To elucidate whether the tyrosine phosphorylation of f3—dystroglycan 
affects its interaction with dystrophin, 'SPOTs' membrane binding assays 
were used. Peptide 'SPOT' blots of the 3—dystroglycan cytoplasmic domain 
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were probed with purified dystrophin fusion protein comprising the 
WW, EF hands and ZZ domains fused to a biotin tag (DYS-PIN) (section 
2.4.10). The purified DYS-PIN fusion protein and the purified biotin tag 
(used as a control) are shown in figure 5.9. 
Figure 5.9 






A construct of dystrophin was made comprising amino-acids 3055-3354, (encompassing the 
WW, EF hand and ZZ domains) and cloned into the PinPoint Xa-3 vector. This construct and 
the vector alone were bacterially expressed to produce a biotin tag (PIN 13kDa) and the DYS-
PIN fusion protein (37.6kDa), which were purified using avidin resin. The purified proteins 
were western blotted with ExtraAvidin-HRP and developed with ECL. The biotin tag alone is 
shown in the left lane and DYS-PIN fusion in the right lane.The large PIN band in the right 
lane is as a result of proteolytic degradation of the fusion protein. 
Initially, the interaction site between f3—dystroglycan and dystrophin was 
confirmed by probing the cytoplasmic domain of 3—dystroglycan with 
DYS-PIN fusion protein. A f3—dystroglycan SPOT blot comprising the 
entire cytoplasmic domain of 3—dystroglycan as 12 overlapping amino-
acid peptides, offset by 4 amino-acids, was used (as shown in figures 5.10A 
and 5.10B). 
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Figure 5.10 
Identification of 3-dystrogIycan peptides which interact with 
DYS-PIN fusion protein (dystrophin WW-EF-ZZ) 
A. 	Spot 1 
2 	 3 	 4 	 5 	 9 	 8 	 9 
LLIAGI IANICYRKKRKGKLTLEDQATF IKKGV 




23 	 24 	 25 	 26 	 27 	 29 	 29 	 30 
Spot 31 








A. Scheme for the synthesis of peptides on the 'SPOTs' membrane. Twelve amino-acid long 
peptides representing part of the transmembrane region and the entire cytoplasmic domain 
of human l3-dystroglycan (amino-acids 764-895) were synthesised on derivatised 'SPOTs' 
membranes with an offset of 4 amino-acids. The transmembrane region is denoted by a 
double underline. Numbers above and below the 3-dystroglycan sequence denote the first 
and last amino-acid of the peptide, respectively, found on the corresponding spot. Brackets 
identify the sequences of spots 1 and 31. Spot 32 is a negative control where no peptide is 
synthesised. B. Numbered circles identify the location of each spot on the membrane. 
C. Control 'SPOTs' membrane described as above probed with PIN protein alone, and 
detected by ECL. The PIN protein bound weakly to spots 2, 3, and 29. D. 'SPOTs' 
membrane described as above probed with dystrophin (DYS-PIN) fusion protein, and 
detected by ECL. The DYS-PIN fusion bound strongly to spots 30 (PKNMTPYRSPPP) and 
31 (TPYRSPPPYVPP) which contains a recognised WW-binding motif. 
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DYS-PIN bound strongly to spots 30 and 31 and weakly to spots 4, 27 and 
29. Some non-specific binding to spots 2, 3, 29 and to a lesser extent spot 4 
was revealed in a control experiment, in which the biotin tag alone (PIN) 
was incubated with the 3—dystroglycan 'SPOTs'. From this it was inferred 
that DYS-PIN was interacting specifically with spots 4, 27, 30 and 31. The 
strongest binding to spots 30 and 31 is equivalent to the carboxyl terminal 
16 amino-acids of f3—dystroglycan interacting with dystrophin. This region 
of 3—dystroglycan includes the PPxY motif which has been previously 
identified as a ligand for dystrophin's WW domain. 
To ascertain whether the phosphorylation of residues in this 16 amino-
acid region of 3—dystroglycan affects its interaction with dystrophin, a 
separate SPOT blot comprising the peptides from spot 30 and 31 as a single 
peptide (KNMTPYRSPPPYVPP) was used for binding assays with DYS-
PIN (figure 5.11). This series of peptides had sequential phospho amino-
acids at all possible phosphorylation sites (i.e. serine, threonine and 
tyrosine residues). DYS-PIN bound strongly to spot 1, equivalent to spots 
30/31 in figure 5.10. The phosphorylation of threonine884, tyrosine886 and 
serine888 (peptides 2 3, and 4) appeared to have no affect on this binding 
However, when tyrosine 112  in the PPPY motif was phosphorylated 
(peptide 5) the binding of dystrophin was greatly reduced. This binding 
was 	further reduced when both tyrosine 886  and tyrosine 112  were 
phosphorylated in peptide 6. Interestingly, in peptide 4 where only 
tyrosine 816  is phosphorylated, binding of dystrophin is not affected, 
indicating that the phosphorylation of tyrosine886 is necessary but not 
sufficient, to completely abolish the interaction. These data therefore 
support the hypothesis that phosphorylation of 3-dystroglycan on Tyr 112  is 
able to regulate f3-dystroglycan's interaction with the C-terminus of 
dystrophin. 
216 
Chapter 5 Phosphorylation of 8-ds t roglyca n 
Figure 5.11 
Phosphorylation of tyrosines in f3-dystroglycan disrupt its 









A 15 amino-acid peptide equivalent to spots 30/31 of 3-dystroglycan cytoplasmic domain was 
synthesised containing the phospho-amino-acids pS, pT and pY at each possible position in 
the peptide, either singly or in multiples. The membrane was probed with dystrophin fusion 
protein (DYS-PIN). The binding of DYS-PIN was greatly reduced by phosphorylation of 
tyrosine 892  in the PPPY motif (peptide 5). This binding was further reduced when both 
tyrosine 886  and tyrosine 112  were phosphorylated (peptides 6 and 8), but was not affected by 
serine/threonine phosphorylation (peptide 7). 
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5.7. Discussion 
5.7.1. f3-dystroglycan is tyrosine phosphorylated in muscle cells 
Dystrophin and the DAPC, initally assumed to be proteins whose primary 
role is structural, have more recently been implicated in signalling events 
(section 1.9). Further studies have led to the reasoning the DAPC can 
actually be thought of as a dynamic complex, and spatially, it is ideally 
placed to transduce signals from the extracellular matrix to the inside of 
cells. Over the past few years there has been a growing body of evidence to 
suggest that the DAPC is involved in signalling pathways, predominantly 
the demonstration of the number of phosphoproteins in the DAPC. The 
phosphorylation of dystrophin on serine and threonine has been 
previously described (reviewed in (Michalak et al., 1996; Winder, 1997)), 
dystrobrevin was originally identified as a phosphoprotein (Wagner et al., 
1993), and analysis of dystrophin and the DAPC using two-dimensional 
gel electrophoresis suggests that dystrophin, 3-dystroglycan and 
potentially other components of the DAPC are phosphorylated 
(Yamamoto et al., 1993). More recently, it has been demonstrated that a-
and y-sarcoglycans are phosphorylated and that 13-dystroglycan is 
phosphorylated in non-muscle cells (James et al., 2000). In this study, it 
has been definitively shown that 3-dystroglycan is phosphorylated in 
muscle cells and this phosphorylation has an affect on protein:protein 
interactions within the DAPC. 
This study describes the phosphorylation of f3-dystroglycan on tyrosine 
residues in C2/C4 myotubes treated with peroxyvanadate. This was 
initially identified by mobility shifts on SDS-PAGE gels of 13-dystroglycan 
from peroxyvanadate-treated myotube extracts (figure 5.2). It was 
subsequently demonstrated that 3-dystroglycan from peroxyvanadate-
treated myotube extracts is recognised by anti-phosphotyrosine antibodies 
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on both one and two-dimensional gels (figures 5.5, 5.7 & 5.8), and this 
recognition is abolished by lambda phosphatase treatment (figure 5.6). 
It is curious that in the two-dimensional gel analysis, 3-dystroglycan from 
myoblasts and myotubes exhibited different mobility characteristics. The 
presence of two species recognised by 13-dystroglycan antibodies in 
untreated myoblasts (figure 5.8) suggests that there is a phosphorylated 
species caused by a peroxyvanadate-independent phosphorylation event. 
However, neither of these 13-dystroglycan species were detected by anti-
phosphotyrosine antibodies. Therefore, if one of these species is a 
phosphorylated form of 13-dystroglycan, it must be phosphorylated on 
serines or threonines. It is also plausible that the presence of two 13-
dystroglycan species is due to different kind of post-translational 
modification e.g. differential glycosylation. 
In addition, three phosphorylated species were detected by anti-
phosphotyrosine antibodies in myoblasts compared to two in myotubes. It 
is possible that 13-dystroglycan is more highly phosphorylated in myoblasts 
compared to myotubes. It is not unexpected that differentiated and 
undifferentiated cells have slightly different characteristics due to their 
specialised roles. For example, myoblasts are more motile than myotubes 
and may require more phosphorylation states. 
5.7.2. Phosphorylation of 3-dystrog1ycan disrupts its interaction 
with dystrophin 
In order to characterise the dystrophin-13—dystroglycan interaction more 
fully, 'SPOT' blots comprising peptides of 13—dystroglycan's cytoplasmic 
domain were probed with the DYS-PIN fusion protein. It was 
demonstrated that DYS-PIN bound to spots 4, 27, 30 and 31. The 
interactions with spots 30 and 31 were the strongest. 
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Spots 30 and 31 comprise the 16 most C-terminal amino-acids of 13- 
dystroglycan. The amino-acid sequence of these peptides were 
subsequently used in the binding assay with phosphorylated residues 
(figure 5.11). This region of 13—dystroglycan has been identified previously 
as being necessary for binding to dystrophin (Jung et al., 1995) and Spot 31 
(TPYRSPPPYVPP) contains the recognised WW-binding motif PPxY 
(Rentschler et al., 1999). In addition, a dystrophin-GST fusion has also 
been observed to bind a similar peptide (Rentschler et al., 1999) and James 
et cii. (2000) showed that a utrophin-MBP (Maltose Binding Protein) 
fusion also bound the same sequence (James et al., 2000). DYS-PIN bound 
strongly to the peptide (PKNMTPYRSPPP) (spot 30), although it does not 
include the whole PPxY motif. It is possible that the strong binding occurs 
because spot 30 overlaps with spot 31 and contains residues involved in 
the association of 13-dystroglycan with the EF hand region of dystrophin 
(Huang et al., 2000). Previous experiments with a dystrophin-GST fusion 
demonstrated strong binding to spot 31 only (Rentschler et al., 1999). The 
finding that spot 30 is also bound may be due to differences in the limits 
of the constructs used (dystrophin residues 3055-3354 (this study) versus 
residues 3046-3447 (Rentschler et al., 1999)). 
It is notable that the putative WW-domain interacting motif PPEY in 13- 
dystroglycan's cytoplasmic domain was not a substrate for DYS-PIN 
binding (figure 5.10). This motif is contained in peptides 15, 16 and 18 
which have no signal after incubation with the DYS-PIN fusion protein. 
Therefore, this excludes the role of this motif in binding WW domains. 
It was demonstrated that the phosphorylation of tyrosine residues within, 
and adjacent to 13—dystroglycan's WW domain disrupt its interaction with 
dystrophin (figure 5.11). Although the WW-mediated interaction is 
necessary for the dystrophin-13—dystroglycan interaction, dystrophin's EF 
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hands and ZZ domain are also involved. It is likely that they have a more 
stabilising role, holding the two proteins in the correct configuration. It is 
probable that the WVV domain is the main site by which the interaction is 
regulated, but the EF hands are also essential for the interaction 
(Rentschler et al., 1999). In addition, from the recent crystal structure of 
dystrophin WW-EF hands region complexed with a 13—dystroglycan 
peptide (Huang et al., 2000), it is clear that the f3—dystroglycan peptide 
binds a composite surface formed by both the WW domains and one of 
the two EF hands (figure 5.12). 
The crystal structure of dystrophin WW-EF hands region complexed with 
a f3—dystroglycan peptide (Huang et al., 2000) also strengthens the evidence 
for an interaction regulated by phosphorylation. The structure reveals the 
importance of tyrosine 892  in the interaction and from it, one can predict 
that phosphorylation of tyrosine 192  in the PPPY motif of 13—dystroglycan 
would disrupt the interaction with the WW domain of dystrophin. 
Tyrosine 192  fits into a hydrophobic pocket of the WW domain and the 
interaction is co-ordinated by a hydrogen bond from the conserved 
histidine residue (His3076) of the WW domain. It is clear that the 
incorporation of a bulky phosphate group on tyrosine 192  would both 
disrupt a hydrogen bond and render the residue too large to fit into the 
WW domain pocket. 
Chen et cii. (1997) have described a similar phenomenon in the WBP-
1 /YAP65 interaction, in that phosphorylation of the tyrosine in the PPPY 
motif of WBP-1 abolishes its interaction with the WW domain of YAP65 
in in vitro 'SPOTs' assays (Chen et al., 1997). Phosphorylation of the 
tyrosine residue in 13—dystroglycan's PPPY motif also disrupts its 
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Figure 5.12 
The structure of dystrophin WW-EF region complexed with a 3-
dystroglycan peptide 
(Figure adapted from lisley etal. (2001a)) 
Pro 889 	Lir8g2 His 307 
EF hands 1WW domain 
Space filling representation of dystrophin's WW domain (yellow) and the region of the EF 
hand domain which comes into contact with 3-dystroglycan (orange). 
The bound 3-dystroglycan peptide (amino-acids 885-893, PYRSPPPYV) is represented in 
stick form and labelled at its N- and C-termini. 
Proline889 and proline890  of the PPxY motif of 3-dystroglycan insert into a concave hydrophobic 
surface formed by tyrosine 31111  and tryptophan3o83of the WW domain (space-filled, turquoise). 
Tyrosine 1192  also fits into a hydrophobic pocket of the WV'! domain and the interaction is co-
ordinated by a hydrogen bond with Histidine3076 of dystrophin (space-filled magenta). 
Tyrosine886  also resides in a pocket of the dystrophin protein, but in the EF-hand region. 
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In addition, James et al. (2000) demonstrated that fusion proteins of 
utrophin WW, EF hand and ZZ domains failed to interact with 1- 
dystroglycan in vivo in peroxyvanadate treated HeLa cells (James et al., 
2000). 
In this study, it was also demonstrated that residues flanking the PPxY 
motif affect 3—dystroglycan's interaction with dystrophin. The 
phosphorylation of tyrosine886 (i.e. spot 6, figure 6.11), which is N-
terminal to the PPPY motif, affects the dystrophin-13—dystroglycan 
interaction. Like tyrosine892, tyrosine886 also resides in a pocket of 
dystrophin protein, but in the EF hand region. Whilst phosphorylation of 
tyrosine 116  alone is not sufficient to prevent binding, in conjunction with 
phosphorylation of tyrosine 892, binding of dystrophin to the 13-
dystroglycan peptide on the 'SPOT' blot is completely abolished. 
Interestingly, in the study of the utrophin-13—dystroglycan interaction, the 
phosphorylation of tyrosine886 did not affect utrophin binding to 13- 
dystroglycan, but the phosphorylation of serine888 in conjunction with 
tyrosine886 completely abolished it (James et al., 2000). This demonstrates 
that there may be different mechanisms of regulation between 13-
dystroglycan and its binding partners, perhaps involving distinct kinases. 
5.7.3. Which kinase phosphorylates 13-dystroglycan? 
The tyrosine kinase involved in the phosphorylation of 13—dystroglycan is, 
as yet, unknown. Various serine/threonine kinases have been implicated 
in phosphorylating dystrophin, for example MAP Kinase, CaM kinase II, 
cdc casein kinase II, p34 2, protein kinase C (Luise et al., 1993; Madhavan and 
Jarrett, 1994; Milner et al., 1993; Shemanko et al., 1995), (table 1.2). 
Importantly, the purified DAPC has been shown to have associated 
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endogenous serine/threonine kinase activity (Luise et al., 1993; 
Madhavan and Jarrett, 1994) but the kinase(s) associated with the DAPC 
have not been identified. The tyrosine phosphorylation of a- and y-
sarcoglycans was inhibited by Herbimycin A (Yoshida et al., 1998) which 
suggests the involvement of the Src family of kinases. However, 13- 
dystroglycan is still receptive to phosphorylation in FAK knockout cells 
and Src knockout cells (James et al., 2000) which excludes the possibility of 
these two kinases directly phosphorylating 13—dystroglycan in HeLa cells. 
No other kinases have been tested, to date. Other candidate kinases could 
be proline-directed kinases such as the Cdk family, GSK-3, the MAP 
kinase family and p34 cdc2• 
Sequence analysis of 13—dystroglycan (PROSITE) does not provide any clues 
towards identifying the kinase involved either: there are no recognised 
tyrosine phosphorylation sites in the cytoplasmic domain, although there 
is one present in the extracellular domain (amino-acids 743-750). More 
investigations need to be carried out in order to determine the nature of 
the kinase involved, which in turn, may lead to the identification of 
signalling pathways that the DAPC is involved in. 
5.7.4. Adhesion-dependent phosphorylation of 13-dystroglycan? 
The DAPC has previously been implicated in integrin-mediated adhesion 
events, in that a- and ?-sarcoglycans from myotubes were found to be 
phosphorylated on tyrosine residues in response to adhesion to 
extracellular matrix proteins fibronectin or collagen type 1 (Yoshida et al., 
1998). This phosphorylation was also induced by the RGDS (integrin 
recognition sequence) peptide, implying that the DAPC is involved in the 
integrin adhesion system (Yoshida et al., 1998). 
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The tyrosine phosphorylation of 3—dystroglycan in non-muscle cells is 
adhesion-dependent. This was first noticed due to a mobility shift on SDS-
PAGE gels of 13-dystroglycan from adherent HeLa cells compared to 
suspended HeLa cells, without the use of peroxyvanadate (James et al., 
2000). Additionally, phosphorylation occurred when HeLa cells were 
plated onto fibronectin or laminin substrates, suggesting an integrin-
mediated event (James et al., 2000). 
The adhesion-dependent phosphorylation of 13-dystroglycan was not 
evident in myoblast or myotube extracts in this study. C2/C4 myotubes 
did not survive the replating process, but myoblasts were re-plated onto 
gelatin, fibronectin, laminin and tissue-culture plastic alone (section 
2.3.7). This was to identify if the adhesion of the myoblasts onto 
extracellular substrates stimulated the phosphorylation of 13-dystroglycan. 
However, no mobility shifts of f3-dystroglycan were observed on SDS-
PAGE gels (data not shown), these being an indication of such a 
phosphorylation event. Treatment with peroxyvanadate after the 
replating process still caused a mobility shift of 13-dystroglycan suggesting 
that the protein was still accessible to phosphorylation after replating. 
These preliminary experiments suggested that the phosphorylation of f3-
dystroglycan in C2/C4 cells is not stimulated by adhesion. Furthermore, 
Yoshida et cii. (1998) did not identify adhesion-dependent phosphorylation 
of 13-dystroglycan in their study (Yoshida et al., 1998). 
The possibility that the phosphorylation of 13-dystroglycan is adhesion-
dependent in non-muscle cells, but not in muscle cells, is intriging. On a 
technical level, one reason for this may be that few myotubes survive 
trypsinisation and the subsequent maintenance in suspension. Or, this 
may be a genuine phenomenon caused by the static nature of the 
differentiated muscle cells compared to HeLa cells and/or a different role 
of the DAPC compared to the utrophin-associated protein complex. 
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However, these reasons do not explain why adhesion-dependent 
phosphorylation of 3-dystroglycan is not observed in myoblasts either. 
5.7.5 The dynamic nature of the DAPC 
The dynamic nature of the 13—dystroglycan/dystrophin interaction is 
illustrated by recent work on the 13—dystroglycan/Grb2 interaction (Russo 
et al., 2000). In vitro studies suggest that dystrophin and Grb2 compete in 
order to bind to 13—dystroglycan which supports the hypothesis that the 
DAPC is actively turned over, but in a highly regulated manner. 
Disruption of this delicate balance by reduction or loss of dystrophin may 
explain some of the poorly understood mechanisms of disease 
progression in Becker and Duchenne muscular dystrophy. 
In addition, it has been demonstrated that 3—dystroglycan's interaction 
with the scaffolding protein caveolin-3 (section 1.6.4.2) is also a W W 
domain-mediated interaction, and dystrophin and caveolin-3 compete for 
the same PPxY motif on 3—dystroglycan (Sotgia et al., 2000). 
One proposed function of the caveolin-3/3-dystroglycan interaction in 
healthy muscle is to competitively regulate the interaction and 
recruitment of dystrophin to the sarcolemma (Sotgia et al., 2000). 
Dystrophin and caveolin co-localise at the sarcolemma, dystrophin has 
numerous cave olin-binding motifs and the two proteins co-
immunoprecipitate. (Song et al., 1996; Couet et al., 1997). Therefore, 
caveolin-3 interacts with both 3-dystroglycan and dystrophin, so could 
plausibly recruit them both to the sarcolemma, and keep them apart until 
they are assembled properly in the DAPC. 
226 
Chapter 5 Phosphori1a tion of ,8-dystroglycan 
Interestingly, unlike dystrophin, caveolin-3 is able to bind phosphorylated 
3—dystroglycan. The WW domain of caveolin-3 is insensitive to the 
phosphorylation of tyrosine 192  in the PPxY motif of 3—dystroglycan (Sotgia 
et al., 2000) (figure 5.13). Therefore, the phosphorylation of 3—dystroglycan 
may act as a switch to alter the affinity of the dystroglycan complex from 
dystrophin to caveolin-3. When 3—dystroglycan phosphorylation is 
induced by the as yet unidentified stimulus, dystrophin is released from 
dystrophin, which would allow a caveolin-3/3—dystroglycan interaction to 
take place. This presumably would alter the function of the dystroglycan 
complex, perhaps involving it in a distinct signalling pathway. Caveolin 
associates with members of the Src-family of kinases which could be 
involved in the phosphorylation of 3—dystroglycan, although it does 
appear that caveolin is an inhibitor of the Src-family of kinases (Li et al., 
1996). 
It has been suggested that disruption of the 3—dystroglycan-dystrophin 
connection could lead to muscular dystrophy (Rentschler et al., 1999). 
Discovering that the f3—dystroglycan-dystrophin is regulated by 
phosphorylation (this study) suggests that this interaction is a dynamic 
one, and suggests that a disruption of the regulation could cause muscular 
dystrophy, rather than, or in addition to, the simple severing of the 
connection. This may have implications for the disease pathogenesis of 
muscular dystrophies and dystroglycan may have a more significant role 
than originally considered. 
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Figure 5.13 
Dystrophin and caveolin-3 compete for the same binding site on 
3-dystroglycan 
Dystrophin and caveolin-3 each have a WW-domain which binds to the PPxY motif in the 
cytoplasmic domain of J3-dystroglycan. The two proteins compete for this site On 13-
dystroglycan. However, when -dystrogIycan is phosphorylated on the tyrosine in the PPxY 
motif, its binding to -dystrogIycan is abolished. Caveolin-3 is insensitive to this 
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Summary 
In this thesis, work has been described which was carried out in order to 
understand more about the interactions of proteins within the 
dystrophin-associated protein complex (DAPC) and how they are 
regulated. The study has also involved the investigation into the 
interactions DAPC protein 13-dystroglycan has with proteins outside of the 
DAPC. 
The model of choice for this work was the C2/C4 mouse muscle cell line. 
This cell line was characterised for its use in these studies (i.e. 
differentiation properties, expression of DAPC proteins) and different 
protein extraction methods were tested to obtain the optimal conditions 
for extracting proteins of the DAPC. Efforts were made to isolate the 
whole DAPC and co-immunoprecipitate it as a whole entity so that 
interactions within the DAPC could be monitored. This proved to be 
difficult either due to the extraction conditions used or the antibodies 
available, or perhaps a combination of both. The co-immunoprecipitation 
of dystrophin and members of the sarcoglycan complex was successful, but 
unfortunately not the co-immunoprecipitation of dystrophin and 3-
dystroglycan. 
13-dystroglycan was found to be phosphorylated on tyrosine residues when 
treated with the phosphatase inhibitor, peroxyvanadate. 
Immunoprecipitation of 3-dystroglycan from peroxyvanadate treated cells 
also demonstrated that phosphoproteins are associated with 1-
dystroglycan. Silver staining of these immunoprecipitations suggest that 
some of these proteins are also associated with 13-dystroglycan in 
unstimulated cells. Investigations are continuing in order identify these 
proteins This includes protein sequencing of proteins isolated from 
immunoprecipitations separated by SDS-PAGE. 
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A yeast two-hybrid assay using the 13-dystroglycan cytoplasmic domain as a 
bait to screen a skeletal muscle cDNA library revealed that 13-dystroglycan 
interacts with actin al. This interaction was subsequently substantiated by 
biochemical assays. Co-sedimentation experiments demonstrated that 13-
dystroglycan and F-actin were sediment together both at high and low 
speed centrifugation, suggesting that the two proteins interact and form 
supermolecular aggregates. Falling ball viscosity assays demonstrated that 
3-dystroglycan cytoplasmic domain increases the viscosity of F-actin at 
least 4-fold. Subsequent electron microscopy studies revealed that 13-
dystroglycan bundles actin filaments. 
The association of the DAPC with the actin cytoskeleton via dystrophin is 
well characterised, but an interaction between 13-dystroglycan and actin has 
not been shown previously. Dystrophin has been shown to bind F-actin 
but have no affect on actin dynamics, acting as an anchor linking to the 
actin cytoskeleton (Winder et al., 1997). In contrast, it has been 
demonstrated here that 3-dystroglycan bundles actin filaments and 
therefore potentially plays an active role in actin re-organisation in the 
cell. 
With 3-dystroglycan's potential role in cell adhesion, actin may link the 
dystroglycan complex to focal adhesions. For example, the 
phosphoproteins observed co-immunoprecipitating with 13-dystroglycan 
may be focal adhesion proteins indirectly associating with 13-dystroglycan. 
In this case, the "linker" protein connecting 13-dystroglycan to the focal 
adhesions may be actin. Previous work has demonstrated that the DAPC 
is associated with focal adhesions either via dystrophin or a-sarcoglycan 
(Yoshida et al., 1998) or Grb2 (Cavaldesi et al., 1999) but the 3-
dystroglycan/actin interaction could further strengthen the link between 
the DAPC and focal adhesions. The fact that 13-dystroglycan bundles actin 
could also explain why overexpression of 3-dystroglycan causes a cdc42-
like phenotype in fibroblast cells, i.e. actin arranged in a ring formation at 
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the periphery of the cell and filopodial projections of the cell membrane 
(Yun-Ju Chen & S.J. Winder, personal communication). 
The role of 13-dystroglycan in actin dynamics is being investigated by 
immunoflorescence studies of 13-dystroglycan-GFP constructs and 
rhodamine-phalloidin-stained actin filaments (Yun-Ju Chen & S. J. 
Winder). In addition, an interaction between 13-dystroglycan and P4 
integrin is also being pursued. A complex of plectin, integrin and 13-
dystroglycan has been isolated by co-immunoprecipitation experiments 
and investigations into the function of this complex continue (Bittner et 
al., 2001). 
Analysis of 13-dystroglycan's protein:protein interactions continues. 
Currently a yeast two-hybrid screen is being carried out in our laboratory 
using the f3-dystroglycan cytoplasmic domain lacking the WW domain as 
bait in a HeLa cell cDNA library. This study should shed light on which 3-
dystroglycan interactions are WW-domain dependent and also identify 
proteins which interact with 13-dystroglycan in non-muscle cells. In 
addition, a yeast two-hybrid screen using a range of deletion constructs of 
the J3-dystroglycan cytoplasmic domain could delineate the interaction site 
of 3-dystroglycan and actin and other interactors of 13-dystroglycan. The 
falling ball assay could also be carried out using purified proteins made 
with a range of 3-dystroglycan deletion constructs to delineate potential 
actin-binding sites. 
The significant role of the PPxY motif in 13-dystroglycan has been 
illustrated in this study. For example, its importance in regulation of the 
3—dystroglycan/ dystrophin interaction, and how it affects 13-dystroglycan's 
protein:protein interactions. It has been demonstrated that the 
phosphorylation of the tyrosine residue in this motif disrupts 3-
dystroglycan's interaction with dystrophin. The effect of the WW domain 
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on 13-dystroglycan's protein:protein interactions was also shown in the 
yeast two-hybrid screen i.e. the high frequency of WW-mediated 
interactions, albeit non-specific. 
To date, the structures of 6 WW domains (representing 3 different W W 
domain classes) have been solved (Huang et al., 2000; Macias et al., 2000; 
Verdecia et al., 2000; Kanelis et al., 2001). Despite the differences in ligand 
specificity and the diverse origins of these structures, they are almost 
completely superimposable (lisley et al., 2001b). 
The finding that the phosphorylation of the tyrosine residue within a 
WW-domain binding motif is not a new phenomenon but it is the first 
time that phosphorylation of flanking tyrosine residue has been shown to 
fully abolish the interaction. Phosphorylation of serine and threonine 
residues flanking the PPxY motif have been reported to positively or 
negatively regulate the WW-domain mediated interaction (James et al., 
2000; Kay et al., 2000) but this is the first time that the involvement of a 
phosphorylated PPxY motif flanking tyrosine has been necessary to 
disrupt the interaction in conjunction with the tyrosine within the motif. 
Despite the high interest in the regulation of WW domain interactions, 
there is still no clear cut in vivo example of tyrosine phosphorylation 
regulating WW ligand complexes and it remains unclear as to what 
kinase might phosphorylate the PPxY motif and its flanking residues. 
It is still not known what the function of the dystroglycans a and 0 are 
separately. Generation of the dystroglycan knockout mouse (Williamson 
et al., 1997) and chimeric mice devoid of dystroglycan (Cote et al., 1999) 
have been useful in understanding the essential functions of the 
dystroglycan complex as whole, but more studies are needed to elucidate 
the exact function of the separate cx and P subunits. Separate cx1I-
dystroglycan knockout mice would provide an insight into separating out 
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the functions of these proteins. This would reduce the complexity and 
give a clearer idea of the roles of the u— and f3—subunits in muscular 
dystrophies, branching epithelial morphogenesis, muscle differentiation, 
neuronal development and NMJ formation. Questions include: is the 3-
dystroglycan knockout lethal or is it just the connection between a-
dystroglycan and the extracellular matrix which is essential for membrane 
formation? And presuming that 13-dystroglycan has the important role in 
signalling that we think it does, what signalling problems would a 3-
dystroglycan knockout have? 
New roles and binding partners are continually emerging for a- and 3-
dystroglycans and the role of dystroglycan as a link between the 
cytoskeleton and extracellular matrix is becoming increasingly complex. 
Some of these functions will undoubtedly involve dystroglycan as a 
member of the DAPC and give us a greater understanding of the part the 
DAPC plays in muscular dystrophies, which in turn, will lead to more 
progressive and effective cures for these diseases. 
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3-dystroglycan amino-acid sequence 
Separated into the extracellular (amino-acids 655-750), transmembrane (amino-acids 751-775) and 
intracellular domains (amino-acids 776-895). The WW-domain interacting motif PPXY is doubly 
underlined. 
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Abstract 
Dystrophin and the dystrophin-associated protein complex (DAPC) have recently been implicated in cell signalling events. These proteins 
are ideally placed to transduce signals from the extracellular matrix (ECM) to the cytoskeleton. Here we show that .-dystroglycan is tyrosine-
phosphotylated in C2/C4 mouse myotubes. Tyrosine phosphorylation was detected by mobility shifts on SDS-polyaciylamide gels (SDS-
PAGE) and confirmed by immunoprecipitalion and two-dimensional gel electrophoresis. The potential functional significance of this tyrosine 
phosphorylation was investigated using peptide 'SPOTs' assays. Phosphorylation of tyrosine in the 15 most C-terminal amino acids of - 
dystroglycan disrupts its interaction with dystrophin. The tyrosine residue in d-dystroglycan's WW-binding motif PPPY appears to be the 
most crucial in disrupting the -dystroglycan dystrophin interaction. -dystroglycan tornis the essential link between dystrophin and the rest 
oIthe DAPC. This regulation by tyrosine phosphorylation may have implications in the pathogenesis and treatment of Duchenne's muscular 
dystrophy (DMD). cl 2001 Elsevier Science Inc. All tights reserved. 
Kevivords: Dystrophin: Dysiroglycan: Tyrosine phosphorylation: Regulation: Muscular dystrophy 
I. Introduction 
Duehenne's muscular dystrophy (DMD) is caused by 
mutations at the DMD locus leading to a total lack of 
dystrophin protein in muscle cells [I]. Dystrophin associates 
with a group of membrane-associated proteins called the 
dystrophin-associated protein complex (DAPC). The func-
tions and the interactions of the dystrophin and DAPC 
proteins are not clearly defined. They are however, crucial 
in maintaining muscle cell integrity, as demonstrated by the 
severe defects when they are disrupted [2]. In skeletal 
muscle, dystrophin is proposed to act as a link between 
the actin cytoskeleton and the extracellular matrix (ECM), 
thus stabilising myofibres during muscle contraction and 
relaxation [3]. Additionally, dystrophin has been implicated 
in cell signalling events. Spatially, it is ideally placed to 
transduee signals from the ECM into the cell, and there is 
* Corresponding author. Tel.: +44-141-330-2773; fax: +44-141-330-
2707. 
E-mail address: s.winder(abio.gla.ac.uk (Si. Winder).  
evidence of direct phosphorylation of dystrophin and the 
DAPC proteins [4-8]. The functional consequences of these 
phosphorylation events are unknown although recently, the 
phosphorylation of - and -y-sareoglyeans was shown to be 
induced by integrin-mediated cell adhesion in muscle cells 
[9]. Furthermore, we have shown that .3-dystroglycan is 
tyrosine-phosphorylated in an adhesion-dependent manner 
in non-muscle cells, and this affects its interaction with 
utrophin, the ubiquitous homologue of dystrophin [10]. 
3-Dystroglycan provides the essential link between dys-
trophin and the DAPC. The dystroglycan gene encodes both 
3-dystroglycan and the extracellular -dystroglyean, which 
interacts with lantinin in the ECM [11]. The importance of 
the dystroglycans is demonstrated by the gene knockout in 
mice, which leads to embryonic lethality at Day 6.5 due to 
failure of the Reichert's membrane to form [12] and embry-
onic stem cells deficient for these proteins are unable to 
assemble basement membrane [13] (see Ref. [14] for 
review). No clinical effects of 3-dystroglycan mutations 
have been identified, presumably because the consequences 
are too profound for survival. 
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It has been shown previously that the cysteine-rich 
region of dystrophin is required for the binding of 3-
dystroglycan and the binding affinity is strengthened by 
the C-terminal domain [1 5-17]. More recently, Rentschler 
et al. [18] have shown that this interaction requires the WW 
and EF hand domains. The ZZ domains are not essential but 
significantly stabilise the interaction. 
In this current study, we show that 3-dystroglycan is 
tyrosine-phosphoiylated in muscle cells and that phosphor- 
ylation is important in the regulation of the dystrophin-3-
dystroglycan interaction. 
Wrexham) and is directed against the C-terminus of 13-
dystroglycan (amino acids 881-895). Polyclonal antisera 
against 3-dystroglycan phosphopeptide CMTPY RSPPP-
pYVPP (poly 3-DG 1710) and human utrophin carboxy-
terminal coiled-coil domain (residues 3204-3433) (RA B5) 
[22] were raised in rabbits using standard techniques. 
Antiphosphotyrosine monoclonals (PY20 and RC20) were 
from Transduction Laboratories. The following dilutions 
were effective for Western blotting: MANDAG2 (1:500), 
NCL-DYSI (1:100), NCL-DYS2 (1:10), PY20 (1:1000), 
RC20 (1:500), and RAB5 (1:10,000). 
2.3. hnmunoprecipilalion assays 
2. Materials and methods 
2. 1. Cell culture 
C2/C4 niyoblasts [19] were maintained in DMEM media 
(Gibco BRL) supplemented with 20% foetal calf serum 
(Gibco BRL) in 5% CO2 atmosphere at 37°C. In order to 
induce differentiation, the amount of foetal calf serum in the 
growth media of confluent or semiconfluent niyoblasts was 
reduced to 2% for up to 9 days. Myoblasts fused to form 
myotubes from Day 4. 
C2/C4 myotubes were treated with peroxyvanadate in 
order to inhibit the activity of tyrosine phosphatases [20]. 
The cells were washed with serum-free DMEM and then 
incubated in peroxyvanadate (2 mM H70, 1 mM sodium 
orthovanadate in serum-free DMEM media) for 45 min at 
37°C. Cells were washed once in cold phosphate-buffered 
saline (50 mM sodium phosphate p1-I 7.2, 150 mM NaCI) 
before being harvested in ice-cold radioimmunoprecipitation 
assay (RIPA) buffer (50 mM Tris—HCI, pH 7.5, 150 mM 
NaCl, 1 mM ethylene glycol-bis-(b-aminoethyl ether) 
N,N,N',W'-tetraacetic acid (EGTA), 1 mM ethylenediaminete-
traacetic acid (EDTA), 1% Triton X-100, 0.5% sodium 
deoxycholate, 0. 11/0 SDS, I mM sodium orthovanadate, 100 
0.M leupeptin, 1 mM phenylmethylsulphonyl fluoride 
(PMSF), 100 sM N-tosyl-L-phenylalanine chloromethyl 
ketone (TPCK). Cells that were not treated with peroxyvana-
date were incubated for an equivalent time in serum-free 
media before being harvested in RIPA as above. After harvest-
ing, cells were briefly sonicated to shear the DNA, centrifuged 
(15,000 rpm, 20 mm), and stored at - 20°C until assay. 
The protein concentration in cell extracts was quantified 
using the BCA protein assay (Pierce) following the nianu-
facturers' instructions. 
2.2. Antisera 
NCL-DYSI and NCL-DYS2 were gifts from L. Ander-
son (University of Newcastle) and are directed against the 
mid-rod domain (amino acids 1181 —1388) and C-terminus 
(amino acids 3669-3685) of dystrophin (commercially 
available from Novacastra Laboratories). MANDAG2 [21] 
was kindly provided by G.E. Morris (NE Wales Institute, 
Cell extracts in RIPA were initially cleared by incubation 
with protein A-Sepharose or protein G-Sepharose for 1-2 h 
at 4°C. The required amount of antibody was added to the 
cleared extract and the cells were incubated overnight at 
4°C. In order to precipitate the antibody—protein complex, 
50 111 of a 50% slurry of protein A-Sepharose was added per 
sample, and incubated for a further 1 —2 h at 4°C. The 
samples were centrifuged briefly to pellet the Sepharose 
beads, and the beads were washed four times with RIPA 
buffer. The final pellet was resuspended in SDS-polyacry-
lamide gels (SDS-PAGE) loading buffer. Immunoprecipita-
tions of 3-dystroglycan were carried out with the following 
antisera at the indicated dilutions: MANDAG2 (1:5), poly 13-
DG 1710 (1:10). 
2.4. Lain bda ph asp hat cise treatment 
Lambda phosphatase (Xppase, New England BioLabs) 
was used to treat im Ill unoprecipitates of 3-dystroglycan. The 
3-dystroglycan immunoprecipitates were treated with 200 
units of Xppase at 30°C for 40 min. A cocktail of Xppase, I  
Xppase buffer, 2 mM MnCl7, and H70 to 10 11.1 was added 
directly to the protein A-Sepharose beads. The reaction was 
stopped by boiling in SDS-PAGE loading buffer for 2 mm. 
2.5. SDS-PAGE and Western blotting 
Samples from immunoprecipitation experiments were 
run on 7.5-20% acrylamide SDS-PAGE with a 5% stacking 
gel under reducing conditions [23] and blotted onto poly-
vinylidene difluoride (PVDF) membranes in 10 mM CAPS, 
20% methanol, and processed for immunodetection as 
previously described [10]. 
2.6. Two-dimensional gel electrophoresis 
.3-Dystroglycan was immunoprecipitated from equal 
amounts of protein from peroxyvanadate-treated or 
untreated cell extracts, prepared as above. The Sepharose 
beads were resuspended in rehydration buffer (8 M urea, 21/o 
CHAPS, 2% ampholine, 20 mM DTT) and incubated for I h 
at room temperature. After centrifugation, the supernatant 
Ii. llsIei el al. / Cellular Signalling /3 (2001) 625-632 
	
627 
was used to rehydrate 180 mm pH 3-1 Iminobiline Dry-
strips (Amersham Pharmacia Biotech) overnight. Strips 
were then subjected to isoelectric focusing on an Amersham 
Pharmacia Biotech Multiphor System in gradient mode (1 
mA, 5 W, and 300 V for 0.01 h, 300 V for 3 h, 3500 V for 5 
h. 3500 V for 12.5 h). Strips were stored at - 80°C prior to 
SDS-PAGE. Strips equilibrated in equilibration buffer (50 
mM Tris—HCI (pH 8.8), 6 M urea, 30% glycerol, 2% SDS, 
1% DTT) for 30 inin were separated in the second dimen-
sion on reducing 3-15% SDS-PAGE with no stacking gel. 
All gels were electroblotted onto PVDF and immunoblotted 
with anti phosphotyrosine or 3-dystroglycan antisera as 
described above. The imniunoblots were developed by 
ECL (Amersham Pharmacia Biotech). 
2.7. Generation qt clystrophin li/sin/I pro/el/I 
The limits of the dystrophin cysteine rich domains WW, 
EF, and ZZ were identified by sequence alignment and 
secondary structure prediction [10]. eDNA encoding resi-
dues 3055-3354 of human dystrophin (encompassing the 
WW, EF, and ZZ domains, see Fig. IA) was amplified by 
Dolymerase chain reaction (PCR). The 5' primer contained a 
HindlIl restriction site and the 3' primer contained a stop 
codon and b/otl restriction site. PCR products were cloned 
into the unique HindIlI and Nod restriction enzyme sites of 
Schematic of dystrophin domains 
3055 	3354 	 3652 
Actin- Triple 	WW EF ZZ 	Coiled- 
binding helical Hands coil 
domain coiled-coil 
B. Expression of dystrophin fusion protein 
MWMarlcers  
48.5 kDa 	 _____ 	DYS-PIN fusion (47.6 kDa) 
26.5 kDa 
S PIN (BIOTIN TAG) (13 kDa) 
Fig. I. (A) Schematic showing the protein domains of dystrophin. A 
construct was made comprising amino acids 3055-3354 (encompassing the 
WW. EF hand, and ZZ domains), fused to a biotin tag (PIN). -3652 across 
the top denotes amino acid numbers. (B) Expression of dystrophin construct 
fused to biotin tag. Amino acids 3055-3354 of dystrophin were cloned into 
the PinPoint Xa-3 vector. This construct and the vector alone were bacterially 
expressed to produce a biotin tag (PIN 13 kDa) and the DYS—PIN fusion 
(37.6 kDa), which were purified using avidin resin. The purified proteins 
were Western blotted with ExtraAvidin-HRP and developed with ECL. 
Biotin tag alone left lane and DYS--PIN Fusion right lane. The large PIN band 
in the right lane is as a result ofproteolytic degradation of the fusion protein. 
the PinPoint Xa-3 vector (Promega) to produce the DYS—
PIN construct. Escherichia co/i (JM109) was transfornied 
with PinPoint Xa-3 (control: expression produces a biotin tag 
only (PIN)) or DYS—PIN and grown at 37°C until the OD600 
reached 0.6, then induced with 0.5 mM lsopropyl-b-D-
thiogalactopyranoside for 2 h. Following harvesting by 
centrifugation (4200 rpm, 10 mm), the cell pellet was stored 
at - 70°C overnight. After thawing, the pellet was resus-
pended in SET buffer (25% w/v sucrose, 50 mM Tris—HCI, 
pH 8, 1 mM EDTA, 100 p.M leupeptin, 1 mM PMSF, 100 ILM 
TPCK, 10 mg/ml STI) and the cell suspension treated with 
lysozyme (0.5 mg/mI), followed by DNAsel (I tg/mI). The 
lysed cells were then sonicated and centrifuged (14,000 rpm. 
20 mm) followed by ultracentrifugation (35,000 rpm, I h). 
Expressed protein was purified by incubation of the crude 
cell supernatant with Softlink soft release avidin resin 
(Promega: I ml resin/2 I culture) overnight, at 4°C. The 
resin was subsequently washed four times with lysis buffer 
(50 mM Tris—HCI, pH 7.5, 50 mM NaCl, 5% glycerol) and 
protein eluted with 5 mM free biotin in lysis buffer, over-
night, at 4°C). The free biotin was subsequently removed by 
dialysis in lysis buffer. The purification was monitored by 
SDS-PAGE and Western blotting using ExtraAvidin-HRP 
(Sigma) followed by detection with ECL (see Fig. IB). 
2.8. Hvbridisation ( t' SPOTS' membranes with D YS—PIN 
fUSiO/l protein 
SPOTs membrane synthesis was carried out as described 
previously [10,18]. A dystrophin WW— EF.-ZZ-biotinylated 
tag fusion protein (DYS—PIN) was purified from bacterial 
lysates as above. SPOTs membranes were blocked over-
night in 10% milk in TBST at 4°C and then probed over-
night with DYS—PIN protein or PIN alone (10 ig/mI). The 
membrane was then washed four times with TBST and 
incubated with ExtraAvidin-HRP diluted 1:1000 in TBST 
for 2 It After four washes with TBST, the blot was 
developed by ECL. 
3. Results 
3. 1. Characterisation of mvotiibe differentiation 
Mouse skeletal muscle cell lines have been widely used 
as a model for studying niyogenesis. On reaching conflu-
ency and/or reduction in serum levels, myoblasts sponta-
neously fuse to fonn multinucleated myotubes and express 
muscle specific proteins. Several different mouse skeletal 
muscle cell lines were assessed for their use in this study. 
The C2/C4 cell line (a recloned C2/C12 line) [19] was 
chosen for its efficient myoblast fusion and the expected 
expression pattern of DAPC proteins. In a time course of 
differentiation, :3-dystroglycan is expressed equally in myo-
blasts and myotubes, as is utrophin (the ubiquitous homo-
logue of dystrophin) whereas dystrophin is only expressed 
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Myoblasts (day 1) Myotubes (day 9) 







MIr 	 (43 kDa) 
Fig. 2. Ditibrentiation time course of C2 C4 myoblasts. (A) Myoblasts on 
Day I (left) compared to multinuclear myotubes after 9 days (right) in low 
scrum diffdrcntialion medium. Scale bar— 50 tim. (B) Western blots for 
dystrophin, utrophin, and t-dystroglycan in fusing myoblasts. The serum 
content in the growth media was reduced tioni 200 to TV,, on Day I when 
the niyoblasls were 500 o continent. Myoblast fusion first started to occur at 
Days 3 and 4. Myotubes appeared idly furmed by Day 5. Dystrophin is 
only expressed in fully 'used myoblasts (Day 5 onwards) whereas the 
ubiquitous utrophin and 3-dystroglycan are expressed equally in myoblasts 
and myotubes. 
in fairly advanced stages of differentiation when myotubes 
are fully formed (see Fig. 2). Previously it has been shown 
that in cultured cells, dystrophin mRNA is expressed only in 
fused myotubes and not myoblasts [24]. 
Fig. 3. Phosphorylation of (-dystroglycan in C'2/C4 myotube extracts. (A) 
Upper panels: Western blot of myotuhe extracts with the anti 
dystroglycan monoclonal antibody MANDACi2. A distinct reduction in 
electrophoretie mobility of 3-dystmg!ycan was observed in pei-oxyvanadate 
+ PV)-treated cell extracts as compared to untreated cell extracts ( - PV) 
blotted for ,-dystroglycan. Lower panels: Western blot of -dystioglyean 
immunoprecipitales with antiphosphotyrosinc antibody RC20. RC20 only 
recognises -dystroglycan in the imm1100precipitations tl'om peroxyvana-
date-treated cell extracts, suggesting that 1-dystroglycan is tyrosine-
phosphotylated under these conditions. (B) Western blot of .)-dystroglycan 
immunoprccip itatcs from either control (tipper panel) or peroxyvanadate-
treated myutube extracts (lower panel) with ( + Xppase) or without 
Xppase) lambda phosphatase treatment. In peroxyvanadate-un tented 
cell extracts >ppase has no alThet on electrophoretic mobility, whereas in 
peroxyvanadate-treated cells, the mobility shill is abolished by Xppase 
treatment, suggest i ng that it is caused by phospho ry liii ion of 3-
dystroglycan. (C) As (B), but 3-dystroglycan immunuprecipitatioii was 
detected with antiphosphotyrosine antisera. Xppase treatment abolishes the 
phospho tyrosine inimunorcactivity on .)-dystroglycan in peroxyvanadale-
ticated cells. (D) Two dimensional gel electrophoresis of 3-dystroglycan 
0Dm peroxyvanadate-treated myotubes. 1-Dystroglycan immunoprecipi-
tales were separated by soclectrie-focusing (IEF) followed by SDS-PAGE 
and blotted with 1-dystroglycan monoclonal antibody MANDAG2. The 
I mmunopreci plates from peroxyvanadate-treated cell extracts have three 
Closely migrating spots (upper right) compared to one clear spot in 
untreated extracts (upper left). Antiphosphutyrosine antisera detects two 
poorly defined spots migrating with the same mobility as .t-dystrogtycnn, 
and only in peroxyvanadatc-treated myotube extracts. 
At 9 weeks of gestation, dystrophin protein in foetal 
muscle samples is barely detectable with antibodies on 
Western blots and only distinct populations of larger myo-
tubes are recognised by dystrophin immLtnostaining. How-
ever, the staining pattern increases and becomes more 
uniform with age, but does not reach the adult pattern of 
expression until 26 weeks of gestation [25]. This suggests 
that the dystrophin expression pattern in C2/C4 myotubes is 
equivalent to the in vivo situation. 
3.2. 43,i'.vtrog/i'caii /JhO.s/)hO/'t'IaliO/t 
We had previously found that peroxyvanadate treatment 
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lity of 3-dystroglycan on Western blots [10]. When extracts 
of peroxyvanadate-treated C2/C4 myotubes were run on 
SDS-PAGE and Western blotted with 3-dystroglycan anti-
sera, a significant upward shift of 3-dystroglycan was seen 
in the treated cells due to a retardation in electrophoretic 
mobility compared to 3-dystroglycan in non-treated cells 
(Fig. 3A, upper panel). C-2 /C4 niyoblasts and myotubes 
treated with peroxyvanadate for 45 min produced the 
maximum mobility shift of 3-dystroglycan on SDS-PAGE. 
When exposed to peroxyvanadate for an hour or more, the 
cells start to round up and detach from the tissue culture 
flask (data not shown). Mobility shifts are indicative of a 
modification of the protein, for example, a phosphorylation 
event. Treatment of the myotubes with calyculin A (an 
inhibitor of Types I and 2A serine/threonine phosphatases 
[26]) did not cause any retardation in electrophoretic mobi-
lity (data not shown), suggesting that if the modification is 
due to a phosphorylation event, it is phosphorylation of 
tyrosine residues rather than serine or threonine residues. To 
establish that this phosphorylation event was in fact tyrosine 
phosphorylation of 3-dystroglycan, immunoprecipitates of 
3-dystroglycan were recognised on Western blots by anti-
phosphotyrosine antisera (Fig. 3A, lower panels). 
Peroxyvanadate has previously been shown to directly 
modify thiol groups in proteins [27]. To further confirm 
that the electrophoretic mobility shift was due to phosphor-
ylation of 3-dystroglycan, Xppase. a serine, threonine, and 
tyrosine phosphatase, was used. When the .3-dystroglycan 
immunoprecipitates from peroxyvanadate-treated cell 
extracts were treated with Xppase the electrophoretic mobi- 








Fig. 4. Identification of 3-dystroglycan peptides that interact with DYS—PIN fusion protein (dvstrophin WW—EF—ZZ). (A) Scheme for the synthesis of 
peptides on the 'SPOTs' membrane. Twelve amino acid long peptides representing part of the transmembrane region and the entire cytoplasmic domain of 
human 3-dystroglycan (amino acids 764-895) were synthesised on derivatised 'SPOTs' membranes with an offset of four amino acids. The transmembrane 
region is denoted by a double underline. Numbers above the 3-dvstroglycan sequence denote the first amino acid of the peptide found on the corresponding 
spot whilst numbers below the sequence denote the last amino acid of the peptide on the corresponding spot. Brackets identify the sequences of spots 1 and 31. 
Spot 32 is a negative control where no peptide is synthesised. (B) Numbered circles identify the location of each spot on the membrane. (C) Control 'SPOTs' 
membrane described as above probed with PIN protein alone, and detected by ECL. The PIN protein bound weakly to spots 2, 3. and 29. (D) 'SPOTs' 
membrane described as above probed with dystrophin (DYS—PIN) fusion protein and detected by ECL. The DYS—PIN fusion bound strongly to spots 30 
(PKNMTPYRSPPP) and 31 (TPYRSPPPYVPP), which contains a recognised WW-binding motif. 
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lity of 13-dystroglycan was returned to levels equivalent to 
3-dystroglycan tiom untreated cells (see Fig. 313, lower 
panels). This strongly suggests that the mobility shift of 13-
dystroglycan in peroxyvanadate-treated myotubes is due to 
a phosphorylation event rather than a modification of tliiol 
groups. This was confirmed in a second experiment where 
-dystroglycan immunoprecipitates from control or perox-
yvanadate-treated cells were Western blotted with antisera 
against phosphotyrosine before and after Xppase treatment. 
As expected, Xppase treatment of the 3-dystroglycan immu-
noprecipitate from peroxyvanadate-treated cells resulted in 
the loss of almost all the phosphotyrosine immunoreactivity 
(Fig. 3C). 
In order to examine the tyrosine phosphorylation of 3-
dystroglycan in more detail, two-dimensional gel electro-
phoresis was carried out on immunoprecipitates of 3-dys-
troglycan from peroxyvanadate-treated and -untreated 
myotube extracts. The immunoprecipitates were separated 
by isoelectric focusing, followed by SDS-PAGE, and West-
ern blotting with 13-dystroglycan antibodies (see Fig. 313, 
Lipper). In extracts from untreated cells, 3-dystroglycan 
appears as a single spot, whereas in peroxyvanadate-treated 
cells, 3-dystroglycan appears as two or possibly three spots, 
indicative of additional charged species, likely to be the 
result of phosphorylation. When 3-dystroglycan imniuno-
precipitates separated by two-dimensional electrophoresis 
were blotted with the antiphosphotyrosine antibody PY20, 
the antibody recognised spots migrating in the same position 
as 3-dystroglycan, but only in peroxyvanadate-treated cells 
(Fig. 3D, lower). 
3.3. SPOTS' membrane binding assays 
The phosphorylation of 3-dystroglycan on tyrosine could 
potentially regulate the interaction between -dystroglycan 
and dystrophin. To elucidate whether the tyrosine phos-
phorylation of 3-dystroglycan affects its interaction with 
dystrophin, peptide 'SPOT' blots of the 13-dystroglycan 
cytoplasmic domain were probed with purified dystrophin 
fusion protein comprising the WW, EF hands, and ZZ 
domains fused to a biotin tag (DYS—PIN). Firstly, the 
interaction site between 3-dystroglycan and dystrophin 
was confirmed by probing the cytoplasmic domain of 3-
dystroglycan with DYS—PIN fusion protein. Fig. 4 shows a 
13-dystroglycan SPOT blot comprising the entire cytoplas-
mic domain of 3-dystroglycan as 12 overlapping amino 
acid peptides, offset by four amino acids. Some non-
specific binding to spots 2, 3, 29, and to a lesser extent 
to spot 4 was revealed in a control experiment, when the 
biotin tag alone (PIN) was incubated with the 3-dystrogly-
can 'SPOTs'. DYS—PIN also bound weakly to spots 4 and 
29, and to spot 27, however DYS—PIN bound very strongly 
to spots 30 and 31. This would suggest that the specific 
dystrophin43-dystroglycan interaction is restricted to spots 
30 and 31, equivalent to the carboxyl terminal 16 aniino 








4 7. KNMpTPYRpSPPPYVPP 
B. KNMpTPpYRpSPPPpYVPP 
Fig. 5. The effect of /l-dystroglycan phosphorylation on binding of 1-
dystroglycan peptides to DYS—PIN fusion protein. (A) A peptide 
equivalent to spots 30/31 synthesised containing the phospho amino acids 
pS, pT, and pY at each possible position in the peptide, either singly or in 
multiples. The membrane was probed with dystrophin (DYS—PIN) as 
described above. The binding of DYS—PIN was greatly reduced by 
phosphorylation otTyr5 in the PPPY motif (pcptide 5). This binding was 
further reduced when both Tyr856 and Tyr"' are phospholylated (peptides 6 
and 5), but not affected by serinc/threoninc phosphorylation (peptide 7). 
To ascertain whether phosphorylation of residues in this 
region of 3-dystroglycan affects its interaction with 3-dys-
trophin, a separate SPOT blot comprising the peptides from 
spots 30 and 31 as a single peptide (KNMTPYRSPPPYVPP) 
was used for binding assays with DYS—Pfl'I (Fig. 5A). A 
series of peptides was synthesised with phospho amino acids 
at all potential phosphorylation sites, i.e., serine, threonine, 
and tyrosine residues (see Fig. 513). DYS—PIN bound 
strongly to spot I, equivalent to spots 30/31 in Fig. 4A. 
The phosphorylation of Thr554, TyrSSt,  and 5cr585 (peptides 
2, 3, and 4) appeared to have no affect on this binding. 
However, when Tyr °2 in the PPPY motif is phosphotylated 
(peptide 5), the binding of dystrophin was greatly reduced. 
This binding is further reduced when both Tyr886 and Tyr892 
are phosphoiylated (peptide 6). Interestingly, in peptide 4 
when only Tyr 886  is phosphorylated, binding of dystrophin 
was not affected, indicating that the phosphorylation of 
Tyr 192  in the PPPY motif is necessary to abolish the 
interaction. These data therefore support the conclusion that 
phosphorylation of 3-dystroglycan on Tyr". 92 is able to 
regulate its interaction with the dystrophin C-terminus. 
4. Discussion 
Dystrophin and the DAPC were initially proposed to be 
proteins whose primary role is structural. More recent 
studies have implicated the DAPC in signalling events, 
and thus it can now be thought of as a more dynamic 
complex. The complex is ideally placed to transduce signals 
from the ECM to the inside of cells. The phosphorylation of 
dystrophin on serine and threonine has been previously 
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described (reviewed in Refs. [28,29]) and analysis of 
dystrophin and the DAPC using two-dimensional gel elec-
trophoresis suggests that dystrophin, -dystroglycan, and 
potentially other components of the DAPC are phosphory-
lated [30]. .3-Dystroglycan is phosphorylated in non-muscle 
cells [10] but 3-dystroglycan has not previously been shown 
to be phosphotylated in muscle cells. 
The WW domain of dystrophin is classified as a Class 1 
WW domain and shares the PPxY ligand motif with other 
members of its class, including the Yes-associated protein 
kinase YAP65 and Nedd-4, a ubiquitin ligase [31]. The 
finding that the tyrosine residue in the PPPY motif was 
critical for binding to Class 1 WW domains [32,33], raised 
the question that tyrosine phosphorylation could regulate 
WW domain binding to its cognate ligand. 
In this study, we have shown that the phosphorylation of 
tyrosine residues within and adjacent to 3-dystroglycan's 
WW domain disrupt its interaction with dystrophin. The 
DYS—PIN fusion protein bound strongly to the peptide 
(TPYRSPPPYVPP) (spot 31), which contains a recognised 
WW-binding motif. A dystrophin—GST fusion has also 
been observed to bind a similar peptide [18] and James et 
al. [10] showed that a utrophin MBP (maltose binding 
protein) fusion also bound the same sequence. This region 
of 3-dystroglycan has been identified previously as being 
necessary for binding to dystrophin [16]. More recently, it 
has been shown that the PPPY motif in this peptide is 
required for 3-dystroglycan binding to the WW domain of 
dystrophin [18]. DYS—PIN also bound strongly to the 
peptide (PKNMTPYRSPPP) (spot 30), possibly because 
it overlaps with spot 31 and contains residues involved in 
the association of 3-dystroglycan with the EF hand region 
of dystrophin [34]. Previous experiments with a dystro-
phin—GST fusion demonstrated strong binding to spot 31 
only [18]. The finding that spot 30 is also bound may be 
due to differences in the limits of the constructs used 
(dystrophin residues 3055-3354 [this study] versus resi-
dues 3046-3447 [18]). 
The EF hands and ZZ domain of dystrophin are also 
involved in its interaction with 3-dystroglycan but they 
probably have a more stabilising role, holding the two 
proteins in the correct orientation. The WW domain is likely 
to be the main site by which the interaction is regulated, but 
the EF hands are clearly also required for binding [18]. The 
recent crystal structure of dystrophin WW—EF hands region 
complexed with a 3-dystroglycan peptide [34], clearly 
shows that the 3-dystroglycan peptide binds a composite 
surface formed by both the WW domains and one of the two 
EF hands (see Fig. 6). The structure also reveals the 
importance of Tyr892 in the interaction. From the structure, 
one can predict that phosphorylation of Tyr 1192  in the PPPY 
motif of 3-dystroglycan would disrupt the interaction with 
the WW domain of dystrophin. Tyr592 fits into a hydro-
phobic pocket of the WW domain and the interaction is co-
ordinated by a hydrogen bond from the conserved histidine 
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Fig. 6. Two different vies of the structure of the dystrophin WW EF hand 
region complexed with a -dystrogIycan peptide (horn Ref. [34]). WW 
domain (yellow) and EF hand legion (orange) are shown in a space filling 
representation, showing His3° (magenta) in the WW domain. Only the 
region of the EF hand region that comes into contact with the 3-dystroglycan 
peptide (shown in slick representation and CPK colouring) is shown for 
clarity. Residues in the 3-dystroglycan peptide that make contact with 
dystrophin are labelled (upper panel). In the lower panel. Tyr555 and Ser585 are 
also labelled to indicate that they are not in close contact with dystrophin. The 
hydrogen bond between Tyr892 and HisTh7S  is represented as a dashed line. 
Tyr 892  would break a hydrogen bond and render it too bulky 
to fit into the WW domain pocket. Tyr586, which is N-
terminal to the PPPY motif, also appears to affect the 
dystrophin-3-dystroglycan interaction when it is phosphory-
lated (see Fig. 5, spot 6). Like Tyr592 it also resides in a 
pocket of dystrophin protein, but in the EF hand region. 
Whilst phosphorylation of Tyr 886  alone is not sufficient to 
prevent binding, in conjunction with phosphorylation of 
Tyr892, binding to the peptide is completely abolished. Chen 
et al. have described a similar phenomenon in the WBP-l/ 
YAP65 interaction, in that phosphorylation of the tyrosine in 
its PPPY motif of WBP-1 abolishes its interaction with the 
WW domain of YAP65 in in vitro 'SPOTs' assays [32]. 
Phosphorylation of the tyrosine residue in 3-dystroglycan 's 
PPPY motif also disrupts its interaction with utrophin, as 
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shown by 'SPOT' blot [10]. This latter study also demon-
strated that fusion proteins of utrophin WW, EF hand, and 
ZZ domains also failed to interact with tyrosine-phosphory-
lated 13-dystroglycan in HeLa cells [10]. 
The tyrosine phosphorylation of i-dystroglycan in non-
muscle cells is adhesion-dependent [10] although in myo-
tubes there does not appear to be adhesion-dependent 
phosphorylation of -dystroglycan (data not shown) Ref. 
[9]. This may be due to the static nature of the differentiated 
muscle cells compared to HeLa cells, or a different role of 
the DAPC compared to the utrophin-associated protein 
complex. However, the DAPC has been implicated in 
integrin-mediated adhesion events previously, in that t-
and y-sarcoglycans from myotubes were found to be phos-
phoTylated on tyrosine residues in response to adhesion. 
This phosphorylation was also induced by the RGDS 
(integrin recognition sequence) peptide, implying that the 
DAPC is involved with the integrin adhesion system [9]. 
This tyrosine phosphorylation was inhibited by Herbirnycin 
A, which suggests the involvement of the Src family of 
kinases. More investigations need to be carried out in order 
to determine the nature of the kinase involved, which will, 
in turn, lead to a greater understanding of the regulation and 
function of dystrophin and the DAPC. 
This study suggests that there is a role for tyrosine 
phosphorylation in regulating 3-dystroglycan- dystrophin 
interactions. It has been suggested that disruption of the 
3-dystroglycan-dystrophin connection could lead to mus-
cular dystrophy [18] but this study suggests that this 
interaction can be regulated in a dynamic way, but in 
muscular dystrophy, the regulation may be disrupted. This 
may have implications for the disease pathogenesis of 
muscular dystrophies. The dynamic nature of the 3-dystro-
glycan-dystrophin interaction is further confirmed by 
recent work on the 3-dystroglycan--Grb2 interaction [35]. 
The Grb2-3-dystroglycan  interaction could facilitate the 
transduction of signals between the DAPC and extracellular 
proteins and other signalling pathways. In vitro studies 
suggest that dystrophin and Grb2 compete in order to bind 
to 3-dystroglycan, which supports the hypothesis that the 
DAPC is actively turned over, but in a highly regulated 
manner. Disruption of this delicate balance by reduction or 
loss of dystrophin may explain some of the poorly under-
stood mechanisms of disease progression in Becker's mus-
cular dystrophy and DMD. 
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Introduction 
Since the identification of the WW domain in 1994 
f 1,2], the WW domain has been implicated in mediating 
protein—protein interactions from viral budding through 
transcription to limb development and muscular dystrophy. 
This smallest of domains, comprising only 35 amino acids 
in a stable fold, occurs in single and multiple copies in 
signalling molecules and adaptors alike, in all species from 
yeast to plants and worms to man. The defining feature of 
the domain, from whence it derived its name, are two 
tryptophan residues (single letter code W) spaced 20-22 
amino acids apart. In this short space of time the WW 
domain has become recognised as a major protein—protein 
interaction module widely distributed in all biological 
systems. Furthermore, the interactions of the WW domain 
have recently been shown to be regulated by phosphoty-
lation giving the domain a status on a par with SH2 and 
5H3 domains (reviewed in Ref. [3]). In this review we will 
discuss the general background to the structure and ligand 
interactions of WW domains, and focus on the role of WW 
domains in linking and regulating specific membrane 
cytoskeletal connections. 
WW domain ligands and structure 
The WW domain comprises 30 amino acids in a compact 
short antiparallel 13-sheet, with the limits of the 13-sheets 
* Corresponding author. Tel.: +44-141-330-2773; fax: +44-141-330- 
2707. 
E-mail address: s,winderbio.gls.ac.Uk S.J. winder). 
being defined by two conserved tryptophan residues (Fig. 1). 
The core of the structure also contains other conserved 
aromatic residues, mainly tyrosine but also a highly con-
served proline 2 residues c-terminal of the second con-
served tryptophan. It is these conserved aromatic residues 
that are key to the specificity of WW domain interactions 
with its proline-containing ligands. The WW domain is the 
smallest protein domain that is stable as a triple stranded 
antiparallel 3-sheet in the absence of disulphide bonds, 
tightly bound ions or ligands [4]. To date the structures of 
six WW domains, representing three different WW domain 
classes, have been solved [4-7]. Despite the differences in 
ligand specificity and the diverse origins of these structures, 
they are almost completely superimposeable (Fig. 2A). A 
common feature of the ligand-binding site of all WW 
domain structures so far determined is the presence of 
stacked aromatic residues that provide a binding surface 
for a proline residue contributed by the WW domain ligand. 
The essential residues in the WW domain are a tyrosine from 
the central 13-strand and the second conserved tryptophan at 
the end of the third 13-strand, this is shown diagrammatically 
in Fig. 213. The interaction with the WW domain is further 
strengthened by the stacking of other aromatic residues in the 
ligand, mainly proline and tyrosine, or by hydrophobic 
interactions with conserved residues, often histidine, in a 
surface formed by the loop between the c-terminus of the 
middle 13-strand and the n-terminus of the third 13-strand (Fig. 
213). The n-terminal conserved tryptophan is essential for the 
structure of the ligand-binding surface as a whole, which in 
essence is a shallow groove containing two hydrophobic 
regions. All WW domains that have so far been characterised 
bind to a variety of short proline-containing motifs with a 
tryptophan residue in the WW domain being essential for the 
interaction with a proline residue in the ligand. However, it is 
0898-6568/0IlS - see front matter © 2001 Elsevier Science Inc. All rights reserved. 
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Structure 
Fig. 1. Primary and secondary structure of WW domains. Sequence 
alignment of dystrophin, utrophin and caveolin-3 WW domains with 
important residues boxed. Other identical or similar residues are indicated 
by asterisks or colons, respectively. The overall consensus for all WW 
domains is shown below with the essential aromatic doublet indicated by 
the Greek letter q). At the bottom is a secondary structure cartoon with the 
three 3-sheet structures represented as broad arrows and numbered 1-3, 
compare Fig. 2A. 
the presence of other residues in the cognate ligand, and their 
phosphorylation state that further determines the type of 
WW interaction (see Table 1), and therefore WW domains 
have been classified according to the ligand with which they 
interact. In Class I WW domains, which have been studied 
most extensively (e.g., YAP65 and dystrophin), the first 
conserved tryptophan, in concert with an exposed tyrosine 
residue, forms a concave hydrophobic binding surface for 
the first two proline residues in the PPxY motif of the ligand 
that stack against the Trp and Tyr residues forming a 
hydrophobic buckle that presumably maintains the stable 
folded structure of the domain. The second conserved 
tryptophan of the WW domain is located on the convex side 
Fig. 2. Tertiary structure of WW domains. (A) Overlay of five WW domain structures using the Hierarchical Protein Structure Superposition programme 
LOCK; http://gene.stanford.eduILOCKI. The  five structures taken from the PDB (IEOL, IEOM, lEON, IF8A and IEG4) were manually edited to represent 
the core of the WW domain fold and only the ligand for 1EG4 (dystrophin 'NW domain with 3-dystroglycan peptide) is shown for clarity. N and C 
represents the amino and carboxyl termini of all five structures with major 13-sheets (light grey) labelled as 1 —3 and intervening turns dark grey. The stick 
representation of the bound peptide shows the Type I ligand from 3-dystroglycan with the amino acids PPxY labelled accordingly from top (N-terminus) to 
bottom (C-terminus). (B) Schematic cartoon of WW domain structure (bottom) showing aromatic stacking of a Type I cognate ligand top, via the X—P 
groove. (C) Schematic cartoon of SH3 domain structure (bottom) showing aromatic stacking of an SH3 Class I ligand top, via two X—P grooves. 
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Table I 
Classification of WW domains based on optimal ligand specificity 
Class 	Motif WW domains References 
PPxY Dystrophin, Ncdd4 WW-3, YAP65 [23,291 
II 	PPLP FBPII, FE65 [16,41) 
III PPR FBP30, FBP2I, FE65 [17] 
IV 	(SIT)p P PinI, Nedd4 WW-2 [33) 
of this region and stabilises the ligand-binding surface. The 
tyrosine residue of the PPxY motif is accommodated by a 
shallow concave surface formed by conserved lie, Gin and 
His residues of the WW domain and forms a hydrogen bond 
with the His residue [5,8]. 
3. WW domains versus SH3 domains 
WW domains resemble SF13 domains functionally due to 
their affinity for proline-rich ligands, but their structures are 
quite distinct. The SH3 domain was originally discovered as 
a 50-amino acid long region of homology shared between 
the Crk and Src gene products and phospholipase C--y 
[9,10]. The SH3 domain mediates binding to proline-rich 
sequences with the minimum consensus sequence of PxxP 
and the specificity of this binding is obtained by unique 
sequences flanking the PxxP motif [11], see Fig. 2C. 
Investigations into the structure of peptide—SH3 complexes 
have shown that peptide ligands can bind in two orientations 
with respect to the SH3 domain [12,13]. The peptides can 
bind in either an N to C-terminal (Class I) or C to N-terminal 
(Class II) orientation relative to the SH3 domain. The 
orientation of the peptide is dictated by the location of a 
positively charged residue relative to the PxxP motif. This 
residue forms a salt bridge with an acidic residue in the SH3 
domain. Therefore, Class I ligands have the motif + xxPxxP 
and Class II ligands have the motif PxxPx+, where + refers 
to a positively charged residue. Some SH3 domains, e.g., 
Src have the ability to bind both Class I and Class 11 ligands, 
the biological relevance of this phenomenon is not clear but 
may enable Src to bind different partners in multicomponent 
protein complexes. The structure of the SH3 domain is such 
that it has three shallow pockets for its ligand to bind 
(Fig. 2C). Two large pockets termed the 'LP dipeptide 
pockets' are parallel to each other and each accommodate  
a proline from the PxxP motif plus an adjacent hydrophobic 
residue (A, 1, L, V, P). The third surface is called the 
'specificity pocket' and holds the positively charged residue 
of the ligand, i.e., N-terminus of Class I and C-terminus of 
Class II ligands. Despite similarities in WW and 5H3 
ligands, especially in Type II WW ligands, compare PPLP 
(Type II WW) with PxxP (SH3), the different three-dimen-
sional structures of the ligand-binding surfaces in WW 
domains and SH3 domains preclude direct competition. A 
detailed comparison of the structures of SH3 and WW 
domains in complex with their polyproline ligands suggests 
that these evolutionarily unrelated domains have converged 
upon a similar solution for proline recognition. The rule of 
one or two 'X-P grooves': one for WW domains and one for 
SH3, provides an elegant and unifying mechanism by which 
SH3 and WW recognise their ligands [14]. However, over-
lapping Class III WW domain and 5H3 domain ligands have 
been found in some proteins. It has been shown that the WW 
domain can compete with the AbI SH3 domain for a proline-
rich region in formin and the two binding domains are 
contained within the same 10 amino acids [15,16]. Having 
these two domains in one protein could allow proteins to 
form different signalling complexes depending on their local 
environment, [17] or even raises the possibility that one of 
the domains regulates the other by the overlapping motifs 
being compatible and/or competitive. 
4. WW domain —dystroglycan interactions 
Dystroglycan is a heterodimeric membrane-associated 
protein comprising extracellular laminin-binding a- and 
transmembrane 3-subunits, posttranslationally cleaved from 
a single precursor peptide (see Ref. [18] for review). The 
cytoplasmic tail of 0-dystroglycan interacts with the cyto-
skeletal proteins dystrophin and utrophin that in turn 
interact with the actin cytoskeleton. Thus the dystrophin—
dystroglycan and utrophin—dystroglycan complexes act as 
cell adhesion structures linking the extracellular matrix to 
the actin cytoskeleton. Perturbations in this link that arise 
through mutations in dystrophin lead to the severe muscle 
wasting disease Duchenne muscular dystrophy. Dystrophin 
and utrophin are large modular linker proteins each around 
400 kDa and comprising at least six identified protein 
WW 	 22 cc cc 	c -uIuIIIIIuIIIuIIuI 
triple-helical coiled-coil repeats 	ABD 
Fig. 3. Schematic representation of dystrophin/utrophin domain organisation showing from N to C terminus; actin binding domain (ABD) comprising two 
calponin homology domains (CH), spectrin-like triple-helical coiled-coil repeats, WW domain (WW), two EF hand regions (EFI, EFII), a ZZ domain zinc 
finger (ZZ) and two other predicted coiled coil regions (cc). 
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domains, some in multiple copies (see Ref. [191), including 
a single WW domain at the start of the c-terminal 'cysteine-
rich' region (Fig. 3). These Type I WW domains were 
amongst the first WW domains to be identified [1,2,20] (see 
Fig. 1). Type I WW domains interact with the ligand PPxY 
(Table 1) and the proline-rich cytoplasmic tail of 3-dystro-
glycan contains two such potential motifs, one starting at 
residue 828 (PPEY) and one at residue 889 (PPPY). 
Peptide-binding studies and fusion protein pull-down 
assays identified the sequences around residue 889, in the 
C-terminal 10-15 residues of 3-dystroglycan, as being 
necessary and sufficient for interactions with the dystrophin 
cysteine-rich region [21,22]. Furthermore, a more rigorous 
analysis of the dystrophin domain organisation needed for 
the WW domain mediated interaction with 3-dystroglycan, 
revealed a requirement for the adjacent EF-hand region of 
dystrophin for ligand binding [23] (see Fig. 3). The apparent 
structural requirement for the dystrophin EF-hand region 
makes the WW domain of dystrophin unique among WW 
domains, in that this WW domain is not capable of supporting 
ligand binding on its own, but requires an 'accessory' domain. 
The reasons for this became clearer upon elucidation of the 
dystrophin WW domain/EF-hand region crystal structure [5], 
which revealed a contribution from the EF-hand region of 
dystrophin, to the binding of the dystroglycan peptide by 
stabilising interactions of the n-terminal of the PPPY motif. 
Closer examination of previous data also revealed that 
dystrophin WW domain alone was not sufficient to mediate 
the binding of 3-dystroglycan, but required at the least the 
EF-hand region [21]. Furthermore, the more extensive 
analyses on dystrophin [23] and also on utrophin [24] not 
only revealed a requirement for the EF-hand region, but 
also the ZZ domain, a zinc finger region c-terminal of the 
EF-hand region [25] (see Fig. 3). The contribution of the 
ZZ domain to the 3-dystroglycan interaction is further 
substantiated by the observations that calmodulin is able 
to interact with the ZZ domain of dystrophin [26] and 
utrophin ([27], and SJ Winder unpublished observations) in 
a calcium-dependent manner and that calcium —calmodulin 
is able to regulate the WW domain-mediated interaction 
between dystrophin or utrophin and 3-dystroglycan [26,27]. 
5. Regulation of WW domain interactions 
5.1. Phosphorylation 
The identification of a tyrosine residue within the Type I 
WW domain binding motif leads to the hypothesis that the 
WW/PPxY interaction could be regulated by tyrosine phos-
phorylation [24,28-30], in a manner analogous to the 
regulation of SH3 domain interactions by tyrosine phos-
phorylation where the ligand contains a tyrosine within the 
PxxP motif. Subsequently, it has been shown biochemically 
that phosphorylation of the tyrosine residue in the PPxY 
motif disrupts its interaction with WW domains in its  
binding partner [31]. Furthermore, it has been shown that 210 
adhesion-dependent or peroxyvanadate-induced tyrosine 211 
phosphorylation of the transmembrane adhesion receptor 212 
3-dystroglycan within a Type I WW domain ligand is able to 213 
regulate the interaction with its cognate WW domain in 214 
utrophin or dystrophin [24,32] (see below). More recently, 215 
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Fig. 4. SPOTs analysis of phosphorylation-regulated interactions between 
WW domains and 3-dystroglycan. Binding of the utrophin (Utr; A, far left) 
and dystrophin (Dys; A, left) WW— EF—ZZ regions to a series of peptide 
spots comprising the carboxy-terminal 15 amino acids of 3-dystroglycan 
with phospho-amino acid substitutions, indicated by underlines (A, Centre). 
Utrophin binding to 3-dystroglycan is sensitive to both serine and tyrosine 
phosphorylation [24) whereas dystrophin binding to 3-dystroglycan, whilst 
also sensitive to tyrosine phosphorylation, is less sensitive to serine 
phosphorylation [5,32]. (A, right) Epitope mapping of the monoclonal 
antibody 43DAG/8D5 [421. Like the 3-dystroglycan monoclonal MAN-
DAG2 [24], this antibody is also sensitive to tyrosine phosphorylation of 
3-dystroglycsn. (A, far right) Detection with the anti-phospho tyrosine 
antibody PY20 confirms the presence of phospho-tyrosine residues in the 
peptide spots. Whilst a powerful method, there are limitations to the 
peptide SPOTs technique. Peptides are synthesised directly onto a solid 
support, thus sequences are not verified by direct sequencing and 
quantitation is not accurate. Unequivocal data on the role of serine 
phosphorylation on WW domain binding to 3-dystroglycan awaits further 
verification in solution- or cell-based assays using rigorously defined 
peptides. Binding of caveolin-3 (Cav-3; B, left) and dystrophin (Dys; B, 
right) WW domain-containing constructs to peptide spots comprising the 
carboxy-terminal 15 amino acids of 3-dystroglycan with phospho-tyrosine 
substitutions, indicated by underlines. Tyrosine phosphorylation inhibits 
the binding of dystrophin to 3-dystroglycan but has no affect on caveolin-3 
binding under these conditions. Caveolin-3 data from Ref. [40) (with 
permission) and dystrophin data from Ref. [32]. 
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has been shown that phosphorylation of a serine or threo-
nine in the binding motif is absolutely required for the 
interaction to take place. Thus the mitotic prolyl isomerase 
Pinl and WW domain 2 of the ubiquitin ligase Nedd4 
interact with their target proteins in a phosphorylation-
dependent manner [33,34]. It is clear that the interaction 
between Type I WW domains and their cognate ligands can 
be negatively regulated by tyrosine phosphorylation and that 
SerfThr phosphorylation is required for Type IV interactions 
that can therefore be negatively regulated by dephosphor-
ylation of the Ser or Thr residue. There is also biochemical 
evidence of regulation by phosphorylation of serine and 
threonine residues flanking Type I WW motifs [35], 
although physiological mediators of these phosphorylation 
reactions have not been identified in vivo. 
5.2. 3-dystroglycan 
The tyrosine phosphorylation of the WW domain ligand 
in 3-dystroglycan in nonmuscle cells is adhesion-dependent 
[24]. In myotubes, however, we and others have been 
unable to demonstrate adhesion-dependent phosphorylation 
of 3-dystroglycan [32,36], but it has been possible to 
stimulate phosphorylation of 13-dystroglycan pharmacolog-
ically using peroxyvanadate [32]. The lack of adhesion-
stimulated 3-dystroglycan phosphorylation in myotubes 
may be due to the static nature of the differentiated muscle 
cells compared to HeLa cells, or a different role for the 
dystrophin—dystroglycan complex in muscle as compared 
to the utrophin—dystroglycan complex in nonmuscle cells. 
Nevertheless, the dystrophin glycoprotein complex has 
previously been implicated in integrin-mediated adhesion 
events, in that - and -y-sarcoglycans from myotubes were 
found to be phosphorylated on tyrosine residues in 
response to adhesion. This phosphorylation was also  
induced by the RGDS (integrin recognition sequence) 
peptide, implying that the dystrophin glycoprotein complex 
is involved in the integrin adhesion system [36]. This 
tyrosine phosphorylation was inhibited by Herbimycin A, 
which suggests the possible involvement of the Src family 
of kinases. Studies carried out in HeLa cells failed to 
identify the kinase involved in the phosphorylation of the 
WW domain ligand in 3-dystroglycan, but did rule out a 
role for Src and focal adhesion kinase [24]. Evidence for 
tyrosine phosphorylation regulating 3-dystroglycan—dys-
trophin interactions has led to the suggestion that disrup-
tion of the 3-dystroglycan—dystrophin connection could 
lead to muscular dystrophy [23]. Tyrosine phosphorylation 
of 3-dystroglycan might imply that the dystrophin—dystro-
glycan interaction can be regulated in a dynamic way, but 
in muscular dystrophy due to perturbations in normal 
signalling processes this regulation may be disrupted. 
Disruption of this delicate balance by reduction or loss 
of dystrophin may explain some of the poorly understood 
mechanisms of disease progression in Becker and Duch-
enne muscular dystrophy. 
Phosphorylation of tyrosine 892 in 3-dystroglycan pre-
vents the interaction with utrophin and dystrophin [24,32] 
(Fig. 4A). From the crystal structure of the WW domain and 
EF-hand region of dystrophin in complex with a 3-dystro-
glycan peptide [5], it is clear that incorporation of a bulky 
phosphate group on tyrosine 892 would disrupt the hydro-
gen bond between tyrosine 892 of 3-dystroglycan and 
histidine 3076 of the dystrophin WW domain, thereby 
disrupting the WW domain interaction [32]. Given the high 
degree of sequence similarity between dystrophin and 
utrophin in this region, (85% identical, 98% similar) it is 
extremely likely that the structure of utrophin in this region 
is the same and that the effect of tyrosine 892 phosphor-
ylation would be mechanistically similar. 
g-DG 	I 
lt-DG 	f3.DG ) phosphorylation 	p-DG 




Fig. 5. Differential binding ofcaveolin-3 or dystrophin to 3-dystroglycan is regulated by tyrosine phosphorylation: a model. Caveolin-3 (Cav-3) and dystrophin 
(and/or utrophin) are in competition for the same binding Site in the c-terminus of -dystroglycan (3-DG) with the equilibrium probably in favour of the 
dystrophin-0-dystroglycan interaction (left). However, on phosphorylation of]3-dystroglycan on tyrosine residues [24,32] utrophin and dystrophin binding to 
dystroglycan is displaced allowing the binding of cavcolin-3 to dystroglycan [40] (right). 
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5.3, Caveolin 
Caveolin-3 is the principal structural protein of caveolae 
in striated muscle and is associated with the dystrophin- 
dystroglycan complex [37]. Mutations in caveolin-3 lead 
to a distinct muscular dystrophy phenotype known as 
limb-girdle muscular dystrophy-IC [38]. Paradoxically 
however, transgenic overexpression of caveolin-3 in stri-
ated muscle leads to a Duchenne muscular dystrophy 
phenotype [39]. A recent intriguing finding is that cav- 
eolin-3 also contains a WW-like domain (see Fig. 1) and 
that it too can interact with 3-dystroglycan [40]. Further-
sore, it was shown that caveolin-3 interacted with the 
same binding site on 3-dystroglycan as dystrophin, and 
that caveolin-3 could compete with dystrophin for binding 
to 0-dystroglycan. These biochemical findings helped 
explain the apparent paradox from the transgenic experi- 
ments, such that despite caveolin-3 being associated with 
the dystrophin-dystroglycan complex, by competing for 
binding sites on0-dystroglycan it excluded dystrophin 
binding to the extent that the link between the actin 
cytoskeleton and the extracellular matrix was disrupted 
leading to a Duchenne muscular dystrophy-like phenotype. 
From the point of view of WW domain biology, perhaps 
the most exciting finding was that the ability of the 
caveolin-3 WW domain to interact with 3-dystroglycan 
was insensitive to the phosphorylation of tyrosine 892 in 
the 3-dystroglycan PPPY motif [40] (see Fig. 413). This 
leads to the possible situation whereby the phosphorylation 
of 3-dystroglycan on tyrosine 892 would act as an 
effective switch to alter the affinity of the dystroglycan 
complex from dystrophin (or utrophin) to caveolin. Such 
that when 3-dystroglycan is not phosphorylated, there is 
an equilibrium between dystrophin (or utrophin) and 
caveolins, probably in favour of dystrophin, for binding 
to 3-dystroglycan. However, when 3-dystroglycan is phos- 
phorylated on tyrosine 892, either by cell adhesion [24] or 
other as yet unidentified, stimuli [32], utrophin or dystro-
phin are released from 3-dystroglycan allowing caveolin 
to bind, thus altering the composition, targeting and 
possible functions of the dystroglycan complex under 
these conditions (Fig. 5). 
6. Summary 
This simplest of structural domains, WW has grown in 
stature and complexity. In the 7 years since its identifica-
tion it has become recognised as a crucial mediator of 
many protein-protein interactions. The mechanistic insight 
afforded by structural and biochemical analyses has 
revealed a complex set of interacting ligands and equally 
complex regulation of these interactions by posttransla-
tional modifications such as phosphorylation. Most 
recently these studies have revealed competition between 
WW domains in caveolin-3 and dystrophin for the same  
ligand in 3-dystroglycan and differential regulation of 
binding by tyrosine phosphorylation that in turn regulates 
the connections between the extracellular matrix and the 
cytoskeleton. The WW domain may be structurally simple, 
but this belies the complexity of interactions in linking cell 
signalling to the membrane cytoskeleton. 
Acknowledgments 
Work was supported by the Muscular Dystrophy 
Campaign and Wellcome Trust grant 042180 (SJW) and 
by MDA (MS). JLI is the recipient of a Muscular Dystrophy 
Campaign Prize Studentship. 
References 
[I] Bork P, Sudol M. Trends Biochem Sci l994;19:531-3. 
Andre B, Springael JY. Biochem Biophys Res Common 1994; 
205:1201 -5. 
Sudol M, Hunter T. Cell 2000; 103:1001 -4. 
Macias MJ, Gervais V, Civera C, Oschkinat H. Nat Struct Biol 2000; 
7:375-9. 
Huang X, Poy F, Zhang R, Joachimiak A, Sudol M, Eck Ml. 
Nat Struct Biol 2000;7:634-8. 
Verdecia MA, Bowman ME, Lu KP, Hunter 1, Noel JP. Nat Struct Biol 
2000;7:639-43. 
[71 Kanclis V, Rotin D, Forinan-Kay JD. Nat Struct Biol 2001;8:407. 
Macias MI, Hyvonen M, Baraldi E, Schultz J, Sudol M, Saraste M, 
Oschkinat H. Nature 1996;382:646-9. 
Stahl ML, Ferenz CR, Kelleher KL, Kriz RW, KnopfiL. Nature 1988; 
332:269-72. 
Mayer BJ, Hamaguchi M, Hanafusa H. Nature 1988;332:272-5. 
[II] Yu H, Chen JK, Feng 5, Dalgamo DC, Brauer AW, Schreiber SL. Cell 
1994;76:933 -45. 
Feng 5, Chen J, Yu H, Simmon J, Schreiber S. Science 1994;266: 
1241-7. 
Lim WA, Richards FM, Fox R. Nature 1994;372:375-9. 
Zarrinpar A, Lim A. Nat Struct Biol 2000;7:611 - 3. 
Chan DC, Bedford MT, Leder P. EMBO J 1996;15:1045-54. 
Bedford MT, Chan DC, Leder P. EMBO J 1997;16:2376-83. 
Bedford MT, Sarbassova D, Xu J, Leder P, Yaffe MB. J Biol Chem 
2000;275:10359-69. 
Winder Si. Trends Biochem Sci 2001;26:118-24. 
Winder SJ. J Muscle Res Cell Motil 1997;18:617-29. 
Hofmann K, Bucher P. FEBS Lett 1995;358:153-7. 
Jung D, Yang B, Meyer J, Chamberlain IS, Campbell KP. J Biol Chem 
1995;270:27305- 10. 
Rosa G, Ceccarini M, Cavaldesi M, Zini M, Petrucci TC. Biochem 
Biophys Res Common 1996;223:272-7. 
Rentschler 5, Linn It, Deininger K, Bedford MT, Espanel X, Sudol M. 
Biol Chem 1999;380:431-42. 
James M, Nuttall A, haley JL, Ottersbach K, Tinsley IN, Sudol M, 
Winder Si. J Cell Sci 2000;l 13:1717-26. 
Ponting CP, Blake DJ, Davies KE, Kendrick-Jones J, Winder Si. TIBS 
1996;21:l 1-3. 
Anderson IT, Rogers PP, Jarrett HW. J Biol Chem 1996-1271:6605 -  10. 
Vignano ATd, Zenzo GD, Sudol M, Cesareni G, Dente L. FEBS Lett 
2000;471:229-34. 
Pirozzi G, McConnell Si, Uveges Al, Carter JM, Sparks All, Kay IlK, 
Fowlkcs DM. J Biol Chem 1997;272:14611 -6. 
Chen Ill, Sudol M. Proc NatI Acad Sci USA 1995;92:7819-23. 
fL. lIsley et al. / Cellular Signalling 14 (2001) 1-7 
Sudol M. Prog Biophys Mol Biol 1996;65:113-32. 
Chen HI, Einbond A, Kwak S-J, Linn H, Koepf E, Peterson S, Kelly 
1W, Sudol M. J Biol Chem 1997;272:17070-7. 
llsley JL, Sudol M, Winder Si. Cell Signal 13 (in press). 
Lu P-J, Zhou XZ, Shen M, Lu KP. Science 1999;283:1325-8. 
Ranganathan R, Lu KY, Hunter 1, Noel JP. Cell 1997;89:875-86. 
Kay BK, Williamson MP, Sudol M. FASEB J 2000;14:231-41. 
Yoshida T, Pan Y, Hanada H, Iwata Y, Shigekawa M. I Biol Chem 
1998;273:1583-90. 
Song KS, et al. J Biol Chem 1996;271:15160-5. 
Minetti C, et al. Nat Genet 1998;18:365-8. 
Galbiati F, et al. Proc NatI Acad Sci USA 2000;97:9689-94. 
Sotgia F, et al. I Biol Chem 2000;275:38048-58. 
Ermekova KS, Zambrsno N, Linn H, Minopoli G, Gertler F, Russo T, 
Sudol M. I Biol Chem 1997;272:32869-77. 
Cullen Mi, Walsh I, Nicholson LVB. Acta Neuropathol 1994; 
87:349-54. 
Journal of Cell Science 113, 1717-1726 (2000) 
	 1717 
Printed in Great Britain © The Company of Biologists Limited 2000 
JCS0874 
Adhesion-dependent tyrosine phosphorylation of 3-dystroglycan regulates its 
interaction with utrophin 
M. James',*, A. NuttaIl1, J. L. I11sIey1, K. Ottersbach",t, J. M. Tinsley2, M. Sud013 and S. J. Winder1'4' 
'Institute of Cell and Molecular Biology, University of Edinburgh, King's Buildings, Mayfield Road, Edinburgh, EH9 3JR, UK 
2Department of Human Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK 
3Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, One Gustav Levy Place, New York, NY 
10029, USA 
4IBLS, Division of Biochemistry and Molecular Biology, Davidson Building, University of Glasgow, Glasgow, G12 800, Scotland, UK 
Present address: Department of Medicine. University of Leicester, Leicester, UK 
tBeatson Institute for Cancer Research, Garscube Estate, Switchback Ad, Bearsden, Glasgow, UK 
§Author for correspondence at address 4 (e-mail: swinder@bio.gla.ac.uk)  
Accepted 9 March; published on WWW 18 April2000 
SUMMARY 
Many cell adhesion-dependent processes are regulated by 
tyrosine phosphorylation. In order to investigate the role of 
tyrosine phosphorylation of the utrophin-dystroglycan 
complex we treated suspended or adherent cultures of 
HeLa cells with peroxyvanadate and immunoprecipitated 
-dystroglycan and utrophin from cell extracts. Western 
blotting of 3-dystroglycan and utrophin revealed adhesion-
and peroxyvanadate-dependent mobility shifts which were 
recognised by anti-phospho-tyrosine antibodies. Using 
maltose binding protein fusion constructs to the carboxy-
terminal domains of utrophin we were able to demonstrate 
specific interactions between the WW, EF and ZZ domains 
of utrophin and -dystroglycan by co-immunoprecipitation 
with endogenous -dystroglycan. In extracts from cells  
treated with peroxyvanadate, where endogenous 13-
dystroglycan was tyrosine phosphorylated, 3-dystroglycan 
was no longer co-immunoprecipitated with utrophin fusion 
constructs. Peptide 'SPOTs' assays confirmed that tyrosine 
phosphorylation of 13-dystroglycan regulated the binding of 
utrophin. The phosphorylated tyrosine was identified as 
Y892 in the 13-dystroglycan WW domain binding motif 
PPxY thus demonstrating the physiological regulation of 
the 3-dystroglycan/utrophin interaction by adhesion-
dependent tyrosine phosphorylation. 
Key words: 3-Dystroglycan, Adhesion, Tyrosine phosphorylation, 
WW domain 
INTRODUCTION 
Utrophin is a ubiquitous cytoskeletal protein forming a link 
between the actin cytoskeleton and the extracellular protein 
laminin via a membrane glycoprotein complex which includes 
a- and 3-dystroglycans (Ervasti and Campbell, 1993; 
Matsumura et al., 1992; Tinsley et al., 1992; Winder et al., 
1995b). In normal skeletal muscle, where utrophin is restricted 
to the myotendinous and neuromuscular junctions, utrophin 
binds to a multimeric protein complex comprising 
dystroglycans and sarcoglycans. This complex is 
indistinguishable from the dystrophin glycoprotein complex 
found in the rest of the sarcolemma (Matsumura et al., 1992), 
though there is differential distribution of the syntrophins 
between these complexes. In non-muscle tissues however, 
sarcoglycans, with the possible exception of 3-sarcoglycan 
(Bonnemann et al., 1995; Lim et al., 1995), and dystrophin 
(except in neuronal tissues) are not expressed and utrophin 
associates specifically with a- and 3-dystroglycan at the cell 
membrane (James et al., 1996; Matsumura et at., 1997). In 
non-muscle cells in culture, utrophin and dystroglycans are 
associated with cell-cell and cell-matrix adhesion structures 
(Belkin and Burridge, 1995a,b; Belkin and Smaliheiser, 1996; 
James et al., 1996; Khurana et al., 1995) and may therefore 
play a role in the organisation of focal adhesions or adherens 
junctions and may exist as distinct cell adhesion complexes in 
their own right. The assembly and disassembly of many 
adhesion structures are known to be regulated by tyrosine 
phosphorylation (Burridge and Chrzanowska-Wodnicka, 
1996). 
Both utrophin and dystroglycans have been demonstrated to 
play a key role in adhesion-mediated events. The dystroglycan 
gene encodes both a- and 3-dystroglycan as a single 
transcript which is post-translationally cleaved (Ibraghimov. 
Beskrovnaya et al., 1992). Disruption of dystroglycan function, 
either by antibodies (Durbeej et al., 1995) or gene knockout 
(Henry and Campbell, 1998; Williamson et al., 1997) has a 
profound effect on developmental processes that rely on cell 
adhesion. Antibodies which block a-dystroglycan binding to 
laminin in epithelial cells inhibit branching morphogenesis 
(Durbeej et al., 1995), whilst transgenic disruption of the 
dystroglycan gene (DAG1) in mice leads to embryonic lethality 
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at around day 6.5 due to the failure of Reichert's membrane to 
form (Williamson et al., 1997). Embryonic stem cells deficient 
for a- and 3-dystroglycan are unable to assemble basement 
membrane (Henry and Campbell, 1998). A significant 
reduction of a- and 3-dystroglycan in the sarcolemma is also 
symptomatic of mutations in the dystrophin gene which lead 
to Duchenne and Becker muscular dystrophies (Ervasti et al., 
1990; Matsumura et al., 1993), resulting in the destabilisation 
of the membrane cytoskeleton and loss of sarcolemmal 
integrity, see Winder (1997) for review. Additionally, antisense 
depletion of utrophin in astrocytes markedly reduces cell-
matrix interactions (Khurana et al., 1995). 
Utrophin is the autosomal homologue of dystrophin, the 
gene affected in Duchenne muscular dystrophy (Tinsley et al., 
1992). Like utrophin, dystrophin interacts with the cytoplasmic 
domain of 3-dystroglycan through a cluster of domains in the 
carboxy terminus of dystrophin known collectively as the 
cysteine-rich region. This region comprises 3 recognised 
modules, a WW domain (Sudol, 1996b), a pair of EF hands 
(Koenig et al., 1988; Tufty and Kretsinger, 1975) and a ZZ 
domain (Ponting et al., 1996). WW domains are 30 amino acid 
modules containing conserved tryptophan residues that are 
involved in protein-protein interactions through proline-rich 
motifs in their cognate ligands. EF hands are highly conserved 
motifs involved in the binding of calcium or magnesium ions 
and may play a regulatory or a structural role. The ZZ domain 
is a putative zinc finger motif found in various functionally 
distinct proteins that is believed to mediate protein-protein 
interactions. It has been shown previously that the cysteine-rich 
region of dystrophin is required for the binding of dystrophin 
to f3-dystroglycan and the C-terminal domain further increases 
the binding affinity (Jung et al., 1995; Rosa et al., 1996; Suzuki 
et al., 1994). Most recently it has been documented that the 
WW domain in concert with the EF hands binds to the C-
terminal PPxY motif of 3-dystroglycan and that this binding is 
enhanced by the presence of the ZZ domain (Rentschler et al., 
1999). 
In this current study we investigated the binding of the 
utrophin carboxy-terminal domains to 3-dystroglycan using 
utrophin fusion proteins as probes to identify 3-dystroglycan 
binding sites in utrophin. In addition we have examined the 
role of adhesion-dependent tyrosine phosphorylation of 0-
dystroglycan in regulating the interaction between 3-
dystroglycan and the carboxy terminus of utrophin. Using a 
phosphorylation state-specific monoclonal antibody we have 
mapped the site of tyrosine phosphorylation to the essential 
tyrosine in the f3-dystroglycan WW domain binding motif 
PPxY and demonstrated that phosphorylation of this tyrosine 
regulates the 3-dystroglycan-utrophin interaction. 
MATERIALS AND METHODS 
Cell culture 
HeLa cells were maintained in RPMI 1640 media (Gibco BRL) 
supplemented with 5% foetal calf serum (Gibco BRL). In order to 
inhibit the activity of tyrosine phosphatases and effectively block the 
cells in a tyrosine phosphorylated state, peroxyvanadate treatment was 
carried out on confluent cultures of HeLa cells. Adherent or suspended 
cells were washed with serum-free RPMI and then incubated in 
peroxyvanadate (2 mM H202, 1 mM sodium orthovanadate in serum- 
free RPMI media) or 100 nM calyculin A (Calbiochem) for various 
times at 37°C. Cells were washed once in cold phosphate buffered 
saline (50 mM sodium phosphate, pH 7.2, 150 mM NaCI) before 
being harvested in ice-cold radio-immunoprecipitation assay (RIPA) 
buffer (50 mM Tris-HCI, pH 7.5, 150 mM NaCl, 1 mM ethylene 
glycol-bis-(3-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA), 1 
mM ethylenediaminetetraacetic acid (EDTA), 1% Triton X- 100, 0.5% 
sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 100 
j.tM leupeptin, 1 mM phenylmethylsulphonyl fluoride (PMSF), 100 
!.IM N-tosyl-L-phenylalanine chioromethyl ketone (TPCK)) for 30 
minutes on ice. Cells which were not treated with phosphatase 
inhibitors were incubated for an equivalent time in serum-free media 
before being harvested in RIPA as above. After harvesting, cells were 
briefly sonicated to shear the DNA and stored at —20°C until assay. 
For studies with cells in suspension, HeLa cells were first removed 
from the culture vessel by PBS/EDTA treatment and resuspended in 
serum free RPMI 1640, with 2% bovine serum albumin to prevent 
non-specific adhesion, and peroxyvanadate as above. Cells were 
maintained at 37°C in a 50 ml tube on a tube roller for 1 hour. Cells 
that were still in suspension after one hour were decanted to a fresh 
tube, recovered by centrifugation and extracted in RIPA buffer as 
above, adapted from Renshaw et al. (1997). 
Antisera 
The anti-3-dystroglycan antibody 43DAG1/8D5 was a gift from L. 
Anderson (University of Newcastle) and MANDAG2 (Helliwell et al., 
1994) was kindly provided by G. E. Morris (NE Wales Institute, 
Wrexham). Polyclonal antisera against bacterially expressed maltose 
binding protein (RA134) and the utrophin carboxy-terminal coiled coil 
domain (RA135), residues 3204-3433 of human utrophin (Winder and 
Kendrick-Jones, 1995) were raised in rabbits using standard 
techniques. RAB4 and RAB5 antisera were effective on western blots 
at dilutions of 1:5,000 and 1:10,000, respectively, and the utrophin 
antiserum did not recognise dystrophin in western blots of whole rat 
muscle extracts or in mouse C2C12 mouse myotubes (data not 
shown). Anti-phospho-tyrosine monoclonal (PY20) was from 
Transduction Laboratories. 
Generation of utrophin fusion-proteins 
The limits of the utrophin cysteine rich domains WW, EF and ZZ 
were identified by sequence alignment (Schultz et al., 1998; Sudol, 
1996a; Thompson et al., 1997) and secondary structure prediction 
(Rost et al., 1994; Schultz et al., 1998). Specific utrophin cysteine-
rich domains were amplified by polymerase chain reaction (PCR) 
using domain specific primers to the residues shown in Fig. 3A. 5' 
primers contained Barn HI and NdeI restriction sites and 3' primers 
contained a stop codon and Sail restriction site. PCR products were 
cloned into the unique Barn HI and Sail restriction enzyme sites of 
pMAL-C2 (New England BioLabs). Cultures of transformed E. coli 
(BL2I (DE3)) were grown at 37°C until the OD000 reached 0.5, and 
induced with 0.5 mM isopropyl-3-D-thiogalactopyranoside for 2 
hours. Following harvesting by centrifugation at 4,000 g for 20 
minutes the cell pellet was re-suspended in 50 ml column buffer (20 
mM Tris-HCI, pH 7.5, 200 mM NaCl, I mM EDTA, 100 pM 
leupeptin, 1 mM PMSF, 100 pM TPCK) and stored at —20°C 
overnight. After thawing, the cell suspension was sonicated in short 
15 second pulses for a total time of 2 minutes before being 
centrifuged at 9,000 g for 30 minutes MBP fusions were purified by 
a single passage over an amylose resin (New England Biolabs) 
column. Bound fusion proteins were eluted using column buffer 
containing 10 mM maltose. Fusion containing fractions identified on 
Coomassie-stained SDS gels were pooled, dialysed against RIPA 
buffer overnight and then stored at —20°C until use. A human 
utrophin construct encompassing the WW, EF and ZZ regions 
(residues 2783-3199) fused to GST was generated by cloning a 
BarnHI and EcoRI digested PCR-generated fragment into the BarnHI 
and EcoRI sites of pGEX-2TK. 
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In vitro binding and immunoprecipitation assays 
For immunoprecipitation of 3-dystroglycan/MBP-fusion complexes, 
fusion proteins were used at a final concentration of 10 jtglml. Cell 
extracts in RIPA were initially cleared by incubation with Protein A-
Sepharose for 60 minutes at 4°C. The required volume of each fusion 
was added to 100 Al aliquots of cleared cells, the total volume of each 
assay was made up to 175 ttl  using RIPA and 50 pA RIPA containing 
1% BSA was added to each tube. After 2 hours incubation at 4°C 10 
Al of 43DAG1/8D5 and/or MANDAG2 was added to each tube and 
the cells were incubated for a further hour at 4°C. In order to 
precipitate the antibody-protein complex, 50 p.1 of a 20% slurry of 
Protein A-Sepharose was added per sample, and the cells were 
incubated for a further hour at 4°C. The samples were centrifuged 
briefly to pellet the Sepharose beads, and the beads were washed 4 
times with RIPA. The final pellet was re-suspended in SDS-PAGE 
loading buffer. Immunoprecipitation of f3-dystroglycan, phospho-
tyrosine containing proteins and utrophin were carried out with the 
relevant antisera at dilutions of 1:20, 1:200 and 1:20 respectively and 
recovered with Protein A-Sepharose as above. 
SOS-PAGE and western blotting 
Samples from immunoprecipitation experiments were run on 3-15% 
acrylamide SDS-polyacrylamide gels with a 3% stacking gel under 
reducing conditions (Laemmli, 1970) and blotted onto polyvinylidene 
difluoride (PVDF) membranes in 25 mM Tris, 198 mM glycine, 10% 
methanol. Membranes were blocked in 5% skimmed milk powder in 
Tris-buffered saline (TBS; 50 mM Tris-HCI, pH 7.5, 150 mM NaCI) 
for 30 minutes and incubated overnight at 4°C in appropriately diluted 
primary antibody in 5% skimmed milk in TBS and washed 3 times in 
TBS with 0.5% Tween-20 before addition of the alkaline-phosphatase 
conjugated secondary antibody in 1% skimmed milk in TBS. 
Membranes were incubated for 2 hours in secondary antibody at room 
temperature. After washing in TBS/Tween, blots were developed using 
0.4 mM nitroblue tetrazolium and 0.4 mM 5-bromo-4-chloro-3-indolyl 
phosphate in 100 mM NaCl, 5 mM MgCl2, 100 mM Tris-HCI, pH 9.5. 
Enhanced chemifluorescence detection of utrophin maltose binding 
protein fusion proteins was performed using a Vistra ECF western 
blotting kit (Amersham Life Sciences) according to the manufacturer's 
instructions, images were captured on a Storm 460 Phosphorimager in 
fluorescence mode and data quantified using ImageQuant software. 
Two-dimensional gel electrophoresis 
3-DystrogIycan was immunoprecipitated from equal amounts of 
protein (as determined by BCA assay; Pierce) from suspended or 
adherent and peroxyvanadate treated or untreated cell extracts, 
prepared as above. Equal amounts of immunoprecipitated complexes 
were subjected to first dimension isoelectric focusing on 180 mm, pH 
3-10 Immobiline Drystrips (Amersham Pharmacia Biotech) on an 
Amersham Pharmacia Biotech Multiphor System according to the 
manufacturers instructions. Equilibrated drystrips were then separated 
in the second dimension on reducing 3-20% SDS-polyacrylamide 
gels. All 4 gels were electroblotted onto PVDF and immunoblotted 
with a cocktail of MANDAG2 and 43DAG/8D5 (1:500 and 1:50, 
respectively). The 4 immunoblots were developed simultaneously by 
ECL (Amersham Pharmacia Biotech) onto the same piece of x-ray 
film to avoid differences in exposure time. Following 3-dystroglycan 
detection, blots were stripped (65°C for 45 minutes in 62.5 mM Tris-
HCI, pH 6.75, 2% SDS, 100 mM mercaptoethanol) blocked as above 
and reprobed with anti-phospho tyrosine antisera and detection by 
ECL as described above. Epitope mapping of 3-dystroglycan 
monoclonal antibody MANDAG2 on SPOTs' membranes (see 
below) was performed as a normal western blot detection as described 
above. Following incubation with MANDAG2 antibody and washing 
blots were developed by ECL. 
'SPOTs' membrane synthesis 
The 'SPOTs' technique of peptide synthesis on derivatised cellulose 
membrane was performed as described (Blankenmeyer-Menge et al., 
1980; Frank and Doring, 1988; Kramer et al., 1993). All reagents and 
equipment, including amino acids, derivatised membranes, incubation 
trays and software ('SPOTs', release 1.0), were purchased from 
Cambridge research Biochemicals and Genosys Biotechnologies, Inc. 
Hybridisation of 'SPOTs' membranes with 32P-labeled 
utrophin GST fusion protein 
A utrophin WW-EF-ZZ-GST fusion protein was purified from 
bacterial lysates on glutathione heads and phosphorylated in situ using 
the catalytic subunit of cAMP-dependent protein kinase as described 
previously (Rentschler et al., 1999). SPOTs membranes were blocked 
as above and then probed with the 32P-labeled utrophin GST-fusion 
protein. 
RESULTS 
Treatment of tissue culture cells with phosphatase inhibitors 
such as peroxyvanadate or okadaic acid results in an apparent 
increase in phosphorylation levels, enabling the visualisation 
of transient phosphorylation events. Western blotting of HeLa 
cell extracts treated with peroxyvanadate, with antibodies to 
phosphotyrosine, showed a dramatic increase in the levels of 
tyrosine phosphorylation up to one hour with a slight decline 
in phospho-tyrosine levels up to six hours. With prolonged 
exposure to peroxyvanadate cells began to round up and detach 
from the substratum (data not shown). Western blotting of 
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Fig. 1. Tyrosine phosphorylation of 3-dystroglycan and utrophin in 
HeLa cells. (A) Western blot of: untreated confluent HeLa cells lane 
1; peroxyvanadate treated HeLa cells lane 2; calyculin A treated 
HeLa cells lane 3; detected with 3-dystroglycan antibody 
MANDAG2. (B,C) Western blots of RIPA extracts of HeLa cells 
with (+) or without (-) peroxyvanadate (PV) treatment, 
immunoprecipitated (IP) and detected (Blot) with the indicated 
antisera; 3-DG, MANDAG2 against 0-dystroglycan; pTyr, PY20 
against phospho tyrosine; Utr, RAB5 against utrophin. Numbers 
represent approximate molecular mass in kDa. 
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revealed a pronounced retardation in electrophoretic mobility 
in extracts treated with peroxyvanadate (Fig. IA; lane I and 2) 
consistent with -dystroglycan being phosphorylated. 
Calyculin A, an inhibitor of type 1 and 2A serine/threonine 
phosphatases (Ishihara et al., 1989), added to HeLa cells over 
the same period however, did not result in any marked 
difference in electrophoretic mobility (Fig. 1A, lane 3). To 
confirm that the change in electrophoretic mobility was indeed 
due to tyrosine phosphorylation and not simply the activation 
of a serine/threonine kinase by a tyrosine kinase, we 
immunoprecipitated with antisera against 3-dystroglycan or 
phospho-tyrosine and western blotted with 13-dystroglycan 
antisera. As shown in Fig. lB. 13-dystroglycan antisera 
immunoprecipitated the authentic 43 kDa 3-dystroglycan band 
and the electrophoretically retarded band (Fig. lB, lanes 1, 2). 
Furthermore the phospho-tyrosine immunoprecipitate was 
recognised by f3-dystroglycan antisera in the peroxyvanadate 
treated cell extracts (Fig. lB. lane 3). Conversely western 


















Fig. 2. Adhesion dependence of f3-dystroglycan tyrosine 
phosphorylation. (A) Effect of peroxyvanadate and/or cell adhesion 
on the SDS-PAG electrophoretic mobility of 0-dystroglycan. HeLa 
cells were maintained in suspension or adherent for 1 hour in the 
presence or absence of peroxyvanadate as indicated. Adhesion and 
peroxyvanadate treatment resulted in a decrease in electrophoretic 
mobility as determined by western blotting of total cell extracts with 
MANDAG2 antisera against 3-dystroglycan. (B) Tyrosine 
phosphorylation of 3-dystroglycan in response to cell adhesion and 
peroxyvanadate. Two-dimensional gel analysis of 13-dystroglycan 
immunoprecipitated from adherent or suspended HeLa cells in the 
presence or absence of peroxyvanadate (PV). Western blots were 
probed with antisera against 3-dystroglycan (3-DO) and detected by 
ECL (lower panel), stripped, and reprobed with anti-phospho-
tyrosine (p-Tyr) and detected by ECL (upper panel). In suspended 
cells in the absence of peroxyvanadate there is no detectable tyrosine 
phosphorylation. Adhesion or peroxyvanadate treatment results in 
one clear spot of tyrosine phosphorylated 3-dystroglycan whereas in 
adherent cells in the presence of peroxyvanadate there are two 
closely migrating spots that appear as an ellipse. 
phospho-tyrosine antibodies also detected 3-dystroglycan (see 
Fig. 213). Taken together, these data demonstrate unequivocally 
that the electrophoretically retarded 3-dystroglycan is tyrosine 
phosphorylated. Similar results were obtained when utrophin 
immunoprecipitates were western blotted with antisera against 
either utrophin or phospho-tyrosine (Fig. 1C). In the presence 
of peroxyvanadate the electrophoretic mobility of utrophin was 
retarded and the electrophoretically retarded band was 
specifically recognised by antibodies to phospho-tyrosine. This 
demonstrates, that like 3-dystroglycan, treatment of HeLa cells 
with peroxyvanadate leads to the phosphorylation of utrophin 
on tyrosine residues. Direct treatment of RIPA cell extracts 
with peroxyvanadate did not alter the electrophoretic mobility 
of 13-dystroglycan or utrophin, indicating that the observed 
mobility shifts were not due to direct modification of thiols in 
3-dystroglycan and utrophin (Mikalsen and Kaalhus, 1998), 
data not shown. Similar results for both 3-dystroglycan and 
utrophin were obtained with a number of cultured cell types 
including; fibroblast, REF52; myoblast, C2C12; epithelial, 
COS-7; and primary umbilical vein endothelial cells (data not 
shown) indicating that this is a widespread regulatory event. 
Peroxyvanadate treatment of cells can cause artefactual 
phosphorylation of proteins due to inappropriate or 
uncontrolled 	activation 	of 	signalling 	cascades. 
Peroxyvanadate, however, has proven immensely useful for 
'trapping' transient tyrosine phosphorylation events. To 
determine if the tyrosine phosphorylation of 3-dystroglycan 
that we had observed was as a result of a physiological stimulus 
and not merely an artefact of the pharmacological dose of 
peroxyvanadate, we examined the effect of peroxyvanadate 
treatment on adherent and suspended HeLa cells. Fig. 2A 
shows a distinct electrophoretic mobility shift in response to 
cell adhesion and peroxyvanadate. Adhesion alone in the 
absence of peroxyvanadate caused a slight electrophoretic 
mobility shift by comparison with suspended cells (Fig. 2A, 
lanes 1, 2), addition of peroxyvanadate caused a further 
electrophoretic mobility shift in both suspended and adherent 
cells (Fig. 2A, lanes 3, 4). Notably the ability of the 
monoclonal antibody MANDAG2 to recognise 3-dystroglycan 
in western blots was reduced with the increase in tyrosine 
phosphorylation, suggesting that the phosphorylated tyrosine 
is within the last 20 amino acids of 3-dystroglycan against 
which the antibody was raised (compare also lanes I and 2 in 
Fig. 113). Two-dimensional gel and western blotting analysis 
of 3-dystroglycan immunoprecipitated from adherent or 
suspended HeLa cells in the presence or absence of 
peroxyvanadate, are shown in Fig. 213. Western blot detection 
with anti-phospho tyrosine antisera reveals an increasing 
number of charged species as a result of both cell adhesion and 
addition of peroxyvanadate, suggesting a possible hierarchy of 
tyrosine phosphorylation leading to the adhesion-dependent 
phosphorylation of two tyrosine residues (Fig. 213, upper 
panel). There is a complete absence of a phospho-tyrosine 
signal in the suspended peroxyvanadate treated cells. One clear 
spot of tyrosine phosphorylated 3-dystroglycan is present in 
suspended cells treated with peroxyvanadate and in untreated 
adherent cells, whereas in adherent cells treated with 
peroxyvanadate we see at least two incompletely resolved 
spots giving the appearance of an ellipse. The pattern of 3-
dystroglycan spots in the lower panel recapitulates those of the 
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Fig. 3. MBP-utrophin fusion constructs, binding to f3-dystroglycan 
and effect of tyrosine phosphorylation. The maltose binding protein 
(MBP) fusion constructs are shown schematically in A. with 
delimiting amino acid numbers corresponding to human utrophin 
above. (B) Top panel, Coomassie blue stained gel of MBP-fusions to 
the carboxy terminus of utrophin, relative position of molecular mass 
markers are shown on the left. Western blots against utrophin-MBP-
fusion proteins immunoprecipitated with 3-dystroglycan antisera. 
MBP-fusions were added to RIPA control extracts of HeLa cells, 
middle panel (—PV) or following treatment with peroxyvanadate for 
1 hour, lower panel (+PV). Lanes in all three panels are: I, MBP-
WW; 2, MBP-WWEF; 3, MBP-WWEFZZ; 4, MBP-EFZZ; 5, MBP-
EF; 6, MBP-ZZ. (C) Loading control for the experiment shown in B 
middle panel, blots were stripped and reprobed with 3-dystroglycan 
monoclonal MANDAG2. (D) Quantification of the blots shown in B 
by densitometric scanning of enhanced chemi-fluorescence 
developed blots, including control immunoprecipitates with MBP 
alone. 
equal amounts of 0-dystroglycan were present in the original 
samples subjected to two-dimensional electrophoresis. These 
data therefore support the notion that 3-dystroglycan is 
phosphorylated on tyrosine in response to cell adhesion. 
In order to identify the f3-dystroglycan binding site on 
utrophin, MBP-fusion proteins to various regions of the 
cysteine rich region of utrophin (Fig. 3A,13, upper) were used 
as affinity probes for 13-dystroglycan in extracts of HeLa cells. 
Fig. 4. Identification of 3-dystroglycan peptides which interact with 
monoclonal MANDAG2. (A) Scheme for the synthesis of peptides 
on the 'SPOTs' membrane. Twelve amino acid long peptides 
representing part of the transmembrane region and the entire 
cytoplasmic domain of human 3-dystroglycan (amino acids 764-895) 
were synthesised on derivatised 'SPOTs' membranes with an offset 
of four amino acids. The transmembrane region of 3-dystroglycan is 
indicated by a double underline. Numbers above the 13-dystroglycan 
sequence denote the first amino acid of the peptide found on the 
corresponding spot whilst numbers below the sequence denote the 
last amino acid of the peptide on the corresponding spot. Brackets 
identify the sequences of spots 1 and 31. Spot 32 is a negative 
control with no peptide synthesised. (B) 'SPOTs' membrane 
described as above probed with monoclonal antiserum MANDAG2 
and detected by ECL. The antiserum recognised spot 31 only. 
(C) Numbered circles identify the location of each spot on the 
membrane. 
Following immunoprecipitation with antibodies MANDAG2 
and 	43DAG 1 /8D5 against 0-dystroglycan, MBP-utrophin 
fusion proteins co-immunoprecipitated with 3-dystroglycan 
were detected by western blotting with anti-MBP antisera 
(Fig. 313, middle). All MBP-fusion constructs were co-
immunoprecipitated with f3-dystroglycan with the exception ol 
MBP-WW. Densitometric quantification of the MBP-fusions 
detected, revealed that almost twice as much MBP-WWEFZZ 
was bound as any other fusion, indicating that the complete 
cysteine-rich region of utrophin is the most effective in binding 
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3-dystrog1ycan under these conditions. Loading controls for f3-
dystroglycan (Fig. 3C) indicate that approximately equal 
amounts of f3-dystroglycan were immunoprecipitated in each 
case. Fusions containing WWEF or EFZZ, as well as EF or ZZ 
alone, all bound equally well but not WW alone, suggesting 
that the presence of the EF and ZZ domains together were 
necessary for the interaction between WW and its presumed 
target motif on 3-dystroglycan. Interactions between MBP-
fusions containing the utrophin EF hand region and 3-  
dystroglycan took place in the effective absence of Ca2 and 
Mg2 (presence of mM EGTA and EDTA). This would suggest 
that if the EF hands in utrophin are functional in terms of 
calcium binding, and this is doubtful (Winder et al., 1995a, 
1997), then the presence of divalent cations is not required for 
binding to 3-dystroglycan under these conditions. 
Treatment of tissue culture cells with peroxyvanadate, but 
not calyculin A, resulted in the adhesion-dependent 
phosphorylation of 3-dystroglycan and utrophin on tyrosine 
residues. We therefore repeated the experiments to identify the 
domains needed for utrophin binding to 3-dystroglycan in 
extracts from HeLa cells that had previously been treated with 
peroxyvanadate. As can be seen in Fig. 3B (lower panel) the 
prior phosphorylation of 3-dystroglycan on tyrosine almost 
completely abolished the ability of utrophin fusions to be co-
immunoprecipitated with f3-dystroglycan, with the exception of 
MBP-ZZ. As shown in Fig. 3D, the binding of the complete 
cysteine-rich region, domains WW, EF and ZZ, was 
completely inhibited by tyrosine phosphorylation of 3-
dystroglycan following treatment with peroxyvanadate as 
compared to MBP alone. There was no evidence from western 
blots of MBP-fusions undergoing mobility 
shifts, to suggest that any of the MBP-fusions 
themselves became phosphorylated during the 	A. 
course of the experiments, suggesting that the 
effect of peroxyvanadate was directly on 3-
dystroglycan within cells. Furthermore, despite 
the apparent inability of the 3-dystroglycan 
monoclonal MANDAG2 to recognise tyrosine 
phosphorylated 3-dystroglycan on western 
blots it was still able to recognise tyrosine 
Fig. 5. Mutagenesis of a C-terminal peptide of 3-
dystroglycan to determine the epitope for 
monoclonal MANDAG2. (A) Fifteen amino acid 
long peptides representing the wild type C terminus 
of 3-dystroglycan (Kgi NMTPYRSPPPYVPP895) 
and sequential single amino acid substitutions of 
the wild type peptide were synthesised on three 
'SPOTs' membranes (see Table 1 for the scheme of 
synthesis and summary of results). The membranes 
were probed with MANDAG2 and detected by 
ECL to identify which amino acids in the C 
terminus of 3-dystroglycan were part of the 
MANDAG2 epitope. Positive reacting spots appear 
with a dark halo around due to the short exposure 
times used and the density of peptide within the 
spot itself reducing the luminescence emission. The 
result, summarised in Table 2, indicates an epitope 
of PxYVP, since P890, Y892, V893 and P994 are 
sensitive to almost any substitution. (B) Numbered 
circles identify the location of each spot on the 
membrane. 
phosphorylated 3-dystroglycan in solution. This is apparent 
from the ability of MANDAG2 to immunoprecipitate tyrosine 
phosphorylated 3-dystroglycan which was detected on two 
dimensional gels with anti -phospho-tyrosine antisera (Fig. 213) 
and to immunoprecipitate the ZZ domain fusion with tyrosine 
phosphorylated 3-dystroglycan (Fig. 313, lower panel). 
As shown in Fig. lB (lanes 1 and 2) and Fig. 2A, the 
monoclonal antibody MANDAG2 was less efficient at 
recognising tyrosine phosphorylated 3-dystroglycan on 
western blots, though this did not appear to affect its ability 
to immunoprecipitate 3-dystroglycan from cell extracts as 
indicated above. We therefore epitope mapped the 
MANDAG2 antibody using a series of 'SPOTs' membranes 
covering the entire cytoplasmic domain of 3-dystroglycan 
(Rentschler et al., 1999). As shown in Fig. 4, MANDAG2 
recognised a single peptide, spot 31, corresponding to 
the ultimate 12 amino acids of 13-dystroglycan 
(TPYRSPPPYVPP). MANDAG2 was originally raised 
against a peptide corresponding to the ultimate 15 amino 
acids of 3-dystroglycan (Helliwell et al., 1994). More 
detailed analysis of the epitope by systematic mutation of the 
peptide recognised in Fig. 4B revealed that the essential 
amino acids in the epitope were PxYVP in the ultimate 5 
amino acids of 3-dystroglycan (Fig. 5, Table 1). Furthermore 
as suggested by the relative inability of MANDAG2 to 
recognise tyrosine phosphorylated 3-dystroglycan (Figs 1, 2), 
MANDAG2 was unable to recognise any peptide containing 
a phospho-tyrosine at the second last position (Y892), but was 
unaffected by phosphorylation of tyrosine, serine or threonine 
alone in any of the other positions in the last 15 amino acids, 
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Table 1. Single amino acid substitutions within the 3-dystroglycan carboxy-terminal peptide that significantly reduce 
binding of MANDAG2 
K N M T P Y R s p p p y V p P 
A 	2 21 40 59 78 97 116 135 154 173 193 212 231 250 269 
C 3 22 41 60 79 98 117 136 155 174 194 213 232 251 270 
D 	4 23 42 61 80 99 118 137 156 175 195 214 233 252 271 
E 5 24 43 62 81 100 119 138 157 176 196 215 234 253 272 
F 	6 25 44 63 82 101 120 139 158 177 197 216 235 254 273 
G 7 26 45 64 83 102 121 140 159 178 198 217 236 255 274 
H 	8 27 46 65 84 103 122 141 160 179 199 218 237 256 275 
1 9 28 47 66 85 104 123 142 161 180 200 219 238 257 276 
K 	x 29 48 67 86 105 124 143 162 181 201 220 239 258 277 
L 10 30 49 68 87 106 125 144 163 182 202 221 240 259 278 
M 	11 31 x 69 88 107 126 145 164 183 203 222 241 260 279 
N 12 x 50 70 89 108 127 146 165 184 204 223 242 261 280 
P 	13 32 51 71 x 109 128 147 x x x 224 243 x x 
Q 14 33 52 72 90 110 129 148 166 185 205 225 244 262 281 
R 	15 34 53 73 91 111 x 149 167 186 206 226 245 263 282 
S 16 35 54 74 92 112 130 x 168 187 207 227 246 264 283 
T 	17 36 55 x 93 113 131 150 169 188 208 228 247 265 284 
V 18 37 56 75 94 114 132 151 170 189 209 229 x 266 285 
W 	19 38 57 76 95 115 133 152 171 190 210 230 248 267 286 
Y 20 39 58 77 96 x 134 153 172 191 211 x 249 268 287 
Summary of the results shown in Fig. 5. Each amino acid of the wild -type peptide was sequentially replaced with the other 19 amino acids, and binding of the 
13-dystroglycan monoclonal MANDAG2 was compared to that of the wild-type peptide. The uppermost row represents the amino acid positions of the wild -type 
il-dystroglycan peptide. The leftmost column represents all the replacement amino acids. The intersections correspond to the spot numbers where substitutions 
occurred. Substitutions which significantly reduced binding are indicated by shading. x' denotes the amino acid of the wild -type peptide. Spot 192 and 288 are 
control spots where no peptide was synthesised. 
(Fig. 6A). MANDAG2 is sensitive to phosphorylation of 
tyrosine in the epitope PxYVP, which in part overlaps the 
WW domain binding motif in 3-dystroglycan PPxY 
(Rentschler et al., 1999) and is therefore an effective reporter 
for tyrosine phosphorylation of the 3-dystroglycan WW 
domain binding motif. From these data and those in Figs 1 
and 2, it is possible to deduce that adhesion-dependent 
tyrosine phosphorylation of 3-dystroglycan on its ultimate 
tyrosine within the WW domain binding motif is able to 
regulate the binding to utrophin. In order to test this more 
A. 	 B. 
KNMTPYRSPPPYVPP 
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Fig. 6. Effect of phosphorylation on the binding of MANDAG2 to a 
C-terminal 3-dystroglycan peptide. (A) A peptide equivalent to that 
described in Fig. 5A was synthesised containing the phospho-amino 
acids pY, pT and pS at each possible position in the peptide, either 
singly or in multiples. The membrane was probed with monoclonal 
MANDAG2 as described above. Only peptides containing a pY at 
Y892 were not recognised by MANDAG2. (B) Actual sequence of the 
corresponding peptide spots in A. 
directly we probed the same SPOTs membranes used in Figs 
4 and 6 with a 32P-labeled GST-fusion protein comprising the 
WWEFZZ region of utrophin. As demonstrated previously 
for the dystrophin WWEFZZ region (Jung et al., 1995: 
Rentschler et al., 1999) utrophin also bound almost 
exclusively to a peptide corresponding to the last 12 amino 
acids of 3-dystroglycan (Fig. 7A). On longer exposure of the 
SPOTS membrane, weaker interactions with other peptides 
are apparent, e.g. peptides 2,3,4,6,7,29,30 and binding of 
utrophin to peptides occurred equally well in the presence ot 
A. ,. B. 
Fig. 7. Identification of 3-dystroglycan peptides which interact with 
GST-utrophin WWEFZZ and the effect of 3-dystroglycan 
phosphorylation. (A) 'SPOTs' membrane as described in Fig. 4 was 
probed with 32P-labelled GST-WWEFZZ. This utrophin WWEFZZ 
fusion protein bound almost exclusively to spot 31. (B) 'SPOTs' 
membrane as described in Fig. 6 was probed with 32P-labelled GST-
WWEFZZ. The binding of the utrophin WWEFZZ fusion protein 
was prevented by phosphorylation of either S888 or Y892. 
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absence of calcium (data not shown). Furthermore 
phosphorylation of the tyrosine residue in the WW domain 
binding motif PPxY was able to completely inhibit the 
binding of utrophin (Fig. 713). Phosphorylation of the serine 
in the n-1 position adjacent to the PPxY motif was also able 
to regulate binding, as has been demonstrated for other WW 
domains binding to their cognate ligands (A. Korosi, A. 
Chang and M. Sudol, unpublished observations). This 
confirms the hypothesis that adhesion-dependent tyrosine 
phosphorylation of j3-dystroglycan within the WW domain 
binding motif is able to regulate the WW domain-mediated 
interaction between utrophin and f3-dystroglycan. This is the 
first demonstration of a physiologically relevant tyrosine 
phosphorylation of a WW domain ligand and has parallels 
with the tyrosine phosphorylation of SH3 domain ligands 
regulating SH3-mediated interactions. 
DISCUSSION 
Numerous studies have described serine/threonine 
phosphorylation of dystrophin in vivo, in vitro or by 
endogenous co-purifying kinases, reviewed in (Michalak et al., 
1996; Winder et al., 1997), although few studies have identified 
functional consequences of these phosphorylation events. 
Dystrophin has been shown to be tyrosine phosphorylated in 
the postsynaptic membrane of Torpedo electric organ (Wagner 
and Huganir, 1994). Two-dimensional gel electrophoretic 
analysis of the dystrophin glycoprotein complex suggests 
phosphorylation of dystrophin, -dystroglycan and possibly 
other components (Yamamoto et al., 1993). More recently, 
Yoshida and colleagues (1998) demonstrated adhesion-
dependent tyrosine phosphorylation of a- and y-sarcoglycan 
but not 3-sarcoglycan or 3-dystroglycan in L6 myoblasts. 
Tyrosine phosphorylation of utrophin and 3-dystroglycan has 
not previously been described. 
The role of f3-dystroglycan in attachment to the extracellular 
matrix and regulation of utrophin binding to 3-dystroglycan by 
tyrosine phosphorylation may be involved in cellular processes 
that require remodelling of cell-substratum interactions and 
cytoskeletal connections associated with them. 3-dystroglycan 
and utrophin are located at sites of cell-cell and cell substratum 
contact (Belkin and Burridge, 1995a,b; Belkin and 
Smaliheiser, 1996; James et al., 1996; Khurana et al., 1995). 
The adhesion-dependent tyrosine phosphorylation of 3-
dystroglycan occurred whether HeLa cells were plated onto 
fibronectin or laminin coated substrates, suggesting that the 
kinase responsible for phosphorylating 3-dystroglycan was 
not specifically activated by the binding of a-dystroglycan 
to laminin (M. James and S. J. Winder, unpublished 
observations), but was a more general adhesion signal 
potentially 	involving 	integrin 	engagement. 	The 
phosphorylation of 3-dystroglycan on tyrosine did still occur 
in focal adhesion kinase null cells (a generous gift from Dr D. 
Ilic, San Francisco) indicating that this kinase was not required 
for 3-dystroglycan phosphorylation (S. J. Winder, unpublished 
observation). The adhesion-dependent phosphorylation of 3-
dystroglycan by as yet unidentified tyrosine kinases and in 
response to cell adhesion, leads to its release from utrophin and 
the underlying cytoskeleton. This may be required for 
processes such as cell adhesion, migration, proliferation and 
differentiation. Furthermore the identification of tyrosine 
phosphorylation on 3-dystroglycan from C2Cl2 myotubes (J. 
L. Ilsley and S. J. Winder, unpublished observations) suggests 
a role for tyrosine phosphorylation in regulating 3-
dystroglycan-dystrophin interactions. Such regulation may 
have implications in the pathogenesis and treatment of 
Duchenne muscular dystrophy. The recent identification of a-
dystroglycan as the cellular receptor for Mycobacterium leprae 
(Rambukkana et al., 1998) and for arenaviruses such as Lassa 
fever virus (Cao et al.. 1998), also raises the possibility that 
infection by these organisms may exert part of their pathogenic 
effect by disruption of signalling events associated with 3-
dystroglycan phosphorylation. 
The modular protein domains of the dystrophin and utrophin 
cysteine-rich region show an extremely high degree of 
sequence identity, see Winder et al. (1997) for review. Studies 
with in vitro translated 3-dystroglycan and dystrophin (Jung et 
al., 1995), showed that high affinity binding of dystrophin 
carboxy terminus GST-fusion proteins to 13-dystroglycan 
required the presence of the complete cysteine-rich domain 
(shown later to comprise WW, EF and ZZ domains) and that 
fusions comprising WW-EF bound weakly and WW alone not 
at all. However, no other dystrophin GST-fusion constructs; EF, 
ZZ, or EF-ZZ were found to bind under the conditions of these 
in vitro assays. These apparently conflicting results may reflect 
differences in the precise limits of the fusion proteins used in 
this study, the use of MBP as tags in recombinant proteins, and 
also that we used tissue cell extracts as a source of 3-
dystroglycan rather than in vitro translated protein. 
Additionally, more recent studies with dystrophin GST-fusion 
constructs containing well demarcated modular domains 
suggest that there is weak interaction between the EF hand 
region and also a contribution from the ZZ domain of 
dystrophin to f3-dystroglycan binding (Rentschler et al., 1999). 
f3-Dystroglycan from cellular sources may also be complexed 
with other proteins, such as the adapter protein Grb2 (Yang et 
al., 1995), or other as yet unidentified proteins, that facilitate 
binding of EF and ZZ domains to 3-dystroglycan (Rentschler 
et al., 1999). The possibility remains that there are fundamental 
differences between the carboxy-terminal domains of utrophin 
and dystrophin with respect to the interaction with 0-
dystroglycan. This seems unlikely, however, as utrophin has 
been shown to effectively replace dystrophin in mouse models 
of muscular dystrophy (Tinsley et al., 1996). 
Tyrosine phosphorylation of 3-dystroglycan prevented the 
binding of all utrophin MBP-fusions with the exception of 
MBP-ZZ, suggesting that ZZ is involved in an interaction 
somehow different to the WW and EF domains, possibly with 
a different region of 3-dystroglycan, or even with another 
protein associated with 3-dystroglycan such as Grb2 (Yang et 
al., 1995). It is largely assumed that dystrophin and utrophin 
WW domains associate with 3-dystroglycan via the WW 
domain binding motif PPxY (Chen and Sudol, 1995) located 
in the extreme carboxy terminus of 3-dystroglycan (see Fig. 
8). A recent thorough detailed analysis of the precise 
requirements for the dystrophin WW domain binding to 3-
dystroglycan has revealed that this is indeed the case 
(Rentschler et al., 1999). As shown here, the presence of both 
the WW domain and ZZ domain are required for the high 
affinity interaction between utrophin and 3-dystroglycan, 
though the precise target sequence for the ZZ domain on 3- 
f3- dystroglycan 
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Fig. 8. Schematic organisation of 0-dystroglycan and utrophin 
carboxy terminus showing potential interactions between the WW, 
EF and ZZ domains of utrophin and the carboxy terminus of the 
cytoplasmic domain of 3-dystroglycan. EF represents the two EF 
hands in the cysteine-rich region of utrophin and ZZ the ZZ domain 
zinc finger. The 12 carboxy-terminal amino acids of 13-dystroglycan, 
including the putative WW domain binding motif PPPY are shown as 
individual dark shaded circles with the phosphotyrosine that 
regulates utrophin binding, as a lighter shaded square. 
dystroglycan has yet to be determined. The cytoplasmic 
domain of 3-dystroglycan contains 5 tyrosine residues, none of 
which is in a known consensus for tyrosine phosphorylation. 
One of these tyrosines however, is within the WW binding 
motif PPxY in the carboxy-terminal 15 amino acids of 13-
dystroglycan (residues 888-892; see Fig. 8), which have been 
shown to be essential for dystrophin binding (Rentschler et al., 
1999). There is also a second potential WW binding motif at 
residues 817-822 but this does not appear to be involved in 
dystrophin binding to 0-dystroglycan (Rentschler et al., 1999). 
Two more tyrosines are within putative PxxP SH3 binding 
motifs (Ren et al., 1993) and therefore in potential sites to 
regulate the binding of SH3 containing proteins, such as Grb2 
(Yang et al., 1995) and others, that may facilitate interactions 
between the carboxy terminus of utrophin and 13-dystroglycan. 
Phosphorylation of the Pin! and Nedd4 WW domain ligands 
on serine or threonine, is a prerequisite for WW domain 
binding (Lu et al,, 1999) see Table 2. It has also been clearly 
demonstrated in vitro, that tyrosine phosphorylation of the Yes-
associated protein WW domain ligand, in the sequence PPxY, 
completely abolishes WW domain binding (Chen et al., 1997). 
Furthermore, we have demonstrated a physiological, adhesion-
dependent, tyrosine phosphorylation of a WW domain ligand, 
and that this phosphorylation is able to regulate binding to the 
utrophin WW domain. Phosphorylation of WW domain 
binding motifs on tyrosine demonstrates that the WW domain 
motif PPxY can be regulated in an analogous way to tyrosine-
containing SH3 motifs (Px[Y]P), see Table 2. This suggests a 
greater role for the WW domain, not only as a protein-protein 
interaction motif, but as a target and mediator of tyrosine 
Table 2. Role of phosphorylation in regulation of Sil and 






SH2 pYxxW* Yes (Yes) 
SH3 PxWP No Yes 
wwi PPLP No No 
WWII PPxY No Yes§ 
wwlll pS1TPJ Yes (Yes) 
A brief list of consensus motifs for interaction with the indicated SH or 
ww domain. Domain, represents the domain class, SH2, SH3 or WW 
domain types 1, II and III. Ligand, represents the defined consensus sequence 
for binding to the respective ligand. Phosphorylation obligatory, defines 
whether phosphorylation of a core ligand residue is required for the 
interaction with the respective domain. Regulated by (de)phosphorylation, 
indicates where dephosphorylation (shown in parentheses) may act as a 
regulatory step or whether phosphorylation of the core residue itself leads 
directly to regulation of binding. *, sit represents any hydrophobic residue. 
1, regulation occurs by phosphorylation of a tyrosine within the PxxP motif. 
§, when the tyrosine is phosphorylated. ¶, this represents the common 
residues identified between Pin  and Cdc25 (Lu et al., 1999) and does not 
represent a true experimentally defined consensus. 
kinase regulated signalling. Furthermore, this raises the 
possibility for SH2 domain mediated interaction with the 
phosphorylated WW domain ligand (Sudol, 1996b). 
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